Commonwealth Coat of Arms

Poisons Standard 2013

made under paragraph 52D(2)(b) of the

Therapeutic Goods Act 1989

**Compilation No. 2**

**Compilation date:** 1 February 2014

**Includes amendments up to:** Poisons Standard Amendment   
No. 1 of 2014

**Registered:** 24 December 2015

**About this compilation**

**This compilation**

This is a compilation of the *Poisons Standard 2013* that shows the text of the law as amended and in force on 1 February 2014 (the ***compilation date***).

This compilation was prepared on 18 December 2015.

The notes at the end of this compilation (the ***endnotes***) include information about amending laws and the amendment history of each amended provision.

**Uncommenced amendments**

The effect of uncommenced amendments is not reflected in the text of the compiled law but the text of the amendments is included in the endnotes.

**Application, saving and transitional provisions for provisions and amendments**

If the operation of a provision or amendment is affected by an application, saving or transitional provision that is not included in this compilation, details are included in the endnotes.

**Modifications**

If a provision of the compiled law is affected by a modification that is in force, details are included in the endnotes.

**Provisions ceasing to have effect**

If a provision of the compiled law has expired or otherwise ceased to have effect in accordance with a provision of the law, details are included in the endnotes.

Contents

1 Citation

2 The New Poisons Standard

3 Commencement

Schedule 1 Standard for the Uniform Scheduling of Medicines and Poisons No. 4

**Index** 277

**Endnotes** 346

Endnote 1—About the endnotes 346

Endnote 2—Abbreviation key 347

Endnote 3—Legislation history 348

Endnote 4—Amendment history 349

**1. Citation**

This instrument is the *Poisons Standard 2013*.

**2. The New Poisons Standard**

The Poisons Standard 2013 consists of the Standard for the Uniform Scheduling of Medicines and Poisons No. 4 (the SUSMP 4) as set out in Schedule 1.

**3. Commencement**

The Poisons Standard 2013 commences on the day after registration.

**Schedule 1-Standard for the Uniform Scheduling of Medicines and Poisons No. 4**

**STANDARD FOR THE UNIFORM SCHEDULING OF**

**MEDICINES AND POISONS**

**No. 4**

**July 2013**

© Commonwealth of Australia 2013

Online ISBN: 978-1-74241-895-7

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the *Copyright Act 1968* or allowed by this copyright notice*,* all other rights are reserved andyou are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or via e-mail to copyright@health.gov.au.

Published by the Australian Government under the *Therapeutic Goods Act 1989*.

Publication approval number: 10329

This publication consolidates the previous Standard for the Uniform Scheduling of Medicines and Poisons and the subsequent amendments to that document. It records decisions made by the Secretary to the Department of Health and Ageing, or the Secretary's delegate, with implementation dates up to and including June 2013. The basis of these decisions can be found in the ‘Reasons for scheduling delegates' final decisions', which can be accessed from the TGA website:

*http://www.tga.gov.au/industry/scheduling-decisions-final.htm*

Further inquiries should be directed to:

The Secretary

Medicines and Poisons Scheduling Secretariat

GPO Box 9848

CANBERRA ACT 2601

Or by email: [*smp@health.gov.au*](mailto:smp@health.gov.au)

Media Liaison Unit

Australian Government Department of Health and Ageing

**Contents**

[INTRODUCTION iii](#_Toc359452330)

[CLASSIFICATION iv](#_Toc359452331)

[PRINCIPLES OF SCHEDULING iv](#_Toc359452332)

[READING THE SCHEDULES v](#_Toc359452333)

[Availability of poisons vi](#_Toc359452334)

[Preparations containing poisons listed in two or more Schedules vi](#_Toc359452335)

[PART 1](#_Toc359452336) - [INTERPRETATION 1](#_Toc359452337)

[PART 2](#_Toc359452338) - [LABELS AND CONTAINERS 9](#_Toc359452339)

[LABELS 9](#_Toc359452340)

[General requirements 9](#_Toc359452341)

[Immediate wrapper 9](#_Toc359452342)

[Primary packs and immediate containers 9](#_Toc359452343)

[Statements of quantity, proportion or strength 15](#_Toc359452344)

[Exemptions 16](#_Toc359452345)

[Selected containers and measure packs 16](#_Toc359452346)

[Ampoules, pre-filled syringes and injection vials 16](#_Toc359452347)

[Transport containers and wrappings 17](#_Toc359452348)

[Dispensary, industrial, laboratory and manufacturing poisons 17](#_Toc359452349)

[Exemptions from label requirements in certain circumstances 17](#_Toc359452350)

[Dispensed medicines 17](#_Toc359452351)

[Gas cylinders 18](#_Toc359452352)

[Paints 18](#_Toc359452353)

[Camphor and naphthalene 18](#_Toc359452354)

[Prohibitions 19](#_Toc359452355)

[CONTAINERS 19](#_Toc359452356)

[Containers for poisons other than Schedule 5 poisons 19](#_Toc359452357)

[Containers for Schedule 5 poisons 20](#_Toc359452358)

[Approved containers 20](#_Toc359452359)

[Child-resistant closures 20](#_Toc359452360)

[Schedule 8 poisons 22](#_Toc359452361)

[Exemptions 23](#_Toc359452362)

[Camphor and naphthalene 23](#_Toc359452363)

[Prohibitions 23](#_Toc359452364)

[PART 3](#_Toc359452365) - [MISCELLANEOUS REGULATIONS 24](#_Toc359452366)

[ADVERTISING 24](#_Toc359452367)

[SALE OR SUPPLY 24](#_Toc359452368)

[Schedule 2 poisons 24](#_Toc359452369)

[Schedule 3 poisons 24](#_Toc359452370)

[Schedule 4 poisons 25](#_Toc359452371)

[Schedule 7 poisons 25](#_Toc359452372)

[PROHIBITIONS ON SALE, PRESCRIBING AND POSSESSION 25](#_Toc359452373)

[STORAGE 25](#_Toc359452374)

[PART 4 -](#_Toc359452375) [THE SCHEDULES 27](#_Toc359452376)

[SCHEDULE 1 28](#_Toc359452377)

[SCHEDULE 2 29](#_Toc359452378)

[SCHEDULE 3 44](#_Toc359452379)

[SCHEDULE 4 50](#_Toc359452380)

[SCHEDULE 5 125](#_Toc359452381)

[SCHEDULE 6 152](#_Toc359452382)

[SCHEDULE 7 189](#_Toc359452383)

[SCHEDULE 8 199](#_Toc359452384)

[SCHEDULE 9 202](#_Toc359452385)

[PART 5 -](#_Toc359452386) [THE APPENDICES 208](#_Toc359452387)

[APPENDIX A](#_Toc359452388) - [General exemptions 209](#_Toc359452389)

[APPENDIX B](#_Toc359452390) - [Substances considered not to require control by scheduling](#_Toc359452391)  [212](#_Toc359452392)

[APPENDIX C](#_Toc359452393) - [Substances, other than those included in Schedule 9,](#_Toc359452394) [of such danger to health as to warrant](#_Toc359452395) [prohibition of sale, supply and use 221](#_Toc359452396)

[APPENDIX D](#_Toc359452397) - [Additional controls on possession or supply of poisons included in Schedule 4 or 8 225](#_Toc359452398)

[APPENDIX E](#_Toc359452399) - [First aid instructions for poisons 227](#_Toc359452400)

[APPENDIX F](#_Toc359452401) - [Warning statements and general safety directions for poisons 242](#_Toc359452402)

[APPENDIX G](#_Toc359452403) - [Dilute preparations 265](#_Toc359452404)

[APPENDIX H](#_Toc359452405) - [Schedule 3 poisons permitted to be advertised 266](#_Toc359452406)

[APPENDIX I](#_Toc359452407) - [Uniform Paint Standard 267](#_Toc359452408)

[APPENDIX J](#_Toc359452409) - [Conditions for availability and use of Schedule 7 poisons 268](#_Toc359452410)

[APPENDIX K](#_Toc359452411) - [Drugs required to be labelled](#_Toc359452412) [with a sedation warning 271](#_Toc359452413)

[APPENDIX L](#_Toc359452414) - [Requirements for dispensing labels for](#_Toc359452415) [human and veterinary medicines 274](#_Toc359452416)

[INDEX 277](#_Toc359452418)

# **INTRODUCTION**

The Poisons Standard 2013, which, under section 2 above consists of the *Standard for the Uniform Scheduling of Medicines and Poisons* (the Standard, or the SUSMP), is made under paragraph 52D(2)(b) of the *Therapeutic Goods Act 1989*, and is a compilation of the decisions made under section 52D of the same Act. The SUSMP should be read in conjunction with the *Scheduling Policy Framework* (SPF) of the National Coordinating Committee on Therapeutic Goods. Further information on the scheduling amendments and the SPF can be accessed at www.tga.gov.au. Refer to Part 1, Interpretation, on page 2 below for definitions of specific terms used in this document including “medicine” and “poison” (noting that the definition of poison includes medicine).

The SUSMP serves two key purposes.

Firstly, the SUSMP contains the decisions of the delegates regarding the classification of poisons into Schedules, as recommendations to Australian States and Territories. The scheduling classification sets the level of control on the availability of poisons. The scheduling of poisons is implemented through relevant State and Territory legislation. Certain advertising, labelling and packaging requirements may also be a consequence of scheduling, but are the subject of other Commonwealth registration schemes.

Secondly, the SUSMP includes model provisions for labelling, containers, storage and possession of poisons in general, which are intended to be adopted for use in each jurisdiction of Australia, according to local requirements and local law. Appropriate labelling and container requirements for products, other than therapeutic goods and agricultural and veterinary chemicals, are imposed through adoption of Parts 1, 2 and 3 of the SUSMP into State or Territory legislation. Other government agencies may also impose controls on certain products, for example cosmetics.

The requirements for labelling and containers in the SUSMP are intended to integrate with existing legislative instruments for labelling and containers. Advertising, labelling and packaging of therapeutic goods and agricultural and veterinary chemicals are also dealt with through the respective product registration schemes provided for in Commonwealth legislation.

Poisons which are packed and sold solely for industrial, manufacturing, laboratory or dispensary use are exempt from all labelling requirements included in the SUSMP as they are covered by Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].Note, however that this exemption does not extend to controls on supply of these poisons.

The SUSMP is presented with a view to promoting uniform:

* scheduling of poisons throughout Australia;
* signal headings on labels for poisons throughout Australia;
* labelling and packaging requirements for poisons throughout Australia;
* additional controls on the availability and use of poisons in Australia.

The various Commonwealth Acts, legislative instruments and other documents which integrate with the SUSMP include:

* the *Agricultural and Veterinary Chemicals Code Act 1994*
* the *Agricultural and Veterinary Chemicals Code Regulations 1995*
* the *Therapeutic Goods Act 1989*
* Therapeutic Goods Order 69 – *General requirements for labels for medicines*
* Therapeutic Goods Order 80 – *Child-Resistant Packaging Requirements for Medicines*
* the *Required Advisory Statements for Medicine Labels* (RASML).

## CLASSIFICATION

Poisons are classified according to the Schedules in which they are included. The following is a general description of the Schedules. For the legal definitions, however, it is necessary to check with each relevant State or Territory authority.

**Schedule 1.** This Schedule is intentionally blank.

**Schedule 2. Pharmacy Medicine** – Substances, the safe use of which may require advice from a pharmacist and which should be available from a pharmacy or, where a pharmacy service is not available, from a licensed person.

**Schedule 3. Pharmacist Only Medicine** – Substances, the safe use of which requires professional advice but which should be available to the public from a pharmacist without a prescription.

**Schedule 4. Prescription Only Medicine,** or **Prescription Animal Remedy** – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription.

**Schedule 5. Caution** – Substances with a low potential for causing harm, the extent of which can be reduced through the use of appropriate packaging with simple warnings and safety directions on the label.

**Schedule 6. Poison** – Substances with a moderate potential for causing harm, the extent of which can be reduced through the use of distinctive packaging with strong warnings and safety directions on the label.

**Schedule 7. Dangerous Poison** – Substances with a high potential for causing harm at low exposure and which require special precautions during manufacture, handling or use. These poisons should be available only to specialised or authorised users who have the skills necessary to handle them safely. Special regulations restricting their availability, possession, storage or use may apply.

**Schedule 8. Controlled Drug** – Substances which should be available for use but require restriction of manufacture, supply, distribution, possession and use to reduce abuse, misuse and physical or psychological dependence.

**Schedule 9. Prohibited Substance** – Substances which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities.

## PRINCIPLES OF SCHEDULING

Poisons are not scheduled on the basis of a universal scale of toxicity. Although toxicity is one of the factors considered, and is itself a complex of factors, the decision to include a substance in a particular Schedule also takes into account many other criteria such as the purpose of use, potential for abuse, safety in use and the need for the substance.

This Standard lists poisons in nine Schedules according to the degree of control recommended to be exercised over their availability to the public.

Poisons for therapeutic use (medicines) are mostly included in Schedules 2, 3, 4 and 8 with progression through these Schedules signifying increasingly restrictive regulatory controls.

For some medicines and agricultural, domestic and industrial poisons, Schedules 5, 6 and 7 represent increasingly stricter container and labelling requirements with special regulatory controls over the availability of the poisons listed in Schedule 7. Products for domestic use must not include poisons listed in Schedule 7.

Schedule 9 contains substances that should be available only for teaching, training, medical or scientific research including clinical trials conducted with the approval of Commonwealth and/or State and Territory health authorities. Although appearing as a Schedule in this Standard, the method by which it is implemented in the States and Territories may vary.

Substances in products which have been considered for scheduling, but have been exempted from this Standard, may be listed in either Appendix A (general exemptions) or Appendix B (substances considered not to require control by scheduling).

Appendix C contains a list of substances or preparations, the sale, supply or use of which should be prohibited because of their known dangerous properties. It is recommended that the provisions of this Appendix be put into effect through inclusion of the substances in appropriate State and Territory legislation.

## READING THE SCHEDULES

Schedule entries have been designed to be as simple as possible while retaining readability, legal integrity and as much freedom from ambiguity and contradiction as possible. As a result, they are expressed in a number of ways, though this number has been kept to a minimum. It is necessary to keep this variety of expression in mind when searching or interpreting Schedule entries.

Firstly, poisons are scheduled individually using their approved names wherever practicable although exceptions are necessary in some cases. Some of those are mentioned overleaf. Older group entries are revised and replaced by individual entries as time permits, although in some of these cases a group term has also been retained to deal with any members of the group or class that may have escaped attention but should be scheduled.

Secondly, Schedule entries have been expressed in either positive or negative terms and care must be taken to distinguish between the two different forms of expression. Thus, selenium is in Schedule 6 only when one of the clauses in this Schedule entry applies, while fluorides are in Schedule 6 unless one of the exempting clauses applies.

Where exceptions are included in an entry, these have been emphasised by printing the word “except” in bold type.

Where the Schedule entries for a poison make a specific exclusion or exemption, the requirements of this Standard do not apply to that poison within the constraints of that exclusion or exemption although controls under other legislation, such as pesticide registration, may apply.

Where a Schedule entry for a poison requires a specific statement to be included on a label as a condition for a product to qualify for an exemption (‘reverse scheduling’), then in cases where it is impracticable for a supplier to use the exact wording of such a statement, its wording may be varied provided that the full intent and meaning of the statement is not changed.

Where a poison has been included in more than one Schedule, the principal entry, where practicable, has been included in the most restrictive Schedule with references to the other Schedule(s) involved.

It is important to remember that a Schedule entry includes preparations containing the poison in any concentration and all salts and derivatives of the poison unless it specifically states otherwise. (See Part 1, Interpretation, subparagraph 1(2).

It is important to note that a substance is not classed as a derivative on the basis of a single, prescriptive set of criteria. Classification of a substance as a derivative of a scheduled poison relies on a balanced consideration of factors to decide if a substance has a similar nature (e.g. structurally, pharmacologically, toxicologically) to a scheduled poison or is readily converted (either physically or chemically) to a scheduled poison. However, a substance is only considered a derivative of a scheduled poison if it is not individually listed elsewhere in the Schedules, or captured by a more restrictive group or class entry. Additionally, some entries specifically exclude derivatives. Once a substance is determined to be a derivative of a scheduled poison, the same scheduling requirements as the scheduled poison, including limits on access, supply and availability, will apply.

Finally, when using this Standard to determine the scheduling status of a poison, it may be necessary to search each relevant Schedule as well as Appendices A, B and C and the Index. In this process, if the poison is not found under its “approved name” it may be shown under a group term such as:

**Group Example**

the parent acid of salts “oxalic acid” to find sodium oxalate

the radical of a salt “chromates” to find potassium

chromate

the element “arsenic” to find arsenic trioxide

a chemical group with similar “hydrocarbons, liquid” to find

toxicological or pharmacological kerosene

activity

a pharmacological group “anabolic steroidal agents” to find

“androsterone”

### **Availability of poisons**

The purpose of classification is to group substances into Schedules that require similar regulatory controls over their availability.

These Schedules have been developed over a long period and contain poisons that may be obsolete for various reasons. Also, as part of the move to harmonise the Australian and New Zealand classifications, many substances have been added to the Schedules for that purpose, irrespective of their availability in either country.

Inclusion of a poison in a Schedule indicates the degree of control required if it is marketed. It does not indicate:

* that the poison is available; nor
* that is has been approved or is efficacious for any use that may be specified in a Schedule; nor
* does it negate any obligation for registration of a therapeutic good, or agricultural or veterinary chemical product containing that poison.

### **Preparations containing poisons listed in two or more Schedules**

If a preparation contains two or more poisons, the provisions relating to each of the Schedules in which those poisons are included apply.

Where it is not possible to comply both with a provision relating to one of those Schedules and with a provision relating to another of those Schedules, the provision of the more restrictive Schedule applies, unless a contrary intention is indicated in the Schedules or relevant legislation.

The Schedules listed in order of greatest to least restriction on access and availability are 9, 8, 4, 7, 3, 2, 6, 5.

Schedule 1 is not currently in use.

Some substances in certain circumstances are also subject to exemptions or additional restrictions as described in the Appendices of this Standard. The table below summarises the purpose of each of the Appendices and the controls imposed on substances included in them.

| **Appendix** | **Title** | **Purpose/ controls imposed** |
| --- | --- | --- |
| Appendix A | General exemptions | List of classes of products or uses exempted from this Standard. |
| Appendix B | Substances considered not to require control by scheduling | List of poisons exempted from scheduling. |
| Appendix C | Substances, other than those included in Schedule 9, of such danger to health as to warrant prohibition of sale, supply and use | List of poisons prohibited from sale, supply or use because of their known potential for harm to human and/or animal health. |
| Appendix D | Additional controls on possession or supply of poisons included in Schedule 4 or 8 | List of poisons included in Schedule 4 or 8 where additional specified controls apply on possession or supply. |
| Appendix E | First aid instructions for poisons | First aid instructions for poisons (other than agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix F | Warning statements and general safety directions for poisons | Warning statements and general safety directions for poisons (other than human medicines, agricultural and veterinary chemicals and chemicals packed and sold solely for industrial, dispensary, manufacturing or laboratory use). |
| Appendix G | Dilute preparations | Concentration cut-offs for specified poisons, below which the requirements of the Standard do not apply |
| Appendix H | Schedule 3 medicines permitted to be advertised | List of medicines included in Schedule 3 that are permitted to be advertised to the public. |
| Appendix I | Uniform Paint Standard | Requirements applying to poisons included in paints or tinters. |
| Appendix J | Conditions for availability and use of Schedule 7 poisons | List of poisons included in Schedule 7 where additional specified conditions apply to their availability and use. |
| Appendix K | Human medicines required to be labelled with a sedation warning | List of human medicines required to be labelled with a warning regarding their sedation potential. |
| Appendix L | Requirements for dispensing labels for medicines | Requirements applying to labels attached to medicines at the time of dispensing. |

This page is intentionally blank.

# **PART 1**

# **INTERPRETATION**

**1.** (1) In this Standard, unless the contrary intention appears —

“**Agricultural chemical**” means a substance that is represented, imported, manufactured, supplied or used as a means of directly or indirectly:

(a) destroying, stupefying, repelling, inhibiting the feeding of, or preventing infestation by or attacks of, any pest in relation to a plant, a place or a thing;

(b) destroying a plant;

(c) modifying the physiology of a plant or pest so as to alter its natural development, productivity, quality or reproductive capacity;

(d) modifying an effect of another agricultural chemical;

(e) attracting a pest for the purpose of destroying it; or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an agricultural chemical product;

but does not include:

(g) a veterinary chemical.

“**Agricultural chemical product**” has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

“**Animal**” means any animal (other than a human being), whether vertebrate or not, and whether a food producing species or not, and includes mammals, birds, bees, reptiles, amphibians, fish, crustaceans and molluscs.

**“Animal feed premix”** means a concentrated preparation, containing one or more poisons, for mixing with food ingredients to produce a bulk feed for a group of animals (including fish or birds), but does not include a preparation for mixing with an individual animal’s food.

“**Appropriate authority**” means:

(a) in the Australian Capital Territory, ACT Government Health Directorate;

(b) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 in Part 2 of this Standard by the Australian Pesticides and Veterinary Medicines Authority, the Chief Executive Officer or their delegate;

(c) in New South Wales, the Director-General of the NSW Ministry of Health;

(d) in the Northern Territory, the Chief Health Officer of the Department of Health;

(e) in Queensland, the Chief Executive of Queensland Health;

(f) in South Australia, the Chief Executive of the Department for Health and Ageing;

(g) in Tasmania, the Secretary of the Department of Health and Human Services;

(h) for the purpose of providing an exemption from all or part of paragraphs 2 to 12 of this Standard

by the Therapeutic Goods Administration, the National Manager or their delegate;

(i) in Victoria, the Secretary to the Department of Health;

(j) in Western Australia, the Chief Executive Officer of the Department of Health.

**“Approved name”** means:

(a) in relation to a poison that is for human therapeutic use, the name approved for use by the Therapeutic Goods Administration;

(b) in relation to a poison that is for animal or agricultural use, the name approved for use by the Australian Pesticides and Veterinary Medicines Authority;

(c) in relation to all other poisons:

(i) the name used in an entry in these Schedules; or, if no such name is given,

(ii) the English name recommended by Standards Australia as the common name for the poison; or, if no such name is given,

(iii) the English name given to the poison by the International Organization for Standardization; or, if no such name is given,

(iv) the English name given to the poison by the British Standards Institution; or, if no such name is given,

(v) the name that would comply with the requirements of part (a) or (b) of this definition, or, if no such name is given,

(vi) the English name given to the poison by the European Committee for Standardization (CEN); or, if no such name is given,

(vii) the international non-proprietary name recommended for the poison by the World Health Organization; or, if no such name is given,

(viii) the International Nomenclature Cosmetic Ingredient name for the poison listed in the *International Cosmetic Ingredient Dictionary & Handbook* published by the Personal Care Products Council of America; or, if no such name is given,

(ix) the accepted scientific name or the name descriptive of the true nature and origin of the poison.

**“Australian Code for the Transport of Dangerous Goods by Road and Rail”** means the seventh edition of the document of that name.

“**Authorised prescriber**” means a registered medical, dental or veterinary practitioner or such other person authorised by the appropriate authority.

**“Blood”** means whole blood extracted from human donors.

“**Blood components**” means therapeutic components that have been manufactured from blood (including red cells, white cells, stem cells, platelets and plasma), except for products derived through fractionation of plasma.

**“Child-resistant closure”** means:

(a) a closure that complies with the requirements for a child-resistant closure in the Australian Standard AS 1928-2007 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) a closure approved by an order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989;* or

(c) in the case of a can fitted with a press-on lid, a lid of the design known as “double tight” or “triple tight”.

See also "Non-access packaging**”**.

**“Child-resistant packaging”** means packaging that:

(a) complies with the requirements of the Australian Standard AS 1928-2007 entitled

*Child resistant packaging – Requirements and testing procedures for reclosable packages* (ISO 8317:2003, MOD);

(b) is reclosable and complies with the requirements of at least one of the following Standards:

(i) the International Organization for Standardization Standard ISO 8317:2003 entitled *Child-resistant packaging – Requirements and testing procedures for reclosable packages*;

(ii) the British Standards Institution Standard BS EN ISO 8317:2004 entitled

*Child-resistant packaging. Requirements and testing procedures for reclosable packages*;

(iii) the Canadian Standards Association Standard CSA Z76.1-06 entitled *Reclosable Child-Resistant Packages;*

(iv) the United States Code of Federal Regulations, Title 16, Section 1700.15, entitled *Poison prevention packaging standards* and Section 1700.20, entitled *Testing procedure for special packaging*;

(c) is approved as child-resistant by any order made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(d) is in the form of blister or strip packaging in which a unit of use is individually protected until the time of release and that complies with Section 3 (Requirements for non-reclosable packages) of Australian Standard AS 1928-2001 entitled *Child-resistant packages.*

See also "Non-access packaging".

**“Compounded**” in relation to a substance means combined with one or more other therapeutically active substances in such a way that it cannot be separated from them by simple dissolution or other simple physical means.

“**Debitterised neem seed oil**” means highly purified oil from the neem seed containing only fatty acids and glycerides of fatty acids.

**“Dermal use”** means application to the skin primarily for localised effect.

**“Designated solvent”** means the following:

acetone

dimethylformamide

N-(N-dodecyl)-2-pyrrolidone

hydrocarbons, liquid

methanol when included in Schedule 5

methyl ethyl ketone

methyl isoamyl ketone

methyl isobutyl ketone

N-methyl-2-pyrrolidone

N-(N-octyl)-2- pyrrolidone

phenyl methyl ketone

styrene

tetrachloroethylene

1,1,1-trichloroethane

**“Dispensing label”** means the label attached to the immediate container of a substance for therapeutic use at the time of dispensing.

**“Distributor”** means a person who imports, sells or otherwise supplies a poison.

**“Divided preparation”** means a preparation manufactured and packed as discrete pre-measured dosage units prior to sale or supply, and includes tablets, capsules, cachets, single dose powders or single dose sachets of powders or granules.

**“Dosage unit”** means an individual dose of a poison for therapeutic use and includes a tablet, capsule, cachet, single dose powder or single dose sachet of powders or granules.

**“Drug”** means a poison intended for human or animal therapeutic use.

**“Essential oils”** means products obtained from natural raw materials either by distillation with water or steam or from the epicarp of citrus fruits by a mechanical process, or by dry distillation. For scheduling purposes it also means:

(a) oils of equivalent composition derived through synthetic means; or

(b) prepared mixtures of oils of equivalent composition comprising a mixture of synthetic and natural components.

**“External”** in relation to the use of a poison means application in the ears, eyes or nose or to a body surface other than in the mouth, rectum, vagina, urethra or other body orifice.

**“First Schedule Paint”** means a paint containing the specified proportion of any substance in the First Schedule to Appendix I of this Standard.

**“Free formaldehyde”** includes all hydrated and non-hydrated formaldehyde present in aqueous solution, including methylene glycol.

**“Graphic material”** means the material which is to be deposited on another material by a graphic instrument during writing, drawing or marking and includes cores of pencils, school pastels or crayons, blackboard chalks, finger or showcard colours, poster paints and watercolour blocks.

**“Height”** in relation to letters used for words, expressions or statements on labels means the height of capital letters or lower case letters having an ascender or a descender.

**“Hemp seed oil”** means the oil obtained by cold expression from the ripened fruits (seeds) of Cannabis sativa.

**“Immediate container**” includes all forms of containers in which a poison is directly packed but does not include any such container intended for consumption or any immediate wrapper.

**“Immediate wrapper”** means metal foil, plastic foil, waxed paper, or any other such material not intended for consumption, when used as the first wrapper for a dosage unit or dressing.

**“Internal use”** means administration:

(a) orally, except for topical effect in the mouth; or

(b) for absorption and the production of a systemic effect;

(i) by way of a body orifice other than the mouth; or

(ii) parenterally, other than by application to unbroken skin.

**“Label”** means:

(a) a written statement on a container of a poison; and

(b) in relation to a therapeutic good, includes a display of printed information about the product:

(i) on, or attached to, the good;

(ii) on, or attached to, a container or primary pack in which the good is supplied; or

(iii) supplied with such a container or pack.

**“Main label”** means, where there are two or more labels on a container or a label is divided into two or more portions:

(a) the part of a label that is most likely to be displayed, presented, shown, or examined under ordinary or customary conditions of display; and

(b) where there are two or more labels or two or more portions of a single label – that label or portion of the label where the product name is more or most conspicuously shown; or

(c) where the product name is equally conspicuous on two or more labels or portions of a label – each such label or portion.

**“Manufacturer”** means a person who manufactures, produces, or packs a poison.

**“Measure pack”** means a sealed container which contains a measured quantity of poison for use on one occasion as a pesticide or domestic product and one or more of which is enclosed in a primary pack.

**“Medicine”** means any poison for therapeutic use**.**

*Note: To be preceded by “human” or “veterinary” where restriction of the “medicine” to human or animal use is intended.*

**“Name and address”** means the name and address, in Australia, of the manufacturer or distributor of a poison but does not include a post office, cable, telegraphic or code address. Where such manufacturer or distributor is a company incorporated in accordance with the appropriate law of any State or Territory of the Commonwealth of Australia or a firm registered under the Business Names Act of any State or Territory, the inclusion in the label of the registered name of the corporation or firm or its branch or its division and the city or town in which a registered office is situated shall be deemed to comply with the requirements.

**“Non-access packaging**” is packaging that complies with the requirements of Australian Standard AS4710-2001 entitled *Packages for chemicals not intended for access or contact with their contents by humans*, in relation to products that are not intended for human therapeutic use.

See also "Child-resistant closure" and "Child-resistant packaging”.”.

**“Non-volatile content”** in relation to a paint or tinter means that portion of a paint or tinter determined to be the non-volatile content by Method 301.1 of Australian Standard AS 1580-301.1-2005entitled *Paints and related materials – Methods of test – Non-volatile content by mass*.

“**Oromucosal use**” means administration to the oral mucosa, specifically the oral cavity and/or the pharynx.

**“Paint”**, without limiting the ordinary meaning, includes any substance used or intended to be used for application as a colouring or protective coating to any surface but does not include graphic material or paints for therapeutic use.

**“Pesticide”** means any substance or mixture of substances used or intended to be used:

(a) for preventing, destroying, repelling, attracting, inhibiting or controlling any insects, rodents, birds, nematodes, bacteria, fungi, weeds or other forms of plant or animal life or viruses, which are pests; or

(b) as a plant regulator, promoter, defoliant or desiccant for food storage, household, industrial, commercial, agricultural and non-agricultural application, but does not include veterinary drugs, stock medicines, stock feeds, stock feed additives, drugs for human use, food additives or fertilisers.

**“Poison”** means any substance or preparation included in a Schedule to this Standard.

**“Primary pack”** means the pack in which a poison and its immediate container or immediate wrapper or measure pack are presented for sale or supply.

**“Required Advisory Statements for Medicine Labels”** means the document made under subsection 3(5A) of the *Therapeutic Goods Act 1989* by the Therapeutic Goods Administration.

**“Restricted flow insert”** means a restriction fitted, or moulded, in the neck of a container which:

(a) cannot readily be removed from the container by manual force; and

(b) limits the delivery of the contents to drops each of which is not more than 200 microlitres.

**“Second Schedule Paint”** means a paint containing the specified proportion of any substance in the Second Schedule to Appendix I of this Standard.

**“Selected container”** means:

(a) an injection vial having a nominal capacity of ten millilitres or less;

(b) a single use syringe; or

(c) any other container for substances for therapeutic use having a nominal capacity of ten millilitres or less.

**“Solid”** is considered to include “powder” for the purposes of scheduling.

**“Therapeutic good”** has the meaning defined in theCommonwealth*Therapeutic Goods Act 1989.*

**“Therapeutic use”** means use in or in connection with:

(a) preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in human beings or animals;

(b) influencing, inhibiting or modifying a physiological process in human beings or animals;

(c) testing the susceptibility of human beings or animals to a disease or ailment;

(d) influencing, controlling or preventing conception in persons or animals;

(e) testing for pregnancy in persons or animals; or

(f) the replacement or modification of parts of the anatomy in persons or animals.

**“Third Schedule Paint”** means a paint containing the specified proportion of any substance in the Third Schedule to Appendix I of this Standard.

**“Tinter”** means any pigment or admixture of pigment with other substances, in powder, semi-solid or liquid form, sold or supplied for the purpose of adding to paint in order to change the colour of the paint.

**“Topical use”** means application of a poison for the purpose of producing a localised effect on the surface of the organ or within the tissue to which it is applied.

**“Toy”** means an object or number of objects manufactured, designed, labelled or marketed as a plaything for a child or children up to the age of fourteen years.

**“Transdermal use”** means application to the skin primarily for systemic effect.

**“Veterinary chemical”** means a substance that is represented as being suitable for, or is manufactured, supplied or used for, administration or application to an animal by any means, or consumption by an animal, as a way of directly or indirectly:

(a) preventing, diagnosing, curing or alleviating a disease or condition in the animal or an infestation of the animal by a pest;

(b) curing or alleviating an injury suffered by the animal;

(c) modifying the physiology of the animal:

(i) so as to alter its natural development, productivity, quality or reproductive capacity; or

(ii) so as to make it more manageable;

(d) modifying the effect of another veterinary chemical

(e) any vitamin, mineral substance, or additive, if, and only if, the vitamin, substance or additive is used for a purpose mentioned in paragraph (a), (b), (c) or (d); or

(f) any active ingredient included in a product declared by regulation under the *Agricultural and Veterinary Chemicals Code Act 1994* to be an veterinary chemical product;

but does not include:

(g) an agricultural chemical.

**“Veterinary chemical product”** has the meaning defined in the *Agricultural and Veterinary Chemicals Code Act 1994*.

**“Writing”** includes the visible representation or reproduction of words or figures in any form, and “to write” and “written” have corresponding meanings.

(2) Unless the contrary intention appears a reference to a substance in a Schedule or an Appendix to this Standard includes:

(a) that substance prepared from natural sources or artificially; and

(b) where the substance is a plant (other than a plant included in Schedule 8 or 9), that plant or any part of that plant when packed or prepared for therapeutic use; and

(c) every salt, active principle or derivative of the substance, including esters and ethers, and every salt of such an active principle or derivative; and

(d) every alkaloid of the substance and every salt of such an alkaloid; and

(e) every stereoisomer of the substance and every salt of such a stereoisomer; and

(f) every recombinant form of the substance; and

(g) a preparation or admixture containing any proportion of the substance,

but does not include:

(h) a preparation or product included in Appendix A, or a substance and the reason for its entry in Appendix B; or

(i) a substance included in Appendix G at a concentration not exceeding the concentration specified in column 2 of that Appendix in respect of that substance; or

(j) any other substance included in Schedules 1 to 6, at a concentration not exceeding 10 mg per litre or 10 mg per kilogram, unless that substance is also included in Schedule 7 or 8; or

(k) any substance present as an impurity in a pesticide, at a concentration at or below the maximum content for that substance, specified for the pesticide in the *Standards for Active Constituents*, as published by the Australian Pesticides and Veterinary Medicines Authority.

(3) Unless the contrary intention appears where a concentration, strength or quantity is specified in a Schedule or an Appendix to this Standard in respect of a substance:

(a) if the substance is present as a salt, active principle or derivative (including an ester or ether), the concentration, strength or quantity is calculated as the equivalent amount of the substance that is listed in the Schedule or Appendix; and

(b) the expression “one per cent” means:

(i) in the case of a liquid preparation, 1 gram of the substance per 100 millilitres of the preparation; or

(ii) in the case of a solid, semi-solid or pressurised spray aerosol preparation, 1 gram of the substance per 100 grams of the preparation; and

(iii) any expression of greater or lesser percentages shall have a corresponding meaning; and

(c) in the case of codeine, such concentration, strength or quantity is calculated as anhydrous codeine.

(4) A reference to a boiling or distillation temperature in the Schedules means that temperature at an atmospheric pressure of 101.325 kPa (760 millimetres of mercury).

# **PART 2**

# **LABELS AND CONTAINERS**

## LABELS

**2**. A person must not sell or supply a poison unless it is labelled in accordance with paragraphs 3 to 19 of this Standard.

## General requirements

**3.** Any word, expression or statement required by this Standard to be written on a label or container must be written:

(1) on the outside face of the label or container; and

(2) in the English language; and

(3) in durable characters; and

(4) in a colour or colours to provide a distinct contrast to the background colour; and

(5) in letters at least 1.5 millimetres in height.

**4.** Subparagraph 3(5) does not apply to a word, expression or statement on a container which has a capacity of 20 millilitres or less, or on the label of such a container if:

(1) an appropriate authority approves the use of smaller letters; and

(2) the letters are at least 1 millimetre in height.

**5.** The label must be printed on, or securely attached to:

(1) the outside of the immediate container; and

(2) if the immediate container is enclosed in a primary pack, the outside of that primary pack.

## Immediate wrapper

**6.** (1) A poison enclosed in an immediate wrapper must be contained in a primary pack labelled in accordance with paragraph 7 of this Standard; and

(2) the immediate wrapper must be conspicuously labelled with:

(a) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for that poison; and

(b) the approved name of the poison; and

(c) a statement of the quantity or strength of the poison in accordance with   
paragraph 8 of this Standard.

## Primary packs and immediate containers

**7.** (1) The primary pack and immediate container of a poison must be labelled as follows:

(a) with the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the following table:

Schedule Purpose Signal words required

2 for any purpose **PHARMACY MEDICINE**

3 for any purpose **PHARMACIST ONLY MEDICINE**

4 for human use **PRESCRIPTION ONLY MEDICINE**

4 for animal use **PRESCRIPTION ANIMAL REMEDY**

5 for any purpose **CAUTION**

6 for any purpose **POISON**

7 for any purpose **DANGEROUS POISON**

8 for any purpose **CONTROLLED DRUG**

written:

(i) on the first line or lines of the main label; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least half the height of the largest letter or numeral on the label but need not be larger than:

(A) 6 millimetres on labels for packages having a nominal capacity of   
2 litres or less; or

(B) 15 millimetres on labels for packages having a nominal capacity of more than 2 litres; and

(iv) if the poison:

(A) is a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail* or a statement of the principal hazard of the poison, written on that line; or

(B) is not a Schedule 5 poison, with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on that line;

(b) if the poison is a Schedule 8 poison, with the cautionary statement –

**POSSESSION WITHOUT AUTHORITY ILLEGAL**

written:

(i) on a separate line or lines immediately below the signal words required by subparagraph 7(1)(a); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with no other statement written on the same line;

(c) with the cautionary statement –

**KEEP OUT OF REACH OF CHILDREN**

written:

(i) on a separate line or lines:

(A) immediately below the signal word or words required by subparagraph 7(1)(a); or

(B) where the cautionary statement “POSSESSION WITHOUT AUTHORITY ILLEGAL” is required by subparagraph 7(1)(b), on the line immediately below that statement; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(d) if the poison is a dry chlorinating compound containing more than 10 per cent of available chlorine, **except** for preparations certified by a relevant State or Territory authority as not being a Dangerous Good of Class 5, Division 5.1: Oxidising substances, as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FIRE AND EXPLOSION HAZARD**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(e) if the poison is an alkaline salt in a dishwashing machine product, with the cautionary statement –

**BURNS SKIN AND THROAT**

written:

(i) on a separate line or lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line of the main label;

(f) if the poison is an aqueous solution of paraquat, with the cautionary statements –

**CAN KILL IF SWALLOWED**

**DO NOT PUT IN DRINK BOTTLES**

**KEEP LOCKED UP**

written:

(i) on separate lines immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same lines of the main label;

(g) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if safety directions are required on the label by subparagraph 7(1)(n), with the cautionary statement –

**READ SAFETY DIRECTIONS BEFORE OPENING**

**OR USING**

or with the cautionary statement –

**READ SAFETY DIRECTIONS**

written:

(i) on a separate line or lines;

(A) immediately below the cautionary statement “KEEP OUT OF REACH OF CHILDREN” as required by subparagraph 7(1)(c); or

(B) if one or more other cautionary statements is required to be on the line immediately below “KEEP OUT OF REACH OF CHILDREN”, immediately below that statement or those statements; and

(ii) in bold-face sans serif capital letters of uniform thickness; and

(iii) in letters at least four-tenths the height of the letters used for the signal word or words; and

(iv) with nothing, other than a Class label as specified in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, written on the same line;

(h) if the poison meets the criteria for a ‘flammable liquid’ in the *Australian Code for the Transport of Dangerous Goods by Road and Rail*, with the cautionary statement –

**FLAMMABLE**

written on the main label in bold-face sans serif capital letters of uniform thickness, unless already present in accordance with the requirements of the *Australian Code for the Transport of Dangerous Goods by Road and Rail*;

(i) if the poison is for the treatment of animals, with the cautionary statement –

**FOR ANIMAL TREATMENT ONLY**

written on the main label in bold-face sans serif capital letters of uniform thickness;

(j) if the poison is a Schedule 5 poison intended for any purpose other than internal or pesticidal use, with the cautionary statement –

DO NOT SWALLOW

written in sans serif capital letters on the main label or as part of the directions for use;

(k) with the approved name of the poison and a statement of the quantity, proportion or strength of the poison in accordance with paragraph 8:

(i) if the poison is for human therapeutic use, written in accordance with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act, 1989*; or

(ii) if the poison is not for human therapeutic use, written in bold-face sans serif capital letters on the main label, unless:

(A) a list of approved names is required; and

(B) it is impractical to include the list on the main label; and

(C) an appropriate authority has authorised its inclusion on another part of the label; or

(iii) if the poison is a Schedule 5 poison referred to in column 1 of the following table the appropriate name opposite thereto in column 2 may be used as the approved name:

**TABLE**

**Column 1 Column 2**

Alkaline salts Alkaline salts

Amines for use as curing Aliphatic amines or

agents for epoxy resins aromatic amines

(unless separately specified

in the Schedules)

Epoxy resins, liquid Liquid epoxy resins

Hydrocarbons, liquid Liquid hydrocarbons

Quaternary ammonium Quaternary ammonium

compounds compound(s)

(iv) if a poison contains a mixture of designated solvents in excess of 25 per cent of the total volume of the poison but the proportion of one or more individual designated solvents in the mixture is equal to or less than 25 per cent, the approved names of those solvents may be expressed as follows:

(A) where the designated solvent is a liquid hydrocarbon as “liquid hydrocarbons”; or

(B) where the designated solvent is a ketone as “ketones”; or

(C) in any other case as “solvents” or “other solvents”;

(l) if the poison is an organophosphorus compound or carbamate for pesticidal use or for the treatment of animals, with the following expression written immediately below the approved name or the list of declared contents –

**AN ANTICHOLINESTERASE COMPOUND**

(i) the requirements of subparagraph 7(1)(l) do not apply to:

(A) dazomet, mancozeb, metiram, propineb, thiram, tri-allate, zineb or ziram; or

(B) an organophosphorus compound or carbamate contained in impregnated plastic resin strips, medallions or granules; or

(C) an organophosphorus compound or carbamate contained in a

pressurised spray pack for household use;

(m) for any poison other than a poison for human therapeutic use labelled in accordance with Therapeutic Goods Order 69 *General requirements for labels for medicines* or in an agricultural or veterinary chemical product labelled in compliance with the *Agricultural and Veterinary Chemicals Code Act 1994*, if the poison is prepared, packed or sold for a specific purpose, with clear and adequate directions for use unless:

(i) the poison is included in Schedule 4 or Schedule 8; or

(ii) it is impractical to include such directions on the label and:

(A) the primary pack and the immediate container are labelled with the statement “DIRECTIONS FOR USE: See package insert”; and

(B) an appropriate authority has authorised the directions for use to be written on a package insert instead of the label; and

(C) the insert is enclosed in the primary pack;

(n) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if use of the poison may be harmful to the user, with appropriate safety directions (see Appendix F), grouped together as a distinct section of the label and prefaced by the words –

**SAFETY DIRECTIONS**

written in bold-face capital letters;

(o) for any poison other than a poison for human therapeutic use labelled in accordance with the *Required Advisory Statements for Medicine Labels,* if any warning statement or statements are required for the poison (see Appendix F), with that warning statement or those statements grouped together:

(i) if safety directions are included on the label, immediately after the words “SAFETY DIRECTIONS”; or

(ii) if there are no safety directions, immediately preceding the directions for use;

(p) if the poison is not for human internal use and is not a Schedule 3, Schedule 4 or Schedule 8 poison, with appropriate first aid instructions (see Appendix E):

(i) grouped together and prefaced by the words –

**FIRST AID**

written in bold-face capital letters; or

(ii) if a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(A) written on each immediate container as specified in subparagraph 7(1)(p)(i); and

(B) replaced on the primary pack with the statement –

FIRST AID: See inner packs;

(q) with the name and address of the manufacturer or distributor.

(2) For the purposes of subparagraph 7(1)(a)(iii) the term “largest letter or numeral” does not include:

(a) a single letter or numeral which is larger than other lettering on the label; or

(b) an affix forming part of the trade name; or

(c) in the case of a poison for therapeutic use, numerals used to distinguish the strength of a preparation from the strengths of other preparations of the same poison.

## Statements of quantity, proportion or strength

**8.** The statement of the quantity, proportion or strength of a poison must be expressed in the most appropriate of the following forms:

(1) if the poison is for human therapeutic use, in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*;

(2) if the poison is for a purpose or purposes other than human therapeutic use and:

(a) if the poison is in a pressurised spray aerosol preparation, as the mass of the poison per stated mass of the preparation;

(b) if the poison is a liquid in a liquid preparation, as the mass or volume of the poison per stated volume of the preparation;

(c) if the poison is a liquid in a solid or semi-solid preparation, as the mass or volume of the poison per stated mass of the preparation;

(d) if the poison is a solid or semi-solid in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(e) if the poison is a solid or semi-solid in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(f) if the poison is a gas in a liquid preparation, as the mass of the poison per stated volume of the preparation;

(g) if the poison is a gas in a solid or semi-solid preparation, as the mass of the poison per stated mass of the preparation;

(h) if the poison is a gas in a gaseous preparation, as the mass of the poison per stated mass of the preparation;

(3) if the poison is a solution of a mineral acid, the proportion of the acid (un-neutralised by any bases present in the preparation) in a preparation may be expressed as the un-neutralised mass of the acid per stated mass of the preparation;

(4) if the poison is an inorganic pigment, the proportion may be expressed as a percentage of the metal present using one of the following expressions as appropriate:

contains not more than 10 per cent of (*insert* *name of the metal*); or

contains not more than 30 per cent of (*insert name of the metal*); or

contains more than 30 per cent of (*insert name of the metal*);

(5) if the poison is included in a paint, other than a paint for therapeutic or cosmetic use, the proportion may be expressed as a range provided that the limits of the range do not differ by more than 5 per cent of the product;

(6) if the poison is a lead-based pigment included in automotive paint, the proportion may be expressed as the maximum content of the lead that may be present in the non-volatile content of the paint;

(7) if a preparation contains more than one derivative of a poison, the quantity or proportion of the poison may be expressed as the equivalent quantity or proportion of one of the derivatives present which it would contain if all of the derivatives were that derivative.

(8) For the purposes of subparagraph 8(7) “derivative” includes alkaloid.

## Exemptions

### **Selected containers and measure packs**

**9.** The requirements of paragraph 7 do not apply to an immediate container that is a measure pack or a selected container (other than an ampoule, a pre-filled syringe or an injection vial to which paragraph 10 or 11 apply) when:

(1) the immediate container is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the immediate container is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) labelled with:

(i) the signal word or words relating to the Schedule in which the poison is included and the purpose for which it is to be used, as shown in the table to subparagraph 7(1)(a); and

(ii) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

(iii) the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(iv) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

### **Ampoules, pre-filled syringes and injection vials**

**10.** The requirements of paragraph 7 do not apply to a selected container, or an ampoule (other than an ampoule to which paragraph 11 applies) when:

(1) the selected container or ampoule is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the selected container or ampoule is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) labelled with:

(i) the approved name of the poison and the quantity, proportion or strength of the poison in accordance with paragraph 8; and

(ii) with the name of the manufacturer or distributor or the brand name or trade name used exclusively by the manufacturer or distributor for the poison; and

(iii) if the poison is for the treatment of animals, with the cautionary statement –

FOR ANIMAL TREATMENT ONLY

written in sans serif capital letters.

**11.** The requirements of paragraph 7 do not apply to a selected container that is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip when:

(1) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is for a therapeutic good and is labelled in the manner prescribed by orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*; or

(2) the selected container is a plastic ampoule that is continuous with a strip of the same material and opens as it is detached from the strip, is:

(a) packed in a primary pack labelled in accordance with paragraph 7; and

(b) the strip is labelled in accordance with paragraph 10; and

(c) the ampoule is labelled with:

(i) the approved name of the poison or the trade name of the product; and

(ii) the quantity, proportion or strength of the poison in accordance with paragraph 8.

### **Transport containers and wrappings**

**12.** The labelling requirements of this Standard do not apply to a transparent cover, or to any wrapper, hamper, packing case, crate or other cover used solely for the purposes of transport or delivery.

### **Dispensary, industrial, laboratory and manufacturing poisons**

**13.** The labelling requirements of this Standard do not apply to a poison that:

(1) is packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes; and

(2) is labelled in accordance with Safe Work Australia's *National Code of Practice for the Labelling of Workplace Substances* [NOHSC: 2012(1994)].

### **Exemptions from label requirements in certain circumstances**

**13A.** (1) The labelling requirements of paragraphs 7 to 12 do not apply to a poison where an appropriate authority has granted a labelling exemption in whole or in part for these sections for a specified product; and

(2) the labelling exemption from an appropriate authority referred to in subparagraph (1) is limited to no more than 12 months from the effective date of the decision for retail supply of the product; and

(3) for the avoidance of doubt this paragraph does not apply to exemptions issued under subparagraph 7(1)(m)(ii)(B) of this Standard.

### **Dispensed medicines**

**14.** Unless otherwise specified by regulation:

(1) The labelling requirements of this Standard do not apply to a medicine that:

(a) is supplied by an authorised prescriber or other person authorised to supply and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(b) is supplied on and in accordance with a prescription written by an authorised prescriber and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard; or

(c) is prepared and supplied by a pharmacist for an individual patient and is labelled in accordance with the requirements of Appendix L Part 1 of this Standard.

(2) A person must not supply a dispensed medicine for human use containing:

(a) a poison listed in column 1 of the table at Appendix L Part 2 of this Standard unless it is clearly labelled with the warning statement(s) specified in column 2 of that table; or

(b) a poison listed in Appendix K unless it is clearly labelled with a sedation warning (being statement 39, 40 or 90 as specified in Appendix F Part 1 of this Standard).

### **Gas cylinders**

**15.** The requirements of subparagraphs 7(1)(a)(iv), 7(1)(c)(iv), and 7(1)(g)(iv) do not apply to a cylinder containing a poison that is a compressed gas.

### **Paints**

**16.** The requirements of paragraph 7 do not apply to:

(1) paint (other than a paint for therapeutic or cosmetic use) which:

(a) contains only Schedule 5 poisons; or

(b) is a First Schedule or Second Schedule paint that is labelled with:

(i) the word “WARNING”, written in bold-face sans serif capital letters, the height of which is not less than 5 mm, on the first line of the main label with no other words written on that line; and

(ii) the expression “KEEP OUT OF REACH OF CHILDREN”, written in bold-face sans serif capital letters, the height of which is not less than 2.5 mm, on a separate line immediately below the word “WARNING”; and

(iii) the appropriate warnings specified for the paint in Appendix F, written immediately below the expression “KEEP OUT OF REACH OF CHILDREN”; and

(iv) the name and proportion of the First Schedule or Second Schedule poisons it contains, provided that where the substance is a metal or metal salt the proportion is expressed as the metallic element present “calculated on the non-volatile content” or “in the dried film” of the paint; or

(2) a tinter which contains:

(a) only Schedule 5 poisons; or

(b) a poison included in the First Schedule or Second Schedule to Appendix I, provided that it is labelled with the name and proportion of that poison, and where the poison is a metal or metal salt, the proportion is expressed as the metallic element present as “calculated on the non-volatile content” or “in the dried film”.

### **Camphor and naphthalene**

**17.** The labelling requirements of subparagraph 3(4) and paragraph 7 do not apply to a device that contains camphor or naphthalene in block, ball, disc, pellet or flake form if the device:

(1) complies with paragraph 28; and

(2) is sold or supplied in a primary pack labelled in accordance with paragraphs 3 and 7.

### **Prohibitions**

**18**. A label used in connection with any poison must not include:

(1) any reference to this Standard, or any comment on, reference to, or explanation of any expression required by this Standard that directly or by implication contradicts, qualifies or modifies such expression; or

(2) any expression or device suggesting or implying that the poison is safe, harmless, non-toxic, non-poisonous, or is recommended or approved by the Government or any government authority unless required by legislation; or

(3) any expression or device which is false or misleading in any particular concerning the safety of the poison or any of its ingredients; or

(4) any trade name or description that:

(a) represents any single constituent of a compound preparation; or

(b) misrepresents the composition or any property or quality of the poison; or

(c) gives any false or misleading indication of origin or place of manufacture of the poison.

**19.** A label must not be attached to the immediate container or primary pack used in connection with any poison in such a manner as to obscure:

(1) any expression required by this Standard to be written or embossed on the container or pack; or

(2) any of the ribs or embossed or printed words required by paragraph 21, 22 or 23 as appropriate.

## CONTAINERS

**20.** A person must not sell or supply a poison unless the immediate container complies with the requirements of paragraphs 21 to 28 of this Standard.

## Containers for poisons other than Schedule 5 poisons

**21.** If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of 2 litres or less, the container must comply with Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances*.

**21a.** Notwithstanding subparagraph 21, a poison which is in Schedule 6 and is an essential oil may be packed in an amber glass container which does not comply with the tactile identification requirements of Australian Standard AS 2216-1997, entitled *Packaging for poisonous substances,* if:

(1) the other safety factors are not diminished; and

(2) the container has a restricted flow insert and a child-resistant closure.

**22**. If a poison, other than a Schedule 5 poison, is sold or supplied in a container with a nominal capacity of more than 2 litres, the container must:

(1) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*; and

(2) have the word “POISON”:

(a) in sans serif capital letters the height of which is at least one thirty second part of the length, height or width of the container, whichever is the greatest:

(i) embossed; or

(ii) indelibly written in a colour in distinct contrast to the background colour;

(b) on the side or shoulder of the container.

## Containers for Schedule 5 poisons

**23.** (1) The container in which any Schedule 5 poison is sold or supplied must:

(a) comply with the container requirements of paragraph 21 or paragraph 22; or

(b) be readily distinguishable from a container in which food, wine or other beverage is sold; and

(i) comply with subsection 1.4 (General Requirements) of Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances*, excluding paragraph 1.4.3;

(ii) be securely closed and, except when containing a preparation for use on one occasion only, be capable of being re-closed to prevent spillage of its contents; and

(iii) have the expression “POISON”, “NOT TO BE TAKEN” or “NOT TO BE USED AS A FOOD CONTAINER” embossed or indelibly written thereon, or printed on a permanent adhesive label designed to adhere to a substrate without lifting and which cannot be removed without damaging either the label or the substrate.

(2) Notwithstanding subparagraph 23(1), the following Schedule 5 poisons namely:

(a) methylated spirit(s);

(b) liquid hydrocarbons when packed as kerosene, lamp oil, mineral turpentine, thinners, reducers, white petroleum spirit or dry cleaning fluid;

(c) petrol;

(d) toluene; or

(e) xylene,

must not be sold or supplied in a bottle or jar having a nominal capacity of 2 litres or less, unless the immediate container complies with the container requirements specified in paragraph 21.

## Approved containers

**24.** Notwithstanding subparagraphs 21, 22 and 23 a poison may be packed in a container that does not comply with the tactile identification requirements of Australian Standard AS2216-1997 entitled *Packaging for poisonous substances* or the requirements of subparagraphs 22(2) or 23(1)(iii) if:

(1) the other safety factors are not diminished;

(2) the container is for a specific purpose; and

(3) an appropriate authority has approved the use of the container for that purpose.

## Child-resistant closures

**25.** (1) If a poison, other than a poison included in a therapeutic good packaged in a manner compliant with orders made under subsection 10(3) of the Commonwealth *Therapeutic Goods Act 1989*, listed in column 1 of the following table is sold or supplied in a container having a nominal capacity specified for that poison in column 2, it must be closed with a child-resistant closure.

**TABLE**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Name of the poison Nominal capacity**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Alkaline salts included in Schedule 5, All sizes  
when packed and labelled as dishwashing

machine tablets.

Alkaline salts included in Schedule 5, 5 litres /kilograms or less  
when packed and labelled as dishwashing

machine liquids, solids or gels.

Alkaline salts included in Schedule 5, when 2.5 litres or less

packed and labelled as a food additive.

Anise oil when included in Schedule 5. 200 millilitres or less

Basil oil when included in Schedule 5. 200 millilitres or less

Bay oil when included in Schedule 6. 200 millilitres or less

Cajuput oil when included in Schedule 6. 200 millilitres or less

Cassia oil when included in Schedule 5. 200 millilitres or less

Cineole when included in Schedule 6. 2 litres or less

Cinnamon bark oil when included 200 millilitres or less

in Schedule 5.

Cinnamon leaf oil when included in Schedule 6. 200 millilitres or less

Clove oil when included in Schedule 6. 200 millilitres or less

Essential oils when included in Schedule 6 200 millilitres or less

because of their natural camphor component.

Ethylene glycol when included in Schedule 6. 5 litres or less

Ethylene glycol when included in 5 litres or less

Schedule 5 in preparations containing

more than 50 per cent of ethylene glycol.

Eucalyptus oil when included in Schedule 6. 2 litres or less

Eugenol when included in Schedule 6. 200 millilitres or less

Hydrocarbons, liquid, when packed 5 litres or less

as kerosene, lamp oil, mineral turpentine,

thinners, reducers, white petroleum spirit

or dry cleaning fluid.

Hydrochloric acid when included in Schedule 6. 5 litres or less

*Leptospermum scoparium* oil (manuka oil) 200 millilitres or less

when included in Schedule 6

Marjoram oil when included in Schedule 5. 200 millilitres or less

Melaleuca oil (tea-tree oil) when included 200 millilitres or less

in Schedule 6.

Methylated spirit excluding preparations or 5 litres or less

admixtures.

Methyl salicylate and preparations containing 200 millilitres or less

more than 50 per cent of methyl salicylate.

Nutmeg oil when included in Schedule 5. 200 millilitres or less

Oil of turpentine. 5 litres or less

Pennyroyal oil when included in Schedule 6. 200 millilitres or less

Potassium hydroxide as such. 2.5 litres or less

Potassium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

d-Pulegone when included in Schedule 6. 200 millilitres or less

Sage oil (Dalmatian) when included 200 millilitres or less

in Schedule 6.

Sodium hydroxide as such. 2.5 litres or less

Sodium hydroxide in oven, hot plate or 5 litres or less

drain cleaners when included in Schedule 6

**except** when in pressurised spray packs.

Thujone when included in Schedule 6. 200 millilitres or less

Thyme oil when included in Schedule 5. 200 millilitres or less

(2) The manufacturer or packer of a poison must ensure that the child-resistant closure is appropriate for the container and the poison and that it retains its child-resistant properties for the expected life of the poison.

## Schedule 8 poisons

**25A.** (1) A person who supplies any Schedule 8 poison must ensure that the Schedule 8 poison is packaged in such a way that its primary pack is so sealed that, when the seal is broken, it is readily distinguishable from other sealed primary packs.

(2) This paragraph does not apply to the supply of a Schedule 8 poison by an:

(a) authorised prescriber or other authorised supplier;

(b) pharmacist on the prescription of an authorised prescriber;

(c) pharmacist employed at a hospital, on the written requisition of a medical practitioner, a dentist or the nurse or midwife in charge of the ward in which the Schedule 8 poison is to be used or stored; or

(d) nurse or midwife on the direction in writing of an authorised prescriber.

## Exemptions

**26.** (1) Paragraphs 21, 22 and 23 do not apply to the immediate container of a poison prepared, packed and sold:

(a) for human internal or animal internal use; or

(b) as a solid or semi-solid preparation for human external or animal external use; or

(c) as a paint, other than a paint for therapeutic or cosmetic use; or

(d) in containers having a nominal capacity of 15 millilitres or less; or

(e) for use in automatic photographic or photocopy processing machines if the container is specifically designed to fit into the machines; or

(f) solely for dispensary, industrial, laboratory or manufacturing purposes.

(2) Paragraph 25 does not apply to a poison prepared, packed and sold solely for dispensary, industrial, laboratory or manufacturing purposes.

**27**. The tactile identification or embossing required by paragraphs 21, 22 or 23 of this Standard or Australian Standard AS 2216-1997 entitled *Packaging for poisonous substances* do not apply to a container that is an aerosol container, a collapsible tube, or a measure pack which is a flexible sachet.

## Camphor and naphthalene

**28**. The container requirements of paragraph 21 do not apply to a device that contains only camphor or naphthalene in block, ball, disc, pellet or flake form for domestic use, if the device:

(1) in normal use, prevents removal or ingestion of its contents; and

(2) is incapable of reacting with the poison; and

(3) is sufficiently strong to withstand the ordinary risks of handling, storage or transport; and

(4) has the word “POISON” and the approved name of the poison embossed or indelibly printed on it.

## Prohibitions

**29.** A person must not sell or supply camphor or naphthalene in ball, block, disc, pellet or flake form for domestic use unless the balls, blocks, discs, pellets or flakes are enclosed in a device which prevents removal or ingestion of its contents.

**30**. A person must not sell or supply a poison in a container which has the name of another poison embossed or indelibly marked thereon.

**31**. A person must not sell any poison which is for internal use or any food, drink or condiment in a container prescribed by paragraph 21, 22 or 23 of this Standard.

**31A.** A person must not sell any poison in a container used expressly for any food, drink or condiment.

# **PART 3**

# **MISCELLANEOUS REGULATIONS**

(It is recommended that the States and Territories implement regulations which   
provide controls similar to those included in this Part of the Standard.)

## ADVERTISING

**32.** A person must not include any reference to a poison included in:

(a) Schedule 3 unless included in Appendix H; or

(b) Schedule 4 or Schedule 8,

of this Standard in any advertisement except in genuine professional or trade journals or other publications intended for circulation only within the medical, nursing, veterinary, dental or pharmaceutical professions or the wholesale drug industry.

**33.** A person must not include any reference to a poison included in Schedule 9 or Appendix C of this Standard in any advertisement.

## SALE OR SUPPLY

## Schedule 2 poisons

**34**. A person, other than a pharmacist (or an assistant under the direction of a pharmacist) or a medical, dental or veterinary practitioner in the lawful practice of their professions, must not sell or supply a Schedule 2 poison unless licensed to do so.

**35**. A person is not eligible to be granted a licence to sell a Schedule 2 poison by way of retail sale unless:

(1) he or she is carrying on the business of selling goods by retail; and

(2) the premises from which the poison will be sold is more than 25 kilometres by the shortest practical route from the nearest pharmacy; and

(3) he or she produces such evidence, as may be required, that he or she is a fit and proper person to be so licensed.

## Schedule 3 poisons

**36**. A person, other than a pharmacist, or a medical, dental or veterinary practitioner, in the lawful practice of his or her profession, must not sell or supply a Schedule 3 poison.

**37.** The person who sells or supplies a Schedule 3 poison must:

(1) provide adequate instructions for use, either written or verbal, at the time of supply or sale; and

(2) label the container with his or her name or the name of the pharmacy and the address from which it was sold or supplied; and

(3) if required by regulation, make a record of the transaction in a prescription book or other approved recording system.

## Schedule 4 poisons

**38**. A person, other than a medical, dental or veterinary practitioner in the ordinary course of their professions or a pharmacist dispensing a legal prescription must not sell or supply a Schedule 4 poison.

**39.** Paragraph 38 does not apply to a pharmacist who sells or supplies a Schedule 4 poison, other than a poison excepted by regulation from this provision, without a prescription if:

(1) the patient is under medical treatment with the poison and continuation of medication is essential; and

(2) the quantity sold or supplied does not exceed 3 days' medication; and

(3) the pharmacist is satisfied that an emergency exists.

**40.** Paragraphs 34, 36, 37 and 38 do not apply to sale by way of wholesale dealing to a pharmacist, medical practitioner, veterinary practitioner, dentist or a person licensed or otherwise authorised to possess, sell or supply such poisons.

## Schedule 7 poisons

**41.** (1) A person must not possess or use a Schedule 7 poison for domestic or domestic garden purposes.

(2) A person must not sell or supply:

(a) a Schedule 7 poison for domestic or domestic garden purposes; or

(b) a Schedule 7 poison being a liquid preparation containing paraquat unless it is coloured blue or green and contains sufficient stenching agent to produce an offensive smell; or

(c) a Schedule 7 poison for which an authorisation to possess or use is required by subparagraph (3) unless the purchaser produces his or her authorisation.

(3) A person must not possess or use any of the following Schedule 7 poisons unless he or she is authorised to do so by the appropriate authority:

Arsenic

Cyanides

Fluoroacetic acid

Fluoroacetamide

Hydrocyanic acid

Strychnine

Thallium.

(4) The appropriate authority may exempt a person or a class of persons from the requirement to hold an authorisation under subparagraph (3) and may vary or revoke the exemption by notice in writing.

## Prohibitions on sale, prescribing and possession

**42.** A person must not:

(1) knowingly have in his or her possession or sell, supply or use a poison listed in Appendix C of this Standard for the purpose or purposes indicated in relation to that poison in Appendix C; or

(2) sell or supply, other than by way of wholesale dealing, or prescribe a poison listed in Appendix D paragraphs 1, 2, 3 or 4 except in accordance with the provisions indicated for that poison in Appendix D; or

(3) knowingly have in his or her possession a poison listed in Appendix D paragraph 5 without authority.

## STORAGE

**43.** A person who sells or supplies Schedule 2 poisons must keep those poisons in such a way that public access to advice from a pharmacist is available if required.

**44**. A person who sells or supplies Schedule 3, Schedule 4 or Schedule 7 poisons must keep those poisons in a part of the premises to which the public does not have access.

# **PART 4**

# **THE SCHEDULES**

## SCHEDULE 1

This Schedule is intentionally blank.

## 

## SCHEDULE 2

(Substances marked † are listed in Appendix C)

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) for therapeutic use.

ACETYLCYSTEINE in preparations for oral use **except** when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACONITUM spp. for therapeutic use in adults:

(a) in preparations for oral use in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids; or

(b) in preparations for dermal use containing 0.02 per cent or less of total alkaloids, in packs each containing 0.2 mg or less of total alkaloids **except** in packs containing 0.02 mg or less of total alkaloids.

ALOXIPRIN.

AMETHOCAINE in preparations for topical use other than eye drops, containing 10 per cent or less of total local anaesthetic substances **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMOROLFINE in preparations for topical use **except** in preparations for the treatment of tinea pedis.

ANTAZOLINE in eye drops.

ASPIRIN **except**:

(a) when included in Schedule 4, 5 or 6;

(b) in individually wrapped powders or sachets of granules each containing 650 mg or less of aspirin as the only therapeutically active constituent other than an effervescent agent when:

(i) enclosed in a primary pack that contains 12 or less such powders or sachets of granules; and

(ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant closure;

(ii) in a primary pack of not more than 25 tablets or capsules, each containing 325  mg or less of aspirin, or in a primary pack of not more than 16 tablets or capsules, each containing 500 mg or less of aspirin; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in tablets or capsules each containing no other therapeutically active constituent other than an effervescent agent when:

(i) packed in blister or strip packaging or in a container with a child-resistant

closure;

(ii) in a primary pack containing 100 or less tablets or capsules, each containing 100 mg or less of aspirin when packed and labelled for the prevention of cardiovascular disease or for the inhibition of platelet aggregation; and

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ATROPA BELLADONNA (belladonna):

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit, when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ATROPINE (excluding atropine methonitrate) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

AZELAIC ACID in dermal preparations.

AZELASTINE:

(a) in preparations for nasal use ; or

(b) in topical eye preparations containing 0.05 per cent or less of azelastine.

BECLOMETHASONE in aqueous nasal sprays delivering 50 micrograms or less of beclomethasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

BENZOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZOYL PEROXIDE in preparations for human external therapeutic use containing 10 per cent or less of benzoyl peroxide **except** in preparations containing 5 per cent or less of benzoyl peroxide.

BENZYDAMINE in preparations for topical use, **except** in preparations for dermal use.

BEPHENIUM SALTS.

BIFONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(b) in preparations for the treatment of tinea pedis.

BROMHEXINE.

BROMPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing brompheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

BUDESONIDE in aqueous nasal sprays delivering 50 micrograms or less of budesonide per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

CARBETAPENTANE **except** in preparations containing 0.5 per cent or less of carbetapentane.

CARBOCISTEINE.

CETIRIZINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CHLOPHEDIANOL.

CHLORBUTOL for human use in topical preparations containing 5 per cent or less of chlorbutol **except** in preparations containing 0.5 per cent or less of chlorbutol.

CHLOROFORM in preparations for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 0.5 per cent or less of chloroform.

CHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing chlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

CICLOPIROX:

1. in preparations for dermal use containing 2 per cent or less of ciclopirox **except** in preparations for the treatment of tinea pedis; or
2. in preparations for application to the nails containing 8 per cent or less of ciclopirox.

CINCHOCAINE in preparations for topical use other than eye drops, containing 0.5 per cent or less of total local anaesthetic substances.

CINNAMEDRINE.

CLOTRIMAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

CODEINE in preparations for the treatment of coughs and colds when:

(a) not combined with any other opiate substance;

(b) compounded with one or more other therapeutically active substances, of which at least one is phenylephrine and not more than one is an analgesic substance:

(i) in divided preparations containing 10 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 60 mg of codeine; and

(d) in packs containing not more than 6 days' supply at the maximum dose recommended on the label.

CREOSOTE derived from wood other than beechwood for human therapeutic use, **except** in preparations containing 10 per cent or less of creosote derived from wood other than beechwood.

DATURA spp. for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids, or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** when separately specified in these Schedules.

DATURA STRAMONIUM (stramonium) for oral use when:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DATURA TATULA (stramonium) for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** for smoking or burning.

DELPHINIUM STAPHISAGRIA **except** in preparations containing 0.2 per cent or less of *Delphinium staphisagria*.

DESLORATADINE in preparations for oral use.

DEXCHLORPHENIRAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing dexchlorpheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DEXTROMETHORPHAN (excluding its stereoisomers) when supplied in a pack containing 600 mg or less of dextromethorphan and with a recommended daily dose of 120 mg or less of dextromethorphan.

DIBROMOPROPAMIDINE for ophthalmic use.

DICLOFENAC when:

1. in divided preparations for oral use containing 12.5 mg or less of diclofenac per dosage unit in a pack containing 20 or less dosage units and labelled with a recommended daily dose of 75 mg or less of diclofenac;
2. in preparations for dermal use containing 4 per cent or less of diclofenac **except** in preparations for dermal use containing 1 per cent or less of diclofenac or for the treatment of solar keratosis; or
3. in transdermal preparations for topical use containing 140 mg or less of diclofenac.

DIHYDROCODEINE when compounded with aspirin and no other therapeutically active substance in divided preparations:

(a) containing 5 mg or less of dihydrocodeine per dosage unit;

(b) packed in blister or strip packaging or in a container with a child-resistant closure;

(c) enclosed in primary packs containing 25 or less dosage units; and

(d) labelled with a recommended dose not exceeding 10 mg of dihydrocodeine.

DIMENHYDRINATE in primary packs of 10 doses or less for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

DIPHENHYDRAMINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing diphenhydramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DOXYLAMINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing doxylamine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

DUBOISIA LEICHHARDTII for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

DUBOISIA MYOPOROIDES for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

ECONAZOLE for human use in dermal preparations **except** in preparations for the treatment of tinea pedis.

ETAFEDRINE.

ETHER for therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 10 per cent or less of ether.

ETHYLMORPHINE when:

(a) compounded with one or more other therapeutically active substances:

(i) in divided preparations containing 10 mg or less of ethylmorphine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of ethylmorphine;

(b) labelled with a recommended dose not exceeding 15 mg of ethylmorphine.

ETOFENAMATE in preparations for external use.

FAMOTIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

FELBINAC in preparations for external use.

FEXOFENADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

1. in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and
2. labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FLUORIDES for human use:

(a) in preparations for ingestion containing 0.5 mg or less of fluoride ion per dosage unit; or

(b) in liquid preparations for topical use containing 1000 mg/kg or less of fluoride ion, in a container with a child-resistant closure:

(i) for therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels* **except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride when fitted with a child-resistant closure and compliant with the requirements of *Required Advisory Statements for Medicine Labels;* or

(ii) for non-therapeutic use when labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 220 mg/kg or less of fluoride ion, in packs containing not more than 120 mg total fluoride, when fitted with a child-resistant closure and labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less,

**except** in preparations containing 15 mg/kg or less of fluoride ion or preparations for supply to registered dental professionals or by approval of an appropriate authority.

FLURBIPROFEN in preparations for topical oral use when:

(a) in divided preparations containing 10 mg or less of flurbiprofen per dosage unit; or

(b) in undivided preparations containing 0.25 per cent or less, or 10 mg or less per dose, of flurbiprofen.

FLUTICASONE in aqueous nasal sprays delivering 50 micrograms or less of fluticasone per actuation when the maximum recommended daily dose is no greater than 400 micrograms and when packed in a primary pack containing 200 actuations or less, for the prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

FOLIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folic acid per recommended daily dose.

FOLINIC ACID for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 500 micrograms or less of folinic acid per recommended daily dose.

† FORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

GUAIPHENESIN in a modified release dosage form of 1200 mg or less of guaiphenesin with a recommended daily dose of 2400 mg or less when not labelled for the treatment of children under 12 years of age.

GELSEMIUM SEMPERVIRENS.

GLUTARALDEHYDE for human therapeutic use.

HEXACHLOROPHANE in preparations for human use containing 3 per cent or less of hexachlorophane **except**:

(a) in preparations containing 0.75 per cent or less of hexachlorophane; or

(b) in preparations for use on infants, as specified in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 0.5 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent **except** unscheduled astringents:

(i) in undivided preparations in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories.

HYDROQUINONE (excluding monobenzone and alkyl ethers of hydroquinone included in Schedule 4) in preparations for human external therapeutic or cosmetic use containing 2 per cent or less of hydroquinone **except**:

(a) in hair preparations containing 0.3 per cent or less of hydroquinone; or

(b) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

8-HYDROXYQUINOLINE and its non-halogenated derivatives for human therapeutic use, **except** in preparations for external use containing 1 per cent or less of such substances.

HYOSCINE (excluding hyoscine butylbromide):

(a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.

HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.

HYOSCYAMINE:

(a) for external use in preparations containing 0.03 per cent or less of total solanaceous alkaloids; or

(b) for oral use:

(i) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2  mg or less total solanaceous alkaloids.

HYOSCYAMUS NIGER for oral use:

(a) in undivided preparations containing 0.03 per cent or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

(b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids,

**except** in a pack containing 0.03 mg or less of total solanaceous alkaloids.

IBUPROFEN in preparations for oral use when labelled with a recommended daily dose of 1200 mg or less of ibuprofen:

(a) in liquid preparations when sold in the manufacturer’s original pack containing 8 grams or less of ibuprofen; or

(b) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units **except** when:

(i) as the only therapeutically active constituent (other than phenylephrine or when combined with an effervescent agent);

(ii) packed in blister or strip packaging or in a container with a child-resistant closure;

(iii) in a primary pack containing not more than 25 dosage units;

(iv) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(v) not labelled for the treatment of children 6 years of age or less; and

(vi) not labelled for the treatment of children under 12 years of age when combined with phenylephrine.

INDANAZOLINE.

INDOMETHACIN in preparations for external use containing 1 per cent or less of indomethacin.

IODINE:

(a) in preparations for human internal therapeutic use containing 300 micrograms or more of iodine per recommended daily dose; or

(b) in preparations for human external therapeutic use containing more than 2.5 per cent of available iodine (excluding salts, derivatives or iodophors),

**except** in oral preparations for use in prophylaxis and treatment in the event of radioactive iodine exposure under an emergency plan approved by an appropriate authority.

IPRATROPIUM in preparations for nasal use.

IRON COMPOUNDS (excluding iron oxides when present as an excipient, in divided preparations containing 10 mg or less of total iron oxides per dosage unit or in undivided preparations containing 1 per cent or less of total iron oxides) for human internal use **except**:

(a) when included in Schedule 4; or

(b) when labelled with a recommended daily dose of 24 mg or less of iron:

(i) in undivided preparations supplied in packs each containing 750 mg or less of iron; or

(ii) in divided preparations:

(A) containing more than 5 mg of iron per dosage unit in packs each containing 750 mg or less of iron; or

(B) containing 5 mg or less of iron per dosage unit.

ISOCONAZOLE for human use in dermal preparations.

ISOPROPAMIDE in preparations for dermal use containing 2 per cent or less of isopropamide.

KETOCONAZOLE in preparations for dermal use **except**:

(a) in preparations containing 1 per cent or less of ketoconazole for the treatment of the

scalp; or

(b) in preparations for the treatment of tinea pedis.

KETOTIFEN for ophthalmic use in preparations containing 0.025 per cent or less of ketotifen.

LEVOCABASTINE in topical eye or nasal preparations.

LIGNOCAINE in preparations for topical use other than eye drops:

(a) containing 10 per cent or less of total local anaesthetic substances, **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(b) in divided preparations containing 200 mg or less of total local anaesthetic substances per dosage unit, **except** in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

LINDANE in preparations for human external therapeutic use containing 2 per cent or less of lindane.

LITHIUM in preparations for dermal use containing 1 per cent or less of lithium **except**:

(a) when present as an excipient at 0.25 per cent or less of lithium; or

(b) in preparations containing 0.01 per cent or less of lithium.

LOBELIA INFLATA **except** for smoking or burning.

LOBELINE **except** in preparations for smoking or burning.

LODOXAMIDE in preparations for ophthalmic use.

LOPERAMIDE in divided preparations for oral use in packs of 20 dosage units or less **except** in preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LORATADINE in preparations for oral use **except** in divided preparations for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(a) in a primary pack containing 5 dosage units or less; and

(b) labelled with a recommended daily dose not exceeding 10 mg of loratadine.

MEBENDAZOLE for human therapeutic use.

MECLOZINE in primary packs containing 12 or less tablets or capsules of meclozine for the prevention or treatment of motion sickness, **except** in preparations for the treatment of children under 2 years of age.

MEFENAMIC ACID in divided preparations for oral use in packs of 30 or less dosage units for the treatment of dysmenorrhoea.

MEPYRAMINE for dermal use.

MERCUROCHROME in preparations for external use containing 2 per cent or less of mercurochrome **except** when included in Schedule 6.

MERCURY for external use in preparations containing 0.5 per cent or less of mercury.

METHOXAMINE in preparations for external use **except** in preparationscontaining 1 per cent or less of methoxamine.

METHOXYPHENAMINE.

METHYLEPHEDRINE.

MICONAZOLE for human use in dermal preparations and for application to the nails **except** in preparations for the treatment of tinea pedis.

MINOXIDIL in preparations for dermal use containing 5 per cent or less of minoxidil.

MOMETASONE in aqueous nasal sprays delivering 50 micrograms or less of mometasone per actuation when the maximum recommended daily dose is no greater than 200 micrograms for the prophylaxis or treatment of allergic rhinitis for up to six months in adults and children 12 years of age and over.

NAPHAZOLINE.

NAPROXEN in divided preparations containing 250 mg or less of naproxen per dosage unit in packs of 30 or less dosage units.

NICLOSAMIDE for human therapeutic use.

NIZATIDINE when sold in the manufacturer’s original pack containing not more than 14 days' supply.

NOSCAPINE.

NYSTATIN in dermal preparations.

OXETACAINE (oxethazaine) in preparations for internal use.

OXICONAZOLE for dermal use **except** in preparations for the treatment of tinea pedis.

OXYMETAZOLINE.

PAPAVERINE **except** when included in Schedule 4.

PARACETAMOL for therapeutic use **except:**

(a) when included in Schedule 4;

(b) in individually wrapped powders or sachets of granules each containing 1000 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:

(i) enclosed in a primary pack that contains not more than 10 such powders or sachets of granules;

(ii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iii) not labelled for the treatment of children 6 years of age or less; and

(iv) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin; or

(c) in tablets or capsules each containing 500 mg or less of paracetamol as the only therapeutically active constituent (other than phenylephrine and/or guaiphenesin or when combined with effervescent agents) when:

(i) packed in blister or strip packaging or in a container with a child-resistant closure;

(ii) in a primary pack containing not more than 20 tablets or capsules;

(iii) compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iv) not labelled for the treatment of children 6 years of age or less; and

(v) not labelled for the treatment of children under 12 years of age when combined with phenylephrine and/or guaiphenesin.

† PARAFORMALDEHYDE (excluding its derivatives) for human therapeutic use **except**:

(a) in oral hygiene preparations containing 0.1 per cent or less of free formaldehyde; or

(b) in other preparations containing 0.2 per cent or less of free formaldehyde.

PENCICLOVIR for external use for the treatment of herpes labialis.

PHEDRAZINE.

PHENAZONE for human external use.

PHENIRAMINE:

(a) in eye drops; or

(b) when combined with one or more other therapeutically active substances in oral preparations when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing pheniramine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PHENOL, or any homologue boiling below 220°C, for human therapeutic use **except**:

(a) when included in Schedule 4; or

(b) in preparations for external use containing 3 per cent or less of such substances.

PHENYLEPHRINE **except**:

(a) when included in Schedule 4;

(b) in oral preparations containing 50 mg or less of phenylephrine per recommended daily dose in packs containing 250 mg or less of phenylephrine; or

(c) in topical eye or nasal preparations containing 1 per cent or less of phenylephrine.

PHOLCODINE:

(a) in liquid preparations containing 0.5 per cent or less of pholcodine and with a recommended dose not exceeding 25 mg of pholcodine; or

(b) when compounded with one or more other therapeutically active substances in divided preparations containing 10 mg or less of pholcodine per dosage unit and with a recommended dose not exceeding 25 mg of pholcodine.

PIPERAZINE for human therapeutic use.

PODOPHYLLOTOXIN in preparations containing 0.5 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 10 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts.

POTASSIUM CHLORATE for therapeutic use **except** in preparations containing 10 per cent or less of potassium chlorate.

PRILOCAINE in preparations for dermal use containing 10 per cent or less of total local anaesthetic substances.

PROCYCLIDINE in preparations containing 5 per cent or less of procyclidine for dermal use.

PROMETHAZINE in oral preparations:

(a) in a primary pack containing 10 dosage units or less for the prevention or treatment of motion sickness; or

(b) when combined with one or more other therapeutically active substances when:

(i) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(ii) in a day-night pack containing promethazine in the bed-time dose where the day and night doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

PROPAMIDINE for ophthalmic use.

PYRANTEL for human therapeutic use.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids, for human therapeutic use in preparations containing more than 10 per cent of such substances.

PYRITHIONE ZINC for human therapeutic use, **except** in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

RANITIDINE in preparations supplied in the manufacturer’s original pack containing not more than 14 days' supply **except** in divided preparations for oral use containing 150 mg or less of ranitidine per dosage unit in the manufacturer’s original pack containing not more than 14 dosage units.

SALICYLAMIDE **except** when included in Schedule 4.

SELENIUM in preparations for human therapeutic use **except**:

(a) for topical use containing 3.5 per cent or less of selenium sulfide;

(b) when included in Schedule 4; or

(c) for oral use with a recommended daily dose of 150 micrograms or less.

SILVER for therapeutic use **except**:

(a) in solutions for human oral use containing 0.3 per cent or less of silver when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in other preparations containing 1 per cent or less of silver.

SODIUM CROMOGLYCATE in preparations for nasal or ophthalmic use.

SODIUM NITRITE for therapeutic use (excluding when present as an excipient).

SQUILL **except** in preparations containing 1 per cent or less of squill.

SULCONAZOLE in preparations for dermal use.

TERBINAFINE for dermal use **except** in preparations for the treatment of tinea pedis.

TETRACHLOROETHYLENE for human therapeutic use.

TETRAHYDROZOLINE.

THIABENDAZOLE for human therapeutic use.

TIOCONAZOLE in preparations for dermal use except in preparations for the treatment of tinea pedis.

TRAMAZOLINE.

TRIAMCINOLONE in aqueous nasal sprays delivering 55 micrograms or less of triamcinolone per actuation when the maximum recommended daily dose is no greater than 220 micrograms, for prophylaxis or treatment of allergic rhinitis for up to 6 months in adults and children 12 years of age and over.

TRIMEPRAZINE when combined with one or more other therapeutically active substances in solid oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing trimeprazine in the bed-time dose where the day and night doses

are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE when combined with one or more other therapeutically active substances in oral preparations when:

(a) at least one of the other therapeutically active substances is a sympathomimetic decongestant; or

(b) in a day-night pack containing triprolidine in the bed-time dose where the day and night

doses are in the same immediate container or immediate wrapper,

**except** in preparations for the treatment of children under 2 years of age.

TUAMINOHEPTANE.

TYMAZOLINE.

XYLOMETAZOLINE.

ZINC CHLORIDE for human dermal use **except** in preparations containing 5 per cent or less of zinc chloride.

## SCHEDULE 3

ADRENALINE in preparations containing 1 per cent or less of adrenaline **except** in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ALCLOMETASONE as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of alclometasone in packs containing 30 g or less of the preparation.

AMINOPHYLLINE in liquid oral preparations containing 2 per cent or less of aminophylline.

AZATADINE in oral preparations.

BROMPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

BUCLIZINE in oral preparations.

BUTOCONAZOLE in preparations for vaginal use.

CHLORAMPHENICOL for ophthalmic use only.

CHLORBUTOL in preparations for human use **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of chlorbutol.

CHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

CICLOPIROX in preparations for dermal use and for application to the nails **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

CIMETIDINE in a primary pack containing not more than 14 days' supply.

CLEMASTINE in preparations for oral use.

CLOBETASONE (clobetasone-17-butyrate) as the only therapeutically active substance in preparations for dermal use containing 0.05 per cent or less of clobetasone in packs containing 30 g or less of the preparation.

CLOTRIMAZOLE in preparations for vaginal use.

CODEINE when:

(a) not combined with any other opiate substance;

(b) compounded with one or more other therapeutically active substances, of which not more than one is an analgesic substance:

(i) in divided preparations containing 12 mg or less of codeine per dosage unit; or

(ii) in undivided preparations containing 0.25 per cent or less of codeine;

(c) labelled with a recommended daily dose not exceeding 100 mg of codeine; and

(d) in packs containing not more than 5 days' of supply at the maximum dose recommended on the label,

**except** when included in Schedule 2.

CYCLIZINE in preparations for oral use.

CYPROHEPTADINE in oral preparations.

DEXCHLORPHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DICLOFENAC in divided preparations for oral use containing 25 mg or less of diclofenac per dosage unit in a pack containing 30 or less dosage units **except** when included in Schedule 2.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 10 mg or less per dosage unit and with a recommended dose not exceeding 15 mg of dihydrocodeine; or

(b) in undivided preparations containing 0.25 per cent or less of dihydrocodeine with a recommended dose not exceeding 15 mg of dihydrocodeine,

**except** when included in Schedule 2.

DI-IODOHYDROXYQUINOLINE (iodoquinol) for vaginal use.

DIMENHYDRINATE in oral preparations **except** when included in Schedule 2.

DIMETHINDENE in oral preparations.

DIPHENHYDRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

DIPHENOXYLATE in packs of 8 or less dosage units, each dosage unit containing 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate.

DITHRANOL for therapeutic use.

DOXYLAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

ECONAZOLE in preparations for vaginal use.

ERYTHRITYL TETRANITRATE for therapeutic use.

FAMCICLOVIR for oral use, in divided preparations containing a total dose of 1500 mg or less of famciclovir for the treatment of herpes labialis (cold sores).

FLAVOXATE.

FLUCONAZOLE in single-dose oral preparations containing 150 mg or less of fluconazole for the treatment of vaginal candidiasis.

FLUORIDES for human topical use:

(a) in liquid preparations containing 5500 mg/kg or less of fluoride ion, in a container with a child-resistant closure **except** when included in or expressly excluded from Schedule 2; or

(b) in non-liquid preparations containing 5500 mg/kg or less of fluoride ion **except**:

(i) in preparations for therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in preparations for non-therapeutic use containing 1500 mg/kg or less of fluoride ion and, when containing more than 1000 mg/kg fluoride ion, labelled with warnings to the following effect:

(A) Do not swallow; and

(B) Do not use [this product/name of product] in children six years of age or less; or

(iii) in preparations for supply to registered dental professionals or by approval of an appropriate authority.

GLUCAGON.

GLYCERYL TRINITRATE:

(a) in preparations for oral use; or

(b) in preparations for rectal use.

GLYCOPYRRONIUM **except** when included in Schedule 4.

HYDROCORTISONE and HYDROCORTISONE ACETATE, but excluding other salts and derivatives, in preparations for human therapeutic use containing 1 per cent or less of hydrocortisone:

(a) for dermal use, in packs containing 30 g or less of such preparations, containing no other therapeutically active constituent other than an antifungal substance; or

(b) for rectal use when combined with a local anaesthetic substance but no other therapeutically active constituent except unscheduled astringents:

(i) in undivided preparations, in packs of 35 g or less; or

(ii) in packs containing 12 or less suppositories,

**except** when included in Schedule 2.

IBUPROFEN in divided preparations, each containing 400 mg or less of ibuprofen in a primary pack containing not more than 50 dosage units when labelled:

(a) with a recommended daily dose of 1200 mg or less of ibuprofen; and

(b) not for the treatment of children under 12 years of age,

**except** when included in or expressly excluded from Schedule 2.

INOSITOL NICOTINATE.

ISOCONAZOLE in preparations for vaginal use.

ISOSORBIDE DINITRATE in oral preparations containing 10 mg or less of isosorbide dinitrate per dosage unit.

KETOPROFEN in divided preparations for oral use containing 25 mg or less of ketoprofen per dosage unit in a pack containing 30 or less dosage units.

LANSOPRAZOLE in oral preparations containing 15 mg or less of lansoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

LEVONORGESTREL for emergency post-coital contraception.

MACROGOLS in preparations for oral use for bowel cleansing prior to diagnostic, medical or surgical procedures.

MAGNESIUM SULFATE for human therapeutic use in divided oral preparations **except** when containing 1.5 g or less of magnesium sulfate per recommended daily dose.

Malathion in preparations for human external use **except** in preparations containing 2 per cent or less of malathion.

MANNITYL HEXANITRATE for therapeutic use.

MEPYRAMINE in oral preparations.

METHDILAZINE in oral preparations.

METOCLOPRAMIDE when combined with paracetamol in divided preparations, packed and labelled only for the treatment of nausea associated with migraine, in packs containing not more than 10 dosage units.

MICONAZOLE for human use in topical preparations:

(a) for the treatment of oral candidiasis; or

(b) for vaginal use.

NICOTINIC ACID for human therapeutic use in divided preparations containing 250 mg or less of nicotinic acid per dosage unit **except**:

(a) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(b) nicotinamide.

NICOTINYL ALCOHOL **except** in preparations containing 100 mg or less of nicotinyl alcohol per dosage unit.

NYSTATIN in preparations for topical use **except** when included in Schedule 2.

OMEPRAZOLE in oral preparations containing 20 mg or less of omeprazole per dosage unit for the relief of heartburn and other gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

ORLISTAT in oral preparations for weight-control purposes containing 120 mg or less of orlistat per dosage unit.

OXICONAZOLE in preparations for vaginal use.

PANTOPRAZOLE in oral preparations containing 20 mg or less of pantoprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

PARACETAMOL when combined with ibuprofen in a primary pack containing 30 dosage units or less.

PHENIRAMINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

PODOPHYLLOTOXIN in preparations containing 1 per cent or less of podophyllotoxin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM EMODI (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PODOPHYLLUM PELTATUM (podophyllin) in preparations containing 20 per cent or less of podophyllin for human use for the treatment of warts other than anogenital warts **except** when included in Schedule 2.

PROCHLORPERAZINE in divided preparations for oral use in packs containing not more than 10 dosage units for the treatment of nausea associated with migraine.

PROMETHAZINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of children under 2 years of age.

PSEUDOEPHEDRINE (other than preparations for stimulant, appetite suppression or weight-control purposes) when supplied in a primary pack:

(a) in liquid preparations containing 800 mg or less of pseudoephedrine hydrochloride (or its equivalent); or

(b) in other preparations containing 720 mg or less of pseudoephedrine hydrochloride (or its equivalent).

RABEPRAZOLE in oral preparations containing 10 mg or less of rabeprazole per dosage unit for the relief of heartburn and other symptoms of gastro-oesophageal reflux disease, in packs containing not more than 14 days' supply.

SALBUTAMOL as the only therapeutically active substance:

(a) in metered aerosols delivering 100 micrograms or less of salbutamol per metered dose; or

(b) in dry powders for inhalation delivering 200 micrograms or less of salbutamol per dose.

SALICYLIC ACID in preparations for dermal use **except** in preparations containing 40 per cent or less of salicylic acid.

SANTONIN.

SODIUM PHOSPHATE in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures.

SODIUM PICOSULFATE in preparations for oral use for bowel cleansing prior to diagnostic medical or surgical procedures.

SULFACETAMIDE in preparations for ophthalmic use containing 10 per cent or less of sulfacetamide.

TERBUTALINE as the only therapeutically active substance:

(a) in metered aerosols delivering 250 micrograms or less of terbutaline per metered dose; or

(b) in dry powders for inhalation delivering 500 micrograms or less of terbutaline per dose.

THEOPHYLLINE in liquid oral preparations containing 2 per cent or less of theophylline.

TIOCONAZOLE in preparations for vaginal use.

TRIAMCINOLONE for buccal use in preparations containing 0.1 per cent or less of triamcinolone in a pack of 5 g or less.

TRIMEPRAZINE:

(a) in solid oral preparations **except** when included in Schedule 2; or

(b) in liquid oral preparations containing 10 mg or less of trimeprazine per 5 mL,

**except** in preparations for the treatment of children under 2 years of age.

TRIPROLIDINE in oral preparations **except**:

(a) when included in Schedule 2; or

(b) for the treatment of children under 2 years of age.

VITAMIN D for human internal therapeutic use in preparations containing 175 micrograms or less of vitamin D per recommended single weekly dose **except** in preparations containing 25 micrograms or less of vitamin D per recommended daily dose.

## SCHEDULE 4

(Substances marked † are listed in Appendix C)

(Substances marked # are listed in Appendix D)

ABACAVIR.

ABATACEPT.

ABIRATERONE ACETATE.

ABCIXIMAB.

ACAMPROSATE CALCIUM.

ACARBOSE.

ACEBUTOLOL.

ACEPROMAZINE.

ACETANILIDE and alkyl acetanilides (excluding when present as an excipient) for human therapeutic use.

ACETARSOL.

ACETAZOLAMIDE.

ACETOHEXAMIDE.

ACETYL ISOVALERYLTYLOSIN.

ACETYLCARBROMAL.

ACETYLCHOLINE.

ACETYLCYSTEINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for oral use when labelled with a recommended daily dose of 1 g or less of acetylcysteine.

ACETYLDIGITOXIN.

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE.

ACETYLSTROPHANTHIDIN.

ACICLOVIR **except** in preparations containing 5 per cent or less of aciclovir for the treatment of herpes labialis in packs containing 10 g or less.

ACIPIMOX.

# ACITRETIN.

ACLIDINIUM BROMIDE.

ACOKANTHERA OUABAIO.

ACOKANTHERA SCHIMPERI.

ACONITUM spp. **except**:

(a) when included in Schedule 2;

(b) in preparations for oral use in adults in packs containing 0.02 mg or less of total alkaloids; or

(c) in preparations for dermal use in adults containing 0.02 per cent or less of total alkaloids in packs containing 0.02 mg or less of total alkaloids.

ACRIVASTINE.

ADALIMUMAB.

ADAPALENE.

ADEFOVIR.

ADENOSINE for human therapeutic use in preparations for injection.

ADIPHENINE.

ADONIS VERNALIS.

ADRAFINIL.

ADRENALINE. **except**:

(a) when included in Schedule 3; or

(b) in preparations containing 0.02 per cent or less of adrenaline unless packed and labelled for injection.

ADRENOCORTICAL HORMONES **except** when separately specified in these Schedules.

AFAMELANOTIDE.

AFATINIB DIMALEATE.

AFLIBERCEPT.

AGALSIDASE.

AGLEPRISTONE.

AGOMELATINE.

ALATROFLOXACIN MESYLATE.

ALBENDAZOLE **except**:

(a) when included in Schedule 5 or 6; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole for the treatment of animals.

ALCLOFENAC.

ALCLOMETASONE **except** when included in Schedule 3.

ALCURONIUM.

ALDESLEUKIN.

ALDOSTERONE.

# ALEFACEPT.

ALEMTUZUMAB.

ALENDRONIC ACID.

ALFACALCIDOL.

ALFUZOSIN.

ALGLUCERASE.

ALGLUCOSIDASE.

ALISKIREN.

ALLERGENS.

ALLOPURINOL.

ALLYLOESTRENOL.

ALOGLIPTIN.

ALOSETRON.

ALPHA1-PROTEINASE INHIBITOR (HUMAN).

ALPHADOLONE.

ALPHAXALONE.

ALPRENOLOL.

ALPROSTADIL.

ALSEROXYLON.

ALTEPLASE.

ALTRENOGEST.

ALTRETAMINE (hexamethylmelamine).

AMANTADINE.

AMBENONIUM CHLORIDE.

# AMBRISENTAN.

AMBUCETAMIDE.

AMBUTONIUM BROMIDE.

AMCINONIDE.

AMETHOCAINE **except**:

(a) when included in Schedule 2; or

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

AMIFOSTINE.

AMIKACIN.

AMILORIDE.

AMINOCAPROIC ACID.

AMINOGLUTETHIMIDE.

5-AMINOLEVULINIC ACID.

AMINOMETRADINE.

† AMINOPHENAZONE (amidopyrine) and derivatives for the treatment of animals.

AMINOPHYLLINE **except** when included in Schedule 3.

AMINOPTERIN.

4-AMINOPYRIDINE for therapeutic use.

AMINOREX.

AMINOSALICYLIC ACID.

AMIODARONE.

AMIPHENAZOLE.

AMISOMETRADINE.

AMISULPRIDE.

AMITRIPTYLINE.

AMLODIPINE.

AMMI VISNAGA.

AMMONIUM BROMIDE for therapeutic use.

AMODIAQUINE.

AMOROLFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for the treatment of tinea pedis.

AMOXAPINE.

AMOXYCILLIN.

AMPHOMYCIN.

AMPHOTERICIN.

AMPICILLIN.

AMPRENAVIR.

AMRINONE.

AMSACRINE.

AMYL NITRITE.

AMYLOBARBITONE when packed and labelled for injection.

AMYLOCAINE.

# ANABOLIC STEROIDAL AGENTS.

ANAGRELIDE.

ANAKINRA.

ANASTROZOLE.

ANCESTIM.

ANCROD and its immunoglobulin antidote.

ANECORTAVE.

# ANDROGENIC STEROIDAL AGENTS.

# ANDROISOXAZOLE.

# ANDROSTANOLONE.

# ANDROSTENEDIOL.

# ANDROSTENEDIONE.

ANGIOTENSIN AMIDE.

ANIDULAFUNGIN.

ANISTREPLASE.

ANTAZOLINE **except** when included in Schedule 2.

ANTIBIOTIC SUBSTANCES **except**:

(a) when separately specified in these Schedules; or

(b) nisin.

ANTIGENS for human therapeutic use **except** when separately specified in this Schedule.

ANTIHISTAMINES **except**:

(a) when included in Schedule 2 or 3; or

(b) when separately specified in this Schedule.

ANTIMONY for therapeutic use **except** when separately specified in these Schedules.

ANTISERA (immunosera) for human use by injection **except** when separately specified in these Schedules.

APIXABAN.

APOCYNUM spp.

APOMORPHINE.

APRACLONIDINE.

APRAMYCIN.

APREPITANT.

APRONAL.

APROTININ.

ARECOLINE.

ARIPIPRAZOLE.

ARSENIC for human therapeutic use **except** when separately specified in these Schedules.

ARTEMETHER.

ARTICAINE.

ASENAPINE.

ASPIRIN:

(a) when combined with caffeine, paracetamol or salicylamide or any derivative of these substances; or

(b) for injection.

ASTEMIZOLE.

# ATAMESTANE.

ATAZANAVIR.

ATENOLOL.

ATIPAMEZOLE.

ATOMOXETINE.

ATORVASTATIN.

ATOSIBAN.

ATOVAQUONE.

ATRACURIUM BESYLATE.

ATROPA BELLADONNA (belladonna) **except** when included in Schedule 2.

ATROPINE **except** when included in Schedule 2.

ATROPINE METHONITRATE.

AURANOFIN.

AUROTHIOMALATE SODIUM.

AVILAMYCIN **except**:

(a) in animal feed premixes containing 15 per cent or less of avilamycin activity; or

(b) in animal feeds containing 50 mg/kg or less of avilamycin activity.

AVIPTADIL.

AXITINIB.

AVOPARCIN.

AZACITIDINE.

AZACYCLONOL.

AZAPERONE.

AZAPROPAZONE.

AZARIBINE.

AZATADINE **except** when included in Schedule 3.

AZATHIOPRINE.

AZELAIC ACID **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 1 per cent or less of azelaic acid for non-human use.

AZELASTINE **except** when included in Schedule 2.

AZITHROMYCIN.

AZLOCILLIN.

AZTREONAM.

BACAMPICILLIN.

BACITRACIN.

BACLOFEN.

BALSALAZIDE.

BAMBERMYCIN (flavophospholipol) **except**:

(a) when included in Schedule 6; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

BAMBUTEROL.

BAMETHAN.

BAMIPINE.

BARBITURATES **except** when separately specified in these Schedules.

BASILIXIMAB.

BAZEDOXIFENE.

BECAPLERMIN.

BECLAMIDE.

BECLOMETHASONE **except** when included in Schedule 2.

BELATACEPT.

BELIMUMAB.

BEMEGRIDE.

BENACTYZINE.

BENAZEPRIL.

BENDROFLUAZIDE.

BENETHAMINE PENICILLIN.

BENORYLATE.

BENOXAPROFEN.

BENPERIDOL.

BENSERAZIDE.

BENZATHINE PENICILLIN.

BENZHEXOL.

BENZILONIUM.

BENZOCAINE **except**:

(a) when included in Schedule 2;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances; or

(c) in lozenges containing 30 mg or less of total local anaesthetic substances per dosage unit.

BENZODIAZEPINE derivatives **except** when separately specified in these Schedules.

BENZOYL PEROXIDE in preparations for human therapeutic use **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 5 per cent or less of benzoyl peroxide.

BENZPHETAMINE.

BENZTHIAZIDE.

BENZTROPINE (benzatropine).

BENZYDAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use.

BENZYLPENICILLIN.

BEPRIDIL.

BERACTANT.

BESIFLOXACINE.

BETAHISTINE.

BETAMETHASONE.

BETAXOLOL.

BETHANECHOL CHLORIDE.

BETHANIDINE.

BEVACIZUMAB.

BEVANTOLOL.

# BEXAROTENE.

BEZAFIBRATE.

BICALUTAMIDE.

BIFONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of bifonazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

BIMATOPROST.

BIPERIDEN.

BISMUTH COMPOUNDS for cosmetic use, **except**:

(a) bismuth citrate when incorporated in hair colourant preparations in concentrations of 0.5 per or less; or

(b) bismuth oxychloride.

BISMUTH COMPOUNDS for human therapeutic use, **except** bismuth formic iodide or bismuth subiodide in dusting powders containing 3 per cent or less of bismuth.

BISOPROLOL.

BIVALIRUDIN.

BLEOMYCIN.

BOCEPREVIR.

# BOLANDIOL.

# BOLASTERONE.

# BOLAZINE.

# BOLDENONE (dehydrotestosterone).

# BOLENOL.

# BOLMANTALATE.

BORON, including boric acid and borax, for human therapeutic use **except**:

(a) in preparations for internal use containing 6 mg or less of boron per recommended daily dose;

(b) in preparations for dermal use containing 0.35 per cent or less of boron, which are not for paediatric or antifungal use; or

(c) when present as an excipient.

BORTEZOMIB.

# BOSENTAN.

BOTULINUM TOXINS for human use **except** when separately specified in these Schedules.

BRETYLIUM TOSYLATE.

BRIMONIDINE.

BRINZOLAMIDE.

BROMAZEPAM.

BROMIDES, inorganic, for therapeutic use **except** when separately specified in

these Schedules.

BROMOCRIPTINE.

BROMOFORM for therapeutic use.

BROMPHENIRAMINE **except** when included in Schedule 2 or 3.

BROMVALETONE.

BRUGMANSIA spp.

BUCLIZINE **except** when included in Schedule 3.

BUDESONIDE **except** when included in Schedule 2.

BUFEXAMAC **except**:

(a) in preparations for dermal use containing 5 per cent or less of bufexamac; or

(b) in suppositories.

BUMETANIDE.

BUPHENINE.

BUPIVACAINE **except** when included in Schedule 5.

BUPROPION.

BUSERELIN.

BUSPIRONE.

BUSULPHAN.

BUTACAINE.

BUTOCONAZOLE **except** when included in Schedule 3.

BUTRACONAZOLE.

BUTYL AMINOBENZOATE **except** in dermal preparations containing 2 per cent or less of total local anaesthetic substances.

BUTYLCHLORAL HYDRATE.

BUTYL NITRITE.

CABAZITAXEL.

CABERGOLINE.

CADMIUM COMPOUNDS for human therapeutic use.

CALCIPOTRIOL.

CALCITONIN.

CALCITRIOL.

CALCIUM CARBIMIDE for therapeutic use.

CALCIUM POLYSTYRENE SULPHONATE.

CALOTROPIS GIGANTEA.

CALOTROPIS PROCERA.

# CALUSTERONE.

CAMPHORATED OIL for therapeutic use.

CAMPHOTAMIDE.

CANAGLIFLOZIN.

CANAKINUMAB.

CANDESARTAN CILEXETIL.

CANDICIDIN.

CANINE TICK ANTI-SERUM.

CANTHARIDIN.

CAPECITABINE.

CAPREOMYCIN.

CAPTODIAME.

CAPTOPRIL.

CAPURIDE.

CARAMIPHEN.

CARBACHOL.

CARBAMAZEPINE.

CARBARYL for human therapeutic use.

CARBAZOCHROME.

CARBENICILLIN.

CARBENOXOLONE for internal use.

CARBETOCIN.

CARBIDOPA.

CARBIMAZOLE.

CARBOCROMEN.

CARBOPLATIN.

CARBOPROST.

CARBROMAL.

CARBUTAMIDE.

CARBUTEROL.

CARINDACILLIN.

CARISOPRODOL.

CARMUSTINE.

CARNIDAZOLE.

CARPROFEN.

CARVEDILOL.

CASPOFUNGIN.

CATHINE.

CATUMAXOMAB.

CEFACETRILE.

CEFACLOR.

CEFADROXIL.

CEFALORIDINE.

CEFAMANDOLE.

CEFAPIRIN.

CEFAZOLIN.

CEFEPIME.

CEFETAMET.

CEFIXIME.

CEFODIZIME.

CEFONICID.

CEFOPERAZONE.

CEFOTAXIME.

CEFOTETAN.

CEFOTIAM.

CEFOVECIN for veterinary use.

CEFOXITIN.

CEFPIROME.

CEFPODOXIME.

CEFQUINOME.

CEFTAROLINE FOSAMIL.

CEFSULODIN.

CEFTAZIDIME.

CEFTIBUTEN.

CEFTIOFUR.

CEFTRIAXONE.

CEFUROXIME.

CELECOXIB.

CELIPROLOL.

CEPHAELIS ACUMINATA (ipecacuanha) **except** in preparations containing 0.2 per cent or less of emetine.

CEPHAELIS IPECACUANHA **except** in preparations containing 0.2 per cent or less of emetine.

CEPHALEXIN.

CEPHALONIUM.

CEPHALOTHIN.

CEPHRADINE.

CERIVASTATIN.

CERTOLIZUMAB PEGOL.

CERULETIDE.

CETIRIZINE **except**

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 10 mg of cetirizine.

CETRORELIX.

CETUXIMAB.

CHENODEOXYCHOLIC ACID.

CHLORAL FORMAMIDE.

CHLORAL HYDRATE **except** in preparations for topical use containing 2 per cent or less of chloral hydrate.

CHLORALOSE **except** when included in Schedule 6.

CHLORAMBUCIL.

CHLORAMPHENICOL **except** when included in Schedule 3.

# CHLORANDROSTENOLONE.

CHLORAZANIL.

CHLORCYCLIZINE.

CHLORDIAZEPOXIDE.

CHLORMERODRIN.

CHLORMETHIAZOLE.

CHLORMEZANONE.

CHLOROFORM for use in anaesthesia.

# 4-CHLOROMETHANDIENONE.

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE.

CHLOROQUINE.

CHLOROTHIAZIDE.

CHLOROTRIANISENE.

# CHLOROXYDIENONE.

CHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

CHLORPHENTERMINE.

CHLORPROMAZINE.

CHLORPROPAMIDE.

CHLORPROTHIXENE.

CHLORQUINALDOL for human topical use.

CHLORTETRACYCLINE **except** when included in Schedule 5.

CHLORTHALIDONE.

CHLORZOXAZONE.

CHOLERA VACCINE.

CHOLESTYRAMINE (colestyramine) for human therapeutic use.

CHYMOPAPAIN for human therapeutic use.

CICLACILLIN.

CICLESONIDE.

CICLOPIROX **except**:

1. when included in Schedule 2 or 3; or
2. in preparations for the treatment of tinea pedis.

CIDOFOVIR.

CILASTATIN.

CILAZAPRIL.

CILOSTAZOL.

CIMETIDINE **except** when included in Schedule 3.

CINACALCET.

CINCHOCAINE **except** when included in Schedule 2.

CINOXACIN.

CIPROFLOXACIN.

CISAPRIDE.

CISATRACURIUM BESYLATE.

CISPLATIN.

CITALOPRAM.

CLADRIBINE.

CLANOBUTIN.

CLARITHROMYCIN.

CLAVULANIC ACID.

CLEMASTINE **except** when included in Schedule 3.

CLEMIZOLE.

CLENBUTEROL.

CLEVIDIPINE.

CLIDINIUM BROMIDE.

CLINDAMYCIN.

† CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human topical use **except** when separately specified in this Schedule.

CLOBAZAM.

CLOBETASOL.

CLOBETASONE (clobetasone-17-butyrate) **except** when included in Schedule 3.

CLOCORTOLONE.

CLODRONIC ACID (includes sodium clodronate).

CLOFARABINE.

CLOFAZIMINE.

CLOFENAMIDE.

CLOFIBRATE.

# CLOMIPHENE.

CLOMIPRAMINE.

CLOMOCYCLINE.

CLONAZEPAM.

CLONIDINE.

CLOPAMIDE.

CLOPIDOGREL.

CLOPROSTENOL.

CLORAZEPATE.

CLOREXOLONE.

CLORPRENALINE.

# CLOSTEBOL (4-chlorotestosterone).

CLOTRIMAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

CLOXACILLIN.

# CLOZAPINE.

COBALT for human therapeutic use **except** as dicobalt edetate in preparations for the treatment of cyanide poisoning.

COBICISTAT.

CODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing 30 mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1 per cent or less of codeine,

**except** when included in Schedule 2 or 3.

CO-DERGOCRINE.

COLASPASE.

COLCHICINE.

COLCHICUM AUTUMNALE.

COLESTIPOL.

COLFOSCERIL PALMITATE for human therapeutic use.

COLISTIN.

COLLAGEN in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

CONVALLARIA KEISKI.

CONVALLARIA MAJALIS.

COPPER COMPOUNDS for human use **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose; or

(c) in other preparations containing 5 per cent or less of copper compounds.

# CORIFOLLITROPIN ALFA.

CORONILLA spp.

CORTICOSTERONE.

CORTICOTROPHIN.

CORTISONE.

CO-TRIMOXAZOLE.

COUMARIN for therapeutic use (excluding when present as an excipient).

CRIZOTINIB.

CROFELEMER.

CRYSTAL VIOLET for human use **except** when used as a dermal marker.

CUPRIMYXIN.

CURARE.

CYCLANDELATE.

CYCLIZINE **except** when included in Schedule 3.

CYCLOBENZAPRINE.

# CYCLOFENIL.

CYCLOHEXIMIDE.

CYCLOPENTHIAZIDE.

CYCLOPENTOLATE.

CYCLOPHOSPHAMIDE.

CYCLOPROPANE for therapeutic use.

CYCLOSERINE.

CYCLOSPORIN.

CYCLOTHIAZIDE.

CYCRIMINE.

CYMARIN.

CYPROHEPTADINE **except** when included in Schedule 3.

CYPROTERONE.

CYSTEAMINE for human therapeutic use.

CYTARABINE.

DABIGATRAN.

DABRAFENIB MESILATE.

DACARBAZINE.

DACLIZUMAB.

DACTINOMYCIN.

DALFOPRISTIN.

DALTEPARIN (includes dalteparin sodium).

DANAPAROID (includes danaparoid sodium).

# DANAZOL.

DANTHRON for human use.

DANTROLENE.

DAPAGLIFLOZIN.

DAPOXETINE.

DAPSONE.

DAPTOMYCIN.

# DARBEPOETIN.

DARIFENACIN.

DARUNAVIR.

DATURA spp. **except**:

(a) when included in Schedule 2; or

(b) when separately specified in this Schedule.

DASATINIB.

DATURA STRAMONIUM (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DATURA TATULA (stramonium) **except**:

(a) when included in Schedule 2; or

(b) for smoking or burning.

DAUNORUBICIN.

DEANOL.

DEBRISOQUINE.

DECAMETHONIUM.

DEFERASIROX.

DEFERIPRONE.

DEFLAZACORT.

DEGARELIX.

# DEHYDROCHLOROMETHYLTESTOSTERONE.

DEHYDROCORTICOSTERONE.

DELAVIRDINE (includes delavirdine mesylate).

DEMBREXINE **except** when included in Schedule 5.

DEMECARIUM.

DEMECLOCYCLINE.

DENOSUMAB.

DEOXYCORTONE.

DEOXYRIBONUCLEASE **except**:

(a) when separately specified in this Schedule; or

(b) for external use.

DERACOXIB.

DESFERRIOXAMINE.

DESFLURANE.

DESIPRAMINE.

DESIRUDIN.

DESLANOSIDE.

DESLORATADINE **except** when included in Schedule 2.

DESLORELIN.

DESMOPRESSIN (D.D.A.V.P.).

DESOGESTREL.

DESONIDE.

DESOXYMETHASONE.

DESVENLAFAXINE.

DETOMIDINE.

DEXAMETHASONE.

DEXCHLORPHENIRAMINE **except** when included in Schedule 2 or 3.

DEXFENFLURAMINE.

DEXMEDETOMIDINE.

DEXTROMETHORPHAN (excluding its stereoisomers) **except** when included in Schedule 2.

# DEXTROPROPOXYPHENE:

(a) in divided preparations containing 135 mg of dextropropoxyphene or less per dosage unit; or

(b) liquid preparations containing 2.5 per cent or less of dextropropoxyphene.

DEXTRORPHAN (excluding its stereoisomers).

DIAMTHAZOLE.

DIAVERIDINE.

DIAZEPAM.

DIAZOXIDE.

DIBENZEPIN.

DIBOTERMIN.

DIBROMOPROPAMIDINE for therapeutic use except when included in Schedule 2.

DICHLORALPHENAZONE.

DICHLOROPHEN for human therapeutic use.

DICHLORPHENAMIDE.

DICLOFENAC **except:**

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use unless:

(i) for the treatment of solar keratosis; or

(ii) containing more than 4 per cent of diclofenac.

DICLOXACILLIN.

DICYCLOMINE.

DIDANOSINE.

DIENESTROL.

DIENOGEST.

DIETHAZINE.

DIETHYLCARBAMAZINE for human therapeutic use.

DIETHYLPROPION.

DIFENOXIN in preparations containing, per dosage unit, 0.5 mg or less of difenoxin and a quantity of atropine sulfate equivalent to at least 5 per cent of the dose of difenoxin.

DIFLORASONE.

DIFLOXACIN.

DIFLUCORTOLONE.

DIFLUNISAL.

DIGITALIS LANATA.

DIGITALIS PURPUREA.

DIGITOXIN.

DIGOXIN.

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F (Ab).

DIHYDRALAZINE.

DIHYDROCODEINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of dihydrocodeine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of dihydrocodeine,

**except** when included in Schedule 2 or 3.

DIHYDROERGOTOXINE.

# DIHYDROLONE.

DIHYDROSTREPTOMYCIN.

DIHYDROTACHYSTEROL.

† DI-IODOHYDROXYQUINOLINE (iodoquinol) **except**:

(a) when included in Schedule 3; or

(b) for human internal use.

DIISOPROPYLAMINE DICHLOROACETATE.

DILTIAZEM.

DIMENHYDRINATE **except** when included in Schedule 2 or 3.

DIMERCAPROL.

# DIMETHANDROSTANOLONE.

# DIMETHAZINE.

DIMETHINDENE **except** when included in Schedule 3.

DIMETHOTHIAZINE.

DIMETHOXANATE.

DIMETHYL FUMARATE.

DIMETHYL SULFOXIDE (excluding dimethyl sulfone) for therapeutic use **except**:

(a) when included in Schedule 6; or

(b) in *in vitro* test kits.

DIMETRIDAZOLE.

2,4-DINITROCHLOROBENZENE for therapeutic use.

DINITROCRESOLS for therapeutic use **except** when separately specified in these Schedules.

DINITRONAPHTHOLS for therapeutic use **except** when separately specified in these Schedules.

DINITROPHENOLS for therapeutic use.

DINITROTHYMOLS for therapeutic use **except** when separately specified in these Schedules.

# DINOPROST.

# DINOPROSTONE.

DIPERODON.

DIPHEMANIL **except** in preparations for dermal use.

DIPHENHYDRAMINE **except** when included in Schedule 2 or 3.

DIPHENIDOL.

DIPHENOXYLATE in preparations containing, per dosage unit, 2.5 mg or less of diphenoxylate and a quantity of atropine sulfate equivalent to at least 1 per cent of the dose of diphenoxylate **except** when included in Schedule 3.

DIPHENYLPYRALINE.

DIPHTHERIA TOXOID.

DIPIVEFRIN.

DIPYRIDAMOLE.

DIRITHROMYCIN.

DIRLOTAPIDE.

DISOPHENOL.

DISOPYRAMIDE.

DISTIGMINE.

DISULFIRAM for therapeutic use.

DISULPHAMIDE.

DITHIAZANINE **except** when included in Schedule 6.

DITIOCARB.

DOBUTAMINE.

DOCETAXEL.

DOFETILIDE.

DOLASETRON.

DOLUTEGRAVIR.

DOMPERIDONE.

DONEPEZIL.

DOPAMINE.

DOPEXAMINE.

DORIPENEM.

DORNASE.

DORZOLAMIDE.

DOTHIEPIN.

DOXANTRAZOLE.

DOXAPRAM.

DOXAZOSIN.

DOXEPIN.

DOXORUBICIN.

DOXYCYCLINE.

DOXYLAMINE **except** when included in Schedule 2 or 3.

DRONEDARONE.

DROPERIDOL.

DROSPIRENONE.

# DROSTANOLONE.

DROTRECOGIN.

DUBOISIA LEICHHARDTII **except** when included in Schedule 2.

DUBOISIA MYOPOROIDES **except** when included in Schedule 2.

DULOXETINE.

DUTASTERIDE.

DYDROGESTERONE.

ECONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

ECOTHIOPATE (includes ecothiopate iodide).

ECTYLUREA.

ECULIZUMAB.

EDETIC ACID for human therapeutic use **except**:

(a) in preparations containing 0.25 per cent or less of edetic acid;

(b) as dicobalt edetate in preparations for the treatment of cyanide poisoning; or

(c) in contact lens preparations.

EDOXUDINE.

EDROPHONIUM.

EFALIZUMAB.

EFAVIRENZ.

EFLORNITHINE.

EFORMOTEROL.

ELETRIPTAN.

ELTENAC.

ELTROMBOPAG.

ELVITEGRAVIR.

EMEPRONIUM.

EMETINE **except** in preparations containing 0.2 per cent or less of emetine.

EMTRICITABINE.

ENALAPRIL.

# ENESTEBOL.

ENFLURANE for therapeutic use.

ENFUVIRTIDE.

# ENOBOSARM.

ENOXACIN.

ENOXAPARIN.

ENOXIMONE.

ENPROSTIL.

ENROFLOXACIN.

ENTACAPONE.

ENTECAVIR.

EPHEDRA spp. **except** in preparations containing 0.001 per cent or less of ephedrine.

# EPHEDRINE.

EPICILLIN.

EPINASTINE.

EPIRUBICIN.

# EPITIOSTANOL.

EPLERENONE.

# EPOETINS.

EPOPROSTENOL.

EPROSARTAN.

EPTIFIBATIDE.

ERGOMETRINE.

ERGOT.

ERGOTAMINE.

ERGOTOXINE.

ERIBULIN MESYLATE.

ERLOTINIB.

ERTAPENEM.

ERYSIMUM spp.

ERYTHROMYCIN.

# ERYTHROPOIETIN.

# ERYTHROPOIETINS **except** when separately specified in these Schedules.

ESCITALOPRAM.

ESMOLOL.

ESOMEPRAZOLE.

ESTRAMUSTINE.

ESTROPIPATE (piperazine oestrone sulfate).

ETANERCEPT.

ETHACRYNIC ACID.

ETHAMBUTOL.

ETHAMIVAN.

ETHANOLAMINE in preparations for injection.

ETHCHLORVYNOL.

ETHER for use in anaesthesia.

ETHINAMATE.

ETHINYLOESTRADIOL.

ETHIONAMIDE.

ETHISTERONE.

ETHOGLUCID.

ETHOHEPTAZINE.

ETHOPROPAZINE.

ETHOSUXIMIDE.

ETHOTOIN.

ETHOXZOLAMIDE.

ETHYL CHLORIDE for human therapeutic use.

# ETHYLDIENOLONE.

† ETHYLHEXANEDIOL for animal use.

ETHYLMORPHINE when compounded with one or more other therapeutically active substances:

(a) in divided preparations containing not more than 100 mg of ethylmorphine per dosage unit; or

(b) in undivided preparations with a concentration of not more than 2.5 per cent of ethylmorphine;

**except** when included in Schedule 2.

# ETHYLOESTRENOL.

ETHYNODIOL.

ETIDOCAINE.

ETIDRONIC ACID (includes disodium etidronate):

(a) for internal use; or

(b) in topical preparations **except** in preparations containing 1 per cent or less of etidronic acid.

ETILEFRIN.

ETIPROSTON.

ETODOLAC.

ETOFENAMATE **except** when included in Schedule 2.

ETONOGESTREL.

ETOPOSIDE.

ETORICOXIB.

ETRAVIRINE.

# ETRETINATE.

EVEROLIMUS.

EXEMESTANE.

EXENATIDE.

EZETIMIBE.

FAMCICLOVIR **except** when included in Schedule 3.

FAMOTIDINE **except** when included in Schedule 2.

FELBINAC **except** when included in Schedule 2.

FELODIPINE.

FELYPRESSIN.

FENBUFEN.

FENCAMFAMIN.

FENCLOFENAC.

FENFLURAMINE.

FENOFIBRATE.

FENOLDOPAM.

FENOPROFEN.

FENOTEROL.

FENPIPRAMIDE.

FENPIPRANE.

FENPROPOREX.

FENPROSTALENE.

FEXOFENADINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

(i) in a primary pack containing 10 dosage units or less and not more than 5 days’ supply; and

(ii) labelled with a recommended daily dose not exceeding 120 mg of fexofenadine.

FIBRINOLYSIN **except** for external use.

FIDAXOMICIN.

FILGRASTIM.

FINASTERIDE.

FINGOLIMOD.

FIROCOXIB.

FLECAINIDE.

FLEROXACIN.

FLOCTAFENINE.

FLORFENICOL.

FLUANISONE.

FLUCLOROLONE.

FLUCLOXACILLIN.

FLUCONAZOLE **except** when included in Schedule 3.

FLUCYTOSINE.

FLUDARABINE.

FLUDROCORTISONE.

FLUFENAMIC ACID.

FLUMAZENIL.

FLUMETHASONE.

FLUMETHIAZIDE.

FLUNISOLIDE.

FLUNIXIN MEGLUMINE.

FLUOCINOLONE.

FLUOCINONIDE.

FLUOCORTIN.

FLUOCORTOLONE.

FLUORESCEIN in preparations for injection.

FLUORIDES in preparations for human use **except** when included in or expressly excluded from Schedule 2 or 3.

FLUOROMETHOLONE.

FLUOROURACIL.

FLUOXETINE.

# FLUOXYMESTERONE.

FLUPENTHIXOL.

FLUPHENAZINE.

FLUPROSTENOL.

FLURANDRENOLONE.

FLURAZEPAM.

FLURBIPROFEN **except** when included in Schedule 2.

FLUROXENE for human therapeutic use.

FLUSPIRILENE.

FLUTAMIDE.

FLUTICASONE **except** when included in Schedule 2.

FLUVASTATIN.

FLUVOXAMINE.

FOLIC ACID in preparations for human use for injection.

FOLINIC ACID in preparations for human use for injection.

FOLLICLE-STIMULATING HORMONE **except** when separately specified in this Schedule.

# FOLLISTATIN.

# FOLLITROPIN ALPHA.

# FOLLITROPIN BETA.

FOMIVIRSEN.

FONDAPARINUX.

# FORMEBOLONE.

FORMESTANE.

FOSAMPRENAVIR.

FOSAPREPITANT.

FOSCARNET.

FOSFESTROL (diethylstilboestrol diphosphate).

FOSINOPRIL.

FOSPHENYTOIN.

FOTEMUSTINE.

FRAMYCETIN.

FULVESTRANT.

FURALTADONE.

# FURAZABOL.

FURAZOLIDONE.

FUROSEMIDE (frusemide).

FUSIDIC ACID.

GABAPENTIN.

GALANTAMINE.

GALANTHUS spp.

GALLAMINE.

GALSULFASE.

GANCICLOVIR.

GANIRELIX.

GATIFLOXACIN.

GEFITINIB.

GEMCITABINE.

GEMEPROST.

GEMFIBROZIL.

GEMIFLOXACIN.

GEMTUZUMAB OZOGAMICIN.

GENTAMICIN.

GESTODENE.

GESTONORONE.

GESTRINONE.

GHRH INJECTABLE PLASMID.

GITALIN.

GLATIRAMER ACETATE.

GLIBENCLAMIDE.

GLIBORNURIDE.

GLICLAZIDE.

GLIMEPIRIDE.

GLIPIZIDE.

GLISOXEPIDE.

GLUTATHIONE for parenteral use.

# GLUTETHIMIDE.

GLYCERYL TRINITRATE **except** when included in Schedule 3.

GLYCOPYRRONIUM in preparations for injection.

GLYMIDINE.

GnRH VACCINE.

GOLIMUMAB.

GONADORELIN.

GONADOTROPHIC HORMONES **except** when separately specified in this Schedule.

GOSERELIN.

GRAMICIDIN.

GRANISETRON.

GREPAFLOXACIN.

GRISEOFULVIN.

GUAIPHENESIN for human therapeutic use **except**:

(a) when included in Schedule 2;

(b) in oral liquid preparations containing 2 per cent or less of guaiphenesin; or

(c) in divided preparations containing 200 mg or less of guaiphenesin per dosage unit.

GUANABENZ.

GUANACLINE.

GUANETHIDINE.

GUANIDINE for therapeutic use.

HACHIMYCIN.

HAEMATIN.

HAEMOPHILUS INFLUENZAE VACCINE.

HALCINONIDE.

HALOFANTRINE.

HALOFENATE.

HALOFUGINONE in preparations containing 0.1 per cent or less of halofuginone for the treatment of animals.

HALOPERIDOL.

HALOTHANE for therapeutic use.

HEMEROCALLIS (*Hemerocallis flava*).

HEPARINS for internal use **except** when separately specified in this Schedule.

HEPATITIS A VACCINE.

HEPATITIS B VACCINE.

HETACILLIN.

HEXACHLOROPHANE:

(a) in preparations for use on infants; or

(b) in other preparations **except**:

(i) when included in Schedule 2 or 6; or

(ii) in preparations containing 0.75 per cent or less of hexachlorophane.

HEXAMETHONIUM.

HEXETIDINE for human internal use.

HEXOBENDINE.

HEXOCYCLIUM.

HEXOPRENALINE.

HISTAMINE for therapeutic use **except** in preparations containing 0.5 per cent or less of histamine.

HMG-CoA REDUCTASE INHIBITORS (including "statins") **except** when separately specified in these Schedules.

HOMATROPINE.

HUMAN CHORIONIC GONADATROPHIN **except** in pregnancy test kits.

HUMAN PAPILLOMAVIRUS VACCINE.

HYALURONIC ACID AND ITS POLYMERS in preparations for injection or implantation:

(a) for tissue augmentation;

(b) for cosmetic use; or

(c) for the treatment of animals.

HYDRALAZINE.

HYDRARGAPHEN.

HYDROCHLOROTHIAZIDE.

HYDROCORTISONE:

(a) for human use **except** when included in Schedule 2 or 3; or

(b) for the treatment of animals.

HYDROCYANIC ACID for therapeutic use.

HYDROFLUMETHIAZIDE.

HYDROQUINONE (other than its alkyl ethers separately specified in this Schedule) in preparations for human therapeutic or cosmetic use **except**:

(a) when included in Schedule 2; or

(b) in hair preparations containing 0.3 per cent or less of hydroquinone; or

(c) in cosmetic nail preparations containing 0.02 per cent or less of hydroquinone.

HYDROXYCHLOROQUINE.

HYDROXYEPHEDRINE.

HYDROXYPHENAMATE.

HYDROXYPROGESTERONE.

# HYDROXYSTENOZOL.

HYDROXYUREA.

HYDROXYZINE.

HYGROMYCIN.

HYOSCINE **except** when included in Schedule 2.

HYOSCYAMINE **except** when included in Schedule 2.

HYOSCYAMUS NIGER **except**:

(a) when included in Schedule 2; or

(b) in a pack containing 0.03 mg or less of total solanaceous alkaloids.

HYPOTHALAMIC RELEASING FACTORS **except** when separately specified in this Schedule.

HYPROMELLOSE in preparations for injection.

IBAFLOXACIN for veterinary use.

IBANDRONIC ACID.

IBOGAINE.

IBRITUMOMAB.

IBUFENAC.

IBUPROFEN **except**:

(a) when included in or expressly excluded from Schedule 2 or 3; or

(b) in preparations for dermal use.

IBUTEROL.

IBUTILIDE.

ICATIBANT.

IDARUBICIN.

IDOXURIDINE **except** in preparations containing 0.5 per cent or less of idoxuridine for dermal use.

IDURSULFASE.

IFOSFAMIDE.

ILOPROST.

IMATINIB.

IMIDAPRIL.

IMIGLUCERASE.

IMIPENIM.

IMIPRAMINE.

IMIQUIMOD.

IMMUNOGLOBULINS for human parenteral use **except** when separately specified in these Schedules.

INDACATEROL.

INDAPAMIDE.

INDINAVIR.

INDOMETHACIN **except** when included in Schedule 2.

INDOPROFEN.

INDORAMIN**.**

INFLIXIMAB.

INFLUENZA AND CORYZA VACCINES:

(a) for parenteral use; or

(b) for nasal administration.

INGENOL MEBUTATE.

# INSULIN-LIKE GROWTH FACTOR I.

# INSULIN-LIKE GROWTH FACTORS **except** when separately specified in this Schedule.

INSULINS.

INTERFERONS.

INTERLEUKINS **except** when separately specified in these Schedules.

IODOTHIOURACIL.

IPILIMUMAB.

IPRATROPIUM **except** when included in Schedule 2.

IPRIFLAVONE.

IPRINDOLE.

IPRONIAZID.

IRBESARTAN.

IRINOTECAN.

IRON COMPOUNDS in injectable preparations for human use.

ISOAMINILE.

ISOAMYL NITRITE.

ISOBUTYL NITRITE.

ISOCARBOXAZID.

ISOCONAZOLE **except** when included in Schedule 2, 3 or 6.

ISOETARINE.

ISOFLURANE for therapeutic use.

ISOMETHEPTENE.

ISONIAZID.

ISOPRENALINE.

ISOPRINOSINE.

ISOPROPAMIDE **except** when included in Schedule 2.

ISOSORBIDE DINITRATE **except** when included in Schedule 3.

ISOSORBIDE MONONITRATE.

# ISOTRETINOIN.

ISOXICAM.

ISOXSUPRINE.

ISRADIPINE.

ITRACONAZOLE.

IVABRADINE.

IVACAFTOR.

IVERMECTIN:

(a) for human use; or

(b) for the treatment of mange in dogs.

IXABEPILONE.

JAPANESE ENCEPHALITIS VACCINE.

KANAMYCIN.

KETANSERIN **except** in topical veterinary preparations containing 0.5 per cent or less of ketanserin.

KETAZOLAM.

KETOCONAZOLE **except**:

(a) when included in Schedule 2;

(b) in preparations for dermal use containing 1 per cent or less of ketoconazole for the treatment of the scalp; or

(c) in preparations for dermal use for the treatment of tinea pedis.

KETOPROFEN **except**:

(a) in preparations for dermal use; or

(b) when included in Schedule 3.

KETOROLAC (includes ketoralac trometamol).

KETOTIFEN **except** when included in Schedule 2.

KHELLIN.

KITASAMYCIN **except**:

(a) when included in Schedule 5 ; or

(b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.

LABETALOL.

LACIDIPINE.

LACOSAMIDE.

LAMIVUDINE.

LAMOTRIGINE.

LANATOSIDES.

LANREOTIDE.

LANSOPRAZOLE **except** when included in Schedule 3.

LANTHANUM for therapeutic use.

LAPATINIB.

LARONIDASE.

LAROPIPRANT.

LATAMOXEF.

LATANOPROST.

LAUDEXIUM.

LAUROMACROGOLS in preparations for injection **except**:

(a) when present as an excipient; or

(b) when separately specified in these Schedules.

† LEAD for human therapeutic use.

LEFETAMINE.

LEFLUNOMIDE.

# LENALIDOMIDE.

LENOGRASTIM.

LEPIRUDIN.

LEPTAZOL.

LERCANIDIPINE.

LETROZOLE.

LEUPRORELIN.

LEVALLORPHAN.

LEVAMISOLE:

(a) for human therapeutic use; or

(b) in preparations for the prevention or treatment of heartworm in dogs.

LEVETIRACETAM.

LEVOBUNOLOL.

LEVOBUPIVACAINE.

LEVOCABASTINE **except** when included in Schedule 2.

LEVODOPA.

LEVOMEPROMAZINE.

LEVONORGESTREL **except** when included in Schedule 3.

LEVOSIMENDAN.

LIDOFLAZINE.

LIGNOCAINE **except**:

(a) when included in Schedules 2 or 5;

(b) in dermal preparations containing 2 per cent or less of total local anaesthetic substances per dosage unit; or

(c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit

LINAGLIPTIN.

LINCOMYCIN.

LINDANE for human therapeutic use **except** when included in Schedule 2.

LINEZOLID.

LIOTHYRONINE.

LIRAGLUTIDE.

LISINOPRIL.

LISURIDE.

LITHIUM for therapeutic use **except**:

(a) when included in Schedule 2;

(b) when present as an excipient in preparations for dermal use containing 0.25 per cent or less of lithium; or

(c) in preparations containing 0.01 per cent or less of lithium.

LIXISENATIDE.

LODOXAMIDE **except** when included in Schedule 2.

LOFEXIDINE.

LOGIPARIN for internal use.

LOMEFLOXACIN.

LOMUSTINE.

LOPERAMIDE **except:**

(a)when included in Schedule 2 ; or

(b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.

LOPINAVIR.

LOPRAZOLAM.

LORACARBEF.

LORATADINE **except**:

1. when included in Schedule 2; or
2. in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:
3. in a primary pack containing 5 dosage units or less; and
4. labelled with a recommended daily dose not exceeding 10 mg of loratadine.

LORAZEPAM.

LORMETAZEPAM.

LOSARTAN.

LOTEPREDNOL. LOXAPINE.

LUMEFANTRINE.

LUMIRACOXIB.

LURASIDONE.

# LUTEINISING HORMONE **except** in ovulation test kits.

LYMECYCLINE.

MAFENIDE **except** when included in Schedule 6.

MANDRAGORA OFFICINARUM.

MANNOMUSTINE.

MAPROTILINE.

MARAVIROC.

MARBOFLOXACIN.

MAROPITANT.

MAVACOXIB.

MAZINDOL.

MEASLES VACCINE.

MEBANAZINE.

MEBEVERINE.

MEBHYDROLIN.

# MEBOLAZINE.

MEBUTAMATE.

MECAMYLAMINE.

MECASERMIN.

MECILLINAM.

MECLOCYCLINE.

MECLOFENAMATE.

MECLOFENOXATE.

MECLOZINE **except** when included in Schedule 2.

MEDAZEPAM.

MEDETOMIDINE.

MEDIGOXIN (methyldigoxin).

MEDROXYPROGESTERONE.

MEDRYSONE.

MEFENAMIC ACID **except** when included in Schedule 2.

MEFENOREX.

MEFLOQUINE.

MEFRUSIDE.

MEGESTROL.

MELAGATRAN.

MELATONIN for human use.

MELENGESTROL **except** when included in Schedule 6.

MELOXICAM.

MELPHALAN.

MEMANTINE.

MENINGOCOCCAL VACCINE.

MENOTROPHIN.

MEPACRINE.

MEPENZOLATE.

MEPHENESIN.

MEPHENTERMINE.

MEPINDOLOL.

# MEPITIOSTANE.

MEPIVACAINE.

MEPROBAMATE.

MEPTAZINOL.

MEPYRAMINE **except** when included in Schedule 2 or 3.

MEQUITAZINE.

MERCAPTOMERIN.

MERCAPTOPURINE.

MERCUROCHROME **except** when included in Schedule 2 or 6.

MERCURY for cosmetic or therapeutic use **except**:

(a) when separately specified in these Schedules; or

(b) in a sealed device which prevents access to the mercury.

MEROPENEM.

MERSALYL.

# MESABOLONE.

MESALAZINE.

MESNA.

# MESTANOLONE (androstalone).

# MESTEROLONE.

MESTRANOL.

# METANDIENONE.

METARAMINOL.

# METENOLONE.

METERGOLINE.

METFORMIN.

METHACHOLINE.

METHACYCLINE.

METHALLENOESTRIL.

# METHANDRIOL.

METHANTHELINIUM.

METHAZOLAMIDE.

METHDILAZINE **except** when included in Schedule 3.

# METHENOLONE.

METHICILLIN.

METHIMAZOLE.

METHISAZONE.

METHIXENE.

METHOCARBAMOL.

METHOHEXITONE.

METHOIN.

METHOTREXATE.

METHOXAMINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for external use containing 1 per cent or less of methoxamine.

METHOXSALEN.

METHOXYFLURANE.

METHSUXIMIDE.

METHYCLOTHIAZIDE.

METHYL AMINOLEVULINATE.

#METHYLANDROSTANOLONE.

# METHYLCLOSTEBOL.

METHYLDOPA.

METHYLENE BLUE in preparations for injection.

METHYLERGOMETRINE.

METHYL MERCURY for therapeutic use.

METHYLNALTREXONE.

METHYLPENTYNOL.

METHYLPHENOBARBITONE.

METHYLPREDNISOLONE.

METHYL SALICYLATE in preparations for internal therapeutic use.

# METHYLTESTOSTERONE.

METHYLTHIOURACIL.

# METHYLTRIENOLONE.

METHYPRYLONE.

METHYSERGIDE.

METOCLOPRAMIDE **except** when included in Schedule 3.

METOLAZONE.

METOPROLOL.

# METRIBOLONE.

METRIFONATE (trichlorfon) for human therapeutic use.

METRONIDAZOLE.

METYRAPONE.

MEXILETINE.

MEZLOCILLIN.

MIANSERIN.

MIBEFRADIL.

# MIBOLERONE.

MICAFUNGIN.

MICONAZOLE **except**:

(a) when included in Schedule 2, 3 or 6; or

(b) in preparations for dermal use for the treatment of tinea pedis.

MIDAZOLAM.

MIDODRINE.

MIFEPRISTONE.

MIGLITOL.

MIGLUSTAT.

MILBEMYCIN OXIME **except** when included in Schedule 5.

MILRINONE.

MINOCYCLINE.

MINOXIDIL **except** when included in Schedule 2.

MIRABEGRON.

MIRTAZAPINE.

MISOPROSTOL.

MITOBRONITOL.

MITOMYCIN.

MITOTANE.

MITOXANTRONE.

MITRATAPIDE.

MIVACURIUM CHLORIDE.

MOCLOBEMIDE.

MODAFINIL.

MOLGRAMOSTIM.

MOLINDONE.

MOMETASONE **except** when included in Schedule 2.

MONENSIN **except**:

(a) when included in Schedule 5 or 6; or

(b) in animal feeds containing 360 mg/kg or less of antibiotic substances.

MONOBENZONE and alkyl ethers of hydroquinone for human therapeutic use or cosmetic use **except** in cosmetic nail preparations containing 0.02 per cent or less of monobenzone or alkyl ethers of hydroquinone.

MONOCLONAL ANTIBODIES for therapeutic use **except**:

(a) in diagnostic test kits; or

(b) when separately specified in these Schedules.

MONTELUKAST.

MOPERONE.

MORAZONE.

MORICIZINE.

MOTRAZEPAM.

MOTRETINIDE.

MOXIDECTIN in preparations for injection containing 10 per cent or less of moxidectin **except** when included in Schedule 5.

MOXIFLOXACIN.

MOXONIDINE.

MUMPS VACCINE.

MUPIROCIN.

MURAGLITAZAR.

MUROMONAB.

MUSTINE (nitrogen mustard).

MYCOPHENOLIC ACID (includes mycophenolate mofetil).

NABUMETONE.

NADOLOL.

NADROPARIN.

NAFARELIN.

NAFTIDROFURYL.

NALBUPHINE.

NALIDIXIC ACID.

NALORPHINE.

NALOXONE.

NALTREXONE.

# NANDROLONE.

NAPROXEN **except** when included in Schedule 2.

NARASIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 100 mg/kg or less of antibiotic substances.

NARATRIPTAN.

NATALIZUMAB.

NATAMYCIN **except** for use as a food additive.

NATEGLINIDE.

NEBACUMAB.

NEBIVOLOL.

NEDOCROMIL.

NEFAZODONE.

NEFOPAM.

NELFINAVIR (includes nelfinavir mesylate).

NEOMYCIN.

NEOSTIGMINE.

NEPAFENAC.

NERIUM OLEANDER.

NESIRITIDE.

NETILMICIN.

NEVIRAPINE.

NIALAMIDE.

NICARDIPINE.

NICERGOLINE.

NICOFURANOSE.

NICORANDIL.

NICOTINE in preparations for human therapeutic use except for use as an aid in withdrawal from tobacco smoking in preparations for oromucosal or transdermal use.

NICOTINIC ACID for human therapeutic use **except**:

(a) when separately specified in these Schedules;

(b) in preparations containing 100 mg or less of nicotinic acid per dosage unit; or

(c) nicotinamide.

NICOUMALONE.

NIFEDIPINE.

NIFENAZONE.

NIKETHAMIDE.

NILOTINIB.

NILUTAMIDE.

NIMESULIDE.

NIMODIPINE.

NIMORAZOLE.

NIRIDAZOLE.

NISOLDIPINE.

NITISINONE.

NITRAZEPAM.

NITRENDIPINE.

NITRIC OXIDE for human therapeutic use.

NITROFURANTOIN.

NITROFURAZONE.

NITROUS OXIDE for therapeutic use.

NITROXOLINE.

NIZATIDINE **except** when included in Schedule 2.

NOMEGESTROL.

NOMIFENSINE.

NORADRENALINE.

# 19-NORANDROSTENEDIOL.

# 19-NORANDROSTENEDIONE.

# NORANDROSTENOLONE.

# NORBOLETHONE.

# NORCLOSTEBOL.

NORELGESTROMIN.

# NORETHANDROLONE.

NORETHISTERONE.

NORFLOXACIN.

NORGESTREL.

NORIBOGAINE.

# NORMETHANDRONE.

NORTRIPTYLINE.

NOVOBIOCIN.

NOXIPTYLINE.

NYSTATIN **except** when included in Schedule 2 or 3.

OCRIPLASMIN.

OCTAMYLAMINE.

OCTATROPINE.

OCTREOTIDE.

OCTYL NITRITE.

OESTRADIOL **except** when included in Schedule 5.

OESTRIOL.

OESTROGENS **except** when separately specified in these Schedules.

OESTRONE.

OFATUMUMAB.

OFLOXACIN.

OLANZAPINE.

OLEANDOMYCIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds for growth promotion containing 50 mg/kg or less of antibiotic substances.

OLEANDRIN.

OLMESARTAN.

OLODATEROL.

OLOPATADINE.

OLSALAZINE.

OMALIZUMAB.

OMEGA-3-ACID ETHYL ESTERS (excluding salts and derivatives) for human therapeutic use, for the treatment of post-myocardial infarction and/or hypertriglyceridaemia.

OMEPRAZOLE **except** when included in Schedule 3.

ONDANSETRON.

OPIPRAMOL.

ORBIFLOXACIN.

ORCIPRENALINE.

ORGANOPHOSPHORUS COMPOUNDS with anticholinesterase activity for human therapeutic use except:

(a) when separately specified in these Schedules; or

(b) in preparations containing 2 per cent or less of malathion for external use.

ORLISTAT **except** when included in Schedule 3.

ORNIDAZOLE.

ORNIPRESSIN.

ORPHENADRINE.

ORTHOPTERIN.

OSELTAMIVIR.

OUABAIN.

# OVANDROTONE.

# OXABOLONE.

OXACILLIN.

OXALIPLATIN.

# OXANDROLONE.

OXAPROZIN.

OXAZEPAM.

OXCARBAZEPINE.

OXEDRINE for human internal use **except** in preparations labelled with a recommended daily dose of 30 mg or less of oxedrine.

OXETACAINE (oxethazaine) **except** when included in Schedule 2.

OXICONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for the treatment of tinea pedis.

OXITROPIUM.

OXOLAMINE.

OXOLINIC ACID.

OXPENTIFYLLINE (pentoxifylline).

OXPRENOLOL.

OXYBUPROCAINE.

OXYBUTYNIN.

# OXYMESTERONE.

# OXYMETHOLONE.

OXYPHENBUTAZONE.

OXYPHENCYCLIMINE.

OXYPHENONIUM.

OXYTETRACYCLINE **except** when included in Schedule 5.

OXYTOCIN.

PACLITAXEL.

PALIFERMIN.

PALIPERIDONE.

PALIVIZUMAB.

PALONOSETRON.

PAMAQUIN.

PAMIDRONIC ACID (includes disodium pamidronate).

PANCREATIC ENZYMES **except**:

(a) in preparations containing 20,000 BP units or less of lipase activity per dosage unit; or

(b) when separately specified in these Schedules.

PANCURONIUM.

PANITUMUMAB.

PANTOPRAZOLE **except** when included in Schedule 3.

PAPAVERINE in preparations for injection.

PARACETAMOL:

(a) when combined with aspirin or salicylamide or any derivative of these substances **except** when separately specified in these Schedules;

(b) when combined with ibuprofen in a primary pack containing more than 30 dosage units;

(c) in slow release tablets or capsules containing more than 665 mg of paracetamol;

(d) in non-slow release tablets or capsules containing more than 500 mg of paracetamol;

(e) in individually wrapped powders or sachets of granules each containing more than 1000 mg of paracetamol; or

(f) for injection.

PARALDEHYDE.

PARAMETHADIONE.

PARAMETHASONE.

PARECOXIB.

PARICALCITOL.

PAROMOMYCIN.

PAROXETINE.

PASIREOTIDE.

PASIREOTIDE.

PAZOPANIB.

PECAZINE.

PEFLOXACIN.

PEGAPTANIB.

PEGFILGRASTIM.

PEGINTERFERON.

PEGVISOMANT.

PEMETREXED.

PEMOLINE.

PEMPIDINE.

PENBUTOLOL.

PENCICLOVIR **except** when included in Schedule 2.

PENETHAMATE.

PENICILLAMINE.

PENTAERYTHRITYL TETRANITRATE.

PENTAGASTRIN.

PENTAMETHONIUM.

PENTAMIDINE (includes pentamidine isethionate).

PENTHIENATE.

PENTOBARBITONE when packed and labelled for injection.

PENTOLINIUM.

PENTOSAN POLYSULFATE SODIUM.

PERGOLIDE.

PERHEXILINE.

PERICYAZINE.

PERINDOPRIL.

PERMETHRIN for human therapeutic use **except** in preparations containing 5 per cent or less of permethrin.

PERPHENAZINE.

PERTUSSIS ANTIGEN.

PERTUZUMAB.

PHENACEMIDE.

PHENACETIN for therapeutic use (excluding when present as an excipient).

PHENAGLYCODOL.

PHENAZONE **except** when included in Schedule 2 or 5.

PHENAZOPYRIDINE.

PHENELZINE.

PHENETICILLIN.

PHENFORMIN.

PHENGLUTARIMIDE.

PHENINDIONE.

PHENIRAMINE **except** when included in Schedule 2 or 3.

PHENISATIN.

PHENOBARBITONE.

PHENOL in preparations for injection.

PHENOLPHTHALEIN for human therapeutic use.

PHENOXYBENZAMINE.

PHENOXYMETHYLPENICILLIN.

PHENSUXIMIDE.

# PHENTERMINE.

PHENTHIMENTONIUM.

PHENTOLAMINE.

PHENYLBUTAZONE.

PHENYLEPHRINE:

(a) in preparations for injection; or

(b) in preparations for human ophthalmic use containing 5 per cent or more of phenylephrine.

PHENYLPROPANOLAMINE.

PHENYLTOLOXAMINE.

PHENYTOIN.

PHOLCODINE:

(a) in divided preparations containing 100 mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5 per cent or less of pholcodine,

**except** when included in Schedule 2.

PHOSPHODIESTERASE TYPE 5 INHIBITORS **except**:

(a) when separately specified in these Schedules; or

(b) when present as an unmodified, naturally occurring substance.

PHTHALYLSULFATHIAZOLE.

PHYSOSTIGMINE.

PICROTOXIN.

PILOCARPINE **except** in preparations containing 0.025 per cent or less of pilocarpine.

PIMECROLIMUS.

PIMOBENDAN.

PIMOZIDE.

PINACIDIL.

PINDOLOL.

PIOGLITAZONE.

PIPECURONIUM.

PIPEMIDIC ACID.

PIPENZOLATE.

PIPER METHYSTICUM (kava) in preparations for human use **except** when included on the Australian Register of Therapeutic Goods in preparations:

(a) for oral use when present in tablet, capsule or teabag form that is labelled with a recommended maximum daily dose of 250 mg or less of kavalactones and:

(i) the tablet or capsule form contains 125 mg or less of kavalactones per tablet

or capsule; or

(ii) the amount of dried whole or peeled rhizome in the teabag does not exceed 3 g;

and, where containing more than 25 mg of kavalactones per dose, compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in topical preparations for use on the rectum, vagina or throat containing dried whole or peeled rhizome or containing aqueous dispersions or aqueous extracts of whole or peeled rhizome; or

(c) in dermal preparations.

PIPERACILLIN.

PIPERIDINE.

PIPERIDOLATE.

PIPOBROMAN.

PIPOTHIAZINE.

PIPRADROL.

PIRACETAM.

PIRBUTEROL.

PIRENOXINE (catalin).

PIRENZEPINE.

PIRETANIDE.

PIROXICAM **except** in preparations for dermal use.

PIRPROFEN.

PITAVASTATIN.

PITUITARY HORMONES **except** when separately specified in these Schedules.

PIVAMPICILLIN.

PIZOTIFEN.

PLICAMYCIN.

PLERIXAFOR.

PNEUMOCOCCAL VACCINE.

PODOPHYLLOTOXIN for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM EMODI (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

PODOPHYLLUM PELTATUM (podophyllin) for human use:

(a) internally;

(b) in preparations for the treatment of anogenital warts; or

(c) in other preparations **except** when included in Schedule 2 or 3.

POLIDEXIDE.

POLIOMYELITIS VACCINE.

POLYACRYLAMIDE in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYESTRADIOL.

POLYLACTIC ACID in preparations for injection or implantation:

(a) for tissue augmentation; or

(b) for cosmetic use.

POLYMYXIN.

POLYSULFATED GLYCOSAMINOGLYCANS in preparations for injection, **except** when separately specified in these Schedules.

POLYTHIAZIDE.

PORACTANT.

POSACONAZOLE.

POTASSIUM BROMIDE for therapeutic use.

POTASSIUM CHLORIDE in oral preparations for human therapeutic use **except**:

(a) when containing less than 550 mg of potassium chloride per dosage unit;

(b) in preparations for oral rehydration therapy;

(c) in preparations for oral use for bowel cleansing prior to diagnostic medical and surgical procedures; or

(d) in preparations for enteral feeding.

POTASSIUM PERCHLORATE for therapeutic use.

PRACTOLOL.

PRADOFLOXACIN.

PRALATREXATE.

PRALIDOXIME.

PRAMIPEXOLE.

PRAMOCAINE.

PRAMPINE.

# PRASTERONE (dehydroepiandrosterone, dehydroisoandrosterone).

PRASUGREL.

PRAVASTATIN.

PRAZEPAM.

PRAZIQUANTEL for human therapeutic use.

PRAZOSIN.

PREDNISOLONE.

PREDNISONE.

PREGABALIN.

PREGNENOLONE.

PRENALTEROL.

PRENYLAMINE.

PRILOCAINE **except** when included in Schedule 2.

PRIMAQUINE.

PRIMIDONE.

PROBENECID.

PROBUCOL.

PROCAINAMIDE.

PROCAINE.

PROCAINE PENICILLIN.

PROCARBAZINE.

PROCHLORPERAZINE **except** when included in Schedule 3.

PROCYCLIDINE **except** when included in Schedule 2.

PROGESTERONE **except** when included in Schedule 5.

PROGESTOGENS **except** when separately specified in these Schedules.

PROGLUMIDE.

PROGUANIL.

PROLINTANE.

PROMAZINE.

PROMETHAZINE **except** when included in Schedule 2 or 3.

PROMOXOLANE.

PROPAFENONE.

PROPAMIDINE for therapeutic use except when included in Schedule 2.

PROPANIDID.

PROPANTHELINE.

PROPENTOFYLLINE.

# PROPETANDROL.

PROPIONIBACTERIUM ACNES for therapeutic use.

PROPOFOL.

PROPRANOLOL.

PROPYLHEXEDRINE.

PROPYLTHIOURACIL.

PROPYPHENAZONE.

PROQUAZONE.

PROSCILLARIDIN.

PROSTAGLANDINS **except** when separately specified in this Schedule.

PROSTIANOL.

PROTAMINE.

PROTHIONAMIDE.

PROTHIPENDYL.

PROTIRELIN.

PROTOVERATRINES.

PROTRIPTYLINE.

PROXYMETACAINE.

PRUCALOPRIDE.

PSEUDOEPHEDRINE **except** when included in Schedule 3.

PYRAZINAMIDE.

PYRIDINOLCARBAMATE.

PYRIDOSTIGMINE.

PYRIDOXINE, PYRIDOXAL OR PYRIDOXAMINE for human therapeutic use **except**:

(a) in oral preparations containing 200 mg or less but more than 50 mg of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(b) in oral preparations containing 50 mg or less of pyridoxine, pyridoxal or pyridoxamine per recommended daily dose.

PYRIMETHAMINE.

PYROVALERONE.

PYRVINIUM.

QUAZEPAM.

QUETIAPINE.

QUINAGOLIDE.

QUINAPRIL.

# QUINBOLONE.

QUINETHAZONE.

QUINIDINE.

QUININE for human therapeutic use **except** when the maximum recommended daily dose is 50 mg or less of quinine.

QUINISOCAINE (dimethisoquin).

QUINUPRISTIN.

RABEPRAZOLE **except** when included in Schedule 3.

RABIES VACCINE.

RACTOPAMINE **except** when included in Schedule 5.

RALOXIFENE.

RALTEGRAVIR.

RALTITREXED.

RAMIPRIL.

RANIBIZUMAB.

RANITIDINE **except**:

(a) when included in Schedule 2; or

(b) in divided preparations for oral use containing 150mg or less of ranitidine per dosage unit when supplied in the manufacturer’s original pack containing not more than 14 dosage units.

RAPACURONIUM.

RASAGILINE.

RASBURICASE.

RAUWOLFIA SERPENTINA.

RAUWOLFIA VOMITORIA.

RAZOXANE.

REBOXETINE.

RED YEAST RICE for human therapeutic use.

REGORAFENIB.

REMOXIPRIDE.

REPAGLINIDE.

RESERPINE.

RETAPAMULIN.

RETEPLASE.

RETIGABINE.

RIBAVIRIN.

RIDAFOROLIMUS.

RIFABUTIN.

RIFAMPICIN.

RIFAMYCIN.

RIFAPENTINE.

RIFAXIMIN.

RILPIVIRINE.

RILUZOLE.

RIMEXOLONE.

RIMITEROL.

RIMONABANT.

RISEDRONIC ACID.

RISPERIDONE.

RITODRINE.

RITONAVIR.

RITUXIMAB.

RIVAROXABAN.

RIVASTIGMINE.

RIZATRIPTAN.

ROBENACOXIB.

ROCURONIUM.

ROFECOXIB.

ROFLUMILAST.

ROLITETRACYCLINE.

ROMIDEPSIN.

ROMIFIDINE.

ROMIPLOSTIM.

RONIDAZOLE.

ROPINIROLE.

ROPIVACAINE.

ROSIGLITAZONE.

ROSOXACIN.

ROSUVASTATIN.

ROTIGOTINE.

# ROXIBOLONE.

ROXITHROMYCIN.

RUBELLA VACCINE.

RUBOXISTAURIN.

RUPATADINE.

RUXOLITINIB.

SALBUTAMOL **except** when included in Schedule 3.

SALCATONIN.

SALICYLAMIDE when combined with aspirin, caffeine or paracetamol or any derivative of these substances.

SALINOMYCIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 60 mg/kg or less of antibiotic substances.

SALMETEROL.

SAPROPTERIN.

SAQUINAVIR.

SAXAGLIPTIN.

SCHOENOCAULON OFFICINALE (sabadilla) **except** in preparations containing 10 mg/kg or 10 mg/L or less of total alkaloids of *Schoenocaulon officinale*.

SCOPOLIA CARNIOLICA for therapeutic use.

# SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM).

SELEGILINE.

SELENIUM:

(a) for human oral use with a recommended daily dose of more than 300 micrograms; or

(b) for the treatment of animals **except**:

(i) when included in Schedule 6 or 7;

(ii) in solid, slow release bolus preparations each weighing 100 g or more and containing 300 mg or less of selenium per dosage unit;

(iii) in other divided preparations containing 30 micrograms or less of selenium per dosage unit;

(iv) as elemental selenium, in pellets containing 100 g/kg or less of selenium; or

(v) in feeds containing 1 g/tonne or less of selenium.

SERMORELIN.

SERTINDOLE.

SERTRALINE.

SEVELAMER.

SEVOFLURANE.

SEX HORMONES and all substances having sex hormonal activity **except** when separately specified in these Schedules.

SIBUTRAMINE.

# SILANDRONE.

SILDENAFIL.

SILICONES for intra-ocular use.

SILVER SULFADIAZINE.

SIMVASTATIN.

SIROLIMUS.

SISOMICIN (sisomycin).

SITAGLIPTIN.

# SITAXENTAN.

SODIUM BROMIDE for therapeutic use.

SODIUM CELLULOSE PHOSPHATE for human internal use.

SODIUM CROMOGLYCATE **except** when included in Schedule 2.

SODIUM MORRHUATE in preparations for injection.

SODIUM NITROPRUSSIDE for human therapeutic use.

SODIUM PHOSPHATE in preparations for oral laxative use.

SODIUM POLYSTYRENE SULPHONATE for human therapeutic use.

SODIUM SALICYLATE in preparations for injection for the treatment of animals.

SODIUM TETRADECYLSULFATE in preparations for injection.

SOLASODINE.

SOLIFENACIN.

SOMATOSTATIN.

SOMATOTROPIN EQUINE.

# SOMATROPIN (human growth hormone).

SONTOQUINE.

SORAFENIB.

SOTALOL.

SPARFLOXACIN.

SPARTEINE.

SPECTINOMYCIN.

SPIRAMYCIN.

SPIRAPRIL.

SPIRONOLACTONE.

# STANOLONE.

# STANOZOLOL.

STAVUDINE.

# STENBOLONE.

STEROID HORMONES **except** when separately specified in these Schedules.

STILBOESTROL (diethylstilboestrol).

STREPTODORNASE.

STREPTOKINASE.

STREPTOMYCIN.

STRONTIUM RANELATE.

STROPHANTHINS.

STROPHANTHUS spp.

STRYCHNINE in preparations containing 1.5 per cent or less of strychnine for the treatment of animals.

STRYCHNOS spp. **except** in preparations containing 1 mg or less per litre or per kilogram of strychnine.

STYRAMATE.

SUCCIMER.

SUGAMMADEX.

SULBACTAM.

SULCONAZOLE **except** when included in Schedule 2.

SULFACETAMIDE **except** when included in Schedule 3 or 5.

SULFADIAZINE **except** when included in Schedule 5.

SULFADIMETHOXINE.

SULFADIMIDINE **except** when included in Schedule 5.

SULFADOXINE.

SULFAFURAZOLE.

SULFAGUANIDINE.

SULFAMERAZINE **except** when included in Schedule 5.

SULFAMETHIZOLE.

SULFAMETHOXAZOLE.

SULFAMETHOXYDIAZINE.

SULFAMETHOXYPYRIDAZINE.

SULFAMETROLE.

SULFAMONOMETHOXINE.

SULFAMOXOLE.

SULFAPHENAZOLE.

SULFAPYRIDINE.

SULFAQUINOXALINE.

SULFASALAZINE.

SULFATHIAZOLE **except** when included in Schedule 5.

SULFATROXAZOLE.

SULFINPYRAZONE.

SULFOMYXIN.

SULFONAMIDES **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 3, 5 or 6; or

(c) when packed and labelled solely for use as a herbicide.

SULFONMETHANE (sulfonal and alkyl sulfonals).

SULINDAC.

SULTAMICILLIN.

SULTHIAME.

SUMATRIPTAN.

SUNITINIB.

SUPROFEN.

SUTILAINS.

SUXAMETHONIUM.

SUXETHONIUM.

TACRINE.

TACROLIMUS.

TADALAFIL.

TAFLUPROST.

TALIGLUCERASE ALFA.

TAMOXIFEN.

TAMSULOSIN.

TANACETUM VULGARE **except** in preparations containing 0.8 per cent or less of oil of tansy.

TASONERMIN.

TAZAROTENE.

TAZOBACTAM.

T-CELL RECEPTOR ANTIBODY.

TEGAFUR.

TEGASEROD.

TELAPREVIR.

TELITHROMYCIN.

TEICOPLANIN.

TELBIVUDINE.

TELMISARTAN.

TEMAZEPAM.

TEMOZOLOMIDE.

TEMSIROLIMUS.

TENECTEPLASE.

TENIPOSIDE.

TENOFOVIR.

TENOXICAM.

TEPOXALIN.

TERAZOSIN.

TERBINAFINE **except**:

(a) when included in Schedule 2; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TERBUTALINE **except** when included in Schedule 3.

TERFENADINE.

TERIFLUNOMIDE.

# TERIPARATIDE.

TERLIPRESSIN.

TERODILINE.

TEROPTERIN.

# TESTOLACTONE.

# TESTOSTERONE **except** when included in Schedule 6.

TETANUS ANTITOXIN **except** when used for short-term protection or treatment of tetanus in animals.

TETANUS TOXOID for human use.

TETRABENAZINE.

TETRACOSACTRIN.

TETRACYCLINE **except** when included in Schedule 5.

TETRAETHYLAMMONIUM.

TETROXOPRIM.

# THALIDOMIDE.

THENYLDIAMINE.

THEOPHYLLINE **except** when included in Schedule 3.

THEVETIA PERUVIANA.

THEVETIN.

THIACETARSAMIDE in preparations for the prevention or treatment of heartworm in dogs.

THIAMBUTOSINE.

THIAZOSULFONE.

THIETHYLPERAZINE.

THIOACETAZONE.

THIOCARLIDE.

THIOGUANINE.

# THIOMESTERONE (tiomesterone).

THIOPENTONE.

THIOPROPAZATE.

THIOPROPERAZINE.

THIORIDAZINE.

THIOSTREPTON.

THIOTEPA.

THIOTHIXENE.

THIOURACIL.

THIOUREA for therapeutic use **except** in preparations containing 0.1 per cent or less of thiourea.

THYMOXAMINE (includes thymoxamine hydrochloride).

THYROID **except** when separately specified in this Schedule.

THYROTROPHIN.

THYROXINE (includes thyroxine sodium).

TIAGABINE.

TIAMULIN.

TIAPROFENIC ACID.

TIARAMIDE.

TIBOLONE.

TICAGRELOR.

TICARCILLIN.

TICLOPIDINE.

TIEMONIUM.

TIENILIC ACID.

TIGECYCLINE.

TIGLOIDINE.

TILDIPIROSIN.

TILETAMINE.

TILMICOSIN.

TILUDRONIC ACID (includes disodium tiludronate).

TIMOLOL.

TINIDAZOLE.

TINZAPARIN (includes tinzaparin sodium).

TIOCONAZOLE **except**:

(a) when included in Schedule 2 or 3; or

(b) in preparations for dermal use for the treatment of tinea pedis.

TIOTROPIUM.

TIPEPIDINE.

TIPRANAVIR.

TIRILAZAD.

TIROFIBAN.

TOBRAMYCIN.

TOCAINIDE.

TOCERANIB.

TOCILIZUMAB.

TOLAZAMIDE.

TOLAZOLINE.

TOLBUTAMIDE.

TOLCAPONE.

TOLFENAMIC ACID.

TOLMETIN.

TOLONIUM.

TOLPROPAMINE.

TOLRESTAT.

TOLTERODINE.

TOLVAPTAN.

TOPIRAMATE.

TOPOTECAN.

TORASEMIDE.

TOREMIFENE.

TOXOIDS for human parenteral use **except** when separately specified in these Schedules.

TRAMADOL.

TRAMETINIB DIMETHYL SULFOXIDE.

TRANDOLAPRIL.

TRANEXAMIC ACID **except** in preparations containing 3 per cent or less of cetyl tranexamate hydrochloride for dermal cosmetic use.

TRANYLCYPROMINE.

TRASTUZUMAB.

TRASTUZUMAB EMTANSINE.

TRAVOPROST.

TRAZODONE.

# TRENBOLONE (trienbolone, trienolone) **except** when included in Schedule 5.

TREOSULPHAN.

TREPROSTINIL.

# TRESTOLONE.

TRETAMINE.

# TRETINOIN.

TRIACETYLOLEANDOMYCIN.

TRIAMCINOLONE **except** when included in Schedule 2 or 3.

TRIAMTERENE.

TRIAZIQUONE.

TRIAZOLAM.

TRICHLORMETHIAZIDE.

TRICHLOROACETIC ACID for human dermal use **except** when in preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE for therapeutic use.

TRICLOFOS.

TRICYCLAMOL.

TRIDIHEXETHYL.

TRIFLUOPERAZINE.

TRIFLUPERIDOL.

TRIFLUPROMAZINE.

TRILOSTANE.

TRIMEPRAZINE **except** when included in Schedule 2 or 3.

TRIMETAPHAN.

TRIMETHOPRIM.

TRIMIPRAMINE.

TRIMUSTINE.

TRINITROPHENOL (excluding its derivatives) in preparations for human therapeutic use.

TRIOXYSALEN.

TRIPELENNAMINE.

TRIPLE ANTIGEN VACCINE.

TRIPROLIDINE **except** when included in Schedule 2 or 3.

TRIPTORELIN.

TROGLITAZONE.

TROMETAMOL in preparations for injection **except** in preparations containing 3 per cent or less of trometamol.

TROPICAMIDE.

TROPISETRON.

TROVAFLOXACIN.

TROXIDONE.

TRYPTOPHAN for human therapeutic use **except** in preparations labelled with a recommended daily dose of 100 mg or less of tryptophan.

TUBERCULIN.

TUBOCURARINE.

TULATHROMYCIN.

TULOBUTEROL.

TYLOSIN **except**:

(a) when included in Schedule 5;

(b) in animal feeds containing 50 mg/kg or less of antibiotic substances:

(i) for growth promotion;

(ii) for the prevention of liver abscesses in cattle; or

(iii) for the prevention of ileitis in pigs; or

(c) in milk replacers for calves, or starter rations for pigs, containing 100 mg/kg or less of antibiotic substances.

TYPHOID VACCINE.

UNOPROSTONE.

URACIL.

URAPIDIL.

URETHANE (excluding its derivatives) for therapeutic use.

# UROFOLLITROPIN.

UROKINASE.

URSODEOXYCHOLIC ACID.

USTEKINUMAB.

VACCINES for human therapeutic use **except** when separately specified in this Schedule.

VACCINES, veterinary live virus **except**:

(a) poultry vaccines;

(b) pigeon pox vaccine; or

(c) scabby mouth vaccine.

VACCINIA VIRUS VACCINE.

VALACICLOVIR.

VALDECOXIB.

VALGANCICLOVIR.

VALNOCTAMIDE.

VALPROIC ACID.

VALSARTAN.

VANCOMYCIN.

VANDETANIB.

VARDENAFIL.

VARENICLINE.

VARICELLA VACCINE.

VASOPRESSIN.

VECURONIUM.

VEDAPROFEN.

VEDOLIZUMAB.

VELAGLUCERASE ALFA.

VEMURAFENIB.

VENLAFAXINE.

VERAPAMIL.

VERATRUM spp. **except** when separately specified in this Schedule.

VERNAKALANT.

VERTEPORFIN.

VIDARABINE.

VIGABATRIN.

VILANTEROL.

VILANTEROL.

VILDAGLIPTIN.

VILOXAZINE.

VINBLASTINE.

VINCAMINE.

VINCRISTINE.

VINDESINE.

VINFLUNINE.

VINORELBINE.

VINYL ETHER for therapeutic use.

VIRGINIAMYCIN **except** when included in Schedule 5.

VISMODEGIB.

VISNADINE.

VITAMIN A for human th**e**rapeutic or cosmetic use except:

(a) in preparations for topical use containing 1 per cent or less of Vitamin A;

(b) in preparations for internal use containing 3000 micrograms retinol equivalents or less of Vitamin A per daily dose; or

(c) in preparations for parenteral nutrition replacement.

VITAMIN D for human internal therapeutic use **except:**

1. in preparations containing 25 micrograms or less of vitamin D per recommended daily dose ; or
2. when included in Schedule 3.

VORICONAZOLE.

VORINOSTAT.

VORTIOXETINE.

WARFARIN for therapeutic use.

XAMOTEROL.

XANTHINOL NICOTINATE.

XIMELAGATRAN.

XIPAMIDE.

XYLAZINE.

YOHIMBINE.

ZAFIRLUKAST.

ZALCITABINE.

ZALEPLON.

ZANAMIVIR .

ZERANOL **except** when included in Schedule 6.

ZIDOVUDINE.

ZILPATEROL.

ZIMELDINE.

ZINC COMPOUNDS for human internal use **except**:

(a) in preparations with a recommended daily dose of 25 mg or less of zinc; or

(b) in preparations with a recommended daily dose of more than 25 mg but not more than 50 mg of zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*.

ZIPRASIDONE.

ZOLAZEPAM.

ZOLEDRONIC ACID.

ZOLMITRIPTAN.

ZOLPIDEM.

ZONISAMIDE.

ZOPICLONE.

ZOXAZOLAMINE.

ZUCLOPENTHIXOL.

## SCHEDULE 5

(Substances marked † are listed in Appendix C)

ABAMECTIN in preparations, for internal use for the treatment of animals, containing 1 per cent or less of abamectin.

ABSCISIC ACID.

ACETIC ACID (excluding its salts and derivatives) in preparations containing more than 30 per cent of acetic acid (CH3COOH) **except**:

(a) when included in Schedule 2 or 6; or

(b) for therapeutic use.

ACETONE **except** in preparations containing 25 per cent or less of designated solvents.

ACRIFLAVINE in preparations for veterinary use containing 2.5 per cent or less of acriflavine.

AKLOMIDE.

ALBENDAZOLE for the treatment of animals, in preparations containing 12.5 per cent or less of albendazole **except** in intraruminal implants each containing 3.85 g or less of albendazole.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination:

(a) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is more than 11.5;

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 11.5 but less than or equal to 12.5;

(c) in other solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(d) in liquid or semi-solid preparations, the pH of which is more than 11.5, unless:

(i) in food additive preparations for domestic use; or

(ii) in automatic dish washing preparations for domestic use with a pH of more than 12.5,

**except** when separately specified in these Schedules.

ALKOXYLATED FATTY ALKYLAMINE POLYMER in preparations containing 50 per cent or less of alkoxylated fatty alkylamine polymer **except** in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN in preparations containing 10 per cent or less of allethrin **except**:

(a) in insecticidal mats; or

(b) in other preparations containing 1 per cent or less of allethrin.

ALLOXYDIM.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 3 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 1.5 per cent or less of alpha-cypermethrin.

AMETRYN.

AMINACRINE in preparations for veterinary use containing 2.5 per cent or less of aminacrine.

AMINES for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

AMITROLE.

AMINOCYCLOPYRACHLOR.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) in preparations containing 5 per cent or less of ammonia **except**:

(a) in preparations for human internal therapeutic use;

(b) in preparations for inhalation when absorbed in an inert solid material; or

(c) in preparations containing 0.5 per cent or less of free ammonia.

AMMONIUM THIOCYANATE **except** in preparations containing 10 per cent or less of ammonium thiocyanate.

ANHYDRIDES, ORGANIC ACID for use as curing agents for epoxy resins **except** when separately specified in these Schedules.

ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of anise oil.

ASPIRIN for the treatment of animals, in divided preparations when packed in blister or strip packaging or in a container with a child-resistant closure.

ATRAZINE.

† AZADIRACHTA INDICA EXTRACTS (neem extracts), extracted from neem seed kernels using water, methanol or ethanol, in preparations containing 5 per cent or less of total limonoids, for agricultural use.

AZOXYSTROBIN.

BACILLUS THURINGIENSIS delta endotoxin encapsulated in killed *Pseudomonas fluorescens*.

BARIUM SILICOFLUORIDE when coated on paper in an amount not exceeding 8 mg of barium silicofluoride per sq. cm.

BASIL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 5 per cent or less of methyl chavicol.

BEAUVERIA BASSIANA in preparations containing 1 x 108 Colony Forming Units (CFU)/mL or less of *Beauveria bassiana*.

BENALAXYL.

BENDIOCARB in preparations containing 2 per cent or less of bendiocarb.

BENTAZONE.

BENZALKONIUM CHLORIDE in preparations containing 10 per cent or less of benzalkonium chloride **except** in preparations containing 5 per cent or less of benzalkonium chloride.

BENZOFENAP.

BENZOYL PEROXIDE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 5 per cent or less of benzoyl peroxide.

BERGAMOT OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.4 per cent or less of bergamot oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

BETACYFLUTHRIN:

(a) in aqueous preparations containing 2.5 per cent or less of betacyfluthrin; or

(b) in solid preparations containing 8 per cent or less of betacyfluthrin in a plastic matrix.

BIFLUORIDES (including ammonium, potassium and sodium salts), in preparations containing 0.3 per cent or less of total bifluorides.

BIOALLETHRIN in preparations containing 10 per cent or less of bioallethrin **except** in preparations containing 1 per cent or less of bioallethrin.

BIORESMETHRIN **except** in preparations containing 10 per cent or less of bioresmethrin.

BISPYRIBAC **except** in preparations containing 10 per cent or less of bispyribac.

BORIC ACID (excluding its salts) and BORAX **except**:

(a) when included in Schedule 4;

(b) in preparations, other than insect baits, containing 1 per cent or less of boron; or

(c) in hand cleaning preparations.

BORON TRIFLUORIDE in preparations containing 0.1 per cent or less of boron trifluoride (BF3).

BROMUCONAZOLE in preparations containing 20 per cent or less of bromuconazole.

BUPIVACAINE in aqueous gel preparations containing 0.5 per cent or less of bupivacaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.

BUPROFEZIN except in preparations containing 40 per cent or less of buprofezin.

BUTHIDAZOLE.

BUTOXYCARBOXIM in solid preparations containing 10 per cent or less of butoxycarboxim.

BUTRALIN.

BUTROXYDIM.

CAMPHOR as a natural component in essential oils containing 10 per cent or less of camphor **except**:

(a) in medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, in essential oils when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(c) in rosemary oil, sage oil (Spanish), or lavandin oils; or

(d) in preparations containing 2.5 per cent or less of camphor.

† CARBAMIDE PEROXIDE in preparations containing 18 per cent or less of carbamide peroxide **except** in preparations containing 9 per cent or less of carbamide peroxide.

CARBARYL:

(a) in preparations containing 10 per cent or less of carbaryl **except** when included in Schedule 4; or

(b) when impregnated into plastic resin material containing 20 per cent or less of carbaryl.

CASSIA OIL **except**:

(a) in food additives;

(b) in preparations for dermal use as a rubefacient containing 5 per cent or less of cassia oil; or

(c) in other preparations containing 2 per cent or less of cassia oil.

CHLORFENAC.

CHLORFENAPYR in preparations containing 0.5 per cent or less of chlorfenapyr.

CHLORFENSON.

CHLORHEXIDINE in preparations containing 3 per cent or less of chlorhexidine **except**:

(a) in preparations containing 1 per cent or less of chlorhexidine; or

(b) when in solid preparations.

CHLORINATING COMPOUNDS containing 20 per cent or less of available chlorine, **except**:

(a) when separately specified in these Schedules;

(b) sodium hypochlorite preparations with a pH of less than 11.5;

(c) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(d) liquid preparations containing less than 2 per cent of available chlorine; or

(e) other preparations containing 4 per cent or less of available chlorine.

CHLORNIDINE.

CHLOROCRESOL **except** in preparations containing 3 per cent or less of chlorocresol.

CHLORPROPHAM.

CHLORPYRIFOS:

(a) in aqueous preparations containing 20 per cent or less of microencapsulated chlorpyrifos;

(b) in controlled release granular preparations containing 10 per cent or less of chlorpyrifos; or

(c) in other preparations containing 5 per cent or less of chlorpyrifos,

**except** in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORSULFURON.

CHLORTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of chlortetracycline, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

CHLORTHAL-DIMETHYL.

CINMETHYLIN.

CINNAMON BARK OIL **except**:

(a) in food additives; or

(b) in preparations containing 2 per cent or less of cinnamon bark oil.

CLETHODIM.

CLIMBAZOLE in preparations containing 40 per cent or less of climbazole **except** in preparations containing 2 per cent or less of climbazole.

CLOFENTEZINE.

CLOPYRALID.

CLOQUINTOCET-MEXYL.

CLORSULON.

CLOTHIANIDIN in preparations containing 20 per cent or less of clothianidin.

CLOVE OIL for topical use in the mouth in a pack containing 5 mL or less of clove oil **except** in preparations containing 25 per cent or less of clove oil.

COPPER ACETATE in preparations containing 20 per cent or less of copper acetate **except** in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS in animal feed additives containing 5 per cent or less of copper **except** in preparations containing 1 per cent or less of copper.

COPPER HYDROXIDE in preparations containing 50 per cent or less of copper hydroxide **except** in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER OXIDES in preparations containing 25 per cent or less of copper oxides **except**:

(a) in preparations for internal use;

(b) in marine paints; or

(c) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE in preparations containing 50 per cent or less of copper oxychloride **except** in preparations containing 12.5 per cent or less of copper oxychloride.

COPPER SULFATE in preparations containing 15 per cent or less of copper sulfate **except**:

(a) in preparations for internal use; or

(b) in other preparations containing 5 per cent or less of copper sulfate.

COUMATETRALYL in rodenticides containing 0.05 per cent or less of coumatetralyl.

4-CPA.

CYANATRYN.

CYANOACRYLATE ESTERS in contact adhesives **except**:

(a) when labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water; or

(b) when packed in sealed measure packs each containing 0.5 g or less of cyanoacrylate esters:

(i) labelled with the approved name or trade name of the poison, the quantity and the warning:

Can cause eye injury. Instantly bonds skin; and

(ii) enclosed in a primary pack labelled with the warning:

KEEP OUT OF REACH OF CHILDREN. Avoid contact with skin and eyes and avoid breathing vapour. Bonds on contact. Should fingers stick together apply a solvent such as acetone to contact areas then wash off with water. Do not use solvents near eyes or open wounds. In case of eye contact immediately flush with water.

CYANURIC ACID (excluding its salts and derivatives).

CYANTRANILIPROLE.

CYAZOFAMID.

CYCLOHEXANONE PEROXIDE.

CYCLOPROTHRIN **except** in preparations containing 10 per cent or less of cycloprothrin.

CYCLOXYDIM.

CYFLUFENAMID.

CYFLUTHRIN:

(a) in wettable powders containing 10 per cent or less of cyfluthrin;

(b) in emulsifiable concentrates containing 2 per cent or less of cyfluthrin; or

(c) in emulsions containing 5 per cent or less of cyfluthrin.

cyhalofop-butyl.

CYMIAZOLE.

CYPERMETHRIN in preparations containing 10 per cent or less of cypermethrin.

CYPHENOTHRIN in preparations containing 10 per cent or less of cyphenothrin.

CYPROCONAZOLE **except** in preparations containing 10 per cent or less of cyproconazole.

CYPRODINIL.

CYSTEAMINE in cosmetic preparations containing 6 per cent or less of cysteamine **except** in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE for the treatment of animals:

(a) in divided preparations containing 30 mg or less of cythioate per dosage unit when packed in blister or strip packaging or in a container with a child-resistant closure; or

(b) in undivided preparations containing 5 per cent or less of cythioate.

2,4-D in preparations containing 20 per cent or less of 2,4-D.

DAMINOZIDE.

2,4-DB.

DECOQUINATE.

DELTAMETHRIN:

(a) when impregnated in plastic resin strip material containing 4 per cent or less of deltamethrin;

(b) in aqueous preparations containing 5 per cent or less of deltamethrin when no organic solvent other than a glycol is present;

(c) in wettable granular preparations containing 25 per cent or less of deltamethrin when packed in child-resistant packaging each containing 3 grams or less of the formulation;

(d) in water-dispersible tablets each containing 500 mg or less of deltamethrin in child-resistant packaging; or

(e) in other preparations containing 0.5 per cent or less of deltamethrin,

**except**:

(a) in factory prepared mosquito nets containing 1 per cent or less deltamethrin; or

(b) in preparations containing 0.1 per cent or less of deltamethrin.

DEMBREXINE in oral preparations for the treatment of animals.

2,4-DES.

DIAFENTHIURON.

N,N-DIALLYLDICHLOROACETAMIDE **except** in preparations containing 10 per cent or less of N,N-diallyldichloroacetamide.

DIAZINON in dust preparations containing 2 per cent or less of diazinon.

DICAMBA (including its salts and derivatives) in preparations containing 20 per cent or less of dicamba.

DICHLONE.

para-DICHLOROBENZENE.

DICHLOROISOCYANURIC ACID containing 40 per cent or less of available chlorine, **except** in:

(a) liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(b) liquid preparations containing less than 2 per cent of available chlorine; or

(c) other preparations containing 4 per cent or less of available chlorine.

DICHLOROMETHANE (methylene chloride) **except**:

(a) in preparations in pressurised spray packs labelled as degreasers, decarbonisers or paint strippers and containing 10 per cent or less of dichloromethane;

(b) in other preparations in pressurised spray packs; or

(c) in paints and tinters containing 5 per cent or less of dichloromethane.

DICHLOROPHEN for the treatment of animals.

DICHLORVOS:

(a) when impregnated in plastic resin strip material containing 20 per cent or less of dichlorvos;

(b) in sustained release resin pellets containing 20 per cent or less of dichlorvos for the treatment of animals; or

(c) in pressurised spray packs containing 10 grams or less of dichlorvos.

DICLOBUTRAZOL.

DICLORAN.

DICOFOL.

DIETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of diethanolamine **except** in preparations containing 5 per cent or less of diethanolamine.

† DIETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except:**

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIETHYLENE GLYCOL MONOBUTYL ETHER **except** in preparations containing 10 per cent or less of diethylene glycol monobutyl ether.

DIETHYLTOLUAMIDE (DEET) **except**:

(a) in medicines for human therapeutic use containing 20 per cent or less of diethyltoluamide, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations for human use, other than medicines, containing 20 per cent or less of diethyltoluamide, when labelled with the warning statement:

**WARNING**: May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time; or

(c) in preparations other than for human use containing 20 per cent or less of diethyltoluamide.

DIFENOCONAZOLE.

DIFLUBENZURON.

DIMETHICODIETHYLBENZALMALONATE **except** when included in preparations containing 10 per cent or less of dimethicodiethylbenzalmalonate.

DIMETHIRIMOL.

DIMETHOMORPH **except** in preparations containing 10 per cent or less of dimethomorph.

DIMETHYLACETAMIDE in preparations containing 20 per cent or less of dimethylacetamide.

DIMETHYLFORMAMIDE in preparations containing 10 per cent or less of dimethylformamide **except** in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DINICONAZOLE.

DI-N-PROPYL ISOCINCHOMERONATE **except** in preparations containing 25 per cent or less of di-N-propyl isocinchomeronate.

DIPHENAMID.

DITHIOPYR.

N-(N-DODECYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of N-(N-dodecyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-dodecyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or N-(N-octyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

DORAMECTIN for internal use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

EMAMECTIN in preparations containing 2 per cent or less of emamectin.

EMODEPSIDE in preparations:

(a) containing 2.5 per cent or less of emodepside for the external treatment of animals; or

(b) containing 30 mg or less of emodepside per dosage unit for the oral treatment of animals.

EPOXICONAZOLE.

EPOXY RESINS, LIQUID.

EPRINOMECTIN in preparations containing 0.5 per cent or less of eprinomectin.

ESBIOTHRIN in preparations containing 10 per cent or less of esbiothrin **except** in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE in preparations containing 0.1 per cent or less of esfenvalerate.

1,2-ETHANEDIAMINE POLYMERWITH (CHLOROMETHYL)OXIRANE AND N-METHYLMETHANAMINE.

ETHANOLAMINE (excluding its salts and derivatives) in preparations containing 20 per cent or less of ethanolamine **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHER in preparations containing more than 10 per cent of ether for use in internal combustion engines.

ETHOFUMESATE.

ETHOXYQUIN **except** in preparations containing 10 per cent or less of ethoxyquin.

ETHOXYSULFURON.

† ETHYLENE GLYCOL (excluding its salts and derivatives) in preparations containing not less than 10 mg/kg of denatonium benzoate as a bittering agent **except**:

(a) in paints or paint tinters;

(b) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(c) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYL METHACRYLATE (excluding its derivatives) for cosmetic use **except** in preparations containing 1 per cent or less of ethyl methacrylate as residual monomer in a polymer.

ETRIDIAZOLE.

EUGENOL for topical use in the mouth in a pack containing 5 mL or less of eugenol **except** in preparations containing 25 per cent or less of eugenol.

EXTRACT OF LEMON EUCALYPTUS, being acid modified oil of lemon eucalyptus (*Corymbia citriodora*) , **except** in preparations containing 40 per cent or less of extract of lemon eucalyptus.

FENARIMOL.

FENBENDAZOLE for the treatment of animals.

FENBUCONAZOLE.

FENCHLORAZOLE-ETHYL.

FENOPROP.

FENOXAPROP-ETHYL.

FENOXAPROP-P-ETHYL.

FENSON.

FENTHION:

(a) in preparations containing 25 per cent or less of fenthion when packed in single-use containers having a capacity of 2 mL or less; or

(b) in preparations containing 10 per cent or less of fenthion.

FIPRONIL in preparations containing 10 per cent or less of fipronil **except** in preparations containing 0.05 per cent or less of fipronil.

FLAMPROP-METHYL.

FLAMPROP-M-METHYL.

FLAZASULFURON.

FLORASULAM.

FLUAZURON.

FLUBENDAZOLE for the treatment of animals.

FLUBENDIAMIDE.

FLUCHLORALIN.

FLUDIOXONIL **except** in preparations containing 10 per cent or less of fludioxonil.

FLUMETHRIN:

(a) when impregnated in plastic resin strip material containing 3 per cent or less offlumethrin; or

(b) in oil based preparations containing 1 per cent or less of flumethrin.

flumiclorac pentyl.

FLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) in preparations for human use; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

FLUVALINATE in aqueous preparations containing 25 per cent or less of fluvalinate.

FLUXAPYROXAD.

FORAMSULFURON.

FORMIC ACID (excluding its salts and derivatives) **except** in preparations containing 0.5 per cent or less of formic acid.

FOSPIRATE when impregnated in plastic resin strip material containing 20 per cent or less of fospirate.

FURALAXYL.

FURATHIOCARB in microencapsulated suspensions containing 50 per cent or less of furathiocarb.

GAMMA-CYHALOTHRIN in aqueous preparations containing 15 per cent or less of microencapsulated gamma-cyhalothrin.

GLUFOSINATE-AMMONIUM.

GLUTARALDEHYDE in preparations containing 5 per cent or less of glutaraldehyde **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYPHOSATE.

HALOSULFURON-METHYL.

HEXACONAZOLE **except** in preparations containing 5 per cent or less of hexaconazole.

HEXAZINONE in preparations containing 25 per cent or less of hexazinone.

HYDRAMETHYLNON in solid baits containing 2 per cent or less of hydramethylnon in welded plastic labyrinths.

HYDROCARBONS, LIQUID, including kerosene, diesel (distillate), mineral turpentine, white petroleum spirit, toluene, xylene and light mineral and paraffin oils (but excluding their derivatives), **except**:

(a) toluene and xylene when included in Schedule 6;

(b) benzene and liquid aromatic hydrocarbons when included in Schedule 7;

(c) food grade and pharmaceutical grade white mineral oils;

(d) in solid or semi-solid preparations;

(e) in preparations containing 25 per cent or less of designated solvents;

(f) in preparations packed in pressurised spray packs;

(g) in adhesives packed in containers each containing 50 grams or less of adhesive;

(h) in writing correction fluids and thinners for writing correction fluids packed in containers having a capacity of 20 mL or less; or

(i) in other preparations when packed in containers with a capacity of 2 mL or less.

HYDROCHLORIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of hydrochloric acid (HCl) **except**:

(a) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl); or

(b) for therapeutic use.

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 0.1 per cent or less of hydrogen fluoride.

† HYDROGEN PEROXIDE (excluding its salts and derivatives):

(a) in hair dye preparations containing 12 per cent or less of hydrogen peroxide **except** in hair dyes containing 6 per cent or less of hydrogen peroxide; or

(b) in other preparations containing 6 per cent (20 volume) or less of hydrogen peroxide **except** in preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 0.1 per cent or less of hydrosilicofluoric acid (H2SiF6).

IMAZALIL.

IMAZAMOX **except** in preparations containing 25 per cent or less of imazamox.

IMAZAPIC **except** in preparations containing 25 per cent or less of imazapic.

IMAZAPYR **except** in preparations containing 25 per cent or less of imazapyr.

IMAZETHAPYR **except** in preparations containing 25 per cent or less of imazethapyr.

IMIDACLOPRIDin preparations containing 20 per cent or less of imidacloprid **except** in preparations containing 5 per cent or less of imidacloprid.

IMIPROTHRIN in preparations containing 50 per cent or less of imiprothrin **except** in preparations containing 10 per cent or less of imiprothrin.

INDOXACARB (includes the R and S enantiomers) in preparations containing 1 per cent or less of

indoxacarb.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) in preparations containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate **except**:

(a) in aqueous preparations not for cosmetic use containing 10 per cent or less 3-iodo-2-propynyl butyl carbamate; or

(b) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IODOSULFURON-METHYL-SODIUM.

IPCONAZOLE in preparations containing 2 per cent or less of ipconazole.

IRON COMPOUNDS:

(a) for the treatment of animals (excluding up to 1 per cent of iron oxides when present as an excipient):

(i) in preparations for injection containing 20 per cent or less of iron **except** in preparations containing 0.1 per cent or less of iron; or

(ii) in other preparations containing 4 per cent or less of iron **except**:

(A) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(B) in animal feeds or feed premixes; or

(b) in garden preparations **except** in preparations containing 4 per cent or less of iron.

ISOEUGENOL in preparations containing 25 per cent or less of isoeugenol **except** in preparations containing 10 per cent or less of isoeugenol.

ISOPHORONE.

ISOXABEN.

ISOXAFLUTOLE.

IVERMECTIN for use in animals:

(a) in preparations for the prophylaxis of heartworm in cats and dogs;

(b) in intraruminal implants containing 160 mg or less of ivermectin;

(c) in preparations containing 3.5 per cent or less of ivermectin when packed in child-resistant packaging or in packaging approved by the relevant registration authority; or

(d) in other preparations containing 2 per cent or less of ivermectin.

KITASAMYCIN in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 1 per cent or less of lambda- cyhalothrin; or

(b) in aqueous preparations containing 2.5 per cent or less of microencapsulated lambda-cyhalothrin.

† LEAD COMPOUNDS in preparations for use as hair cosmetics.

LEMON OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.05 per cent or less of lemon oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LEVAMISOLE in preparations containing 15 per cent or less of levamisole for the treatment of animals **except**:

(a) when included in Schedule 4; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LIGNOCAINE in aqueous gel preparations containing 4.5 per cent or less of lignocaine, for the dermal spray-on treatment of wounds associated with 'mulesing' of sheep.

LIME OIL **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 0.5 per cent or less of lime oil;

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

LINDANE in preparations containing 10 per cent or less of lindane **except** when included in Schedule 2 or 4.

LUFENURON **except**:

(a) in divided preparations each containing 500 mg or less of lufenuron for the treatment of animals; or

(b) in single use syringes each containing 500 mg or less of lufenuron for the treatment of animals.

MADURAMICIN in animal feed premixes containing 1 per cent or less of antibiotic substances.

MAGNESIUM CHLORATE **except** in preparations containing 10 per cent or less of magnesium chlorate.

MALACHITE GREEN in preparations for veterinary use containing 10 per cent or less of malachite green.

MALATHION in preparations containing 10 per cent or less of malathion except:

(a) for human therapeutic use; or

(b) in dust preparations containing 2 per cent or less of malathion.

MANCOZEB.

MANDIPROPAMID.

MARJORAM OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of marjoram oil.

MCPA:

(a) in preparations containing25 per cent or less of MCPA (acid); or

(b) in preparations containing 50 per cent or less of the salts and esters of MCPA.

MCPB.

MEBENDAZOLE for the treatment of animals:

(a) in divided preparations each containing 300 mg or less of mebendazole per dosage unit; or

(b) in undivided preparations containing 25 per cent or less of mebendazole.

MECLOFENAMIC ACID for the treatment of animals.

MECOPROP in preparations containing 2 per cent or less of mecoprop.

MEFENPYR-DIETHYL.

MEPIQUAT.

MESOTRIONE.

METAFLUMIZONE.

METALAXYL in preparations containing 35 per cent or less of metalaxyl.

METALDEHYDE in preparations containing 2 per cent or less of metaldehyde.

METHABENZTHIAZURON.

METHANOL (excluding its derivatives) in preparations containing 10 per cent or less of methanol **except** in preparations containing 2 per cent or less of methanol.

METHIOCARB in pelleted preparations containing 2 per cent or less of methiocarb.

METHOXYCHLOR.

METHYLATED SPIRIT(S) (being ethanol denatured with denatonium benzoate, methyl isobutyl ketone and fluorescein) **except**:

(a) when included in preparations or admixtures; or

(b) when packed in containers having a capacity of more than 5 litres.

METHYLENE BLUE in preparations for veterinary use containing 50 per cent or less of methylene blue.

METHYL ETHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ETHYL KETONE PEROXIDE.

METHYL ISOAMYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

METHYL ISOBUTYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

N-METHYL-2-PYRROLIDONE:

(a) when packed in single use containers having a capacity of 2 mL or less; or

(b) in preparations containing 50 per cent or less of N-methyl-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-methyl-2-pyrrolidone, N-(N-octyl)-2-pyrrolidone or N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE in preparations containing 25 per cent or less of methyl salicylate except:

(a) in preparations for therapeutic use; or

(b) in preparations containing 5 per cent or less of methyl salicylate.

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE.

METIRAM.

METOLACHLOR.

METRAFENONE in preparations containing 50 per cent or less of metrafenone.

MILBEMECTIN in preparations containing 1 per cent or less of milbemectin.

MILBEMYCIN OXIME for the prophylaxis of heartworm in dogs and cats.

MONENSIN in intraruminal implants for cattle, each containing 35 g or less of monensin.

MONEPANTEL.

MORANTEL in preparations containing 25 per cent or less of morantel **except** in preparations containing 10 per cent or less of morantel.

MOXIDECTIN:

(a) in preparations for external use for the treatment of animals other than cats and dogs, containing 0.5 per cent or less of moxidectin;

(b) in preparations for external use for the treatment of cats and dogs, containing 2.5 per cent or less of moxidectin packed in single dose tubes with a volume of 1 mL or less; or

(c) for internal use for the treatment of animals:

(i) in divided preparations for dogs, containing 250 micrograms or less of moxidectin per dosage unit in a pack containing six or less dosage units; or

(ii) in other preparations containing 2 per cent or less of moxidectin.

MYCLOBUTANIL.

NAA **except** in preparations containing 25 per cent or less of NAA.

NALED when impregnated in plastic resin strip material containing 20 per cent or less of naled.

NAPTALAM.

NETOBIMIN for the treatment of animals, in preparations containing 12.5 per cent or less of netobimin.

NITRIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of nitric acid (HNO3) **except** in preparations containing 0.5 per cent or less of nitric acid.

NITROSCANATE for the treatment of animals.

NONOXINOL 9 in preparations containing 25 per cent or less of nonoxinol 9 **except**:

(a) when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(b) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(c) in preparations for human use.

NORBORMIDE.

NUTMEG OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of nutmeg oil.

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE **except** in preparations containing 10 per cent or less of

N-octyl bicycloheptene dicarboximide.

N-(N-OCTYL)-2-PYRROLIDONE in preparations containing 50 per cent or less of

N-(N-octyl)-2-pyrrolidone or preparations containing 50 per cent or less of a mixture of any two or more of N-(N-octyl)-2-pyrrolidone, N-methyl-2-pyrrolidone or

N-(N-dodecyl)-2-pyrrolidone **except** in preparations containing 25 per cent or less of designated solvents.

OESTRADIOL in implant preparations for growth promotion in animals.

OLEANDOMYCIN in animal feed premixes for growth promotion.

OMETHOATE in pressurised spray packs containing 0.2 per cent or less of omethoate.

ORANGE OIL (BITTER) **except**:

(a) when steam distilled or rectified;

(b) in preparations for internal use;

(c) in preparations containing 1.4 per cent or less of orange oil (bitter);

(d) in soaps or bath or shower gels that are washed off the skin;

(e) in medicines for human therapeutic use, when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(f) in other preparations when packed in containers labelled with the statement:

Application to the skin may increase sensitivity to sunlight.

OXADIARGYL.

OXADIXYL.

OXANTEL EMBONATE for the treatment of animals.

OXFENDAZOLE for the treatment of animals.

OXIBENDAZOLE for the treatment of animals.

OXYCARBOXIN.

OXYTETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of oxytetracycline per dose, when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

OXYTHIOQUINOX.

PACLOBUTRAZOL.

PENCONAZOLE.

PENDIMETHALIN.

PENFLUFEN.

PENTHIOPYRAD **except** in preparations containing 20 per cent or less of penthiopyrad.

PERACETIC ACID in concentrations of 10 per cent or less of peracetic acid.

PERMETHRIN (excluding preparations for human therapeutic use):

(a) in preparations containing 25 per cent or less of permethrin; or

(b) in preparations for external use, for the treatment of dogs, containing 50 per cent or less of permethrin when packed in single use containers having a capacity of 4 mL or less,

**except** in preparations containing 2 per cent or less of permethrin.

PETROL **except** preparations containing 25 per cent or less of petrol.

PHENAZONE for the external treatment of animals.

PHENISOPHAM.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, when in animal feed additives containing 15 per cent or less of such substances, **except** in preparations containing 3 per cent or less of such substances.

PHENYL METHYL KETONE **except** in preparations containing 25 per cent or less of designated solvents.

ortho-PHENYLPHENOL **except** in preparations containing 5 per cent or less of o-phenylphenol.

PHOSPHONIC ACID (excluding its salts and derivatives) **except** in preparations containing 10 per cent or less of phosphonic acid (H3PO3).

PHOSPHORIC ACID (excluding its salts and derivatives) in preparations containing 35 per cent or less of phosphoric acid (H3PO4) **except**:

(a) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(b) in solid or semi-solid preparations; or

(c) in professional dental kits.

ortho-PHTHALALDEHYDE in preparations containing 1 per cent or less of ortho-phthalaldehyde.

PICARIDIN **except** in preparations containing 20 per cent or less of picaridin.

PINE OILS in preparations containing 25 per cent or less of pine oils when packed and labelled as a herbicide.

PINOXADEN in preparations containing 10 per cent or less of pinoxaden.

PIPERAZINE for animal use.

PIRIMICARB in preparations containing 0.5 per cent or less of pirimicarb.

POLIHEXANIDE **except** in preparations containing 5 percent or less of polihexanide.

POLIXETONIUM SALTS in preparations containing 60 per cent or less of polixetonium salts **except** in preparations containing 1 per cent or less of polixetonium salts.

POLYETHANOXY (15) TALLOW AMINE.

POLY(OXY-1,2-ETHANEDIYL), α -[2-[(2-HYDROXYETHYL)AMINO]-2-OXOETHYL]- α -HYDROXY-,MONO-C13-15-ALKYL ETHERS.

POTASSIUM CHLORATE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 10 per cent or less of potassium chlorate.

† POTASSIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of potassium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

POTASSIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of potassium metabisulphite.

POTASSIUM NITRITE in preparations containing 1 per cent or less of potassium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of potassium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is less than 2.5; or

(b) liquid or semi-solid preparations, the pH of which is less than 2.5.

POTASSIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of potassium sulfide.

PRALLETHRIN (cis:trans=20:80) in preparations containing 10 per cent or less of prallethrin **except** in insecticidal mats containing 1 per cent or less of prallethrin.

PROFOXYDIM **except** in preparations containing 20 per cent or less of profoxydim.

PROGESTERONE:

(a) in implant preparations or controlled release pessaries for synchronisation of oestrus in cattle, sheep or goats; or

(b) in implant preparations for growth promotion in cattle.

PROHEXADIONE CALCIUM.

PROMETRYN.

PROPAMOCARB.

PROPANIL.

PROPAQUIZAFOP.

PROPICONAZOLE in preparations containing 20 per cent or less of propiconazole.

PROPIONIC ACID (excluding its salts and derivatives) in preparations containing 80 per cent or less of propionic acid, **except**:

(a) in preparations containing 30 per cent or less of propionic acid; or

(b) for therapeutic use.

PROPOXUR:

(a) when impregnated in plastic resin strip material containing 10 per cent or less of propoxur;

(b) in dust preparations containing 3 per cent or less of propoxur;

(c) in granular sugar-based fly baits containing 1 per cent or less of propoxur, a dark colouring agent and a separate bittering agent;

(d) in pressurised spray packs containing 10 g or less of propoxur; or

(e) in printed paper sheets for pest control containing 0.5 per cent or less of propoxur and in any case not more than 100 mg of propoxur per sheet.

PROPYZAMIDE.

PROTHIOCONAZOLE-DESCHLORO **except** in preparations containing 0.5 per cent or less of prothioconazole-deschloro.

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE **except** in preparations containing 0.5 per cent or less of prothioconazole-triazolidinethione.

PYMETROZINE.

PYRACLOSTROBIN.

PYRAFLUFEN-ETHYL.

PYRASULFOTOLE.

PYRETHRINS, naturally occurring, being pyrethrolone, cinerolone or jasmolone esters of chrysanthemic or pyrethric acids except:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 10 per cent or less of such substances.

PYRIDABEN in preparations containing 25 per cent or less of pyridaben.

PYRIFENOX.

PYRITHIOBAC SODIUM.

PYRITHIONE ZINC in paints containing 0.5 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint **except** in paints containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content of the paint.

QUATERNARY AMMONIUM COMPOUNDS in preparations containing 20 per cent or less of quaternary ammonium compounds **except**:

(a) when separately specified in these Schedules;

(b) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(c) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUINCLORAC.

QUININE in preparations for veterinary use containing 1 per cent or less of quinine.

QUINTOZENE.

QUIZALOFOP-P-ETHYL in aqueous preparations containing 40 per cent or less of

quizalofop-p-ethyl.

RACTOPAMINE in animal feed premixes containing 10 per cent or less of ractopamine.

RESMETHRIN in preparations containing 10 per cent or less of resmethrin.

RIMSULFURON.

ROBENIDINE **except** in preparations containing 20 per cent or less of robenidine.

SAFLUFENACIL in water dispersible granule preparations.

SALICYLANILIDE.

SEDAXANE.

SELAMECTIN **except** in preparations containing 12 per cent or less of selamectin.

SETHOXYDIM.

SIDURON.

SILICOFLUORIDES in preparations containing 3 per cent or less of fluoride ion **except**:

(a) barium silicofluoride when separately specified in this Schedule; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SINBIOALLETHRIN in preparations containing 10 per cent or less of sinbioallethrin **except** in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM CHLORATE **except** in preparations containing 10 per cent or less of sodium chlorate.

SODIUM DIACETATE **except** in preparations containing 60 per cent or less of sodium diacetate.

SODIUM DODECYLBENZENE SULFONATE **except** in preparations containing 30 per cent or less of sodium dodecylbenzene sulfonate.

SODIUM HYDROGEN SULFATE **except** in preparations containing 10 per cent or less of sodium hydrogen sulfate.

SODIUM HYDROSULFITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium hydrosulfite.

† SODIUM HYDROXIDE (excluding its salts and derivatives) in preparations containing 5 per cent or less of sodium hydroxide being:

(a) solid preparations, the pH of which in a 10 g/L aqueous solution is more than 11.5; or

(b) liquid or semi-solid preparations, the pH of which is more than 11.5 **except** in food additive preparations for domestic use.

SODIUM LAURETH-6 CARBOXYLATE **except** in preparations containing 1 per cent or less of sodium laureth-6 carboxylate.

SODIUM METABISULPHITE when packed for domestic use **except** in preparations containing 10 per cent or less of sodium metabisulphite.

SODIUM NITRITE in preparations containing 1 per cent or less of sodium nitrite **except**:

(a) in preparations containing 0.5 per cent or less of sodium nitrite;

(b) when present as an excipient in preparations for therapeutic use; or

(c) in aerosols.

SODIUM PERCARBONATE (CAS No. 15630-89-4) in preparations containing 35 per cent or less of sodium percarbonate **except** in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM POLYSTYRENE SULPHONATE in preparations for cosmetic use **except** in preparations containing 10 per cent or less of sodium polystyrene sulphonate.

SODIUM STANNATE **except** in preparations for cosmetic use containing 1 per cent or less of sodium stannate.

SODIUM SULFIDE in preparations for metal treatment in containers each containing 50 g or less of sodium sulfide.

SPINETORAM.

SPINOSAD **except** in aqueous suspensions containing 25 per cent or less of spinosad.

STAR ANISE OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 50 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of star anise oil.

STYRENE (excluding its derivatives).

SULFACETAMIDE when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

SULFADIAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFADIMIDINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMERAZINE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFAMIC ACID (excluding its salts and derivatives) in preparations containing 10 per cent or less of sulfamic acid (H3NO3S).

SULFATHIAZOLE when packed and labelled for treatment of ornamental caged birds or ornamental fish only.

SULFOMETURON-METHYL.

SULFOXAFLOR in preparations containing 25 per cent or less of sulfoxaflor.

† SYMPHYTUM spp. (Comfrey) for dermal use.

2,3,6-TBA.

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) in preparations containing 10 per cent or less of TDE.

TEBUCONAZOLE.

TEBUFENOZIDE.

TEFLUTHRIN in preparations containing 2 per cent or less of tefluthrin.

TEMEPHOS:

(a) in liquid preparations containing 10 per cent or less of temephos;

(b) in powders containing 2 per cent or less of temephos; or

(c) in preparations containing 40 per cent or less of temephos when packed in single use containers having a capacity of 2 mL or less.

TEPRALOXYDIM.

TERBUTRYN.

TETRACHLOROETHYLENE in preparations containing 5 per cent or less of tetrachloroethylene **except**:

(a) when included in Schedule 2;

(b) in preparations for the treatment of animals; or

(c) when absorbed into an inert solid.

TETRACHLORVINPHOS **except** in animal feeds containing 0.2 per cent or less of tetrachlorvinphos.

TETRACONAZOLE in preparations containing 20 per cent or less of tetraconazole.

TETRACYCLINE in preparations:

(a) for topical application to animals for ocular use only; or

(b) containing 40 per cent or less of tetracycline when packed and labelled for the treatment of ornamental caged birds or ornamental fish only.

TETRAMETHRIN [(R, cis): (R, trans) = 20:80] **except** in pressurised spray packs.

THIABENDAZOLE:

(a) for the treatment of animals; or

(b) when packed and labelled for use as a fungicide **except** in preparations containing 50 per cent or less of thiabendazole.

THIAMETHOXAM in preparations containing 60 per cent or less of thiamethoxam.

THIAZOPYR.

THIFENSULFURON.

THIOBENCARB.

THIODICARB in pelleted preparations containing 1.5 per cent or less of thiodicarb.

THIOPHANATE-METHYL in preparations containing 25 per cent or less of thiophanate-methyl.

THYME OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert, and labelled with the warning:

KEEP OUT OF REACH OF CHILDREN; or

(c) in preparations containing 50 per cent or less of thyme oil.

TIOCARBAZIL.

TOLCLOFOS-METHYL.

TOLTRAZURIL.

TRALKOXYDIM.

TRENBOLONE in implant preparations for growth promotion in animals.

TRIADIMEFON in wettable powders containing 25 per cent or less of triadimefon.

TRIADIMENOL.

TRI-ALLATE.

TRIBENURON-METHYL.

TRICHLOROACETIC ACID, alkali salts of.

† 1,1,1-TRICHLOROETHANE **except**:

(a) in preparations packed in pressurised spray packs;

(b) in preparations containing 25 per cent or less of designated solvents;

(c) in preparations, other than writing correction fluids or thinners for writing correction fluidsin containers having a capacity of 50 mL or less; or

(d) in writing correction fluids or thinners for writing correction fluids, in containers having a capacity of 50 mL or less labelled with:

(i) the word “Trichloroethane” written in letters not less than 1 mm in height and in

distinct contrast to the background; and

(ii) the expression:

**WARNING** − DO NOT DELIBERATELY SNIFF THIS PRODUCT. SNIFFING MIGHT HARM OR KILL YOU;

written in bold face sans serif capital letters not less than 1 mm in height and in distinct contrast to the background.

TRIDIPHANE.

TRIETAZINE.

TRIETHANOLAMINE (excluding its salts and derivatives) **except** in preparations containing 5 per cent or less of triethanolamine.

TRIFLOXYSTROBIN.

TRIFLUMIZOLE.

TRIFLUMURON.

TRIISOPROPANOLAMINE LAURYL ETHER SULFATE **except** in preparations containing 30 per cent or less of triisopropanolamine lauryl ether sulfate when labelled with the statements:

Avoid contact with eyes and skin; and

Wash hands after handling.

TRINEXAPAC-ETHYL **except**:

(a) when packed in a sealed water-soluble measure pack; or

(b) in solid preparations containing 25 per cent or less of trinexapac-ethyl in packs of 50 g or less.

3,6,9-TRIOXAUNDECANEDIOIC ACID **except** in preparations containing 5 per cent or less of

3,6,9-trioxaundecanedioic acid, the pH of which is 3.5 or greater.

TRITICONAZOLE.

TURPENTINE OIL **except** in preparations containing 25 per cent or less of turpentine oil.

TYLOSIN in animal feed premixes containing 5 per cent or less of antibiotic substances:

(a) for growth promotion;

(b) for the prevention of liver abscesses in cattle; or

(c) for the prevention of ileitis in pigs.

VIRGINIAMYCIN in animal feed additives containing 1 per cent or less of virginiamycin for the prevention of laminitis in horses when in a pack of 5 kg or less.

VERNOLATE.

WARFARIN in rodent baits containing 0.1 per cent or less of warfarin.

ZINEB.

## SCHEDULE 6

(Substances marked † are listed in Appendix C)

ABAMECTIN:

(a) in preparations for pesticidal use containing 4 per cent or less of abamectin **except** when included in Schedule 5; or

(b) in slow-release plastic matrix ear tags for livestock use containing 1 g or less of abamectin.

ACEPHATE.

ACETAMIPRID **except** in preparations containing 1 per cent or less of acetamiprid.

ACETIC ACID (excluding its salts and derivatives) and preparations containing more than 80 per cent of acetic acid (CH3COOH) **except** when included in Schedule 2.

ACETIC ANHYDRIDE excluding its derivatives.

ACIFLUORFEN.

ACINITRAZOLE **except** in preparations containing 20 per cent or less of acinitrazole.

ALBENDAZOLE for the treatment of animals **except:**

(a) when included in Schedule 5; or

(b) in intraruminal implants each containing 3.85 g or less of albendazole.

ALDRIN.

† ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for non-domestic use:

(a) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALKOXYLATED FATTY ALKYLAMINE POLYMER **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 20 per cent or less of alkoxylated fatty alkylamine polymer.

ALLETHRIN **except**:

(a) when included in Schedule 5;

(b) in insecticidal mats containing 20 per cent or less of allethrin; or

(c) in other preparations containing 1 per cent or less of allethrin.

ALPHA-CYPERMETHRIN:

(a) in aqueous preparations containing 25 per cent or less of alpha-cypermethrin; or

(b) in other preparations containing 10 per cent or less of alpha-cypermethrin,

**except** when included in Schedule 5.

AMICARBAZONE.

AMIDITHION.

AMINOCARB in preparations containing 25 per cent or less of aminocarb.

AMINOETHOXYVINYLGLYCINE **except** in preparations containing 15 per cent or less of aminoethoxyvinylglycine.

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE.

AMINOPYRALID.

AMITRAZ.

AMMONIA (excluding its salts and derivatives other than ammonium hydroxide) **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal therapeutic use;

(c) in preparations for inhalation when absorbed in an inert solid material; or

(d) in preparations containing 0.5 per cent or less of ammonia.

AMMONIUM PERSULFATE in hair preparations.

ANILINE (excluding its salts and derivatives) **except** in preparations containing 1 per cent or less of aniline.

ANTIMONY COMPOUNDS **except**:

(a) when included in Schedule 4;

(b) antimony chloride in polishes;

(c) antimony titanate pigments in paint; or

(d) in paints or tinters containing 5 per cent or less of antimony calculated on the non-volatile content of the paint or tinter.

ARSENIC:

(a) in ant poisons containing 0.4 per cent or less of arsenic;

(b) in animal feed premixes containing 4 per cent or less of arsenic; or

(c) in preparations for the treatment of animals **except** thiacetarsamide when included in Schedule 4,

**except** when separately specified in this Schedule.

ASPIRIN for the treatment of animals **except** when included in Schedule 4 or 5.

AZACONAZOLE **except** in preparations containing 1 per cent or less of azaconazole.

† AZADIRACHTA INDICA (Neem) including its extracts and derivatives **except**:

(a) when included in Schedule 5;

(b) in preparations for human internal use;

(c) debitterised neem seed oil;

(d) in preparations for human dermal therapeutic use containing cold pressed neem seed oil, when in a container fitted with a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*; or

(e) in preparations for dermal use containing 1 per cent or less of cold pressed neem seed oil.

AZAMETHIPHOS.

AZOBENZENE.

BAMBERMYCIN (flavophospholipol) in animal feed premixes for growth promotion containing 2 per cent or less of antibiotic substances.

BARIUM SALTS **except**:

(a) when included in Schedule 5;

(b) barium sulfate; or

(c) in paints or tinters containing 5 per cent or less of barium calculated on the non-volatile content of the paint or tinter.

† BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) **except**:

(a) in preparations for skin colouration and dyeing of eyelashes or eyebrows; or

(b) in hair dye preparations containing 1 per cent or less of Basic Orange 31 when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN;

If in eyes wash out immediately with water; and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height.

BAY OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of bay oil.

BEAUVERIA BASSIANA **except** when included in Schedule 5.

BENDIOCARB:

(a) in wettable powders containing 80 per cent or less of bendiocarb when packed in containers or primary packs containing not less than 100 g of bendiocarb;

(b) in wettable powders containing 20 per cent or less of bendiocarb and not less than 0.002 per cent of denatonium benzoate when packed in containers or primary packs containing not less than 48 g of bendiocarb and labelled for use as a fly control preparation;

(c) in insoluble granular preparations containing 5 per cent or less of bendiocarb; or

(d) when impregnated in plastic resin strip material containing 10 per cent or less of bendiocarb,

**except** when included in Schedule 5.

BENQUINOX.

BENSULIDE.

1,2-BENZENEDIOL.

BENZALKONIUM CHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of benzalkoniumchloride.

6-BENZYLADENINE **except** in preparations containing 2 per cent or less of 6-benzyladenine.

BERYLLIUM.

BETACYFLUTHRIN in preparations containing 12.5 per cent or less of betacyfluthrin **except** when included in Schedule 5.

BETA-CYPERMETHRIN.

BHC (excluding lindane).

BIFENTHRIN in preparations containing 25 per cent or less of bifenthrin except in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) in preparations containing 3 per cent or less of total bifluorides **except** when included in Schedule 5.

BIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of bioallethrin.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo- (2.2.1)heptane-2,5-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE **except** in preparations containing 1 per cent or less of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine,

or a combination of N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,5-dimethanamine and

N,N-bis(phenylmethylene)-bicyclo-(2.2.1)heptane-2,6-dimethanamine, when labelled with statements to the effect of:

IRRITANT;

REPEATED EXPOSURE MAY CAUSE SENSITISATION;

Avoid contact with eyes;

Avoid contact with skin;

Wear protective gloves when mixing or using; and

Ensure adequate ventilation when using.

† BITHIONOL for treatment of animals.

BORON TRIFLUORIDE in preparations containing 1 per cent or less of boron trifluoride (BF3) **except** when included in Schedule 5.

BRODIFACOUM in preparations containing 0.25 per cent or less of brodifacoum.

BROMADIOLONE in preparations containing 0.25 per cent or less of bromadiolone.

BROMETHALIN in rodent baits containing 0.01 per cent or less of bromethalin.

BROMOFORM **except** when included in Schedule 4.

BROMOPHOS.

BROMOPHOS-ETHYL.

BROMOXYNIL.

BROMUCONAZOLE **except** when included in Schedule 5.

BROTIANIDE.

BUNAMIDINE.

BUTACARB.

BUTOXYCARBOXIM **except** when included in Schedule 5.

2-BUTOXYETHANOL and its ACETATES **except** in preparations containing 10 per cent or less of such substances.

2-BUTOXY-2’-THIOCYANODIETHYL ETHER.

BUTYRIC ACID in preparations for use as insect lures.

CACODYLIC ACID:

(a) in animal feed premixes containing 4 per cent or less of arsenic; or

(b) in herbicide or defoliant preparations containing 10 per cent or less of cacodylic acid.

CADMIUM COMPOUNDS **except**:

(a) when included in Schedule 4; or

(b) in paints or tinters containing 0.1 per cent or less of cadmium calculated on the non-volatile content of the paint or tinter.

CADUSAFOS in aqueous preparations containing 20 per cent or less of microencapsulated cadusafos.

CAJUPUT OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cajuput oil; or

(f) in oils containing 25 per cent or less of cajuput oil.

CALCIFEROL in rodent baits containing 0.1 per cent or less of calciferol.

CAMBENDAZOLE.

CAMPHOR **except**:

(a) when included in Schedule 4 or 5;

(b) when enclosed in an inhaler device which prevents ingestion of its contents;

(c) in solid or semi-solid preparations containing 12.5 per cent or less of camphor;

(d) in liquid preparations containing 2.5 per cent or less of camphor;

(e) in essential oils when the camphor is present as a natural component of the oil:

(i) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(ii) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(iii) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(iv) in essential oils other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in rosemary oil, sage oil (Spanish), or lavandin oil as such.

CAPTAN.

CARBARYL **except** when included in Schedule 4 or 5.

CARBON DISULFIDE.

† CARBAMIDE PEROXIDE **except**:

(a) when included in Schedule 5; or

(b) in other preparations containing 9 per cent or less of carbamide peroxide.

CASTOR OIL, MONOMALEATE (excluding its salts and derivatives) in preparations for cosmetic use **except** in wash-off preparations containing 1 per cent or less of castor oil, monomaleate.

CHLORALOSE (alpha-CHLORALOSE) when packed and labelled for use as a pesticide.

CHLORDANE.

CHLORFENAPYR in preparations containing 36 per cent or less of chlorfenapyr **except** when included in Schedule 5.

CHLORFENETHOL.

CHLORHEXIDINE in preparations containing 7 per cent or less of chlorhexidine **except**:

(a) when included in Schedule 5;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) when in solid preparations.

CHLORINATING COMPOUNDS **except**:

(a) when included in Schedule 5;

(b) when separately specified in these Schedules;

(c) sodium hypochlorite preparations with a pH of less than 11.5;

(d) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(e) in liquid preparations containing less than 2 per cent of available chlorine; or

(f) in other preparations containing 4 per cent or less of available chlorine.

CHLORMEQUAT.

CHLOROFORM **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of chloroform.

ALPHA-CHLOROHYDRIN.

CHLOROPHACINONE.

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL

(uniconazole-p) **except** in preparations containing 5 per cent or less of

(E)-(S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol.

CHLOROPICRIN in preparations containing 5 per cent or less of chloropicrin.

CHLOROTHALONIL **except** in water-based paint containing 0.5 per cent or less of chlorothalonil.

CHLORPYRIFOS **except**:

(a) when included in Schedule 5; or

(b) in prepared potting or soil mixes containing 100 g or less of chlorpyrifos per cubic metre.

CHLORPYRIFOS-METHYL.

CHLORTHIAMID.

CHROMATES(including dichromates) **except** in paints or tinters containing 5 per cent or less of chromium as the ammonium, barium, potassium, sodium, strontium or zinc chromate calculated on the non-volatile content of the paint or tinter.

CHROMIUM TRIOXIDE (excluding its salts and derivatives).

CINEOLE **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations containing 25 per cent or less of cineole;

(f) in oils containing 25 per cent or less of cineole; or

(g) in rosemary oil or camphor oil (white).

CINNAMON LEAF OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of cinnamon leaf oil.

CLIMBAZOLE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of climbazole.

CLODINAFOP-PROPARGYL.

CLOMAZONE.

CLOSANTEL.

CLOTHIANIDIN **except** when included in Schedule 5.

CLOTRIMAZOLE for external treatment of animals.

CLOVE OIL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of clove oil.

N-COCO-1,3-DIAMINOPROPANE.

COPPER ACETATE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of copper acetate.

COPPER COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) in preparations for human internal use containing 5 mg or less of copper per recommended daily dose;

(c) pigments where the solubility of the copper compound(s) in water is 1 gram per litre or less;

(d) in feed additives containing 1 per cent or less of copper; or

(e) in other preparations containing 5 per cent or less of copper compounds.

COPPER HYDROXIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent or less of copper hydroxide.

COPPER NITRATE in preparations containing copper chloride for the treatment of footrot in sheep.

COPPER OXIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use;

(c) in marine paints; or

(d) in other preparations containing 5 per cent or less of copper oxides.

COPPER OXYCHLORIDE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 12.5 per cent of less of copper oxychloride.

COPPER SULFATE **except**:

(a) when included in Schedule 5;

(b) in preparations for internal use; or

(c) in other preparations containing 5 per cent or less of copper sulfate.

COUMAPHOS:

(a) in slow-release plastic matrix ear tags for livestock use containing 6 g or less of coumaphos; or

(b) in other preparations containing 5 per cent or less of coumaphos.

COUMATETRALYL in rodenticides containing 1 per cent or less of coumatetralyl **except** when included in Schedule 5.

CREOSOTE derived from wood other than beechwood **except**:

(a) when included in Schedule 2;

(b) in preparations for human therapeutic use containing 10 per cent or less of creosote derived from wood other than beechwood; or

(c) in other preparations containing 3 per cent or less of phenols and homologues of phenol boiling below 220°C.

CROTOXYPHOS.

CRUFOMATE.

CYANAMIDE.

CYANAZINE.

CYCLANILIDE.

N-cyclohexyldiazeniumdioxy-potassium.

CYFLUTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of cyfluthrin.

CYOMETRINIL.

CYPERMETHRIN **except** when included in Schedule 5.

CYPHENOTHRIN **except** when included in Schedule 5.

CYSTEAMINE for cosmetic use **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of cysteamine.

CYTHIOATE **except** when included in Schedule 5.

2,4-D **except** when included in Schedule 5.

DAZOMET.

DELTAMETHRIN:

(a) in aqueous preparations containing 25 per cent or less of deltamethrin, when no organic solvent, other than 10 per cent or less of a glycol, is present;

(b) in wettable granular preparations containing 25 per cent or less of deltamethrin;

(c) in water-dispersible tablets each containing 500 mg or less of deltamethrin;

(d) in emulsifiable concentrates containing 11 per cent or less of deltamethrin in a solvent containing 40 per cent or less of acetophenone and 45 per cent or less of liquid hydrocarbons; or

(e) in other preparations containing 3 per cent or less of deltamethrin,

**except:**

(a) when included in Schedule 5;

(b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or

(c) in preparations containing 0.1 per cent or less of deltamethrin.

DERQUANTEL.

DIAZINON **except** when included in Schedule 5.

DICAMBA (including its salts and derivatives) **except** when included in Schedule 5.

DICHLOBENIL.

DICHLOFENTHION.

DICHLOFLUANID.

ortho-DICHLOROBENZENE.

DICHLOROETHYL ETHER.

DICHLOROISOCYANURIC ACID **except**:

(a) when included in Schedule 5;

(b) in liquid preparations containing not less than 2 per cent but not more than 4 per cent of available chlorine when labelled with the statements:

**WARNING** – Ensure adequate ventilation when using. Vapour may be harmful. May give off dangerous gas if mixed with other products;

(c) in liquid preparations containing less than 2 per cent of available chlorine; or

(d) in other preparations containing 4 per cent or less of available chlorine.

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE.

DICHLOROPHEN **except**:

(a) when included in Schedules 4 or 5; or

(b) in fabrics other than when:

(i) for human therapeutic use; or

(ii) as part of a registered pesticidal product.

1,2-DICHLOROPROPANE.

2,4-DICHLORPROP (including the R and S enantiomers).

DICHLORVOS in preparations containing 50 per cent or less of dichlorvos **except** when included in Schedule 5.

DICLOFOP-METHYL.

DICYCLANIL **except** in preparations containing 5 per cent or less of dicyclanil.

DIDECYLDIMETHYLAMMONIUM SALTS **except** in preparations containing 1 per cent or less of didecyldimethylammonium salts labelled with the statement:

Avoid contact with eyes.

DIELDRIN.

DIETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of diethanolamine.

† DIETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of diethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of diethylene glycol.

DIFENACOUM in preparations containing 0.25 per cent or less of difenacoum.

DIFENZOQUAT.

DIFETHIALONE in rodent baits containing 0.0025 per cent or less of difethialone.

† 5,6-DIHYDROXYINDOLINE.

DIMETHENAMID-P.

DIMETHIPIN.

DIMETHOATE.

DIMETHYLACETAMIDE **except** when included in Schedule 5.

DIMETHYLFORMAMIDE **except**:

(a) when included in Schedule 5; or

(b) in silicone rubber mastic containing 2 per cent or less of dimethylformamide.

DIMETHYL SULFOXIDE(excluding dimethyl sulfone):

(a) when not for therapeutic use; or

(b) for the treatment of animals:

(i) when combined with no other therapeutic substance(s);

(ii) in liquid preparations containing copper salicylate and 1 per cent or less of methyl salicylate as the only other therapeutic substances; or

(iii) in clay poultices containing 2 per cent or less of dimethyl sulfoxide.

DINITROCRESOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DINITROPHENOLS and their homologues in preparations containing 5 per cent or less of such compounds **except**:

(a) when included in Schedule 4; or

(b) when separately specified in this Schedule.

DIOXACARB.

DIOXANE.

DIPHACINONE.

DIQUAT in preparations containing 20 per cent or less of diquat.

DISULFIRAM **except** when included in Schedule 4.

DISULFOTON in granular preparations containing 5 per cent or less of disulfoton.

DITHIANON.

DITHIAZANINE in preparations containing 2 per cent or less of dithiazanine for the treatment of animals.

DIUREDOSAN.

N-(N-DODECYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

DODINE.

DORAMECTIN for external use for the treatment of animals, in preparations containing 2 per cent or less of doramectin.

DSMA in herbicide or defoliant preparations containing 10 per cent or less of DSMA.

ECONAZOLE for external treatment of animals.

EMAMECTIN in preparations containing 5 per cent or less of emamectin **except** when included in Schedule 5.

EMODEPSIDE for the treatment of animals **except** when included in Schedule 5.

ENDOSULFAN in aqueous preparations containing 33 per cent or less of microencapsulated endosulfan.

ENDOTHAL in preparations containing 20 per cent or less of endothal.

EPTC.

ESBIOTHRIN **except**:

(a) when included in Schedule 5; or

(b) in pressurised spray packs containing 1 per cent or less of esbiothrin.

ESFENVALERATE **except** when included in Schedule 5.

ETHANOLAMINE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations containing 5 per cent or less of ethanolamine.

ETHEPHON (excluding its salts and derivatives).

ETHER **except**:

(a) when included in Schedule 2, 4 or 5; or

(b) in preparations containing 10 per cent or less of ether.

ETHIOFENCARB.

ETHOATE-METHYL.

ETHOPROPHOS in granular formulations containing 10 per cent or less of ethoprophos and 2 per cent of linseed oil.

ETHYL BROMIDE.

Ethyl formate when packed and labelled for use as a fumigant.

ETHYLENE CHLOROHYDRIN.

ETHYLENE DICHLORIDE.

† ETHYLENE GLYCOL (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in paints or paint tinters;

(c) in toothpastes or mouthwashes containing more than 0.25 per cent of ethylene glycol; or

(d) in other preparations containing 2.5 per cent or less of ethylene glycol.

ETHYLENE GLYCOL MONOALKYL ETHERS and their ACETATES, **except**:

(a) when separately specified in these Schedules; or

(b) in preparations containing 10 per cent or less of such substances.

ETRIMFOS.

EUCALYPTUS OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of eucalyptus oil.

EUGENOL **except**:

(a) when included in Schedule 5;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(e) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(f) in preparations containing 25 per cent or less of eugenol.

FAMPHUR in preparations containing 20 per cent or less of famphur.

FEBANTEL **except**:

(a) in divided preparations containing 1000 mg or less of febantel per dosage unit; or

(b) in undivided preparations containing 10 per cent or less of febantel.

FENAMIPHOS in granular preparations containing 5 per cent or less of fenamiphos.

FENAZAFLOR.

FENBUTATIN OXIDE.

FENCHLORPHOS.

FENITROTHION.

FENOXACRIM in preparations for the treatment of carpets during manufacture.

FENPYROXIMATE.

FENTHION in preparations containing 60 per cent or less of fenthion **except** when included in Schedule 5.

FENVALERATE.

FIPRONIL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.05 per cent or less of fipronil.

FLOCOUMAFEN in preparations containing 0.005 per cent or less of flocoumafen.

FLONICAMID.

FLUAZIFOP-BUTYL.

FLUAZIFOP-P-BUTYL.

FLUAZINAM.

FLUCOFURON in preparations for the treatment of carpets during manufacture.

FLUMETHRIN **except** when included in Schedule 5.

FLUMIOXAZIN when contained in water soluble bags individually packed in sealed sachets.

FLUORIDES **except**:

(a) when included in Schedule 5;

(b) in preparations for human use; or

(c) in preparations containing 15 mg/kg or less of fluoride ion.

FLUPROPANATE.

FLUQUINCONAZOLE.

FLUSILAZOL.

FLUTRIAFOL **except** in fertilisers containing 0.5 per cent or less of flutriafol.

FLUVALINATE **except** when included in Schedule 5.

† FORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

FORMOTHION.

FOSPIRATE **except** when included in Schedule 5.

FUMAGILLIN.

GLUTARALDEHYDE **except**:

(a) when included in Schedule 2 or 5; or

(b) in preparations containing 0.5 per cent or less of glutaraldehyde when labelled with the statements:

IRRITANT; and

Avoid contact with eyes.

GLYCERYL THIOGLYCOLLATE in hair waving preparations **except** when labelled with directions for use that include the statement:

Wear protective gloves when using. Keep out of eyes.

GLYCOLIC ACID (including its salts and esters) in cosmetic products or when packed and labelled for use as an agricultural chemical **except**:

(a) in cosmetic preparations for salon use only, when labelled in accordance with Safe Work Australia’s *National Code of Practice for the Labelling of Workplace Substances* [NOHSC:2012(1994)];

(b) in preparations containing 5 per cent or less of glycolic acid; or

(c) in preparations containing 20 per cent or less of glycolic acid with a pH of 3.5 or greater.

GUANIDINE **except**:

(a) when included in Schedule 4; or

(b) in preparations containing 1 per cent or less of guanidine.

GUAZATINE.

HALOXON.

HALOXYFOP.

HEPTACHLOR.

HEXACHLOROPHANE in preparations for the treatment of animals.

HEXAZINONE **except** when included in Schedule 5.

HEXYLOXYETHANOL **except** in preparations containing 10 per cent or less of hexyloxyethanol.HYDRAMETHYLNON **except** when included in Schedule 5.

HYDRAZINE.

HYDROCHLORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 0.5 per cent or less of hydrochloric acid (HCl).

HYDROFLUORIC ACID (excluding its salts and derivatives) and admixtures that generate hydrofluoric acid, in preparations containing 1 per cent or less of hydrogen fluoride **except** when included in Schedule 5.

† HYDROGEN PEROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in hair dye preparations containing 6 per cent (20 volume) or less of hydrogen peroxide; or

(c) in other preparations containing 3 per cent (10 volume) or less of hydrogen peroxide.

HYDROQUINONE **except**:

(a) when included in Schedule 2 or 4; or

(b) in preparations containing 10 per cent or less of hydroquinone.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) in preparations containing 1 per cent or less of hydrosilicofluoric acid (H2SiF6) **except** when included in Schedule 5.

IMIDACLOPRID **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 5 per cent or less of imidacloprid.

IMIDOCARB.

iminoctadine trialbesilate.

IMIPROTHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of imiprothrin.

INDAZIFLAM.

INDOXACARB (includes the R and S enantiomers) **except** when included in Schedule 5.

IODINE (excluding its salts, derivatives and iodophors) **except**:

(a) when included in Schedule 2; or

(b) in solid or semi-solid preparations containing 2.5 per cent or less of available iodine.

IODOPHORS **except** in preparations containing 1.5 per cent or less of available iodine.

3-IODO-2-PROPYNYL BUTYL CARBAMATE (Iodocarb) **except**:

(a) when included in Schedule 5;

(b) in aqueous preparations not for cosmetic use containing 10 per cent or less of 3-iodo-2-propynyl butyl carbamate (Iodocarb); or

(c) in cosmetic preparations (other than aerosolised preparations) containing 0.1 per cent or less of 3-iodo-2-propynyl butyl carbamate.

IOXYNIL.

IPCONAZOLE **except** when included in Schedule 5.

IRON COMPOUNDS (excluding up to 1 per cent of iron oxides when present as an excipient) for the treatment of animals **except**:

(a) when included in Schedule 5;

(b) in liquid or gel preparations containing 0.1 per cent or less of iron; or

(c) in animal feeds or feed premixes.

ISOCONAZOLE for external treatment of animals.

ISOCYANATES, free organic, boiling below 300°C, **except** in:

(a) viscous polyurethane adhesives; or

(b) viscous polyurethane sealants;

containing not more than 0.7 per cent of free organic isocyanates boiling below 300°C.

ISOEUGENOL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of isoeugenol.

LAMBDA-CYHALOTHRIN:

(a) in aqueous preparations containing 25 per cent or less of microencapsulated lambda-cyhalothrin; or

(b) in other preparations containing 1 per cent or less of lambda-cyhalothrin,

**except** when included in Schedule 5.

LASALOCID **except** in animal feeds containing 100 mg/kg or less of antibiotic substances.

LAURETH CARBOXYLIC ACIDS (excluding its salts and derivatives) **except**:

(a) in leave-on preparations containing 1.5 per cent or less of laureth carboxylic acids;

(b) in wash-off preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; or

(c) in other preparations containing 30 per cent or less of laureth carboxylic acids and, if containing more than 5 per cent of laureth carboxylic acids, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

LAURYL ISOQUINOLINIUM BROMIDE.

† LEAD COMPOUNDS **except**:

(a) when included in Schedule 4 or 5;

(b) in paints, tinters, inks or ink additives;

(c) in preparations for cosmetic use containing 100 mg/kg or less of lead;

(d) in pencil cores, finger colours, showcard colours, pastels, crayons, poster paints/colours or coloured chalks containing 100 mg/kg or less of lead; or

(e) in ceramic glazes when labelled with the warning statement:

CAUTION − Harmful if swallowed. Do not use on surfaces which contact food or drink.

written in letters not less than 1.5 mm in height.

LEPTOSPERMUM SCOPARIUM OIL (manuka oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings;  
  
KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of *Leptospermum scoparium* oil.

LEVAMISOLE for the treatment of animals **except**:

(a) when included in Schedule 4 or 5; or

(b) in preparations for the treatment of ornamental birds or ornamental fish, in packs containing 10 mg or less of levamisole.

LINDANE **except** when included in Schedule 2, 4 or 5.

MAFENIDE when packed and labelled for the treatment of ornamental fish only.

MALATHION except:

(a) when included in Schedule 5;

(b) for human therapeutic use; or

(c) in dust preparations containing 2 per cent or less of malathion.

MCPA **except** when included in Schedule 5.

MEBENDAZOLE for the treatment of animals **except** when included in Schedule 5.

MECOPROP **except** when included in Schedule 5.

MECOPROP-P.

MEFLUIDIDE.

MELALEUCA OIL (tea tree oil) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN;

(d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(e) in preparations containing 25 per cent or less of melaleuca oil.

MELENGESTROL ACETATE when used as an animal feed additive.

MENAZON.

2-MERCAPTOETHANOL in preparations for use as insect lures.

MERCURIC OXIDE for the treatment of animals, in preparations for ocular use.

MERCUROCHROME for the treatment of animals, in preparations for topical use.

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT for the treatment of animals.

METALAXYL **except** when included in Schedule 5.

METALDEHYDE **except** when included in Schedule 5.

METHACRIFOS in preparations containing 60 per cent or less of methacrifos.

METHAM.

METHANOL (excluding its derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 2 per cent or less of methanol.

METHIOCARB in preparations containing 20 per cent or less of methiocarb **except** when included in Schedule 5.

METHOMYL in fly-baits containing 1 per cent or less of methomyl and not less than 0.002 per cent of denatonium benzoate as a bittering agent.

Methylcyclopentadienyl Manganese Tricarbonyl in preparations containing 10 per cent or less of methylcyclopentadienyl manganese tricarbonyl when fitted with a child-resistant closure.

† METHYLDIBROMO GLUTARONITRILE **except** in preparations intended to be in contact with the skin, including cosmetic use.

METHYLENE BISTHIOCYANATE **except** in preparations containing 1 per cent or less of methylene bisthiocyanate.

METHYLEUGENOL **except** in preparations containing 1 per cent or less of methyleugenol.

METHYL ISOTHIOCYANATE.

† METHYL METHACRYLATE (excluding its derivatives) **except**:

(a) for cosmetic use; or

(b) in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

METHYL NEODECANAMIDE **except** in liquid preparations containing 2 per cent or less of methyl neodecanamide.

METHYLNORBORNYLPYRIDINE.

N-METHYL-2-PYRROLIDONE  **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

METHYL SALICYLATE **except**:

(a) when included in Schedule 5;

(b) in preparations for therapeutic use; or

(c) in preparations containing 5 per cent or less of methyl salicylate.

METOFLUTHRIN.

METOSULAM.

METRAFENONE **except** when included in Schedule 5.

METRIBUZIN.

MICONAZOLE for the external treatment of animals.

MILBEMECTIN **except** when included in Schedule 5.

MONENSIN:

(a) in animal feed premixes containing 12.5 per cent or less of antibiotic substances; or

(b) in stockfeed supplements, blocks or licks containing 0.75 per cent or less of antibiotic substances.

MORANTEL **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 10 per cent or less of morantel.

MOXIDECTIN for external use:

(a) in preparations containing 2.5 per cent or less of moxidectin when packed in single dose tubes for the treatment of cats and dogs; or

(b) in preparations containing 2 per cent or less of moxidectin for the treatment of animals,

**except** when included in Schedule 5.

MSMA in herbicide or defoliant preparations containing 10 per cent or less of MSMA.

NALED **except** when included in Schedule 5.

NAPHTHALENE (excluding its derivatives) **except** in liquid hydrocarbons as an impurity.

NAPHTHALOPHOS in preparations containing 80 per cent or less of naphthalophos.

NARASIN in animal feed premixes containing 12 per cent or less of narasin.

NETOBIMIN for the treatment of animals **except** when included in Schedule 5.

NICKEL SULFATE.

NICOTINE in preparations containing 3 per cent or less of nicotine when labelled and packed for the treatment of animals.

NIMIDANE in preparations containing 25 per cent or less of nimidane.

NITENPYRAM **except** in divided preparations containing 100 mg or less of nitenpyram.

NITRIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 0.5 per cent or less of nitric acid (HNO3).

NITROBENZENE **except**:

(a) in solid or semi-solid polishes;

(b) in soaps containing 1 per cent or less of nitrobenzene; or

(c) in other preparations containing 0.1 per cent or less of nitrobenzene.

NITROPHENOLS, ortho, meta and para, **except** when separately specified in these Schedules.

NITROPRUSSIDES in preparations containing 2.5 per cent or less of nitroprussides **except** when included in Schedule 4.

NITROXYNIL.

NONOXINOL 9 **except**:

(a) when included in Schedule 5;

(b) in preparations containing 25 per cent or less of nonoxinol 9 when labelled with the statements:

IRRITANT; and

Avoid contact with eyes;

(c) in preparations containing 12.5 per cent or less of nonoxinol 9; or

(d) in preparations for human use.

1-Octen-3-ol **except** in preparations containing 5 per cent or less of 1-octen-3-ol.

OCTHILINONE **except** in paints, jointing compounds and sealants containing 1 per cent or less of octhilinone calculated on the non-volatile content.

N-(N-OCTYL)-2-PYRROLIDONE **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 25 per cent or less of designated solvents.

OLAQUINDOX **except** in preparations containing 10 per cent or less of olaquindox.

N-OLEYL-1,3-DIAMINOPROPANE.

OMETHOATE in preparations containing 30 per cent or less of omethoate **except** when included in Schedule 5.

OXADIAZON.

OXALIC ACID **except** its derivatives and insoluble salts.

OXYCLOZANIDE.

PAECILOMYCES LILACINUS Strain 251.

† PARAFORMALDEHYDE (excluding its derivatives) in preparations containing 0.05 per cent or more of free formaldehyde **except**:

(a) for human therapeutic use;

(b) in oral hygiene preparations;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde;

(d) in nail hardener cosmetic preparations containing 0.2 per cent or less of free formaldehyde when labelled with the statement:

PROTECT CUTICLES WITH GREASE OR OIL;

(e) in all other cosmetic preparations; or

(f) in other preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PARATHION-METHYL in aqueous preparations containing 45 per cent or less of microencapsulated parathion-methyl.

PARBENDAZOLE.

PEBULATE.

PENNYROYAL OIL **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of d-pulegone.

PENTACHLOROPHENOL in preparations containing 1.5 per cent or less of pentachlorophenol.

PERACETIC ACID **except** when included in Schedule 5.

PERFLUIDONE.

PERMANGANATES **except** potassium permanganate in aqueous solutions containing 1 per cent or less of potassium permanganate.

PERMETHRIN **except**:

(a) when included in Schedule 4 or 5;

(b) in preparations for human therapeutic use containing 5 per cent or less of permethrin; or

(c) in preparations containing 2 per cent or less of permethrin.

PHENOL, including cresols and xylenols and any other homologue of phenol boiling below 220°C, **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5; or

(c) in preparations containing 3 per cent or less of such substances.

PHENOTHIAZINE (excluding its derivatives) **except** in preparations containing 10 per cent or less of phenothiazine.

† PHENYLENEDIAMINES and alkylated phenylenediamines not elsewhere specified in these Schedules:

(a) in preparations packed and labelled for photographic purposes;

(b) in preparations packed and labelled for testing water **except** tablets containing 10 mg or less of diethyl-para-phenylenediamine or dimethyl-para-phenylenediamine in opaque strip packaging provided the directions for use include the statement, “Do not discard testing solutions into the pool”;

(c) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(d) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

PHOSALONE.

PHOSMET.

PHOSPHORIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 15 per cent or less of phosphoric acid (H3PO4);

(c) in solid or semi-solid preparations; or

(d) in professional dental kits.

PHOXIM.

ortho-PHTHALALDEHYDE **except** when included in Schedule 5.

PINDONE.

PINE OILs when packed and labelled as a herbicide **except** when included in Schedule 5.

PINOXADEN **except** when included in Schedule 5.

PIPEROPHOS.

PIRIMICARB **except** when included in Schedule 5.

PIRIMIPHOS-ETHYL.

PIRIMIPHOS-METHYL.

POLIXETONIUM SALTS **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of polixetonium salts.

POTASSIUM AZELOYL DIGLYCINATE **except** in preparations for cosmetic use containing 1 per cent or less of potassium azeloyl diglycinate.

POTASSIUM BROMATE **except** in preparations containing 0.5 per cent or less of potassium bromate.

POTASSIUM CYANATE.

† POTASSIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of potassium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

POTASSIUM NITRITE in preparations containing 40 per cent or less of potassium nitrite **except**:

(a) when included in Schedule 5;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT **except**:

(a) when included in Schedule 5;

(b) in solid orthodontic device cleaning preparations, the pH of which as an “in-use” aqueous solution is 2.5 or more, but not more than 11.5; or

(c) in preparations containing 5 per cent or less of potassium peroxomonosulfate triple salt being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 2.5 or more; or

(ii) liquid or semi-solid preparations, the pH of which is 2.5 or more.

POTASSIUM PERSULFATE in hair preparations.

PRALLETHRIN (cis:trans=20:80) **except**:

(a) when included in Schedule 5; or

(b) in insecticidal mats containing 1 per cent or less of prallethrin.

PROCHLORAZ.

PROFENOFOS.

PROMACYL.

PROPACHLOR.

PROPARGITE.

PROPETAMPHOS.

PROPICONAZOLE **except** when included in Schedule 5.

PROPINEB.

PROPIONIC ACID (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 30 per cent or less of propionic acid; or

(c) for therapeutic use.

PROPOXUR **except** when included in Schedule 5.

PROQUINAZID.

PROSULFOCARB.

PROSULFURON.

PROTHIOFOS.

d-PULEGONE **except** in preparations containing 4 per cent or less of d- pulegone.

PYRACLOFOS.

PYRAZOPHOS.

PYRIDABEN **except** when included in Schedule 5.

Pyridalyl.

PYRIDATE.

PYRIPROLE.

pyrithione copper.

PYRITHIONE ZINC **except**:

(a) when included in Schedule 2 or 5;

(b) for human use in preparations for the treatment of the scalp containing 2 per cent or less of pyrithione zinc when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(c) in semi-solid hair preparations for animal use;

(d) in shampoos for animal use containing 2 per cent or less of pyrithione zinc when labelled with the statements “Keep out of eyes” and “If in eyes rinse well with water”;

(e) when immobilised in solid preparations containing 0.5 per cent or less of pyrithione zinc; or

(f) in paints, jointing materials or sealants containing 0.1 per cent or less of pyrithione zinc calculated on the non-volatile content.

PYROXASULFONE.

PYROXSULAM.

QUATERNARY AMMONIUM COMPOUNDS **except**:

(a) when separately specified in these Schedules;

(b) when included in Schedule 5;

(c) dialkyl or dialkoyl quaternary ammonium compounds where the alkyl or alkoyl groups are derived from tallow or hydrogenated tallow or similar chain length (C16/C18) sources; or

(d) in preparations containing 5 per cent or less of such quaternary ammonium compounds.

QUIZALOFOP ETHYL.

QUIZALOFOP-P-ETHYL **except** when included in Schedule 5.

QUIZALOFOP-P-TEFURYL.

RESMETHRIN **except** when included in Schedule 5.

ROTENONE **except** in solid or semi-solid preparations containing 2 per cent or less of rotenone.

† SAFROLE **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SAGE OIL (Dalmatian) **except**:

(a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and compliant with the requirements of the *Required Advisory Statements for Medicine Labels*;

(b) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and a child-resistant closure and labelled with the warnings:

KEEP OUT OF REACH OF CHILDREN; and

NOT TO BE TAKEN; or

(c) in preparations containing 4 per cent or less of thujone.

SALINOMYCIN in animal feed premixes containing 12 per cent or less of antibiotic substances.

SASSAFRAS OIL **except**:

(a) for internal use; or

(b) in other preparations containing 1 per cent or less of safrole.

SELENIUM:

(a) in preparations containing 2.5 per cent or less of selenium when packed and labelled:

(i) for the blueing of gun barrels;

(ii) for photographic purposes; or

(iii) for the colouring of lead or lead alloys;

(b) in coated granules containing 1 per cent or less of selenium for application to pasture **except** in fertilisers containing 200 g/tonne or less of selenium; or

(c) for the treatment of animals:

(i) in a drench, injection, paste, stocklick, vaccine or horse feed supplement containing 0.5 per cent or less of selenium;

(ii) in animal feed premixes containing 2 per cent or less of selenium for the preparation of feeds containing 1 g/tonne or less of selenium;

(iii) in controlled release bolus preparations containing 25 mg or less of selenium with a release rate not greater than 0.25 mg/day; or

(iv) as barium selenate in preparations for injection containing 5 per cent or less of selenium.

SEMDURAMICIN in animal feed premixes for coccidiosis prevention containing 5 per cent or less of antibiotic substances.

SILICOFLUORIDES **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 mg/kg or less of fluoride ion.

SILVER NITRATE **except**:

(a) when included in or expressly excluded from Schedule 2; or

(b) in preparations containing 1 per cent or less of silver.

SINBIOALLETHRIN **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 1 per cent or less of sinbioallethrin.

SODIUM ALUMINATE (excluding its salts and derivatives) **except**:

(a) in solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(b) in liquid preparations, the pH of which is 11.5 or less.

SODIUM BROMATE **except** in preparations containing 0.5 per cent or less of sodium bromate.

† SODIUM HYDROXIDE (excluding its salts and derivatives) **except**:

(a) when included in Schedule 5;

(b) in preparations containing 5 per cent or less of sodium hydroxide being:

(i) solid preparations, the pH of which in a 10 g/L aqueous solution is 11.5 or less; or

(ii) liquid or semi-solid preparations, the pH of which is 11.5 or less; or

(c) liquid or semi-solid food additive preparations, the pH of which is more than 11.5, for domestic use.

SODIUM LAURYL SULFATE (excluding its salts and derivatives) **except:**

(a) in wash-off preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with a warning to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER;

(b) in leave-on preparations containing 1.5 per cent or less of sodium lauryl sulfate;

(c) in toothpaste and oral hygiene preparations containing 5 per cent or less of sodium lauryl sulfate;

(d) in other preparations for animal use containing 2 per cent or less of sodium lauryl sulfate; or

(e) in other preparations containing 30 per cent or less of sodium lauryl sulfate and, if containing more than 5 per cent of sodium lauryl sulfate, when labelled with warnings to the following effect:

IF IN EYES WASH OUT IMMEDIATELY WITH WATER; and

IF SKIN OR HAIR CONTACT OCCURS, REMOVE CONTAMINATED CLOTHING AND FLUSH SKIN AND HAIR WITH RUNNING WATER.

SODIUM NITRITE in preparations containing 40 per cent or less of sodium nitrite **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

SODIUM PERCARBONATE (CAS No. 15630-89-4) **except**:

(a) when included in Schedule 5; or

(b) in preparations containing 15 per cent or less of sodium percarbonate.

SODIUM PERSULFATE:

(a) in hair preparations; or

(b) in products for the treatment of water for swimming pools and spas.

SODIUM SULFIDE in preparations for use as insect lures.

SPIROTETRAMAT.

SPIROXAMINE.

SULCOFURON in preparations for the treatment of carpets during manufacture.

SULFAMIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5.

SULFLURAMID.

SULFOXAFLOR **except** when included in Schedule 5.

SULFURIC ACID (excluding its salts and derivatives) **except**:

(a) in fire extinguishers; or

(b) in preparations containing 0.5 per cent or less of sulfuric acid (H2SO4).

SULFURYL FLUORIDE.

SULPROFOS.

2,4,5-T.

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE and TALLOW ALKYLAMINE ACETATES.

TAR ACIDS distilling within the range 230-290°C inclusive.

TCMTB (2-[thiocyanomethylthio]benzothiazole).

TDE (1,1-dichloro-2,2-bis[4-chlorophenyl]ethane) **except** when included in Schedule 5.

TEBUFENPYRAD.

TEBUTHIURON.

TEMEPHOS **except** when in Schedule 5.

TERBUTHYLAZINE **except** in preparations containing 5 per cent or less of terbuthylazine.

TERPENES, CHLORINATED.

TESTOSTERONE in implant preparations for use in animals.

TETRACHLOROETHYLENE **except**:

(a) when included in Schedule 2 or 5;

(b) in preparations containing 6 per cent or less of tetrachloroethylene when absorbed into an inert solid; or

(c) in preparations for the treatment of animals.

TETRACONAZOLE **except** when included in Schedule 5.

TETRADIFON.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE in amitraz formulations containing 2 per cent or less of 2,2’,6,6’-tetraisopropyl-diphenyl-carbodiimide.

TETRAMISOLE in preparations for the treatment of animals.

THIACLOPRID.

THIAMETHOXAM **except** when included in Schedule 5.

THIAZAFLURON.

THIODICARB **except** when included in Schedule 5.

THIOMETON.

THIOPHANATE-METHYL **except** when included in Schedule 5.

THIOUREA AND ALKYL THIOUREAS **except**:

(a) when separately specified in these Schedules; or

(b) for therapeutic use.

THIRAM **except** in paint containing 0.5 per cent or less of thiram.

THUJONE **except** in preparations containing 4 per cent or less of thujone.

THYMOL when packed and labelled for the control of *Varroa* mites in bee hives.

TOLUENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of toluene or toluene and xylene.

†TOLUENEDIAMINE not elsewhere specified in these Schedules:

(a) in hair dye preparations **except** when the immediate container and primary pack are labelled with the following statements:

KEEP OUT OF REACH OF CHILDREN, and

WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to the accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

written in letters not less than 1.5 mm in height; or

(b) in eyelash and eyebrow tinting products when the immediate container and primary pack are labelled with the following statement:

WARNING − This product contains ingredients which may cause skin irritation to certain individuals, and when used for eyelash and eyebrow tinting may cause injury to the eye. A preliminary test according to the accompanying directions should be made before use.

written in letters not less than 1.5 mm in height.

TOLYLFLUANID.

TRANSFLUTHRIN **except**:

(a) in preparations containing 1 per cent or less of transfluthrin; or

(b) in a cartridge for vaporiser use containing 600 mg or less of transfluthrin per cartridge.

TRIADIMEFON **except**:

(a) when included in Schedule 5; or

(b) in fertilisers containing 5 g/kg or less of triadimefon.

TRICHLORFON **except** metrifonate included in Schedule 4.

TRICHLOROACETIC ACID **except**:

(a) when included in Schedule 4 or 5; or

(b) in human dermal preparations containing 12.5 per cent or less of trichloroacetic acid for the treatment of warts other than anogenital warts.

TRICHLOROETHYLENE **except** when included in Schedule 4.

TRICHLOROPHENOL.

TRICLABENDAZOLE **except** in preparations containing 20 per cent or less of triclabendazole.

TRICLOPYR.

TRICLOSAN in cosmetic preparations for human use containing more than 0.3 per cent of triclosan.

TRIDEMORPH.

TRIETHYL PHOSPHATE.

TRIFLUOROMETHANESULFONIC ACID.

TRINITROPHENOL (excluding its derivatives) **except**:

(a) in preparations for human therapeutic use; or

(b) in preparations containing 5 per cent or less of trinitrophenol.

TRISODIUM NITRILOTRIACETATE **except** in preparations containing 20 per cent or less of trisodium nitrilotriacetate.

VAMIDOTHION.

WARFARIN **except** when included in Schedule 4 or 5.

XYLENE (excluding its derivatives) **except** in preparations containing 50 per cent or less of xylene or xylene and toluene.

ZERANOL in ear implants for use as a growth promotant in steer cattle.

ZETA-CYPERMETHRIN in preparations containing 10 per cent or less of zeta-cypermethrin.

ZINC BORATE (excluding its derivatives) for use as an agricultural chemical.

ZINC CHLORIDE **except**:

(a) when included in Schedule 2; or

(b) in preparations containing 5 per cent or less of zinc chloride.

ZINC para-PHENOLSULFONATE **except** in preparations containing 5 per cent or less of zinc para-phenolsulfonate.

ZINC SULFATE **except**:

(a) when included in or expressly excluded from Schedule 4; or

(b) in other preparations containing 5 per cent or less of zinc sulfate.

ZIRAM in granular preparations.

## SCHEDULE 7

ABAMECTIN **except** when included in Schedule 5 or 6.

ACIBENZOLAR-S-METHYL.

ACRIFLAVINE for veterinary use **except** when in Schedule 5.

ACROLEIN.

ACRYLONITRILE.

ALACHLOR.

ALDICARB.

ALDOXYCARB.

ALLYL ALCOHOL.

ALPHA-CYPERMETHRIN **except** when included in Schedule 5 or 6.

AMINACRINE for veterinary use **except** when included in Schedule 5.

AMINOCARB **except** when included in Schedule 6.

4-AMINOPYRIDINE **except** when included in Schedule 4.

AMITON.

ARPRINOCID.

ARSENIC **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 4 or 6;

(c) as selenium arsenide in photocopier drums;

(d) as 10,10’-oxydiphenoxarsine in silicone rubber mastic containing 120 mg/kg or less of arsenic;

(e) as 10,10’-oxydiphenoxarsine contained in polyvinyl chloride and polyurethane extruded and moulded articles containing 160 mg/kg or less of arsenic other thanwhen included in articles:

(i) in contact with food stuffs, animal feeds or potable water;

(ii) of clothing and footwear in contact with the skin;

(iii) used as infant wear; or

(iv) intended for use as packaging materials;

(f) in animal feeds containing 75 g/tonne or less of arsenic; or

(g) in paints containing 0.1 per cent or less of arsenic calculated on the non-volatile content of the paint.

AZAFENIDIN.

AZINPHOS-ETHYL.

AZINPHOS-METHYL.

AZOCYCLOTIN.

BENDIOCARB **except** when included in Schedule 5 or 6.

BENOMYL **except** in paints containing 0.5 per cent or less of benomyl.

BENZENE (excluding its derivatives) **except**:

(a) preparations containing 15 mL/L or less of benzene; or

(b) petrol containing 50 mL/L or less of benzene.

BETACYFLUTHRIN **except** when included in Schedule 5 or 6.

BIFENTHRIN **except**:

(a) when included in Schedule 6; or

(b) in preparations containing 0.5 per cent or less of bifenthrin.

BIFLUORIDES (including ammonium, potassium and sodium salts) **except** when included in Schedule 5 or 6.

BORON TRIFLUORIDE **except** when included in Schedule 5 or 6.

BRODIFACOUM **except** when included in Schedule 6.

BROMADIOLONE **except** when included in Schedule 6.

BROMETHALIN **except** when included in Schedule 6.

BROMINE (excluding its salts and derivatives).

BRUCINE **except** in alcohol containing 0.02 per cent or less of brucine as a denaturant.

CACODYLIC ACID **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 75 g/tonne or less of arsenic.

CADUSAFOS **except** when included in Schedule 6.

CALCIFEROL for use as a rodenticide **except** when included in Schedule 6.

CAPTAFOL.

CARBADOX.

CARBENDAZIM **except** in paints, jointing compounds and sealants containing 0.1 per cent or less of carbendazim.

CARBOFURAN.

CARBON TETRACHLORIDE **except** in chlorinated rubber based paint containing 1 per cent or less of carbon tetrachloride.

CARBONYL SULFIDE when packed and labelled for use as a fumigant.

CARBOPHENOTHION.

CARBOSULFAN.

CHLORDECONE.

CHLORDIMEFORM.

CHLORFENAPYR **except** when included in Schedules 5 or 6.

CHLORFENVINPHOS.

CHLORINE (excluding its salts and derivatives).

CHLORHEXIDINE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 1 per cent or less of chlorhexidine; or

(c) in solid preparations.

CHLOROMETHIURON.

5-CHLORO-3-METHYL-4-NITROPYRAZOLE.

4-CHLORO-o-TOLUIDINE.

CHLOROPICRIN **except** when included in Schedule 6.

CHLORTHIOPHOS.

COLECALCIFEROL for use as a rodenticide.

COUMAPHOS **except** when included in Schedule 6.

COUMATETRALYL **except** when included in Schedule 5 or 6.

CREOSOTE derived from coal.

CREOSOTE derived from beechwood.

CYANIDES, metallic **except**:

(a) ferricyanides;

(b) ferrocyanides; or

(c) when separately specified in these Schedules.

CYANOGEN.

CYHALOTHRIN (aRS,1R,cis,Z):(aRS,1S,cis,Z) = 50:50.

CYHEXATIN.

DELTAMETHRIN **except:**

(a) when included in Schedules 5 or 6; or

(b) in factory prepared mosquito nets containing 1 per cent or less of deltamethrin; or

(c) in preparations containing 0.1 per cent or less of deltamethrin.

DEMETON.

DEMETON-O-METHYL.

DEMETON-S-METHYL.

DIALIFOS.

4,4-DIAMINODIPHENYLMETHANE (Methylene dianiline).

1,2-DIBROMO-3-CHLOROPROPANE.

1,3-DICHLOROPROPENE.

DICHLORVOS **except** when included in Schedule 5 or 6.

DICROTOPHOS.

DIFENACOUM **except** when included in Schedule 6.

DIFETHIALONE **except** when included in Schedule 6.

DIMEFOX.

4-DIMETHYLAMINOAZOBENZENE (N,N-dimethyl-4-[phenylazo]-benzenamine).

DIMETHYL SULFATE.

DIMETILAN.

DINITROCRESOLS **except** when included in Schedule 4 or 6.

DINITROPHENOLS **except** when included in Schedule 4 or 6.

DINOCAP.

DINOSEB.

DIQUAT **except** when included in Schedule 6.

DISULFOTON **except** when included in Schedule 6.

DORAMECTIN **except** when included in Schedule 5 or 6.

DSMA **except** when included in Schedule 6.

EMAMECTIN **except** when included in Schedule 5 or 6.

ENDOSULFAN **except** when included in Schedule 6.

ENDOTHAL **except** when included in Schedule 6.

ENDRIN.

EPICHLOROHYDRIN.

EPIDERMAL GROWTH FACTOR **except** in preparations for human therapeutic use.

EPRINOMECTIN **except** when included in Schedule 5.

ETACONAZOLE.

ETHION.

ETHOPROPHOS **except** when included in Schedule 6.

ETHYLENE DIBROMIDE.

ETHYLENE OXIDE.

FAMPHUR **except** when included in Schedule 6.

FENAMIPHOS **except** when included in Schedule 6.

FENOXACRIM **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FENSULFOTHION.

FENTHION **except** when included in Schedule 5 or 6.

FENTHION-ETHYL.

FLOCOUMAFEN **except** when included in Schedule 6.

FLUCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

FLUCYTHRINATE.

FLUMIOXAZIN **except** when included in Schedule 6.

FLUOROACETAMIDE.

FLUOROACETIC ACID.

FOLPET.

FORMETANATE.

FURATHIOCARB **except** when included in Schedule 5.

GAMMA-CYHALOTHRIN **except** when included in Schedule 5.

HALOFUGINONE **except** when included in Schedule 4.

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS.

HCB.

HYDROCARBONS LIQUID AROMATIC (including aromatic extract oils), any

fraction of which boils above 350°C **except**:

(a) when in solid polymers;

(b) when containing 1 per cent or less of total polycyclic aromatic compounds as measured by IP 346; or

(c) when having a Mutagenicity Index of zero as measured by ASTM E1687-95.

HYDROCYANIC ACID **except**:

(a) when included in Schedule 4; or

(b) its salts and derivatives other than cyanides separately specified in this Schedule.

HYDROFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

HYDROGEN SULFIDE.

HYDROSILICOFLUORIC ACID (excluding its salts and derivatives) **except** when included in Schedule 5 or 6.

IODOMETHANE.

ISOCARBOPHOS.

ISOFENPHOS.

ISOPROTURON.

IVERMECTIN **except** when included in Schedule 4 or 5.

LAMBDA-CYHALOTHRIN **except** when included in Schedule 5 or 6.

LEPTOPHOS.

LITHIUM PERFLUOROOCTANE SULFONATE **except** in sealed bait stations containing 1 per cent or less of lithium perfluorooctane sulfonate.

MADURAMICIN **except**:

(a) when included in Schedule 5; or

(b) in animal feeds containing 5 mg/kg or less of antibiotic substances.

MALACHITE GREEN for veterinary use **except** when included in Schedule 5.

MAZIDOX.

MECARBAM.

MERCURIC CHLORIDE when prepared for use for agricultural, industrial, pastoral or horticultural purposes.

MERCURY **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 2, 4 or 6;

(c) in preparations containing 0.01 per cent or less of mercury in organic form as a preservative;

(d) mercury (metallic) in scientific instruments;

(e) dental amalgams; or

(f) in a sealed device, for therapeutic use, which prevents access to the mercury.

METHACRIFOS **except** when included in Schedule 6.

METHAMIDOPHOS.

METHAPYRILENE.

METHAZOLE.

METHIDATHION.

METHIOCARB **except** when included in Schedule 5 or 6.

METHOMYL **except** when included in Schedule 6.

METHOXYETHYLMERCURIC ACETATE.

METHOXYETHYLMERCURIC CHLORIDE.

METHYL BROMIDE.

Methylcyclopentadienyl Manganese Tricarbonyl **except**:

(a) when included in Schedule 6;

(b) when used in laboratory analysis; or

(c) when packed for industrial use in containers with a nominal capacity of 100 L or more.

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA).

METHYLENE BLUE for veterinary use **except** when included in Schedules 4 or 5.

MEVINPHOS.

MIPAFOX.

MIREX.

MOLINATE.

MONOCROTOPHOS.

MOXIDECTIN **except** when included in Schedule 4, 5 or 6.

MSMA **except** when included in Schedule 6.

NAPHTHALOPHOS **except** when included in Schedule 6.

NICOTINE **except**:

(a) when included in Schedule 6;

(b) in preparations for human therapeutic use; or

(c) in tobacco prepared and packed for smoking.

NIMIDANE **except** when included in Schedule 6.

NITROFEN.

NITROPRUSSIDES **except** when included in Schedule 4 or 6.

OMETHOATE **except** when included in Schedule 5 or 6.

OXAMYL.

OXYDEMETON METHYL.

PARAQUAT.

PARATHION.

PARATHION-METHYL **except** when included in Schedule 6.

PENTACHLOROPHENOL **except** when included in Schedule 6.

PHENYLMERCURIC ACETATE **except** in preparations containing 0.01 per cent or less of mercury as a preservative.

PHORATE.

PHOSFOLAN.

PHOSPHIDES, METALLIC.

PHOSPHINE.

PHOSPHORUS, YELLOW (excluding its salts and derivatives).

POTASSIUM NITRITE **except**:

(a) when included in Schedule 5 or 6;

(b) in preparations containing 0.5 per cent or less of potassium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of potassium nitrite.

PROCYMIDONE.

PROPYLENE OXIDE.

PYRINURON.

QUININE for veterinary use **except** when included in Schedule 5.

SAFLUFENACIL **except** when included in Schedule 5.

SCHRADAN.

SELENIUM **except**:

(a) when included in Schedule 6;

(b) as selenium arsenide in photocopier drums;

(c) in preparations for therapeutic use other than:

(i) drench concentrates containing 2.5 per cent or less of selenium; or

(ii) pour-on preparations containing 0.5 per cent or less of selenium;

(d) in paints or tinters containing 0.1 per cent or less of selenium calculated on the non-volatile content of the paint or tinter; or

(e) in fertilisers containing 200 g/tonne or less of selenium.

SEMDURAMICIN **except**:

(a) when included in Schedule 6; or

(b) in animal feeds containing 25 mg/kg or less of antibiotic substances.

SODIUM NITRITE **except**:

(a) when included in Schedule 2, 5 or 6;

(b) in preparations containing 0.5 per cent or less of sodium nitrite;

(c) when present as an excipient in preparations for therapeutic use; or

(d) in aerosols containing 2 per cent or less of sodium nitrite.

STRYCHNINE **except** when included in Schedule 4.

SULCOFURON **except**:

(a) when included in Schedule 6; or

(b) in treated carpets.

SULFENTRAZONE.

SULFOTEP.

TEFLUTHRIN **except** when included in Schedule 5.

TEPP.

TERBUFOS.

TETRACHLOROETHANE.

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE **except** when included in Schedule 6.

THALLIUM.

THIOFANOX.

TIN ORGANIC COMPOUNDS, being di-alkyl, tri-alkyl and tri-phenyl tin compounds where the alkyl group is methyl, ethyl, propyl or butyl **except**:

(a) when separately specified in this Schedule;

(b) in plastics;

(c) in semi-solid sealants, adhesives or elastomers containing 1 per cent or less of the dialkyl, trialkyl or triphenyl tin component; or

(d) in paint containing 1 per cent or less of such compounds calculated as tin in the non-volatile content of the paint.

ortho-TOLIDINE **except** in solid-state diagnostic therapeutic reagents.

TRIAMIPHOS.

TRIAZBUTIL.

TRIBUFOS (s,s,s-tributylphosphorotrithioate).

VINCLOZOLIN.

VINYL CHLORIDE.

ZETA-CYPERMETHRIN **except** when included in Schedule 6.

ZIRAM **except** when included in Schedule 6.

## SCHEDULE 8

(Substances marked # are listed in Appendix D.)

ACETYLDIHYDROCODEINE.

ACETYLMETHADOL.

ACETYLMORPHINES.

ALFENTANIL.

ALPHACETYLMETHADOL.

ALPHAPRODINE.

ALPRAZOLAM.

AMPHETAMINE.

AMYLOBARBITONE **except** when included in Schedule 4.

ANILERIDINE.

BENZYLMORPHINE.

BEZITRAMIDE.

BUPRENORPHINE.

BUTOBARBITONE.

BUTORPHANOL.

CARFENTANYL.

COCAINE.

CODEINE **except** when included in Schedule 2, 3 or 4.

CODEINE-N-OXIDE.

CONCENTRATE OF POPPY STRAW (the material arising when poppy straw has entered into a process for concentration of its alkaloids).

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (Pethidine intermediate A).

CYCLOBARBITONE.

DEXAMPHETAMINE.

DEXTROMORAMIDE.

DEXTROPROPOXYPHENE **except** when included in Schedule 4.

DIFENOXIN **except** when included in Schedule 4.

DIHYDROCODEINE **except** when included in Schedule 2, 3 or 4.

DIHYDROMORPHINE.

DIPHENOXYLATE **except** when included in Schedule 3 or 4.

DIPIPANONE.

# DRONABINOL (*delta*-9-tetrahydrocannabinol) when prepared and packed for therapeutic use.

DROTEBANOL.

ETHYLAMPHETAMINE.

ETHYLMORPHINE **except** when included in Schedule 2 or 4.

FENTANYL.

FLUNITRAZEPAM.

HYDROCODONE.

HYDROMORPHINOL.

HYDROMORPHONE.

KETAMINE.

LEVAMPHETAMINE.

LEVOMETHAMPHETAMINE.

LEVOMORAMIDE.

LEVORPHANOL (excluding its stereoisomers).

LISDEXAMFETAMINE

.

METHADONE.

METHYLAMPHETAMINE.

METHYLDIHYDROMORPHINE.

METHYLPHENIDATE.

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (Pethidine intermediate C).

MORPHINE.

MORPHINE METHOBROMIDE.

MORPHINE-N-OXIDE.

NABILONE.

# NABIXIMOLS (botanical extract of *Cannabis sativa* which includes the following cannabinoids: tetrahydrocannabinol, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acid, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinol and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use.

NORCODEINE.

NORMETHADONE.

OPIUM **except** the alkaloids noscapine in Schedule 2 and papaverine when included in Schedule 2 or 4.

OXYCODONE.

OXYMORPHONE.

PENTAZOCINE.

PENTOBARBITONE **except** when included in Schedule 4.

PETHIDINE.

PHENDIMETRAZINE.

PHENMETRAZINE.

PHENOPERIDINE.

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (Pethidine intermediate B).

PHOLCODINE **except** when included in Schedule 2 or 4.

PIRITRAMIDE.

PROPIRAM.

QUINALBARBITONE.

RACEMORAMIDE.

REMIFENTANIL.

SECBUTOBARBITONE.

SUFENTANIL.

TAPENTADOL.

THEBACON.

THEBAINE.

TILIDINE.

## SCHEDULE 9

(Trivial or unofficial names are marked \*)

ACETORPHINE.

ACETYL-ALPHA-METHYLFENTANYL.

ALKOXYAMPHETAMINES and substituted alkoxyamphetamines **except** when separately specified in these schedules.

ALKOXYPHENYLETHYLAMINES and substituted alkoxyphenylethylamines **except** when separately specified in these Schedules.

ALKYLTHIOAMPHETAMINES and substituted alkylthioamphetamines **except** when separately specified in these schedules.

ALLYLPRODINE.

ALPHAMEPRODINE.

ALPHA-METHYLFENTANYL.

ALPHA-METHYLTHIOFENTANYL.

ALPHAMETHADOL.

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM).

5-(2-AMINOPROPYL)INDAN and substituted 5-(2-aminopropyl)indans **except** when separately specified in these schedules.

BENZETHIDINE.

BENZOYLINDOLES **except** when separately specified in these Schedules.

BENZYLPIPERAZINE \*(BZP).

BETACETYLMETHADOL.

BETA-HYDROXYFENTANYL.

BETA-HYDROXY-3-METHYLFENTANYL.

BETAMEPRODINE.

BETAMETHADOL.

BETAPRODINE.

1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE \*(Bromo-Dragonfly).

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA).

BUFOTENINE.

CANNABIS **except**:

(a) when separately specified in these Schedules; or

(b) processed hemp fibre containing 0.1 per cent or less of tetrahydrocannabinol and products manufactured from such fibre.

CATHINONE.

CLONITAZENE.

COCA LEAF.

CODOXIME.

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE.

CYCLOHEXYLPHENOLS **except** when separately specified in these Schedules.

DESOMORPHINE.

DIAMPROMIDE.

DIBENZOPYRANS **except** when separately specified in these Schedules.

DIETHYLTHIAMBUTENE.

N,N-DIETHYLTRYPTAMINE \*(DET).

DIMENOXADOL.

DIMEPHEPTANOL.

2,5-DIMETHOXYAMPHETAMINE \*(DMA).

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB).

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET).

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2).

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I).

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7).

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE or PSILOTSIN).

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(DMHP).

N, α -DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA).

N,N-DIMETHYLAMPHETAMINE (Dimetamfetamine).

DIMETHYLTHIAMBUTENE.

N,N-DIMETHYLTRYPTAMINE \*(DMT).

DIOXAPHETYL BUTYRATE.

ECGONINE.

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE \*(N-ETHYL MDA).

ETHYLMETHYLTHIAMBUTENE.

ETICYCLIDINE \*(PCE).

ETONITAZENE.

ETORPHINE.

ETOXERIDINE.

FENETYLLINE.

4-FLUORO-N-METHYLAMPHETAMINE.

1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE \*(AM-694).

FURETHIDINE.

HARMALA ALKALOIDS **except** in herbs, or preparations, for therapeutic use:

(a) containing 0.1 per cent or less of harmala alkaloids; or

(b) in divided preparations containing 2 mg or less of harmala alkaloids per recommended daily dose.

HEROIN.

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL).

4-HYDROXYBUTANOIC ACID and its salts. \*(GAMMA HYDROXYBUTYRATE (GHB) ).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(Cannabicyclohexanol or CP 47,497 C8 homologue).

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497).

HYDROXYPETHIDINE.

ISOMETHADONE.

KETOBEMIDONE.

LEVOMETHORPHAN (excluding its stereoisomers).

LEVOPHENACYLMORPHAN.

LYSERGIC ACID.

LYSERGIDE.

MECLOQUALONE.

METAZOCINE.

METHAQUALONE.

METHCATHINONE.

5-METHOXY- α -METHYLTRYPTAMINE \*(5-MeO-AMT).

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA).

4-METHOXY- α -METHYLPHENYLETHYLAMINE \*(PMA).

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250).

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE \*(SALVINORIN A).

4-METHYLAMINOREX.

METHYLDESORPHINE.

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA).

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV).

3-METHYLFENTANYL.

4-METHYLMETHCATHINONE \*(MEPHEDRONE).

N- α -[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(N-HYDROXY MDA).

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE \*(MBDB).

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (Moramide intermediate).

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP).

4-METHYLTHIOAMPHETAMINE.

3-METHYLTHIOFENTANYL.

METOPON.

MITRAGYNA SPECIOSA.

MITRAGYNINE.

MORPHERIDINE.

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200).

MUSCIMOL.

MYROPHINE.

NAPHTHOYLINDOLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDOLES **except** when separately specified in these Schedules.

NAPHTHOYLPYRROLES **except** when separately specified in these Schedules.

NAPHTHYLMETHYLINDENES **except** when separately specified in these Schedules.

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE \*(JWH-073).

NICOCODINE.

NICODICODINE.

NICOMORPHINE.

NORACYMETHADOL.

NORLEVORPHANOL.

NORMORPHINE.

NORPIPANONE.

PARA-FLUOROFENTANYL.

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. \*(JWH-122).

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018).

PHENADOXONE.

PHENAMPROMIDE.

PHENAZOCINE.

PHENCYCLIDINE \*(PCP).

N-PHENETHYL-4-PIPERIDONE.

PHENOMORPHAN.

PHENYLACETYLINDOLES **except** when separately specified in these Schedules.

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP).

PIMINODINE.

PROHEPTAZINE.

PROPERIDINE.

PSILOCYBINE.

RACEMETHORPHAN.

RACEMORPHAN.

ROLICYCLIDINE \*(PHP or PCPY).

SALVIA DIVINORUM.

TENOCYCLIDINE \*(TCP).

SYNTHETIC CANNABINOMIMETICS **except** when separately specified in these Schedules.

TETRAHYDROCANNABINOLS and their alkyl homologues **except**:

(a) when separately specified in this Schedule;

(b) when included in Schedule 8;

(c) in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with a warning statement:

Not for internal use; or

Not to be taken; or

(d) in products for purposes other than internal human use containing 50 mg/kg or less of tetrahydrocannabinols.

THIOFENTANYL.

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP).

TRIMEPERIDINE.

3,4,5-TRIMETHOXY- α -METHYLPHENYLETHYLAMINE \*(TMA).

3,4,5-TRIMETHOXYPHENETHYLAMINE (mescaline) and other substances structurally derived from methoxy-phenylethylamine **except**:

(a) methoxyphenamine; or

(b) when separately specified in this Schedule.

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE.

# **PART 5**

# **THE APPENDICES**

## APPENDIX A

## GENERAL EXEMPTIONS

This Standard does not apply to a poison in any of the following products:

ALGICIDES, BACTERIOCIDES OR SLIMICIDES for industrial use that do not fit the definition of an agvet chemical product.

BACTERIAL CULTURE MEDIA containing antibiotics.

CERAMICS.

CHEMISTRY SETS for toy and educational use, when complying with the requirements of Australian Standard AS 8124.4-2003 *Safety of toys* entitled *Part 4: Experimental sets for chemistry and related activities*.

COPPER COMPOUNDS in paints.

DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES used as plasma substitutes−/blood volume expanders−.

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS or LAMPS.

ELECTRONIC COMPONENTS.

ENHANCING AGENTS for use in ultrasonic and magnetic resonance imaging.

EXPLOSIVES.

FOOD **except**:

(a) food additives before incorporation into food; or

(b) when used as a means of administering a poison for therapeutic use.

FRITTED GLAZING OR ENAMELLING PREPARATIONS in which the poison is confined as a non-migratory component of glassy solid flakes or granules.

GLASS (including CRYSTAL WARE).

GLAZED POTTERY.

HUMAN BLOOD PRODUCTS including:

(a) whole blood;

(b) blood components including red cells, white cells, platelets and plasma (including cryoprecipitate); and

(c) the following plasma-derived therapeutic proteins; and their equivalent recombinant alternatives:

(i) albumin;

(ii) anticoagulation complex;

(iii) C1 esterase inhibitors;

(iv) clotting factors;

(v) fibrinogen;

(vi) protein C;

(vii) prothrombin complex concentrate (PCC) ; and

(viii) thrombin.

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS containing 0.001 per cent or less of a poison included in Schedules 1 to 8.

INTRAOCULAR VISCOELASTIC PRODUCTS.

LUBRICANTS **except** soluble oils and solvent-deposited lubricating agents.

MATCHES.

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS −−−.

MEDICAL DEVICES classified as Class III by the classification rules set out in Schedule 2 to the *Therapeutic Goods (Medical Devices) Regulation 2002*, **except**:

(a) injectable tissue reconstructive, augmentation and restoration materials−, including collagen;

(b) medical devices which include anticoagulants;

(c) artificial tears;

(d) urinary catheters; or

(e) intra-articular fluids.

MOTOR, HEATING or FURNACE FUELS− **except**:

(a) when the contrary intention appears in any Schedule;

(b) when containing methanol;

(c) toy or hobby fuels; or

(d) petrol or kerosene when packed in containers having a capacity of 20 litres or less.

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION.

PAPER **except**:

(a) when prepared for pesticidal use; or

(b) when containing a poison included in Schedule 8 or 9.

PHOTOGRAPHIC PAPER or FILM.

PIGMENTS when immobilised in a polymer.

PORCELAIN.

PRINTING INKS or INK ADDITIVES **except**:

(a) when containing a pesticide; or

(b) preparations containing more than 0.1 per cent of lead calculated on the non-volatile content of the ink or ink additive.

RADIOGRAPHIC CONTRAST MEDIA (radiopaques) for therapeutic use.

RADIOISOTOPES for therapeutic use.

SEEDS treated with seed protectants.

SINGLE-USE TUBES for the estimation of alcohol content of breath.

TERMITE BARRIERS consisting of an active ingredient, other than arsenic, approved by the relevant registration authority, and laminated between impervious sheeting.

TIMBER or WALLBOARD.

VITREOUS ENAMELS.

WRITING CORRECTION PENS which do not allow ingestion of the contents and which contain no scheduled poison other than designated solvents included in Schedule 5.

## APPENDIX B

## SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL BY SCHEDULING

(This Appendix should be read in conjunction with Appendix A.)

## INTRODUCTION

Substances for which the available information suggests that inclusion in the Poisons Schedules is not necessary, or not the most appropriate means of controlling the risk to public health, have been considered at various times.

Listing in Appendix B indicates that a decision has been taken not to list substances anywhere in the Schedules, either for a specific purpose, or generally. It is an inclusive, but not an exhaustive, list i.e. there may be substances not included in the Schedules, and not included in Appendix B, which may be hazardous or non-hazardous, but have not been considered in relation to the need for scheduling.

Substances may be included in Appendix B because they have intrinsically low toxicity, or where other factors suggest that the potential public health risk would be minimal. Factors which are considered when determining an Appendix B entry include:

• the toxicology profile was adequately characterised and not consistent with inclusion in any of the Schedules;

• the use, purpose or product presentation minimised any hazard to the public such as to not require scheduling; or

• the public access was limited such that scheduling was inappropriate or unnecessary.

The list was developed from scheduling files and historical records. For transparency, where the reason for entry and/or purpose or use for the substance was apparent in the consideration, this has been included in the columns “Reason for Entry” and “Area of Use”.

Inclusion in Appendix B will not prevent reconsideration of the scheduling of a substance where adverse information becomes available about the Appendix B entry for that substance.

Applications are considered for scheduling. Applications for inclusion in Appendix B will not be accepted.

**APPENDIX B**

**PART 1**

**REASONS FOR ENTRY**

a Low Toxicity.

b Use pattern restricts hazard.

c Presentation/packaging restricts hazard.

d Industrial use only.

**PART 2**

**AREAS OF USE**

1. Agricultural

1.1 Herbicide

1.2 Insecticide

1.2.1 Insecticide for codling moth

1.2.2 Termiticide

1.3 Fungicide

1.3.1 On seed fungicide

1.4 Bird Repellent

1.5 Fertiliser

1.6 Plant Growth Regulator

1.7 Insect Pheromone

1.8 Mushroom Bactericide

1.9 Acaricide

1.10 Biological control agent

2. Veterinary

2.1 For animal use

2.2 Treatment of mastitis in cows

2.3 Coccidiostat

2.4 Feed additive

2.5 Antiseptic

2.6 Scabicide

2.7 Anthelmintic

2.8 Vitamin/Mineral

2.9 Growth Promotant

2.10 Ectoparasiticide

3. Domestic

3.1 Aromatherapy

3.2 Food additive

3.3 Cosmetic

3.4 Human use

3.5 Miticide

4. Industrial

4.1 Water treatment

4.2 Biological control agent

5. Environmental

5.1 Mosquito control

6. Human therapeutic use

6.1 Diagnostic agent

6.2 Medical device

6.3 Antiseptic

6.4 Sunscreen

6.5 External use

6.6 Laxative

6.7 Antiseborrheic

6.8 Cytoprotective

6.9 Vitamin/Mineral

6.10 Eye Drops

7. General

7.1 Any use

7.2 Excipient

7.3 Synergist

7.4 Flux

7.5 Pesticide

7.6 Insect repellent

7.7 Solvent

7.8 Disinfectant

7.9 Preservative

7.10 Antioxidant

7.11 Resin activator/accelerant

7.12 Sweetener artificial

7.13 Food additive

**APPENDIX B**

**PART 3**

**SUBSTANCES CONSIDERED NOT TO REQUIRE CONTROL   
BY SCHEDULING**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**REASON AREA  
 DATE OF FOR OF  
SUBSTANCE ENTRY LISTING USE**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

4-[4-(ACETYLOXY)PHENYL]-2-

BUTANONE Feb 2005 b 1.7

*AGROBACTERIUM RADIOBACTER* Nov 1989 a 1

ALCOHOL, DEHYDRATED Aug 2000 b 6

ALUM May 1997 a 7.1

ALUMINIUM AMMONIUM SULFATE May 1997 a 7.1

ALUMINIUM POTASSIUM SULFATE May 1997 a 7.1

ALUMINIUM SILICATE Nov 1974 a 7.1

ALUMINIUM tris (ETHYLPHOSPHONATE) Aug 1986 a 1

AMETOCTRADIN May 2012 a 1.3

AMMONIUM PHOSPHATE Nov 1974 a 7.1

AMMONIUM THIOSULPHATE Nov 1974 a 7.1

AMPROLIUM Jun 1969 a 2.3

AMYL ACETATE Nov 1974 a 7.1

α -AMYLASE derived from *Aspergillus niger* Feb 2005 a 2.4

ANDROSTENEDIONE ALBUMEN

 CONJUGATE WITH DEA DEXTRAN

 ADJUNCT Jun 2004 a 2.1

ASPARTIC ACID - a 6

ASULAM May 1986 a 1

AZIMSULFURON Jun 2003 a 1.1

*BACILLUS SPHAERICUS* STRAIN 2362 Feb 2003 a 5.1

*BACILLUS THURINGIENSIS* May 1992 a 5.1  
 (excluding endotoxin) Jun 2003 a 2.10

*BACILLUS TOYOI* Aug 1980 a 2.9

BACULOVIRUS *CYDIA POMONELLA* Jun 2006 a 1.2

BENFLURALIN - a 1.1

BENSULFURON-METHYL Aug 1987 a 1

BENTONITE Jun 2002 a 7.1

BENZYL BENZOATE Aug 1989 a 1.3.4

BETAINE HYDROCHLORIDE Nov 1974 a 7.1

BIFENAZATE Oct 2002 a 1.9

BISMUTH SUBNITRATE Nov 1999 b, c 2.1

BISTRIFLURON Feb 2014 a 1.2.2

BIURET Nov 1974 a 2.4

BOSCALID June 2003 a 1.3

BOVINE SOMATOTROPHIN May 1992 a 2

BROMACIL Aug 1987 a 1

BROMOPROPYLATE Nov 1994 a 1

BUPIRIMATE Nov 1990 a 1

BUTAFENACIL May 2000 a 1

BUTOXYPOLYPROPYLENE GYLCOL Nov 1974 a 7.7

n-BUTYL BUTYRATE - a 7.1

n-BUTYL LACTATE - a 7.1

CARBETAMIDE Aug 1991 a 1

CARBOXIN Aug 1987 a 1

CARFENTRAZONE-ETHYL Aug 1998 a 1

CELLULASE derived from  
 *Aspergillus niger*  
 Feb 2005 a 2.4

CETYL ALCOHOL Nov 1974 a 7.1

CHAMOMILE OIL Feb 2000 a 3.1

CHINA CLAY Nov 1974 a 7.1

CHLORANTRANILIPROLE Sep 2008 a 1.2

CHLORFLUAZURON Oct 2005 a 1.2.2

CHLORFLURENOL Feb 1974 a 1.6

CHLORIDAZON May 1988 a 1

CHLOROXYLENOLS Feb 1975 a 7.8

CITRONELLA OIL Feb 2000 a 7.1

CLARY SAGE OIL Feb 2000 a 7.1

CLOPIDOL Nov 1974 d 2.3

COBALT NAPHTHENATE - d 7.1

COLOPHONY Feb 1997 b 7.4

CROSPOVIDONE Aug 1996 a 2

*CULICINOMYCES CLAVOSPORUS* Nov 1982 a 5.1

CYCLAMIC ACID Nov 1971 a 7.1

CYCLOHEXANE Nov 1974 a 7.7

CYCLOHEXANOL ACETATE - a 7.7

CYROMAZINE Nov 1980 a 2

DICLAZURIL Nov 2001 a 2.3

DIETHYL CARBONATE - a 7.1

DIFLUFENICAN Feb 1987 a 1

DIKEGULAC-SODIUM Mar 1980 a 1.6

DIMETHICONE a 7.1

DIMETHYL ETHER Nov 1988 d 4

DIPHENYLAMINE Feb 1988 a 1

DIPROPYLENE GLYCOL   
 MONOMETHYL ETHER Nov 1987 a 4

DIURON Nov 1987 a 1

DOCUSATE SODIUM   
 (DIOCTYL SODIUM SULFOSUCCINATE) Feb 1970 a 7.1

2,2-DPA Nov 1989 a 1

drometrizole trisiloxane Oct 2003 a 6.4

EPSIPRANTEL Nov 1991 a 2

ETHAMETSULFURON-METHYL Nov 2000 a 1.1

ETHOPABATE Jun 1969 d 2.3

ETHYL ACETATE Nov 1974 a 7.1

ETHYL ALCOHOL Nov 1974 a 7.1

ETHYLBUTYLACETYL-  
 AMINOPROPRIONATE Aug 2000 a 3.4

ETHYL BUTYRATE - a 7.1

ETHYL LACTATE - a 7.1

ETOXAZOLE Oct 2003 a 1.2

*Eubacterium* sp. strain DSM11798 Sep 2013 a 2.4

FENFURAM May 1977 a 1.3.1

FENHEXAMID Feb 1999 a 1

FENOXYCARB Feb 1988 a 1

FLUFENOXURON Feb 1997 a 1

FLUMETSULAM Feb 1992 a 1

FLUOMETURON Aug 1989 a 1

FLUTOLANIL Nov 2001 a 1.3

FLUROXYPYR May 1986 a, c 1

FORCHLORFENURON Feb 2005 a 1.6

FULLERS EARTH Nov 1974 a 7.1

FUNGAL PROTEASE derived from

*Aspergillus niger* Feb 2005 a 2.4

GERANIUM OIL Feb 2000 a 7.1

GIBBERELLIC ACID Nov 1974 a 1.6

β-GLUCANASE derived from *Aspergillus niger* Feb 2005 a 2.4

HEXAFLURON Nov 1988 a 1

HEXYL ACETATE - a 7.7

HEXYTHIAZOX Feb 1988 a 1

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) Aug 2001 b 6.2

HYDROPRENE Feb 1988 a 1

HYDROXYPROPYL CELLULOSE Nov 1982 a 7.1

ICODEXTRIN Nov 2000 b 6

INDOLE-3-ACETIC ACID Feb 1985 b 1.6

ISOPRENE ALCOHOL - a 7.1

IPRODIONE Feb 1997 a 1

ISOSTEARYL ALCOHOL ETHOXYLATE Nov 1999 a 5.1

KAOLIN Nov 1974 a 7.1

KRESOXIM-METHYL Aug 1999 a 1

KUNZEA OIL Feb 2000 a 7.1

LAURIC ACID Oct 2005 a 7.1

LAURYL ALCOHOL (1-DODECANOL) Nov 1974 a 7.1

LAVANDIN OIL Feb 2000 a 7.1

LAVENDER OIL Feb 2000 a 7.1

LEAD METALLIC - a 7.1

LEMONGRASS OIL Feb 2000 a 7.1

LEPIDOPTEROUS SEX PHEROMONES Nov 1990 a 1

LIMONENE (DIPENTENE) Jun 2002 a 7.1

LINOLEIC ACID Oct 2005 a 7.1

LINSEED FATTY ACIDS Aug 1990 a 2.1

LINURON Feb 1990 a 1

LIQUORICE, DEGLYCYRRHISINISED May 1999 a 7.1

MALEIC HYDRAZIDE Nov 1992 a 1

MANGANESE DIOXIDE May 1999 b 1

*Megasphaera elsdenii* strain 41125 Sep 2013 a 2.4

MESOLSULFURON-METHYL Feb 2002 a 1.1

*METARHIZIUM ANISOPLIAE* Feb 2000 b 4.2

*METARHIZIUM ANISOPLIAE* Jun 2003 a 1.10

METHOPRENE Aug 1987 a 1

METHOXYFENOZIDE Nov 2000 a 1

METHYL ACETATE - a 7.7

METHYL BENZOQUATE Nov 1974 d 2.3

1-METHYLCYCLOPROPENE Jun 2003 a 1.6

METHYL p-HYDROXYBENZOATE Nov 1974 a 7.9

METSULFURONMETHYL Nov 1985 a 1.1

MYRISTIC ACID Oct 2005 a 7.1

NAPROPAMIDE Aug 1987 a 1

NAPTHYL ACETAMIDE Nov 1974 a 1.6

NEROLI OIL Feb 2000 a 7.1

NICARBAZIN Jun 1969 d 2.3

NISIN Jun 2003 a 3.2

NORFLURAZON Nov 1983 a 1.1

NOVALURON Nov 2000 a 1

Nuclear Polyhedrosis Virus of   
 *Helicoverpa armigera* occlusion bodies Feb 2004 a 1.2

OCTYL ALCOHOLS Nov 1974 a 7.1

OLEIC ACID Oct 2005 a 7.1

ORANGE OIL, SWEET Aug 2000 a 7.1

OXABETRINIL Feb 1987 a 1

OXYFLUORFEN May 2001 a 1

PALMAROSA OIL Feb 2000 a 7.1

PALMITIC ACID Oct 2005 a 7.1

PATCHOULI OIL Feb 2000 a 7.1

PECTINASE derived from *Aspergillus niger* Feb 2005 a 2.4

PENCYCURON Aug 1994 a 1

PENTADECANOIC ACID Oct 2005 a 7.1

PEPPERMINT OIL Feb 2000 a 7.1

PHENMEDIPHAM May 1989 a 1.1

d-PHENOTHRIN Feb 1982 a 7.5, 1.2

PHYTASE Feb 1996 a 2.4

PICLORAM Aug 1987 a 1

PICOLINAFEN May 2000 a 1

PIMELIC ACID Oct 2005 a 7.1

PIPERONYL BUTOXIDE Aug 1991 a 7.5

POLOXALENE Nov 1974 a 7.1

POLY DIALLYL DIMETHYL AMMONIUM   
 CHLORIDE (PolyDADMAC) Nov 1997 a 4.1

POLYHEDROSIS VIRUS of   
  *Helico zea* occlusion bodies Nov 1996 a 1

POLY (GNRF) OVALBUMIN Feb 1990 a 2

POLYSORBATE 20 May 2001 a 1

PORCINE SOMATOTROPHIN Nov 1991 c 2

potassium sorbate Oct 2004 a 1.3

POTASSIUM BICARBONATE Jun 2004 a 1

PROPYL ACETATES - a 7.1

PROPYLENE GLYCOL Nov 1974 a 7.1

2-PROPYLENE GLYCOL 1-MONOMETHYL   
 ETHER Nov 1987 a 4

PROTHIOCONAZOLE June 2005 a 1.3.1

*PSEUDOMONAS FLUORESCENS* May 1985 a 1.8

PYRIMETHANIL Feb 1996 a 1

PYRIPROXYFEN Aug 1994 a 1

QUASSIA Nov 1974 d 6, 2.1

QUINOXYFEN Nov 2001 a 1.3

ROSEMARY OIL Feb 2000 a 7.1

SAGE OIL (Spanish) Feb 2000 a 7.1

SANDALWOOD OIL Feb 2000 a 7.1

SEAWEED & UNFRACTIONED   
  SEAWEED EXTRACTS Feb 1985 d 1.5

SIMAZINE Nov 1987 a 1.1

SODIUM BICARBONATE Jun 2004 a 1

sodium propionate Oct 2004 a 1.3

STERIC ACID Oct 2005 a 7.1

SUCRALFATE Aug 1982 a 6.8

SULESOMAB Jun 2002 b 6.1

SULFOSULFURON Feb 1998 a 1

SULPHATED POLYSACCHARIDES - a 7.1

TANNIC ACID Dec 1965 a 7.1

TANNIC ACID/BENZYL ALCOHOL   
 PRODUCT Nov 1993 a 7.1

TERBACIL Aug 1987 a 1

THAUMATIN Nov 1990 a 3.2

THIDIAZURON Nov 1989 a 1

TRIASULFURON Feb 1988 a 1

TRICHODERMA HARZIANUM May 1996 a 1

(Z)-9-TRICOSENE Aug 1991 a 1

TRIETHYLENE GLYCOL Nov 1974 a 7.1

TRIFLOXYSULFURON Feb 2002 a 1.1

TRIFLURALIN Aug 1990 a 1

TRIFORINE Aug 1987 a 1

Ulocladium oudemansii Oct 2003 a 1.10

UREA Nov 1974 a 7.1

13C-UREA May 2001 a 6.1

VETIVER OIL Feb 2000 a 7.1

VINYL ETHER Nov 1987 b 6

VITAMIN K Jul 1963 a 6.9, 2.8

XANTHOPHYLL (lutein) Nov 1974 a 7.1

XYLANASE derived from *Aspergillus niger* Feb 2005 a 2.4

YLANG YLANG OIL Feb 2000 a 7.1

ZINC NAPHTHENATE - a 1.3

## APPENDIX C

## SUBSTANCES, OTHER THAN THOSE INCLUDED IN SCHEDULE 9,

## OF SUCH DANGER TO HEALTH AS TO WARRANT

## PROHIBITION OF SALE, SUPPLY AND USE

ABRUS PRECATORIUS (Jequirity) seed or root for therapeutic use.

ACORUS CALAMUS (calamus) for human therapeutic use.

ALKALINE SALTS, being the carbonate, silicate or phosphate salts of sodium or potassium alone or in any combination for domestic use:

(a) in liquid or semi-solid food additive preparations, the pH of which is more than 11.5;

(b) in solid automatic dishwashing preparations, the pH of which in a 500 g/L aqueous solution or mixture is more than 12.5; or

(b) in liquid or semi-solid automatic dishwashing preparations, the pH of which is more than 12.5.

ALLYLISOPROPYLACETYLUREA for therapeutic use.

AMINOPHENAZONE (amidopyrine) and its derivatives for human therapeutic use.

AMYGDALIN for therapeutic use.

ANCHUSA OFFICINALIS for therapeutic use.

ARISTOLOCHIA spp. for therapeutic use.

ARISTOLOCHIC ACID(S) for human therapeutic use.

ASARUM spp. containing aristolochic acid(s) for human therapeutic use.

AZADIRACHTA INDICA (neem) including its extracts and derivatives, in preparations for human internal use **except** ‘debitterised neem seed oil’*.*

BASIC ORANGE 31 (2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride) in preparations for skin colouration and dyeing of eyelashes or eyebrows.

BITHIONOL for human therapeutic use.

BORAGO OFFICINALIS (Borage) for therapeutic use **except** the fixed oil derived from the seeds of Borago officinalis.

BRAGANTIA spp. containing aristolochic acid(s) for human therapeutic use.

BUCLOSAMIDE for therapeutic use.

BUNIODYL SODIUM for therapeutic use.

1,4-BUTANEDIOL (excluding its derivatives) in non-polymerised form in preparations for domestic use.

CACALIA spp. for therapeutic use.

CARBAMIDE PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 18 per cent of carbamide peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

CINCHOPHEN and its derivatives for therapeutic use.

CLIOQUINOL and other halogenated derivatives of 8-hydroxyquinoline for human internal use **except** when being used solely for experimental purposes in humans and where such use:

(a) is in accordance with:

(i) an approval granted under paragraph 19(1)(b) of the *Therapeutic Goods Act 1989*, including any conditions specified in the notice of approval; and

(ii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(1A) of the *Therapeutic Goods Act 1989*; and

(iii) any conditions specified in the *Therapeutic Goods Regulations 1990* for the purposes of subsection 19(4A) of the *Therapeutic Goods Act 1989*; or

(b) is in accordance with the requirements of item 3 of Schedule 5A to the *Therapeutic Goods Regulations 1990*.

COAL TAR for cosmetic use other than in therapeutic goods.

CONIUM MACULATUM (coniine) for therapeutic use.

COTARNINE for therapeutic use.

CROTALARIA spp. for therapeutic use.

CROTON TIGLIUM for therapeutic use.

CYNOGLOSSUM spp. for therapeutic use.

DICOPHANE (DDT) for therapeutic use.

DIETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25 per cent or less of diethylene glycol.

DIETHYLHEXYL PHTHALATE for cosmetic use.

DIETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of diethylphthalate.

5,6-DIHYDROXYINDOLINE for cosmetic use in preparations containing more than 2 per cent of 5,6-dihydroxyindoline.

1,3-DIMETHYLAMYLAMINE (DMAA).

DIMETHYLPHTHALATE in sunscreens, personal insect repellents or body lotion preparations for human use **except** in preparations containing 0.5 per cent or less of dimethylphthalate.

DULCIN for therapeutic use.

ETHYLENE GLYCOL for use in toothpastes or mouthwashes **except** in preparations containing 0.25 per cent or less of ethylene glycol.

ETHYLHEXANEDIOL for human use.

EUPATORIUM CANNABINUM (Hemp Agrimony) for therapeutic use.

FARFUGIUM JAPONICUM for therapeutic use.

FORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

HELIOTROPIUM spp. for therapeutic use.

HYDROGEN PEROXIDE (excluding its salts and derivatives) in teeth whitening preparations containing more than 6 per cent (20 volume) of hydrogen peroxide **except** in preparations manufactured for, and supplied solely by, registered dental practitioners as part of their dental practice.

JUNIPERUS SABINE [savin(e)] for therapeutic use.

LEAD COMPOUNDS in paints, tinters, inks or ink additives **except** in preparations containing 0.1 per cent or less of lead calculated on the non-volatile content of the paint, tinter, ink or ink additive.

LIGULARIA DENTATA for therapeutic use.

MELIA AZEDARACH including its extracts and derivatives.

METHYLDIBROMO GLUTARONITRILE in preparations intended to be in contact with the skin, including cosmetic use.

METHYL METHACRYLATE for cosmetic use **except** in preparations containing 1 per cent or less of methyl methacrylate as residual monomer in a polymer.

OXYPHENISATIN for therapeutic use.

PARAFORMALDEHYDE (excluding its derivatives):

(a) in oral hygiene preparations containing more than 0.1 per cent of free formaldehyde;

(b) in aerosol sprays for cosmetic use containing 0.005 per cent or more of free formaldehyde;

(c) in nail hardener cosmetic preparations containing 5 per cent or more of free formaldehyde; or

(d) in all other cosmetic preparations containing 0.05 per cent or more of free formaldehyde **except** in preparations containing 0.2 per cent or less of free formaldehyde when labelled with the warning statement:

CONTAINS FORMALDEHYDE.

PETASITES spp. for therapeutic use.

PHENYLENEDIAMINES in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

POTASSIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

PTERIDIUM spp. for therapeutic use.

PULMONARIA spp. for therapeutic use.

SAFROLE for internal therapeutic use **except** in preparations containing 0.1 per cent or less of safrole.

SENECIO spp. for therapeutic use.

SILICONES for injection or implantation **except** when included in Schedule 4.

SODIUM HYDROXIDE (excluding its salts and derivatives), in liquid or semi-solid food additive preparations, for domestic use, the pH of which is more than 11.5.

SYMPHYTUM spp. (Comfrey) for therapeutic or cosmetic use **except** when included in Schedule 5.

TOLUENEDIAMINE in preparations for skin colouration and dyeing of eyelashes or eyebrows **except** when included in Schedule 6.

1,1,1-TRICHLOROETHANE in pressurised spray packs for therapeutic use.

TRICHODESMA AFRICANA for therapeutic use.

TRIPARANOL for therapeutic use.

TUSSILAGO FARFARA for therapeutic use.

## APPENDIX D

## ADDITIONAL CONTROLS ON POSSESSION OR SUPPLY OF POISONS INCLUDED IN SCHEDULE 4 OR 8

(The following controls apply for the substances shown only when included in Schedule 4 or Schedule 8.)

**1. Poisons available only from or on the prescription or order of an authorised medical practitioner.**

CLOMIPHENE for human use.

CLOZAPINE for human use.

CORIFOLLITROPIN ALFA (recombinant follicle stimulant) for human use.

CYCLOFENIL for human use.

DINOPROST for human use.

DINOPROSTONE for human use.

FOLLITROPIN ALPHA (recombinant human follicle-stimulating hormone) for human use.

FOLLITROPIN BETA (recombinant human follicle-stimulating hormone) for human use.

LUTEINISING HORMONE for human use.

NABIXIMOLS.

TERIPARATIDE for human use.

UROFOLLITROPIN (human follicle-stimulating hormone) for human use.

**2. Poisons available only from or on the prescription or order of a specialist physician or a dermatologist and for which the prescriber must, where the patient is a woman of child-bearing age:**

(1) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(2) if the drug is -

(a) acitretin or etretinate, advise the patient to avoid becoming pregnant during or for a period of 24 months after completion of treatment; or

(b) bexarotene, isotretinoin or thalidomide, advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

ACITRETIN for human use.

BEXAROTENE for human use.

ETRETINATE for human use.

ISOTRETINOIN for human oral use.

THALIDOMIDE for human use.

**3. Poisons available only from or on the prescription or order of a medical practitioner authorised or approved by the Secretary of the Commonwealth Department of Health and Ageing under section 19 of the *Therapeutic Goods Act 1989*.**

DRONABINOL (delta-9-tetrahydrocannabinol).

**4. Poisons available only from or on the order of a specialist physician and for which the prescriber must, where the patient is a woman of child bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during or for a period of 1 month after completion of treatment.

LENALIDOMIDE.

TRETINOIN for human oral use.

**5. Poisons for which possession without authority is illegal (e.g. possession other than in accordance with a legal prescription).**

ANABOLIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

ANDROGENIC STEROIDAL AGENTS, including those separately specified in Schedule 4.

BENZODIAZEPINE DERIVATIVES, including those separately specified in Schedule 4 and Schedule 8.

DARBEPOETIN.

DEXTROPROPOXYPHENE.

EPHEDRINE.

EPOETINS.

ERYTHROPOIETIN.

ERYTHROPOIETINS **except** when separately specified in this Appendix.

FOLLISTATIN.

GLUTETHIMIDE.

INSULIN-LIKE GROWTH FACTORS.

PHENTERMINE.

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM), including those separately specified in Schedule 4.

SOMATROPIN (human growth hormone).

**6. Poisons available only from or on the prescription or order of a specialist physician and for which the prescriber must, where the patient is a woman of child-bearing age:**

(a) ensure that the possibility of pregnancy has been excluded prior to commencement of treatment; and

(b) advise the patient to avoid becoming pregnant during and for a period of 3 months after completion of treatment.

AMBRISENTAN for human use.

BOSENTAN for human use.

SITAXENTAN for human use.

**7. Poisons available only from or on the prescription or order of a dermatologist.**

ALEFACEPT for human use.

## APPENDIX E

## FIRST AID INSTRUCTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the

Australian Pesticides and Veterinary Medicines Authority and medicines for human use

when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Directions for First Aid Attention**

Under poisons legislation, scheduled substances and their preparations are required to be labelled with appropriate directions for first aid attention in case of poisoning. It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the first aid instructions included on the label of a poison are appropriate for a specific product. The following code has been prepared as a guide for health authorities and manufacturers in drafting suitable first aid directions for this purpose. Standard statements specified in this Appendix may be varied provided that the intent is not changed.

The directions listed for any particular substance may require modification to take into account combination of that substance with other substances, both toxic and non toxic, in a formulation, as well as the physical form and presentation of the product. Any such modification should be concise and readily understood.

These First Aid Instructions include action to be taken in case of eye contamination from substances recognised as causing direct poisoning via the eye, causing severe eye damage or requiring prolonged flushing to free the absorbed substance from the eye tissue. However, it is recognised that many other substances or preparations will require a statement of varying nature depending on the detailed formulation. While the necessity to flush the eyes in case of accident will be so self-evident as not to justify label space in many instances, a statement such as “If in eyes rinse well with water” may be appropriate.

**Modified First Aid Instruction on Primary Pack**

Where a primary pack contains two or more immediate containers of poisons each requiring different first aid instructions:

(a) each immediate container must be labelled with first aid instructions appropriate for its contents; and

(b) the primary pack must be labelled with the statement:

FIRST AID: See inner packs.

**Exempt Preparations**

This Appendix applies only to scheduled poisons. The directions are for substances and their preparations at the concentrations at which the Schedules apply. If it is thought desirable to show first aid instructions for a substance exempted from the schedules, it is the responsibility of the manufacturer to ensure they are appropriate.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX E**

**PART 1**

**STANDARD STATEMENTS**

To be grouped together and prefaced with the words “FIRST AID” (see subparagraph 7(p) of this Standard).

*Basic*

A For advice, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor (at once).

Z First aid is not generally required. If in doubt, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

*General*

G1 Urgent hospital treatment is likely to be needed.   
(Note − the words ‘at once’ to be added to instruction A).

G2 If swallowed, give activated charcoal if instructed.   
(Note − the words ‘at once’ to be added to instruction A).

G3 If swallowed, do NOT induce vomiting.

G4 Immediately give a glass of water.

G5 Avoid giving milk or oils.

G6 If sprayed in mouth, rinse mouth with water.

*Eyes*

E1 If in eyes wash out immediately with water.

E2 If in eyes, hold eyelids apart and flush the eye continuously with running water. Continue flushing until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor, or for at least 15 minutes.

*Respiratory system*

R1 If inhaled, remove from contaminated area. Apply artificial respiration if not breathing.

R2 If swallowed or inhaled, remove from contaminated area. Apply artificial respiration if not breathing. Do not give direct mouth-to-mouth resuscitation. To protect rescuer, use air-viva, oxy-viva or one-way mask. Resuscitate in a well-ventilated area.

*Skin*

S1 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water.

S2 If skin or hair contact occurs, remove contaminated clothing and flush skin and hair with running water. Continue flushing with water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S3 If on skin, remove any contaminated clothing, wash skin thoroughly with soap and water, then methylated spirit if available. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S4 If on skin, immediately remove any contaminated clothing, wash skin with methylated spirit or PEG (polyethylene glycol) 300 or 400 if available, then flush under running water until advised to stop by a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor.

S5 If skin contact occurs, immediately remove contaminated clothing. Flush skin under running water for 15 minutes. Then apply calcium gluconate gel. Contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766).

*Special Purpose*

SP1 If swallowed, splashed on skin or in eyes, or inhaled, contact a Poisons Information Centre (e.g. phone Australia 13 11 26; New Zealand 0800 764 766) or a doctor at once. Remove any contaminated clothing and wash skin thoroughly. If swallowed, activated charcoal may be advised. Give atropine if instructed.

**APPENDIX E**

**PART 2**

**FIRST AID INSTRUCTIONS**

Standard statements in this Appendix apply to poisons other than agricultural and veterinary chemicals (including pesticides) registered by the Australian Pesticides and Veterinary Medicines Authority. Labelling is not required at concentrations below scheduled levels (see the Introduction to this Appendix).

**POISON** **STANDARD** **STATEMENT**S

Acetic acid A,G3,E2,S1

Acetic anhydride A,G3,E2,S1

Acetone A,G3

Acrolein A,G1,G2,G3,E2,R2,S2

Alkaline salts A,G3,E2,S1

Amines for use as curing agents A,G3,E1,S1

4-Aminopyridine A,G1,G2,E1,S1

Ammonia

• 5 per cent or less A

• above 5 per cent A,G3,E1,R1,S1

Ammonium persulfate A,G3,E2

Ammonium thiocyanate A

Anhydrides, organic acid, for use as   
curing agents for epoxy resins A,G3,E1,S1

Aniline A,E2,R1,S1

Anise oil A,G3

Antimony chloride A,E2,S2

Antimony compounds, **except** antimony chloride A

Azadirachta indica (neem) including its extracts   
and derivatives when included in Schedule 6. A,E1

Barium salts, **except** barium sulfate A

Basil oil A,G3

Bay oil A,G3

Benzalkonium chloride

• when included in Schedule 5 A,G3,E2

• when included in Schedule 6 A,G3,E2,S1

Benzene A,G3,E1,R1,S1

1,2-Benzenediol (catechol) A,E1,S1

Benzoyl peroxide

• above 20 per cent A,E2,S1

• above 10 per cent up to 20 per cent A,E1

• 10 per cent or less A

Bergamot oil A,G3

Bifluorides   
(including ammonium, potassium and sodium salts)

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Borax A

Boric acid A

Boron trifluoride

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Bromoform A,G3,E2,R1,S2

Brucine A,G1,G2,G3,R2

2-Butoxyethanol and its acetates A,E2,S1

Cadmium compounds A

Cajuput oil A,G3

Camphor A,G1,G3,G5

Carbamide peroxide

• more than 9 per cent up to 60 per cent A,G3,E2,S1

• more than 60 per cent A,G1,G3,G4,E2,S1

Carbon disulfide A,G3,E2,R1,S2

Carbon tetrachloride A,G3,E1,R1,S1

Cassia oil A,G3

Chlorinating compounds, **except** when   
separately specified, containing

• above 4 per cent and below 10 per cent   
 of available chlorine A,G3,E1,S1

• 10 per cent or more of available chlorine A,G3,E2,S1

Chlorine (gas) A,E1,R1

Chlorocresol A,G3,E2,S2

Chloroform A,G3,E1,R1,S1

Chromates A,G3,E2,S1

Chromium trioxide A,G3,E2,S1

Cineole A,G1,G3

Cinnamon bark oil A,G3

Cinnamon leaf oil A,G3

Climbazole A

Clove oil A,G1,G3,E2

Cocoyl glycinate E1

Copper sulfate A,G3,E2,S1

Creosote A,G3,E2,S1

Cresols A,G3,E2,S3

Cresols in pressurised spray packs A,G6,E1,S1

Cyanides A,G1,E1,R2

Cyanoacrylic acid esters A

Cyanuric acid A

Cyclohexanone peroxide A,G3,E2,S1

Cysteamine E1

ortho-Dichlorobenzene A,G3,E1,S1

para-Dichlorobenzene (PDB) A

Dichloroethyl ether A,G3,E1,R1,S1

Dichloroisocyanurates A,G3,E1,S1

Dichloromethane (methylene chloride) A,G3,G5,E1,R1,S1

• in pressurised spray packs A,G6,S1

Dichromates A,G1,G3,E2,S1

Didecyldimethylammonium salts A,G3

Diesel (distillate) A,G3

Diethanolamine

• when included in Schedule 5 A,G3

• when included in Schedule 6 A,G3,E2,S1

5,6-Dihydroxyindoline E1

Dimethylformamide

• less than 75 per cent A

• 75 per cent or more A,E1,R1,S1

Dimethyl sulfoxide A,G3,E1,S1

Dinitrocresols A,G1,E1,S1

Dinitrophenols A,G1,E1,S1

Dioxane A,G3,E1,R1,S1

Distillate A,G3

N-(N-Dodecyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Epoxy resins liquid A,G3,E2,S1

Essential oils containing camphor as natural   
component unless otherwise specified. A,G3

Ethanolamine

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Ether A,G3,E1,R1

Ethyl bromide A,E2,S1,R1

Ethylene glycol A

Ethylene glycol monoalkyl ethers and their   
acetates, **except** when separately specified A,G3,E2,S1

Ethylene oxide A,E2,R1

Eucalyptus oil A,G1,G3

Eugenol A,G1,G3,E2

Fluorides **except** when separately specified

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

Formaldehyde (see also paraformaldehyde) A,G3,E2,R1,S1

Formic acid A,G3,E2,S1

Glutaraldehyde

• below 5 per cent A,G3,E1

• 5 per cent or more A,G3,E2,S1

Glycolic acid A,G3,E2

Guanidine when included in Schedule 6 A,G3,E2,S1

Hexachlorophane when included in Schedule 6 A

Hexyloxyethanol A,G3,E2,S1

Hydrazine A,G1,G3,E2,R1,S1

Hydrocarbons, liquid A,G3

Hydrochloric acid A,G3,E2,S1

• when included in Schedule 5 A,G3

Hydrofluoric acid and admixtures that   
generate hydrofluoric acid

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Hydrogen peroxide

• more than 3 per cent up to 20 per cent A,G3,E2,S1

• more than 20 per cent A,G1,G3,G4,E2,S1

Hydroquinone

• when included in Schedule 2 A

• when included in Schedule 4 or 6 A,G2,G3,E2,R2,S1

Hydrosilicofluoric acid

• when included in Schedule 5 A

• when included in Schedule 6 or 7 A,G3,E2,S5

Iodine (excluding salts, derivatives and iodophors)

• 2.5 per cent or more for human external use A,E2

• 2.5 per cent or more for other uses A,E2,S1

• below 2.5 per cent A

Iodophors A

Isocyanates, free organic A,E2,S1

Isophorone A,G3,E2,S1

Kerosene A,G3

Laureth carboxylic acids

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

Lauryl isoquinolinium bromide A,E1

Lead compounds

• in hair cosmetics A

• in other preparations A,S1

Lemon oil A,G3

*Leptospermum scoparium* oil (manuka oil) A,G1,G3

Lime oil A,G3

Magnesium chlorate A

Malathion at 20 per cent or less A

Marjoram oil A,G3

Melaleuca oil A,G1,G3

Mercuric chloride

• for external therapeutic use A

• for other uses A,G1,G3,E2,R2,S1

Mercuric iodide A,G1,G3,E2,R2,S1

Mercuric nitrate A,G1,G3,E2,R2,S1

Mercuric oxide A,G1,G3

Mercuric potassium iodide A,G1,G3,E2,R2,S1

Mercuric thiocyanate A,G1,G3,E2,R2,S1

Mercurochrome A

Mercurous chloride A

Mercury metallic A

Mercury, organic compounds A,S1

• in preparations for human external use A

Metaldehyde A,E1,S1

Methanol

• above 10 per cent A,G3

• 10 per cent or less A

Methylated spirit A,G3

Methyl ethyl ketone A,G3

Methyl ethyl ketone peroxide A,G3,E2,S1

Methyleugenol A

Methyl isoamyl ketone A,G3

Methyl isobutyl ketone A,G3

N-Methyl-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

Methyl salicylate liquid when included   
in Schedule 5 or 6 A,G3,E1

Naphthalene A,G1,G3

Nitric acid A,G3,E2,S1

Nitrobenzene A,G3,E1,S1

Nitrophenol A,G3,E2,S1

Nitroprussides

• in aerosols A,G6,R1

• in other preparations A,G3

Nonoxinol 9 A,E2

Nutmeg oil A,G3

2-Octyl-4-isothiazolin-3-one (Ocithilinone) A,G3,E2,S1

N-(N-Octyl)-2-pyrrolidone

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2

Orange oil (bitter) A,G3

Oxalic acid A,G3,E2,S1

Paraformaldehyde A,G3,E2,R1,S1

Pennyroyal oil A,G3

Peracetic acid

• when included in Schedule 5 A,G3,E1,S1

• when included in Schedule 6 A,G3,E2,S1

Petrol A,G3,R1

Phenols

• 25 per cent and less A,G3,E2,S3

• above 25 per cent A,G3,E2,S4

Phenols in pressurised spray packs A,E1

Phenylenediamines and   
alkylated phenylenediamines

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

Phenyl methyl ketone

• as such, or in preparations of similar viscosity A,G3,E1

N,N-bis(phenylmethylene)-bicyclo  
-(2.2.1)heptane-2,5-dimethanamine A,E2,S1

N,N-bis(phenylmethylene)-bicyclo-  
(2.2.1)heptane-2,6-dimethanamine A,E2,S1

ortho-Phenylphenol A,G3,E2,S1

• in pressurised spray packs A,G6,E2,S1

Phosphonic acid A,G3,E2,S1

• neutralised to pH 6 (approx) A

• in spray packs A,E2,S1

Phosphoric acid A,G3,E2,S1

Phosphorus, yellow A,G1,G3,E2,R2,S2

ortho-Phthalaldehyde

• when included in Schedule 5 A,E1

• when included in Schedule 6 A,G3,E2,S1

Picric acid A,G1,G3,E2,R1,S1

Polyethanoxy (15) tallow amine A,E2,S1

Poly(oxy-1,2-ethanediyl), α -  
[2-[(2-hydroxyethyl)amino]-2-  
oxoethyl]- α -hydroxy-,mono-C13-15-alkyl ethers A,E1

Potassium bromate A

Potassium chlorate A

Potassium cyanate A,E1,S1

Potassium hydroxide A,G3,E2,S1

Potassium metabisulphite A

Potassium nitrite

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

Potassium peroxomonosulfate triple salt

• when included in Schedule 5 A,G3,E1

• when included in Schedule 6 A,G3,E2,S1

Potassium persulfate A,G3,E2

Potassium sulfide A,G3,E2,S1

Propionic acid A,G3,E1,S1

d-Pulegone A,G3

Pyrithione zinc A,E1

Quaternary ammonium compounds **except**

when separately specified

• above 20 per cent A,G3,E2

• 20 per cent and below A,E2

• in pressurised spray packs A,E2,G6

Safrole A,G1,G3

Sage oil (Dalmatian) A,G3

Sassafras oil A,G1,G3

Selenium compounds A,G1,E1,S1

Silicofluorides

• when included in Schedule 5 A

• when included in Schedule 6 A,G1,G3,E2,S1

Silver salts A,E2

Sodium aluminate A,G3,E2,S1

Sodium bromate A,G1

Sodium chlorate A

Sodium diacetate A,G3,E2,S1

Sodium dichloroisocyanurate A,G3,E1,S1

Sodium dodecylbenzene sulfonate A,G3,E2,S1

Sodium hydrogen sulfate A,G3,E1,S1

Sodium hydrosulfite A,G3,E2,S1

Sodium hydroxide A,G3,E2,S1

Sodium laureth-6 carboxylate A

Sodium lauryl sulfate

• leave-on or wash-off preparations above 5 per cent E1

• other preparations above 5 per cent E1,S1

Sodium metabisulphite A, G3

Sodium nitrite

• when included in Schedule 7 A,G1,G3

• when included in Schedule 5 or 6 A,G3

Sodium percarbonate

• when included in Schedule 5 A,G3,S1

• when included in Schedule 6 A,G3,E2,S1

Sodium persulfate A,G3,E2

Sodium stannate A,E1

Sodium sulfide A,G3,E2,S1

Sodium trichloroacetate A

Strychnine A,G1,G2,G3,R2

Styrene A,G3,S1,E1

Sulcofuron A

Sulfamic acid A,G3,E2,S1

Sulfuric acid A,G3,E2,S1

Terpenes, chlorinated A,G3

Tetrachloroethane A,G3,E1,R1,S1

Tetrachloroethylene A,G3,E2,R1,S1

Thiourea A

Thujone A,G3

Thyme oil A,G3

ortho-Tolidine A

Toluene

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A

Toluenediamine

• in hair dyes A,E1

• in other preparations A,G1,G3,E1,S1

Trichloroacetic acid A,G3,E2,S1

Trichloroacetic acid alkali salts A

1,1,1-Trichloroethane A,G3,E1,R1,S1

Trichloroethylene A,G3,E1,R1,S1

Trichloroisocyanuric acid A,G3,E1,S1

Triethanolamine A,G3,E1,S1

Triethyl phosphate A,E1

Trifluoromethanesulfonic acid A,G3,E2

Triisopropanolamine lauryl ether sulfate A,E1,S1

Turpentine (mineral) A,G3

Turpentine oil (vegetable) A,G3,E2

White spirit A,G3

Xylene

• above 75 per cent A,G3,E1,R1,S1

• 75 per cent and below A,G3

• in pressurised spray packs A,G6,E1,S1

Xylenols A,G3,E2,S3

• in pressurised spray packs A,E1

Zinc chloride A,G3,E2,S1

Zinc sulfate A,G3,E2,S1

## APPENDIX F

## WARNING STATEMENTS AND GENERAL SAFETY DIRECTIONS FOR POISONS

(other than agricultural and veterinary chemicals (including pesticides) registered by the

Australian Pesticides and Veterinary Medicines Authority and medicines for human use

when compliant with the requirements of the *Required Advisory Statements for Medicine Labels*)

**INTRODUCTION**

**Warning Statements and Safety Directions**

It is the responsibility of the manufacturer, packer and supplier of a drug or poison to ensure that the purchaser or user of a product is given sufficient information to be able to use it correctly and safely.

Under poisons legislation, scheduled substances, which may be harmful to the user, must be labelled with appropriate warning statements and/or safety directions. The selection of warning statements and safety directions will depend on the formulation of the product, and the use for which it is sold or supplied. The following code has been prepared as a guide for this purpose.

The wording of warning statements and safety directions specified in this Appendix may be varied provided that the intent is not changed. Additional statements also may be added to ensure that the user of a product is sufficiently advised of its harmful nature and how to avoid any deleterious effects.

**Poisons Information Centre Telephone Numbers**

Companies should use the Poisons Information Centre telephone number(s) (Australia 13 11 26; New Zealand 0800 764 766) appropriate to the country(ies) of sale for the product.

Companies wishing to use a poisons information centre telephone number other than the national telephone numbers for Australia and New Zealand in warning statement No. 99 in Part 1 of this Appendix must meet the following criteria:

1. the poisons information service whose number is used must be attended by adequately trained staff for 24 hour emergency poisons information; and

2. calls must be logged and submitted for incorporation into the official collection of poisoning data.

**APPENDIX F**

**PART 1**

**WARNING STATEMENTS**

1. Highly corrosive.

2. Corrosive.

3. Corrosive liquid.

4. Strongly alkaline.

5. Irritant.

6. May cause cancer.

7. WARNING − Causes birth defects.

8. WARNING − May be fatal to children.

9. Can be fatal to children if sucked or swallowed.

10. May produce severe burns.

11. WARNING − Vapour may be harmful.

12. Vapour is harmful to health on prolonged exposure.

13. May be fatal if inhaled, swallowed or absorbed through skin.

14. Dust will irritate and burn eyes, nose and skin.

15. Liquid will cause burns.

16. Forms dangerous gas near radiators or naked flames.

17. Contact with eyes even for short periods can cause blindness.

18. Product will irritate the eyes, nose, throat and skin.

19. WARNING − Skin contact may be dangerous. Take every precaution to avoid contact - wash off after spillage and after use.

20. May give off dangerous gas if mixed with other products.

21. WARNING − This product contains ingredients which may cause skin irritation to certain individuals. A preliminary test according to accompanying directions should be made before use. This product must not be used for dyeing eyelashes or eyebrows; to do so may be injurious to the eye.

22. Highly reactive oxidising chlorine compound.

23. May cause fire or explosion.

24. For external washing only. Rinse skin thoroughly after use.

25. Do not use on broken skin. Wash hands thoroughly after use.

26. (Powder) (and) (concentrated solutions) are dangerous if swallowed.

27. Not for therapeutic use.

28. (Over) (Repeated) exposure may cause sensitisation.

29. If congestion persists, consult your doctor or pharmacist.

30. WARNING − Do not use on face or on anal or genital areas.

31. WARNING − Do not use on face or on anal or genital areas except on doctor’s advice.

32. This preparation should be part of an overall treatment plan regularly assessed with your doctor.

33. Do not take for periods longer than four weeks except on medical advice.

34. WARNING − This medication may be dangerous when used in large amounts or for a long time (period).

35. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged use without medical supervision could be harmful.

or

CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Prolonged or excessive use without medical supervision could be harmful.

36. For use under medical supervision only.

37. Consult a doctor before giving this medication to children or teenagers with chicken pox, influenza or fever.

38. CAUTION − Do not use for children under 2 years old unless a doctor has told you to.

39. This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol.

40. This medication may cause drowsiness and may increase the effects of alcohol. If affected do not drive a motor vehicle or operate machinery.

41. Do not give to children under 12 years of age. Do not use beyond 48 hours or in pregnancy or lactation except on doctor’s advice.

42. WARNING − Overuse may stain the skin or mouth.

43. Use of this product is not necessary in areas supplied with fluoridated water.

44. WARNING − May be dangerous, particularly to children, if you use large amounts on the skin, clothes or bedding or on large areas of the body, especially if you keep using it for a long time.

45. WARNING − If a pigmented spot or mole has recently become darker, changed colour, become enlarged or itchy, or bleeds, do not use this product, see your doctor immediately. Do not use on children. Do not use near the eyes. Mild irritation may occur; stop use if it becomes severe. If fading is not evident in three months, seek doctor’s advice.

46. WARNING − Contains (name of substance) which causes birth defects in laboratory animals. Women of child bearing age should avoid contact with (name of substance).

47. WARNING − This product contains (name of substance) which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

48. WARNING − This product forms cyhexatin which causes birth defects in certain laboratory animals. Women of child bearing age are advised not to mix, load or spray this product. They should keep out of crops being sprayed.

49. WARNING − Do not mix with other medication except on veterinarian’s advice.

50. Unless adequately fired, utensils glazed with this preparation must not be used as containers for food or beverages; to do so may cause lead poisoning.

51. Irritant to skin, eyes, mucous membranes and upper respiratory tract.

52. Breathing vapour or spray mist is harmful and may cause an asthma-like reaction.

53. CAUTION − (Name of substance) should not be used by pregnant women.

54. Seek medical advice before first course of treatment.

55 Keep from eyes, lips, mouth and sensitive areas of the neck. If excessive swelling, irritation, redness or peeling occurs, discontinue use. If these persist, consult a physician. Avoid excessive exposure to sunlight and other sources of ultra violet light.

56. WARNING − Can cause elevated blood pressure and interact adversely with other medication.

57. Not to be applied to infants under 12 months of age unless on doctor’s advice.

58. Highly reactive oxidising bromine and chlorine compound.

59. May cause allergy.

60. Do not mix with detergents or other chemicals.

61. WARNING − Can react with other medicines. Ask your doctor or pharmacist before taking.

62. Do not use if pregnant.

63. See a doctor if you are pregnant or diabetic.

64. See a doctor (or) *(dentist)* if no better after (Insert number of days as per approved Product Information) days.

65. If getting better, keep using for (Insert number of days as per approved Product Information ) days.

66. See a doctor if problem returns.

67. Do not use if pregnant or likely to become pregnant.

68. If symptoms persist beyond 5 days consult a doctor (or) *(dentist)*.

69. If symptoms recur within two weeks of completing the course, consult a doctor.

70. Use only under medical supervision if you are taking other medicines.

71. Do not use during the last three months of pregnancy.

72. Do not use in the eyes.

73. Do not use for acne.

74. Do not use under waterproof bandages unless a doctor has told you to.

75. Do not use for more than 7 days unless a doctor has told you to.

76. Do not become pregnant during use or within (*Insert number of months as per approved Product Information*) month(s) of stopping treatment.

77. WARNING − May cause birth defects.

78. Attacks skin and eyes.

79. Will irritate eyes.

80. (Intentionally blank)

81. (Intentionally blank)

82. (Intentionally blank)

83. This paint is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use on, in or around the home.

84. Breathing the vapour is dangerous.

Provide adequate ventilation during application.

Do not use in the presence of a naked flame.

Do not smoke.

85. This paint contains lead and is dangerous to health, even when dry.

For industrial use only.

Do not use on toys or furniture.

Do not use for painting any building or fixed structure.

Do not use where contact with food or drinking water is possible.

86. This tinter contains lead.

Do not add to any paint which is for application to any toy, furniture, building (interior or exterior), fixed structure or to anything which may contact food or drinking water.

87. (*Insert brand name*) remains in the body for many months after treatment has stopped. Do not become pregnant or father a child before consulting your doctor.

88. This product is not recommended for dyeing eyelashes or eyebrows. To do so may be injurious to the eye.

89. Application to skin may increase sensitivity to sunlight.

90. This preparation is to aid sleep. Drowsiness may continue the following day. If affected do not drive or operate machinery. Avoid alcohol.

91. CAUTION − Total iodine intake may exceed recommended level when taking this preparation.

92. WARNING − Contains iodine - do not take when pregnant **except** on physician’s advice.

93. Causes severe burns, which are not likely to be immediately painful or visible.

94. WARNING − Contains nitrite. Substitution for table or cooking salt may be dangerous, particularly for young children.

95.CAUTION − Do not use for children under 12 years old unless a doctor has told you to.

96. CAUTION − This preparation is for the relief of minor and temporary ailments and should be used strictly as directed. If symptoms persist or recur within two weeks, consult a doctor.

97*. Adults:* Keep to the recommended dose. Don’t take this medicine for longer than a few days at a time unless advised to by a doctor.

98. *Children and adolescents:* Keep to the recommended dose. Do not give this medicine for longer than 48 hours at a time unless advised to by a doctor.

99. If an overdose is taken or suspected, ring the Poisons Information Centre (Australia 13 11 26; New  Zealand 0800 764 766) or go to a hospital straight away even if you feel well because of the risk of delayed, serious liver damage.

100. Do not take with other products containing paracetamol, unless advised to do so by a doctor or pharmacist.

101. Don’t use [this product/name of the product]:  
If you have a stomach ulcer

In the last 3 months of pregnancy *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea.]*

If you are allergic to (name of substance) or anti-inflammatory medicines.

102. Unless a doctor has told you to, don’t use [*this prouct/name of the product*]:

For more than a few days at a time

With other medicines containing aspirin or other anti-inflammatory medicines

If you have asthma

In children under 12 years of age

In children 12-16 years of age with or recovering from chicken pox, influenza or fever

If you are pregnant.

103. See a doctor before taking [this product/name of the product] for thinning the blood or for your heart. [*This statement may be omitted in products for inhibition of platelet aggregation or with additional active ingredients*.]

104. Unless a doctor has told you to, don’t use [this product/name of the product]:

For more than a few days at a time

With other medicines containing (name of substance) or other anti-inflammatory medicines

If you have asthma

If you are pregnant *[This statement may be omitted in preparations used exclusively for the treatment of dysmenorrhoea]*.

105. Do not use on the bedding or clothing of infants or in the bedrooms of children 3 years of age or less.

106. Contains formaldehyde.

**APPENDIX F**

**PART 2**

**SAFETY DIRECTIONS - GENERAL**

To be grouped together and prefaced with the words “SAFETY DIRECTIONS” (see Part 2, Labels and Containers, subparagraph 7(n) to this Standard).

1. Avoid contact with eyes.

2. Attacks eyes − protect eyes when using.

3. Wear eye protection when mixing or using.

4. Avoid contact with skin.

5. Wear protective gloves when mixing or using.

6. Wash hands after use.

7. Wash hands thoroughly after use.

8. Avoid breathing dust (or) vapour (or) spray mist.

9. Use only in well ventilated area.

10. Ensure adequate ventilation when using.

11. No smoking.

12. Do not allow product to come into contact with other chemicals, especially acids.

13. Do not allow product to come into contact with combustible materials such as paper, fabric, sawdust or kerosene.

14. Do not allow to get damp.

15. Store under cover in a dry, clean, cool, well ventilated place away from sunlight.

16. Store and transport in an upright container.

17. Do not mix with other chemicals.

18. Do not mix with different types of chlorinating chemicals.

19. Use clean containers for dispensing.

20. Mix with water only.

21. Do not add water to product − add product to water, but in case of fire drench with water.

22. In case of spillage flush with large quantities of water.

23. Keep away from heat, sparks and naked flames.

24. Avoid contact of the crystals or strong solutions with the eyes, mouth, nose and other mucous membranes.

25. Avoid contact with food.

26. Avoid contact with clothing.

27. Wear a positive-pressure air-supplied full-face respirator whilst spraying and until spray mist has been effectively dispersed.

28. Do not mix with hot water.

29. Obtain a supply of calcium gluconate gel.

30. (Intentionally blank.)

31. Do not use on broken skin.

32. Do not use under occlusive dressing.

33. Mix strictly according to instructions.

34. May cause fire if it comes into contact with other chemicals, paper or other flammable materials.

35. Wash gloves thoroughly, immediately after use.

36. Protect cuticles with grease or oil.

**APPENDIX F**

**PART 3**

**POISONS (other than agricultural and veterinary chemicals)   
TO BE LABELLED WITH WARNING STATEMENTS**

**OR SAFETY DIRECTIONS**

(Where more than one statement or direction is required, they may be combined to form simple sentences where appropriate.)

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**WARNING SAFETY**

**POISON** **STATEMENTS DIRECTION**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Acetic acid in concentrations of 80 per cent 2 1,4,8

or more **except** when in Schedule 2.

Acetic anhydride 2 1,4,8

Acetone in concentrations greater than 75 per cent. 1,4,8

Acitretin 7,62,76

Adapalene for topical use. 62,77

Alclometasone when included in Schedule 3. 38,72,73,74,75

Alkaline salts 4 1,4

Ambrisentan 7,62,76

Amines used as curing agentsfor epoxy resins. 1,3,4,5,8

Ammonia/ammonium hydroxide in concentrations 4 1,4,8

greater than 20 per cent ammonia **except**

in smelling salts.

Ammonium persulfate 5,21,25 1,5,23,33,34

Anhydrides, organic acid, for use as curing agents 1,3,4,5,8

for epoxy resins.

Aniline 13 1,4,8

Antihistamines not separately specified 39 or 40

in this Appendix **except**:

(a) dermal, ocular, parenteral and   
paediatric preparations;

(b) oral preparations of astemizole,

desloratadine, fexofenadine,

loratadine or terfenadine;

(c) nasal preparations of azelastine; or

(d) preparations for the treatment of animals.

Aromatic extract oils 1,3,4,5,6

Aspirin

(a) for inhibition of platelet aggregation. 36

(b) in sustained release preparations 36  
containing 650 mg or more of aspirin.

(c) in other preparations. 101,102,103

Astemizole 61

Azadirachta indica (neem) including its extracts  
and derivatives when included in Schedule 6. 67

Azocyclotin 48

Benomyl 46

Benzene 12 1,4,9

1,2-Benzenediol (catechol) 51,59 1,4,8

Benzoyl peroxide when included in Schedule 2. 55

Benzoyl peroxide when included in Schedule 5. 1,4,8

Bergamot oil 89

Beryllium 1,4,8

Bexarotene

(a) for human use. 7,62,76

(b) for topical use. 62,77

Bifluorides (including ammonium, potassium and sodium salts)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Bithionol for the treatment of animals. 1,4,8

Boron trifluoride (including mixtures that

generate boron trifluoride)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Bosentan 7,62,76

Bromoform 1,4,8

2-Butoxy-2’-thiocyanodiethyl ether 1,4,8

2-Butoxyethanol and its acetates 1,4,8

Camphor

(a) in block, ball, disc, pellet or flake form, 9

enclosed in a device which, in normal use,

prevents removal or ingestion of its contents.

(b) in other forms. 9 1

Carbamide peroxide

(a) more than 9 per cent up to 30 per cent. 5 1

(b) more than 30 per cent up to 60 per cent. 5 2

(c) more than 60 per cent. 2 2,4

Carbon disulphide 12 1,4,8,9,23

Carbon tetrachloride 12 1,4,8,9

Cassia oil 4

Chlorinating compounds

(a) in household cleaning or bleaching 20

preparations.

(b) in preparations containing less than 11 1,4,10

10 per cent of available chlorine.

(c) in liquid preparations containing 3,18 1,4,6,8,10, 15,16,

10 per cent or more of available chlorine. 17,18, 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,

or more of available chlorine. 14,15,16,17, 18,

19,20,21, 22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,  
 or more of available chlorine certified by a 14,15,16,17,  
 relevant State or Territory authority as not 18,19,20,21,  
 being a Dangerous Good of Class 5, 22,26  
 Division 5.1:Oxidising substances, as

specified inthe *Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in compressed block or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine 17,18,19,21  
 **except** in preparations for use in toilet   
 cisterns only, containing 15 g or less of

trichloroisocyanuric acid.

(g) in other compressed blocks or tablets 10,22 12,13,14,15,

containing 10 per cent or more of available 17,18,19,21

chlorine certified by a relevant State or

Territory authority as not being a Dangerous

Good of Class 5, Division 5.1: Oxidising

substances, as specified inthe *Australian*

*Code for the Transport of Dangerous Goods*

*by Road and Rail* **except** in preparations for

use in toilet cisterns only, containing 15 g or

less of trichloroisocyanuric acid.

Chloroform when included in Schedule 6 1,4,8

alpha-Chlorohydrin 13,51 1,4,8,9

Chromates (including dichromates) of alkali metals or ammonia 1,4,8

Chromium trioxide 2,14,15,23 1,4,8,13

Cimetidine when included in Schedule 3 70,96

Cinnamon bark oil 4

Clobetasone when included in Schedule 3. 72,73,74,75,95

Clotrimazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Clove oil 1

Cyanides when included in Schedule 7. 13 4,8

Cyanuric acid 1,4,8

Cyclohexanone peroxide 1,4,8

Cysteamine 1

4,4-Diaminodiphenylmethane (methylene dianiline) 1,4,8

ortho-Dichlorobenzene 1,4,8

para-Dichlorobenzene 1,4

Dichloroethylene 1,4,8

Dichloroethyl ether 1,4,8

Dichloroisocyanurates

(a) in household cleaning or bleaching 20  
 preparations.

(b) in preparations containing less than 11 1,4,10  
 10 per cent of available chlorine. .

(c) in liquid preparations containing 10 per cent 3,18 1,4,6,8,10,  
 or more of available chlorine. 15,16,17,18,  
 . 19,20,22,26

(d) in dry preparations containing 10 per cent 10,18,22,23 1,4,8,12,13,14,  
 or more of available chlorine. 15,16,17,18,19,  
 . 20,21,22,26

(e) in dry preparations containing 10 per cent 10,18,22 1,4,8,12,13,14,

or more of available chlorine certified by a 15,16,17,18,19,

relevant State or Territory authority as not 20,21,22,26

being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as

specified in*the Australian Code for the*

*Transport of Dangerous Goods by Road*

*and Rail.*

(f) in anti-bacterial tablets containing 2.5 g or 60  
 less of sodium dichloroisocyanurate..

(g) in other compressed blocks or tablets containing 10,22,23 12,13,14,15,  
 10 per cent or more of available chlorine **except** 17,18,19,21  
 in preparations containing 21 g or less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(h) in other compressed blocks or tablets containing 10,22 12,13,14,15,17,

10 per cent or more of available chlorine 18,19,21

certified by a relevant State or Territory authority

as not being a Dangerous Good of Class 5,

Division 5.1: Oxidising substances, as specified

in*the Australian Code for the Transport of*

*Dangerous Goods by Road and Rail* **except** in

preparations containing 21 g less of sodium

dichloroisocyanurate for use in toilet cisterns only.

(i) in other compressed blocks or tablets containing

10 per cent or more of available chlorine in

preparations containing 5 g or less of sodium

dichloroisocyanurate for use in toilet bowls only:

(i) during storage 10,22,23 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

(j) in other compressed blocks or tablets containing

10 per cent or more of available chlorine certified

by a relevant State or Territory authority as not

being a Dangerous Good of Class 5, Division 5.1:

Oxidising substances, as specified inthe

*Australian Code for the Transport of Dangerous*

*Goods by Road and Rail* in preparations

containing 5 g or less of sodium dichloroisocyanurate

for use in toilet bowls only.

(i) during storage 10,22 12,13,14,15,17,

18,21

(ii) during use 5 1,4,7,12

Dichloromethane (methylene chloride)

(a) in paint or lacquer removers. 12,16 1,4,8,11

(b) other than in paint or lacquer removers 1,4,8,25

.

Diclofenac 101,104

Dienestrol 67

Diethanolamine when included in Schedule 5. 5 1,4

Diethanolamine when included in Schedule 6. 2,11,18 1,4,8

Diethyltoluamide for human use. 44

5,6-Dihydroxyindoline 21,28

Dimethylformamide 1,4,8

Dimethyl sulfate 2 1,4,8

Dimethyl sulfoxide

(a) when not packed and labelled for therapeutic use. 27 1,4,5,8

(b) when packed and labelled for treatment of animals. 49 1,4,5,8

Dinitrocresols (and their homologues) **except** when for 1,4,8

therapeutic use.

Dinitrophenols (and their homologues) **except** when 1,4,8

for therapeutic use.

Dinocap 47

Dioxane 1,4,8

Diphenoxylate when included in Schedule 3. 39 or 40,41

Econazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Ephedrine in nasal preparations for topical use. 29

Epichlorohydrin 2 1,4,8

Epoxy resins, liquid. 1,3,4,5,8

Ethanolamine when included in Schedule 5. 5 1,4

Ethanolamine when included in Schedule 6. 2,11,18 1,4,8

Ether when included in Schedule 5 or 6. 1,4,8

Ethoxyethylmercuric chloride 1,4

Ethyl bromide 1,4,8

Ethylene chlorohydrin 1,4,8

Ethylene glycol monoalkyl ethers and their acetates 1,4,8

except when separately specified.

Ethylene oxide 1,4,8

Ethylmercuric chloride 1,4

Ethyl methacrylate 28 4,9,23

Etretinate 7,62,76

Eugenol 1

Famotidine when included in Schedule 2. 96

Fenoterol in metered aerosols. 32

Fluconazole in oral preparations when included in 64   
Schedule 3.

Fluorides (including silicofluorides) when included in 1,4

Schedule 5 or 6 **except** when separately specified.

Formaldehyde

(a) in nail hardener cosmetics. 106 1,4,8,36

(b) in other preparations. 106 1,4,8

Formic acid 1,4,8

Glazing preparations containing lead compounds.. 50

Glutaraldehyde **except** when in Schedule 2

(a) 25 per cent or less. 5,59 1,4,5

(b) more than 25 per cent. 3,59 1,4,5,8

Glycolic acid 79 1,5,6,31

Hexachlorophane in preparations for skin cleansing 24

purposes containing 3 per cent or less of

hexachlorophane.

Hexyloxyethanol 2 1,4,8

Hydrazine 1,4,8

Hydrochloric acid

(a) 30 per cent or less of HCl. 1,4

(b) more than 30 per cent of HCl. 1,4,8

Hydrocortisone

(a) for dermal use when included in 38,72,73,74,75

Schedule 2 or 3.

(b) for topical rectal use when includeed 38,75

in Schedule 2 or 3.

Hydrocyanic acid when included in Schedule 7. 13 4,8

Hydrofluoric acid (including mixtures that generate

hydrofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

Hydrogen peroxide

(a) more than 3 per cent up to 10 per cent. 5 1

(b) more than 10 per cent up to 20 per cent. 5 2

(c) more than 20 per cent. 2 2,4

Hydroquinone

(a) when in Schedule 2. 45

(b) **except** when in Schedule 2 or 4. 1,4

Hydrosilicofluoric acid (including mixtures

that generate hydrosilicofluoric acid)

(a) when included in Schedule 5. 2 1,4

(b) when included in Schedule 6 or 7. 1,17,93 1,3,4,5,8,29,35

8-Hydroxyquinoline (including salts and 33

derivatives) when prepared for

internal use.

Ibuprofen 101,104

Iodine

(a) more than 20 per cent. 1,4,8

(b) in preparations for human internal therapeutic 91,92   
 use containing 300 micrograms or more of

iodine per recommended daily dose.

Ipratropium bromide in metered aerosols. 32

Isocyanates (free organic)

(a) when in paint. 28,52 1,5,8,10,27

(b) other than in paint. 28,52 1,4,8

Isoprenaline in metered aerosols 32

Isotretinoin

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

Lead compounds

(a) in hair cosmetics. 25

(b) when in Schedule 6. 1,4,8

Leflunomide 7,62,87

Lemon oil 89

Lenalidomide 7,62,76

Levocabastine

(a) in eye or nasal preparations containing 62

0.5 mg/mL or less of levocabastine.

(b) in other preparations. 62 and

either 39 or 40

Lime oil 89

Loperamide when in Schedule 2. 41

Magnesium chlorate 1,4

Mefenamic acid 101,104

Mercuric thiocyanate 1,4

Metacresolsulphonic acid and formaldehyde 1,4

condensation product for the treatment of animals.

Methanol **except** in methylated spirit. 1,4,8

Methoxamine in nasal preparations for topical use. 29

Methyl chloride 1,4,8

Methyl ethyl ketone 5 1,4,8

Methyl ethyl ketone peroxide 2 2,3,4,6

Methyl iso-amyl ketone 1,4,8

Methyl iso-butyl ketone 1,4,8

Methyl iso-thiocyanate 5,12 1,4,8

Methyl methacrylate 28 4,9,23

Methyldibromo glutaronitrile 28 1,4,7

Methylene bisthiocyanate 1,4

Methyleugenol 1,6

Methylnorbornylpyridine 59

1-(beta-Methyl sulphonamidoethyl)- 2-amino-3-

N,N-diethylaminobenzene 1,4,8

Miconazole in vaginal preparations when included 54,63,64,66

in Schedule 3.

Misoprostol 53

Naphazoline in nasal preparations for topical use. 29

Naphthalene

(a) in block, ball, disc, pellet or flake form, 9,105

enclosed in a device which, in normal

use, prevents removal or ingestion of its

contents.

(b) in other forms. 9,105 1

Naproxen 101,104

Nicotine **except** when in tobacco or when included 1,4  
in Schedule 2.

Nitric acid

(a) 75 per cent or less HNO3. 2 1,4

(b) more than 75 per cent HNO3. 2 1,4,8

Nitrobenzene 1,4,8

Nitrophenols 1,4

Nitroprussides in aerosols. 84 8

Nizatidine when included in Schedule 2. 96

Noradrenaline in metered aerosols. 32

Nystatin in vaginal preparations when included 54,63,64,65,66

in Schedule 3.

Orange oil (bitter) 89

Orciprenaline in metered aerosols. 32

Oxalates, metallic 4,8

Oxalic acid 2 4,8

Oxymetazoline in nasal preparations for topical use. 29

Paint

(a) First Schedule paints. 83

(b) Second Schedule paints. 84

Paracetamol 97 and/or 98,99,100

Pentachlorophenol 1,4,8

Peracetic acid 2 1,4,8

Permanganates 2 24

Phenol and any other homologue of phenol. 1,4

Phenols 5

Phenylenediamines and alkylated   
phenylenediamines

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

Phenylephrine in nasal preparations 29

for topical use.

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,5-dimethanamine 5,28 1,4,5,10

N,N-bis(phenylmethylene)-bicyclo-

(2.2.1)heptane-2,6-dimethanamine 5,28 1,4,5,10

ortho-Phenylphenol **except** when in 1,4

antiseptics.

Phenylpropanolamine 56

Phenytoin in pastes for the treatment of horses. 9

Phosphonic acid 1,4

Phosphoric acid 1,4

Phosphorus (yellow) 2 1,4

ortho-Phthalaldehyde

(a) when included in Schedule 5. 51,52,59 1,4,5,8,10

(b) when included in Schedule 6. 51,52,59 2,4,5,8,10

Picric acid (more than 20 per cent). 1,4

Podophyllin

(a) in preparations specifically for use on 36

anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

Podophyllotoxin

(a) in preparations specifically for 36

use on anal or genital area.

(b) in other liquid preparations when included 31

in Schedule 2 or Schedule 3.

(c) in other solid or semi-solid preparations 30

when included in Schedule 2.

Polihexanide 1,4,8

Polyethanoxy (15) tallow amine 1,4

Poly(oxy-1,2-ethanediyl), α -[2-[(2-hydroxyethyl)amino] 5,88 1,5

-2-oxoethyl]- α -hydroxy-,mono-C13-15 -alkyl ethers

Potassium hydroxide

(a) in preparations containing 5 1,4,6  
 0.5 per cent or less of potassium

hydroxide.

(b) in solid preparations containing 2,10,78 3,5,28

more than 0.5 per cent of potassium   
 hydroxide.

(c) in liquid preparations containing 2,10,78 3,5  
 more than 0.5 per cent of potassium   
 hydroxide.

Potassium metabisulphite 5,26 1,4

Potassium nitrite in pickling or curing salts. 94

Potassium persulfate 5,21,25 1,5,23,33,34

Potassium sulfide 2 1,4

Propionic acid when in Schedule 6. 2 1,4

Ranitidine when included in Schedule 2. 96

Safrole

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

Salbutamol in metered aerosols or in dry 32  
powder formulations.

Salicylamide 34 or 35

Sassafras oil

(a) in preparations for therapeutic use. 1

(b) other than for therapeutic use. 1,4

Selenium compounds **except** when for 1,4,8

therapeutic use (human or animal).

Silver in smoking deterrents. 42

Sitaxentan 7, 62, 76

Sodium aluminate 2 1,4

Sodium chlorate 1,4

Sodium dodecylbenzene sulfonate 79 1

Sodium fluoride in preparations for 43

human ingestion when in Schedule 2.

Sodium hydrogen sulfate 1,4,8

Sodium hydrosulfite 5,26 1,4,8

(more than 50 per cent)

Sodium hydroxide

(a) in preparations containing 0.5 per cent 5 1,4,6  
 or less of sodium hydroxide.

(b) in solid preparations containing more than 2,10,78 3,5,28  
 0.5 per cent of sodium hydroxide.

(c) in liquid preparations containing more than 2,10,78 3,5  
 0.5 per cent of sodium hydroxide.

Sodium laureth-6 carboxylate 79 1

Sodium metabisulphite 5,26 1,4

(more than 50 per cent)

Sodium nitrite in pickling or curing salts 94

Sodium persulfate 5,21,25 1,5,23,33,34

Sodium sulfide 2 1,4

Styrene 1,4,8

Sulfamic acid 2 1,4

Sulfuric acid 2 1,4

Symphytum spp. (Comfrey) when included in Schedule 5. 31,32

Tazarotene for topical use. 77,62

Terbutaline in metered aerosols or in dry powder formulations. 32

Terfenadine 61

Teriflunomide. 7,62,87

Terpenes, chlorinated 1,4,8

Tetrachloroethane 12 8

Tetrachloroethylene when in Schedule 5 or 6. 12,16 1,4,8,11

Tetrahydrozoline in nasal preparations for topical use. 29

Thalidomide 7,62,76

Thiourea 1,4

Toluene 1,4,8

Toluenediamine

(a) in hair dyes. 21

(b) in preparations other than hair dyes. 1,4,8

Tramazoline in nasal preparations for topical use. 29

Tretinoin

(a) for human oral use. 7,62,76

(b) for topical use. 62,77

Triamcinolone when in topical preparations 64 or 68

for the treatment of mouth ulcers.

Trichloroacetic acid **except** when for 2 1,4

therapeutic use.

1,1,1-trichloroethane 8,9

Trichloroethylene **except** when for 12 1,4,5,8,9  
therapeutic use.

Trichlorophenol 1,4,8

Triethanolamine 5 1,4

Triethyl phosphate 1,4,8

Trifluoromethanesulfonic acid

(a) more than 10 per cent. 1,17 1,4,8

(b) 10 per cent or less. 1,4,8

Triisopropanolamine lauryl ether sulfate 1,4,6

3,6,9-Trioxaundecanedioic acid 5 1

Tymazoline in nasal preparations for topical use. 29

Vinclozolin 46

Xylene 1,4,8

Xylometazoline in nasal preparations for topical use. 29

Zinc chloride 1,4

Zinc sulfate when in Schedule 6. 1,4

## APPENDIX G

## DILUTE PREPARATIONS

The requirements of this Standard do not apply to a poison listed in Column 1 of this Appendix at a concentration not more than that specified in Column 2 in respect of that poison.

**Column 1 Column 2**

**Poison Concentration**

**(quantity per litre**

**or kilogram**)

ACETYLCHOLINE 1 mg

ALDOSTERONE 10 micrograms

ANTIMONY COMPOUNDS 1 mg

APOMORPHINE 1 mg

ARSENIC 1 mg

ATROPA BELLADONNA (belladonna) 300 micrograms

ATROPINE 300 micrograms

CANTHARIDIN 10 micrograms

CHLORINE 5 mg

CROTON TIGLIUM (croton oil) 1 mg

DIOXANE 100 mg

ERYSIMUM spp. 1 mg

FOLLICLE-STIMULATING HORMONE 100 micrograms

GELSEMIUM SEMPERVIRENS 1 mg

GLUCAGON 100 micrograms

GLYCERYL TRINITRATE 100 micrograms

GROWTH HORMONE 10 micrograms

HALOPERIDOL 1 mg

HYDROCYANIC ACID 1 microgram

HYOSCINE 300 micrograms

HYOSCYAMINE 300 micrograms

HYOSCYAMUS NIGER 300 micrograms

HYPOTHALAMIC RELEASING FACTORS 10 micrograms

INDOMETHACIN 1 mg

MERCURY 1 mg

METHYLMERCURY 300 micrograms

NAPHTHALENE 1 mg

NERIUM OLEANDER 1 mg

OESTRADIOL 10 micrograms

OESTRONE 100 micrograms

OXYTOCIN 1 microgram

PHOSPHORUS 1 mg

PODOPHYLLUM RESIN (podophyllin) 1 mg

PROGESTERONE 1 mg

PROPRANOLOL 1 mg

SELENIUM 100 micrograms

STROPHANTHUS spp. 1 mg

STRYCHNINE 1 mg

TESTOSTERONE 1 mg

THYROXINE 10 micrograms

## APPENDIX H

## SCHEDULE 3 POISONS PERMITTED TO BE ADVERTISED

.

Butoconazole.

Clotrimazole.

Diclofenac.

Dimenhydrinate for the prevention and relief of motion sickness.

Diphenoxylate.

Econazole.

Fluconazole.

Hydrocortisone.

Miconazole.

Nystatin.

## APPENDIX I

## UNIFORM PAINT STANDARD

This Appendix provides regulations for adoption by the States and Territories.

1. A person must not manufacture, sell, supply or use a First Schedule Paint for application to:

(1) a roof or any surface to be used for the collection or storage of potable water; or

(2) furniture; or

(3) any fence, wall, post, gate or building (interior or exterior) other than a building which is used exclusively for industrial purposes or mining or any oil terminal; or

(4) any premises used for the manufacture, processing, preparation, packing or serving of products intended for human or animal consumption.

2. A person must not manufacture, sell, supply or use a Third Schedule paint.

3. A person must not manufacture, sell, supply or use a paint for application to toys unless the paint complies with the specification for coating materials contained in Australian/New Zealand Standard AS/NZS ISO 8124.3:2012 entitled *Safety of toys Part 3: Migration of certain elements* (ISO 8124-03:2010, MOD).

4. A person must not manufacture, sell, supply, or use a paint containing a pesticide except a fungicide, algicide, bactericide or antifouling agent.

**The First Schedule**

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

**Substance Proportion**

ANTIMONY or antimony compounds other than more than 5 per cent

antimony titanate pigments

BARIUM salts **except** barium sulfate or barium metaborate more than 5 per cent

CADMIUM or cadmium compounds more than 0.1 per cent

CHROMIUM as chromates of ammonia, barium, potassium, more than 5 per cent

sodium, strontium or zinc

SELENIUM or selenium compounds more than 0.1 per cent

**The Second Schedule**

**Substance Proportion**

DICHLOROMETHANE (methylene chloride) more than 5 per cent by wt

ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates more than 10 per cent by vol

HEXYLOXYETHANOL more than 10 per cent by vol

TOLUENE more than 50 per cent by vol

XYLENE more than 50 per cent by vol

**The Third Schedule**

The proportion of a substance for the purposes of this Schedule is calculated as a percentage of the element present in the non-volatile content of the paint.

**Substance Proportion**

LEAD or lead compounds more than 0.1 per cent

## APPENDIX J

## CONDITIONS FOR AVAILABILITY AND USE OF SCHEDULE 7 POISONS

**PART 1**

**CONDITIONS FOR AVAILABILITY AND USE**

The following controls are recommended for poisons only when included in Schedule 7. These conditions for availability and use may be implemented through poisons controls or other State or Territory legislation.

1. Not to be available except to authorised or licensed persons.

2. Not to be used in printing inks.

3. Not to be used except by or in accordance with the directions of accredited government vermin control officers.

4. Not to be used in industries which handle, process or store foods, animal feeds or packaging materials.

**APPENDIX J**

PART 2

A poison listed in this Appendix is to be available only in accordance with the conditions specified beside it in the “Conditions” column. The conditions apply only when the poison is included in Schedule 7.

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**POISONS CONDITIONS**

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Abamectin 1

Acibenzolar-s-methyl 1

Acrolein 1

Acrylonitrile 1

Alachlor 1

Allyl alcohol 1

4-Aminopyridine 1

Arprinocid 1

Arsenic 1

Azocyclotin 1

Benzene 1

Bifluorides (including ammonium, potassium and sodium salts) 1

Boron trifluoride 1

Brodifacoum 1

Bromadiolone 1

Bromine 1

Brucine 1

Calciferol 1

Captafol 1

Carbadox 1

Carbonyl sulphide 1

Carbon tetrachloride 1

Chlordecone 1

Chlordimeform 1

Chlorine 1

Chloromethiuron 1

Chloropicrin 1

4-Chloro-o-toluidine 1

Colecalciferol 1

Coumatetralyl 1

Cyanogen 1

Cyhexatin 1

4,4-Diaminodiphenylmethane (methylene dianiline) 1

1,2-Dibromo-3-chloropropane 1

1,3-Dichloropropene 1

Difenacoum 1

4-Dimethylaminoazobenzene 1

Dinitrocresols 1

Dinitrophenols 1

Dinoseb 1

Epichlorohydrin 1

Epidermal growth factor 1

Etaconazole 1

Ethylene dibromide 1

Ethylene oxide 1

Fluoracetamide 3

Fluoroacetic acid 3

Folpet 1

Halofuginone 1

Halogenated dibenzodioxins and dibenzofurans 1

HCB 1

Hydrocyanic acid and cyanides 1

Hydrofluoric acid 1

Hydrosilicofluoric acid 1

Iodomethane 1

Maduramicin 1

Mercury 1

Methacrifos 1

Methoxyethylmercuric acetate 1

Methoxyethylmercuric chloride 1

Methyl bromide 1

4,4’-Methylenebis[2-chloroaniline] 1

Mirex 1

Molinate 1

Nicotine 1

Nitrofen 1

Phenylmercuric acetate 1

Phosphides, metallic 1

Phosphine 1

Propylene oxide 1

Pyrinuron 1

Strychnine 1

Sulcofuron 1

Tetrachloroethane 1

2,2’,6,6’-Tetraisopropyl-diphenyl-carbodiimide 1

Thallium 3

ortho-Tolidine 1

Trichloroisocyanuric acid 1

Vinyl chloride 1

## APPENDIX K

## DRUGS REQUIRED TO BE LABELLED

## WITH A SEDATION WARNING

(see Part 2, Labels and Containers, subparagraph 14(2))

Alprazolam

Amisulpride

Amitriptyline

Amylobarbitone

Aripiprazole

ASENAPINE

Azatadine

Baclofen

Benztropine

Bromazepam

Brompheniramine

Buclizine

Buprenorphine

Butobarbitone

Cetirizine

Chloral hydrate

Chlordiazepoxide

Chlormethiazole

Chlorpheniramine

Chlorpromazine

Clemastine

Clomipramine

Clonazepam

Clonidine

Clorazepate

Clozapine

Codeine **except** when included in Schedule 2 or 3.

Cyclizine

Cyclobarbitone

Cycloserine

Cyproheptadine

Cysteamine

Dantrolene

Desipramine

Dexchlorpheniramine

Dextromoramide

Dextropropoxyphene

Diazepam

Difenoxin

Dihydrocodeine

Dimenhydrinate

Dimethindene

Diphenhydramine

Diphenoxylate

Diphenylpyraline

Dothiepin

Doxepin

Doxylamine

Dronabinol (*delta*-9-tetrahydrocannabinol)

Droperidol

Duloxetine

Ethylmorphine

Fenfluramine

Flunitrazepam

Flupenthixol

Fluphenazine

Flurazepam

Gabapentin

Gemcitabine

Glutethimide

Haloperidol

Hydrocodone

Hydromorphone

Hydroxyzine

Imipramine

Lamotrigine

Levetiracetam

Levocabastine

Lorazepam

LURASIDONE.

Mazindol

Mebhydrolin

Meclozine

Medazepam

Meprobamate

Mepyramine

Methadone

Methdilazine

Methocarbamol

Methylphenobarbitone

Mianserin

Mirtazapine

Morphine

Nabiximols

Nalbuphine

Nitrazepam

Normethadone

Nortriptyline

Olanzapine

Opium in any form **except** the alkaloids noscapine and papaverine.

Oxazepam

Oxycodone

Paliperidone

Papaveretum

Pentazocine

Pentobarbitone

Pericyazine

Perphenazine

Pethidine

Phenelzine

Pheniramine

Phenobarbitone

Phenoperidine

Phenyltoloxamine

Pholcodine

Pimozide

Pizotifen

Prazepam

Pregabalin

Prochlorperazine

Promazine

Promethazine

Protriptyline

Quetiapine

Quinalbarbitone

RETIGABINE

Risperidone

Rotigotine

RUPATADINE

Secbutobarbitone

TAPENTADOL

Temazepam

Thenyldiamine

Thiethylperazine

Thiopropazate

Thioridazine

Thiothixene

Tramadol

Tranylcypromine

Trifluoperazine

Trimeprazine

Trimipramine

Triprolidine

Ziprasidone

Zolpidem

Zonisamide

Zopiclone

## APPENDIX L

## REQUIREMENTS FOR DISPENSING LABELS FOR

## HUMAN AND VETERINARY MEDICINES

**PART 1**

**GENERAL REQUIREMENTS FOR DISPENSING LABELS**

(see Part 2, Labels and Containers, subparagraph 14(1))

(1) All details, words and other required information on a label on a container of a substance for therapeutic use must be in the English language in letters at least 1.5 millimetres in height.

(2) All symbols, numbers and words on a label must be in durable characters.

(3) The label on a container of a substance for therapeutic use must contain the following details:

(a) the name, address and telephone number of the dispenser supplying the substance;

(b) the approved name of the substance and/or its proprietary name (unless it is a preparation compounded in accordance with the dispenser’s own formula);

(c) adequate directions for use;

(d) the strength and form of the substance;

(e) the total quantity of the goods in the container;

(f) the words “KEEP OUT OF REACH OF CHILDREN” in red on a white background;

(g) if the substance is intended for external use only, the word “POISON”, or the words “FOR EXTERNAL USE ONLY”, in red on a white background;

(h) if the substance is a medicine, the name of the person for whom it was dispensed; and

(i) if the substance is a veterinary chemical, the species of animal, the name of the animal’s owner and the words “FOR ANIMAL TREATMENT ONLY”.

(4) The label on a container of a medicine or veterinary chemical that is supplied on prescription must also include:

(a) the prescription reference number;

(b) the date on which the prescription was supplied (unless that date is clear from the prescription reference number); and

(c) the directions for use set out in the prescription.

**APPENDIX L**

**PART 2**

**ADDITIONAL LABELLING REQUIREMENTS FOR CERTAIN HUMAN MEDICINES**

(see Part 2, Labels and Containers, subparagraph 14(2))

Medicines required to be labelled with certain warning statements A substance listed in Column 1 of the following table must be labelled with the warning statement in Appendix F, Part 1, as specified opposite in Column 2.

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**Column 1 Column 2**

**Substance Warning statement**

**\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

Acitretin:

1. for oral use. 7,62 and 76
2. for topical use. 62 and 77

Adapalene:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Ambrisentan. 7, 62 and 76

Bexarotene:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Bosentan. 7, 62 and 76

Dienestrol. 67

Etretinate:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Fingolimod. 76

Isotretinoin:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Leflunomide. 7, 62 and 76

Lenalidomide:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Levocabastine. 62

Misoprostol. 53

Sitaxentan. 7, 62 and 76

Teriflunomide. 7, 62 and 87

Thalidomide:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

Tretinoin:

1. for oral use. 7, 62 and 76
2. for topical use. 62 and 77

# **INDEX**

(

(1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE \*(JWH-200) 203

(1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE) \*(AM-694) 202

(E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL (uniconazole-p) 158

(Z)-9-TRICOSENE 217

1

1-(3,4,5-TRIMETHOXYPHENYL)-2-AMINOBUTANE 205

1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE \*(TFMPP) 205

1-(BETA-METHYL SULPHONAMIDOETHYL)- 2-AMINO-3-N,N-DIETHYLAMINOBENZENE 257

1,1,1-TRICHLOROETHANE 149, 222, 238, 262

*See also* DESIGNATED SOLVENT 4

1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE 147

*See* TDE 184, 147

1,2-DIBROMO-3-CHLOROPROPANE 190, 267

1,2-DICHLOROPROPANE 163

1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and N-METHYLMETHANAMINE 133

1,3-DICHLOROPROPENE 190, 267

1,3-DIMETHYLAMYLAMINE 220

1,4-BUTANEDIOL 219

13C-UREA 218

19-NORANDROSTENEDIOL 97

19-NORANDROSTENEDIONE. 98

1-AMINOMETHANAMIDE DIHYDROGEN TETRAOXOSULFATE 152

1-DODECANOL

*See* LAURYL ALCOHOL 215

1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE \*(MPPP) 203

1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID (PETHIDINE INTERMEDIATE C) 198

1-METHYLCYCLOPROPENE 216

1-OCTEN-3-OL 176

1-PENTYL-3-(1-NAPHTHOYL)INDOLE \*(JWH-018) 204

1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE \*(JWH-122) 204

1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE \*(PEPAP) 204

2

2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE \*(JWH-250) 203

2-(4-CHLOROPHENYL)-(1,2,4)TRIAZOLO[5,1-A]ISOQUINOLINE 64

2,2’,6,6’-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE 184, 195, 268

2,2-DPA 214

2,3,6-TBA 147

2,4,5-T 183

2,4-D 130, 162

2,4-DB 131

2,4-DES 131

2,4-DICHLORPROP 163

2,4-DINITROCHLOROBENZENE 72

2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE \*(2C-T-7) 201

2,5-DIMETHOXY-4-BROMOAMPHETAMINE \*(DOB) 201

2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE \*(DOET) 201

2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE \*(2C-T-2) 201

2,5-DIMETHOXY-4-IODOPHENETHYLAMINE \*(2C-I) 201

2,5-DIMETHOXYAMPHETAMINE \*(DMA) 201

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL \*(CANNABICYCLOHEXANOL OR CP 47,497 C8 HOMOLOGUE) 202

2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL \*(CP 47,497) 202

2-[(4-AMINOPHENYL)AZO]-1,3-DIMETHYL-1H-IMIDAZOLIUM CHLORIDE

*See* BASIC ORANGE 31 153, 219

2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE

*See* TCMTB 183

2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE \*(STP or DOM) 200

2-BUTOXY-2’-THIOCYANODIETHYL ETHER 156, 250

2-BUTOXYETHANOL AND ITS ACETATES 229, 250

2C-I

*See* 2,5-DIMETHOXY-4-IODOPHENETHYLAMINE 201

2C-T-2

*See* 2,5-DIMETHOXY-4-ETHYLTHIOPHENETHYLAMINE 201

2C-T-7

*See* 2,5-DIMETHOXY-4-(N)-PROPYLTHIOPHENETHYLAMINE 201

2-MERCAPTOETHANOL 173

2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID (MORAMIDE INTERMEDIATE) 203

2-METHYLTHIO-4-(2-METHYLPROP-2-YL) AMINO-6-CYCLOPROPYLAMINO-5- TRIAZINE 140

2-OCTYL-4-ISOTHIAZOLIN-3-ONE (OCITHILINONE) 235

2-PROPYLENE GLYCOL 1-MONOMETHYL ETHER 217

3

3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (B,D) PYRAN \*(DMHP) 201

3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE \*(PSILOCINE OR PSILOTSIN) 201

3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) 205

3,4,5-TRIMETHOXY-α-METHYLPHENYLETHYLAMINE \*(TMA) 205

3,4-METHYLENEDIOXY-N-α-DIMETHYLPHENYLETHYLAMINE

*See* N,A-DIMETHYL-3,4-(METHYLENEDIOXYL)PHENYLETHYLAMINE

3,4-METHYLENEDIOXYAMPHETAMINE \*(MDA) 203

3,4-METHYLENEDIOXYPYROVALERONE \*(MDPV) 203

3,6,9-TRIOXAUNDECANEDIOIC ACID 149, 262

3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN \*(PARAHEXYL) 202

3-IODO-2-PROPYNYL BUTYL CARBAMATE (iodocarb) 136, 170

3-METHYLFENTANYL 203

3-METHYLTHIOFENTANYL 203

4

4,4’-METHYLENEBIS[2-CHLOROANILINE] 268

4,4’-METHYLENEBIS[2-CHLOROANILINE] (MOCA) 193

4,4-DIAMINODIPHENYLMETHANE (METHYLENE DIANILINE) 190, 251, 267

1-(8-BROMOBENZO[1,2-B 200

4,5-DICHLORO-2-N-OCTYL-3(2H)-ISOTHIAZOLONE 163

4-[4-(ACETYLOXY)PHENYL]-2-BUTANONE 213

4-AMINOPYRIDINE 53, 187, 228, 267

4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE \*(BDMPEA 200

4-CHLOROMETHANDIENONE 64

4-CHLORO-O-TOLUIDINE 189, 267

4-CHLOROTESTOSTERONE

*See* CLOSTEBOL 66

4-CPA 129

4-CYANO-1-METHYL-4-PHENYLPIPERIDINE (PETHIDINE INTERMEDIATE A) 197

4-CYANO-2-DIMETHYLAMINO-4,4’-DIPHENYLBUTANE 201

4-DIMETHYLAMINOAZOBENZENE 190, 267

4-FLUORO-N-METHYLAMPHETAMINE 202

4-FLUORO-N-METHAMPHETAMINE

*See* 4-FLUORO-N-METHYLAMPHETAMINE

4-HYDROXYBUTANOIC ACID (GAMMA HYDROXYBUTYRATE (GHB)) 202

4-METHOXY-α-METHYLPHENYLETHYLAMINE \*(PMA) 203

4-METHYLAMINOREX 203

4-METHYLHEXANE-2-AMINE

*See* 1,3-DIMETHYLAMYLAMINE

4-METHYLMETHCATHINONE \*(MEPHEDRONE) 203

4-METHYLTHIOAMPHETAMINE 203

4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER (PETHIDINE INTERMEDIATE B) 199

5

5-(2-AMINOPROPYL)INDAN 200

5,6-DIHYDROXYINDOLINE 164, 220, 231, 253

5-AMINOLEVULINIC ACID 53

5-CHLORO-3-METHYL-4-NITROPYRAZOLE 189

5-MeO-AMT

*See* 5-METHOXY-α-METHYLTRYPTAMINE 202

5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE \*(MMDA) 203

5-METHOXY-α-METHYLTRYPTAMINE \*(5-MeO-AMT) 202

6

6-BENZYLADENINE 154

8

8-HYDROXYQUINOLINE 36, 255

*See also* CLIOQUINOL 65, 220

A

ABACAVIR 50

ABAMECTIN 124, 187, 267

ABATACEPT 50

ABCISIC ACID 124

ABCIXIMAB 50

ABIRATERONE ACETATE 50

ABRUS PRECATORIUS (JEQUIRITY) 219

ACAMPROSATE CALCIUM 50

ACARBOSE 50

ACEBUTOLOL 50

ACEPHATE 151

ACEPROMAZINE 50

ACETAMIPRID 151

ACETANILIDE 50

ACETARSOL 50

ACETAZOLAMIDE 50

ACETIC ACID 29, 124, 151, 228, 248

ACETIC ANHYDRIDE 151, 228, 248

ACETOHEXAMIDE 50

ACETONE 124, 228, 248

*See also* DESIGNATED SOLVENT 3

ACETORPHINE 200

ACETYL ISOVALERYLTYLOSIN 50

ACETYL-ALPHA-METHYLFENTANYL 200

ACETYLCARBROMAL 50

ACETYLCHOLINE 50, 263

ACETYLCYSTEINE 29, 50

ACETYLDIGITOXIN 50

ACETYLDIHYDROCODEINE 197

ACETYLMETHADOL 197

ACETYLMETHYLDIMETHYLOXIMIDOPHENYLHYDRAZINE 50

ACETYLMORPHINES 197

ACETYLSTROPHANTHIDIN 50

ACIBENZOLAR-S-METHYL 187, 267

ACICLOVIR 50

ACIFLUORFEN 151

ACINITRAZOLE 151

ACIPIMOX 50

ACITRETIN 50, 223, 248, 273

ACOKANTHERA OUABAIO 50

ACOKANTHERA SCHIMPERI 50

ACONITUM 29, 50

ACORUS CALAMUS (CALAMUS) 219

ACRIFLAVINE 51, 124, 187

ACRIVASTINE 51

ACROLEIN 187, 228, 267

ACRYLONITRILE 187, 267

ADALIMUMAB 51

ADAPALENE 51, 248, 273

ADEFOVIR 51

ADENOSINE 51

ADHESIVES, GLUES AND CEMENTS − MEDICAL AND VETERINARY 208

ADIPHENINE 51

ADONIS VERNALIS 51

ADRAFINIL 51

ADRENALINE 44, 51

ADRENOCORTICAL HORMONES 51

ADVERTISING 24

AFAMELANOTIDE 51

AFLIBERCEPT 51

AGALSIDASE 51

AGLEPRISTONE 51

AGOMELATINE 51

AGRICULTURAL CHEMICAL 1

AGRICULTURAL CHEMICAL PRODUCT 1

AGROBACTERIUM RADIOBACTER 213

AKLOMIDE 124

ALACHLOR 187, 267

ALATROFLOXACIN MESYLATE 51

ALBENDAZOLE 51, 124, 151

ALBUMIN

*See* HUMAN BLOOD PRODUCTS 207

ALCLOFENAC 51

ALCLOMETASONE 44, 51, 248

ALCOHOL, DEHYDRATED 213

ALCURONIUM 51

ALDESLEUKIN 51

ALDICARB 187

ALDOSTERONE 51, 263

ALDOXYCARB 187

ALDRIN 151

ALEFACEPT 52, 224

ALEMTUZUMAB 52

ALENDRONIC ACID 52

ALFACALCIDOL 52

ALFENTANIL 197

ALFUZOSIN 52

ALGICIDES 207

ALGLUCERASE 52

ALGLUCOSIDASE 52

ALISKIREN 52

ALKALINE SALTS 13, 21, 124, 151, 219 228, 248

ALKOXYAMPHETAMINES 200

ALKOXYLATED FATTY ALKYLAMINE POLYMER 124, 151

ALKOXYPHENYLETHYLAMINES 200

ALKYL ACETANILIDES

*See* ACETANILIDE 50

ALKYL SULFONALS

*See* SULFONMETHANE 114

ALKYL THIOUREAS

*See* THIOUREA AND ALKYL THIOUREAS 184

ALKYLATED PHENYLENEDIAMINES

*See* PHENYLENEDIAMINES 177, 235

ALKYLTHIOAMPHETAMINES 200

ALLERGENS 52

ALLETHRIN 124, 151

ALLOPURINOL 52

ALLOXYDIM 124

ALLYL ALCOHOL 187, 267

ALLYLISOPROPYLACETYLUREA 219

ALLYLOESTRENOL 52

ALLYLPRODINE 200

ALOGLIPTIN 52

ALOSETRON 52

ALOXIPRIN 29

ALPHA1-PROTEINASE INHIBITOR (HUMAN) 52

ALPHACETYLMETHADOL 197

ALPHA-CHLORALOSE

*See* CHLORALOSE 157

ALPHA-CHLOROHYDRIN 158, 251

ALPHA-CYPERMETHRIN 125, 152, 187

ALPHADOLONE 52

ALPHAMEPRODINE 200

ALPHAMETHADOL 200

ALPHA-METHYLFENTANYL 200

ALPHA-METHYLTHIOFENTANYL 200

ALPHAPRODINE 197

ALPHAXALONE 52

ALPRAZOLAM 52, 269

ALPRENOLOL 52

ALPROSTADIL 52

ALSEROXYLON 52

ALTEPLASE 52

ALTRENOGEST 52

ALTRETAMINE (hexamethylmelamine) 52

ALUM 213

ALUMINIUM AMMONIUM SULFATE 213

ALUMINIUM POTASSIUM SULFATE 213

ALUMINIUM SILICATE 213

ALUMINIUM tris (ETHYLPHOSPHONATE) 213

AM-694

*See* 1-(5-FLUOROPENTYL)-3-(2-IODOBENZOYL)INDOLE 202

AMANTADINE 52

AMBENONIUM CHLORIDE 52

AMBRISENTAN 52, 224, 248, 273

AMBUCETAMIDE 52

AMBUTONIUM BROMIDE 52

AMCINONIDE 52

AMETHOCAINE 29, 52

AMETOCTRADIN 213

AMETRYN 125

AMICARBAZONE 152

AMIDITHION 152

AMIDOPYRINE

*See* AMINOPHENAZONE 53, 219

AMIFOSTINE 53

AMIKACIN 53

AMILORIDE 53

AMINACRINE 125, 187

AMINES FOR USE AS CURING AGENTS FOR EPOXY RESINS 13, 125, 228, 248

AMINOCAPROIC ACID 53

AMINOCARB 152, 187

AMINOCYCLOPYRACHLOR 125

AMINOETHOXYVINYLGLYCINE 152

AMINOGLUTETHIMIDE 53

AMINOMETRADINE 53

AMINOPHENAZONE (amidopyrine) 53, 219

AMINOPHYLLINE 44, 53

AMINOPTERIN 53

AMINOPYRALID 152

AMINOREX 53

AMINOSALICYLIC ACID 53

AMIODARONE 53

AMIPHENAZOLE 53

AMISOMETRADINE 53

AMISULPRIDE 53, 269

AMITON 187

AMITRAZ 152

AMITRIPTYLINE 53, 269

AMITROLE 125

AMLODIPINE 53

AMMI VISNAGA 53

Ammonia 125, 152, 228, 248

*See also* CHROMATES 251

AMMONIUM BIFLUORIDE

*See* BIFLUORIDES

AMMONIUM BROMIDE 53

AMMONIUM CHROMATE

*See* CHROMATES 158

*See* CHROMIUM 265

AMMONIUM HYDROXIDE

*See also* AMMONIA 125, 152

*See* AMMONIA/AMMONIUM HYDROXIDE 248

AMMONIUM PERSULFATE 152, 228, 248

AMMONIUM PHOSPHATE 213

AMMONIUM SALTS

*See* BIFLUORIDES 126, 154, 188, 229, 249, 267

AMMONIUM THIOCYANATE 125, 228

AMMONIUM THIOSULPHATE 213

AMODIAQUINE 53

AMOROLFINE 29, 53

AMOXAPINE 53

AMOXYCILLIN 53

AMPHETAMINE 197

AMPHOMYCIN 53

AMPHOTERICIN 53

AMPICILLIN 54

AMPRENAVIR 54

AMPROLIUM 213

AMRINONE 54

AMSACRINE 54

AMYGDALIN 219

AMYL ACETATE 213

AMYL NITRITE 54

AMYLOBARBITONE 54, 197, 269

AMYLOCAINE 54

ANABOLIC STEROIDAL AGENTS vi, 54, 224

ANAGRELIDE 54

ANAKINRA 54

ANALYTICAL PREPARATIONS

*See* IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS 208

ANASTROZOLE 54

ANCESTIM 54

ANCHUSA OFFICINALIS 219

ANCROD 54

ANDROGENIC STEROIDAL AGENTS 54, 224

ANDROISOXAZOLE 54

ANDROSTALONE

*See* MESTANOLONE 92

ANDROSTANOLONE 54

ANDROSTENEDIOL 54

ANDROSTENEDIONE 54

ANDROSTENEDIONE ALBUMEN CONJUGATE WITH DEXTRAN ANDJUNCT 213

ANDROSTERONE vi

*See* ANABOLIC STEROIDAL AGENTS

ANECORTAVE 54

ANGIOTENSIN AMIDE 54

ANHYDRIDES, ORGANIC ACID FOR USE AS CURING AGENTS FOR EPOXY RESINS 125, 228, 248

ANIDULAFUNGIN 54

ANILERIDINE 197

ANILINE 152, 228, 248

ANIMAL 1

ANIMAL FEED PREMIX 1

ANISE OIL 21, 125, 228

ANISTREPLASE 54

ANTAZOLINE 29, 54

ANTIBIOTIC SUBSTANCES 54

*See also* BACTERIAL CULTURE MEDIA 207

ANTICOAGULANT MEDICAL DEVICES

*See* MEDICAL DEVICES 208

ANTICOAGULATION COMPLEX

*See* HUMAN BLOOD PRODUCTS 207

ANTIGENS 54

ANTIHISTAMINES 54, 248

ANTIMONY 55, 265

*See also* ANTIMONY COMPOUNDS 152

ANTIMONY CHLORIDE 228

*See also* ANTIMONY COMPOUNDS 152, 228

ANTIMONY COMPOUNDS 152, 228, 263

*See also* ANTIMONY 265

ANTIMONY TITANATE

*See* ANTIMONY 265

*See* ANTIMONY COMPOUNDS 152

ANTISERA (immunosera) 55

APIXABAN 55

APOCYNUM spp 55

APOMORPHINE 55, 263

APPROPRIATE AUTHORITY 1

APPROVED NAME 2

APRACLONIDINE 55

APRAMYCIN 55

APREPITANT 55

APRONAL 55

APROTININ 55

ARECOLINE 55

ARIPIPRAZOLE 55, 269

ARISTOLOCHIA spp 219

ARISTOLOCHIC ACID(s) 219

*See also* ASARUM spp 219

*See also* BRAGANTIA 219

AROMATIC EXTRACT OILS 249

*See also* HYDROCARBONS LIQUID AROMATIC 191

ARPRINOCID 187, 267

ARSENIC vi, 25, 55, 152, 187, 263, 267

*See also* CACODYLIC ACID 156, 188

*See also* TERMITE BARRIERS 209

ARSENIC TRIOXIDE vi

*See* ARSENIC

ARTEMETHER 55

ARTICAINE 55

ARTIFICIAL TEARS

*See* MEDICAL DEVICES 208

ASARUM spp. 219

ASENAPINE 269

ASPARTIC ACID 213

ASPERGILLUS NIGER

*See* CELLULASE 214

ASPERGILLUS NIGER

*See* FUNGAL PROTEASE 215

*See* PECTINASE 216

*See* XYLANASE 218

*See* α-AMYLASE 213

*See* β-GLUCANASE 215

ASPIRIN 29, 55, 125, 152, 249

*See also* DIHYDROCODEINE (+ aspirin) 33

*See also* PARACETAMOL(*+* aspirin) 101

*See also* SALICYLAMIDE (+ aspirin) 111

ASTEMIZOLE 55, 249

*See also* ANTIHISTAMINES 248

ASULAM 213

ATAMESTANE 55

ATAZANAVIR 55

ATENOLOL 55

ATIPAMEZOLE 55

ATOMOXETINE 55

ATORVASTATIN 55

ATOSIBAN 55

ATOVAQUONE 55

ATRACURIUM BESYLATE 55

ATRAZINE 125

ATROPA BELLADONNA (belladonna) 30, 55, 263

ATROPINE 30, 56, 227, 263

ATROPINE METHONITRATE 56

*See also* ATROPINE 30

ATROPINE SULFATE

*See* DIFENOXIN (+ atropine sulfate) 71

*See* DIPHENOXYLATE (+ atropine sulfate) 45, 72

AURANOFIN 56

AUROTHIOMALATE SODIUM 56

AUSTRALIAN CODE FOR THE TRANSPORT OF DANGEROUS GOODS BY ROAD AND RAIL 2

AUTHORISED PRESCRIBER 2

AVILAMYCIN 56

AVIPTADIL 56

AVOPARCIN 56

AXITINIB 56

AZACITIDINE 56

AZACONAZOLE 152

AZACYCLONOL 56

AZADIRACHTA INDICA (NEEM) 153, 228, 249

AZADIRACHTA INDICA EXTRACTS (neem extracts) 125

AZAFENIDIN 187

AZAMETHIPHOS 153

AZAPERONE 56

AZAPROPAZONE 56

AZARIBINE 56

AZATADINE 44, 56, 269

AZATHIOPRINE 56

AZELAIC ACID 30, 56

AZELASTINE 30, 56

*See also* ANTIHISTAMINES 248

AZIMSULFURON 213

AZINPHOS-ETHYL 188

AZINPHOS-METHYL 188

AZITHROMYCIN 56

AZLOCILLIN 56

AZOBENZENE 153

AZOCYCLOTIN 188, 249, 267

AZOXYSTROBIN 125

AZTREONAM 56

B

BACAMPICILLIN 56

BACILLUS SPHAERICUS STRAIN 2362 213

BACILLUS THURINGIENSIS 213

BACILLUS THURINGIENSIS DELTA ENDOTOXIN 125

BACILLUS TOYOI 213

BACITRACIN 56

BACLOFEN 56, 269

BACTERIAL CULTURE MEDIA 207

BACTERIOCIDES 207

BACULOVIRUSCYDIA POMONELLA 213

BALSALAZIDE 56

BAMBERMYCIN (flavophospholipol) 56, 153

BAMBUTEROL 57

BAMETHAN 57

BAMIPINE 57

BARBITURATES 57

BARIUM

*See* BARIUM SALTS 153

BARIUM CHROMATE

*See* CHROMATES 158

*See* CHROMIUM 265

BARIUM METABORATE

*See* BARIUM SALTS 265

BARIUM SALTS 153, 228, 265

BARIUM SELENATE

*See* SELENIUM 182

BARIUM SILICOFLUORIDE 125

*See also* SILICOFLUORIDES 145

BARIUM SULFATE

*See* BARIUM SALTS 153, 228, 265

BASIC ORANGE 31 153, 219

BASIL OIL 21, 125, 228

BASILIXIMAB 57

BATTERIES

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 207

Bay oil 21, 153, 228

BAZEDOXIFENE 57

BDMPEA

*See* 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE 200

BEAUVERIA BASSIANA 126, 154

BECAPLERMIN 57

BECLAMIDE 57

BECLOMETHASONE 30, 57

BEECHWOOD

*See* CREOSOTE 32, 161, 189

BELATACEPT 57

BELIMUMAB 57

BELLADONNA

*See* ATROPA BELLADONNA 30, 55, 263

BEMEGRIDE 57

BENACTYZINE 57

BENALAXYL 126

BENAZEPRIL 57

BENDIOCARB 126, 154, 188

BENDROFLUAZIDE 57

BENETHAMINE PENICILLIN 57

BENFLURALIN 213

BENOMYL 188, 249

BENORYLATE 57

BENOXAPROFEN 57

BENPERIDOL 57

BENQUINOX 154

BENSERAZIDE 57

BENSULFURON-METHYL 213

BENSULIDE 154

BENTAZONE 126

BENTONITE 213

BENZALKONIUM CHLORIDE 126, 154, 228

BENZATHINE PENICILLIN 57

BENZATROPINE

*See* BENZTROPINE 58

BENZENE 188, 229, 249, 267benzene

*See also* HYDROCARBONS, LIQUID 135

BENZETHIDINE 200

BENZHEXOL 57

BENZILONIUM 57

BENZOCAINE 30, 57

BENZODIAZEPINE DERIVATIVES 57

BENZOFENAP 126

BENZOYL PEROXIDE 30, 57, 126, 229, 249

BENZOYLINDOLES 200

BENZPHETAMINE 58

BENZTHIAZIDE 58

BENZTROPINE 269

BENZTROPINE (benzatropine) 58

BENZYDAMINE 30, 58

BENZYL BENZOATE 213

BENZYLMORPHINE 197

BENZYLPENICILLIN 58

BENZYLPIPERAZINE \*(BZP) 200

BEPHENIUM SALTS 30

BEPRIDIL 58

BERACTANT 58

BERGAMOT OIL 126, 229, 249

BERYLLIUM 154, 249

BESIFLOXACIN HYDROCHLORIDE 58

BETACETYLMETHADOL 200

BETACYFLUTHRIN 126, 154, 188

BETA-CYPERMETHRIN 154

BETAHISTINE 58

BETA-HYDROXY-3-METHYLFENTANYL 200

BETA-HYDROXYFENTANYL 200

BETAINE HYDROCHLORIDE 213

BETAMEPRODINE 200

BETAMETHADOL 200

BETAMETHASONE 58

BETAPRODINE 200

BETAXOLOL 58

BETHANECHOL CHLORIDE 58

BETHANIDINE 58

BEVACIZUMAB 58

BEVANTOLOL 58

BEXAROTENE 58, 223, 249, 273

BEZAFIBRATE 58

BEZITRAMIDE 197

BHC 154

BICALUTAMIDE 58

BIFENAZATE 213

BIFENTHRIN 154, 188

BIFLUORIDES 126, 154, 188, 229, 249, 267

BIFONAZOLE 30, 58

BIMATOPROST 58

BIOALLETHRIN 126, 155

BIORESMETHRIN 127

BIPERIDEN 58

BISMUTH CITRATE

*See* BISMUTH COMPOUNDS 58

BISMUTH COMPOUNDS 58, 59

BISMUTH FORMIC IODIDE

*See* BISMUTH COMPOUNDS 59

BISMUTH OXYCHLORIDE

*See* BISMUTH COMPOUNDS 58

BISMUTH SUBIODIDE

*See* BISMUTH COMPOUNDS 59

BISMUTH SUBNITRATE 213

BISOPROLOL 59

BISPYRIBAC 127

BISTRIFLURON 213

BITHIONOL 155, 219, 249

BIURET 213

BIVALIRUDIN 59

BLEACHES

*See* CHLORINATING COMPOUNDS

BLEOMYCIN 59

BLOOD 2

*See also* BLOOD COMPONENTS 2

*See also* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES 207

*See also* HUMAN BLOOD PRODUCTS 207

BLOOD COMPONENTS

*See* HUMAN BLOOD PRODUCTS 207

BOCEPREVIR 59

BOLANDIOL 59

BOLASTERONE 59

BOLAZINE 59

BOLDENONE (dehydrotestosterone) 59

BOLENOL 59

BOLMANTALATE 59

BORAGE

*See* BORAGO OFFICINALIS 219

BORAGO OFFICINALIS (Borage) 219

BORATES

*See* BORON

BORAX 127, 229

*See also* BORON 59

BORIC ACID 127, 229

*See also* BORON 59

BORON 59

*See also* BORIC ACID 127

BORON COMPOUNDS

*See* BORON

BORON TRIFLUORIDE 127, 155, 188, 229, 249, 267

*See* also BORON

BORTEZOMIB 59

BOSCALID 213

BOSENTAN 59, 224, 249, 273

BOTULINUM TOXINS 59

BOVINE SOMATOTROPHIN 213

BRAGANTIA spp 219

BRETYLIUM TOSYLATE 59

BRIMONIDINE 59

BRINZOLAMIDE 59

BRODIFACOUM 155, 188, 267

BROMACIL 213

BROMADIOLONE 155, 188, 267

BROMAZEPAM 59, 269

BROMETHALIN 155, 188

BROMHEXINE 31

BROMIDES 59

BROMINE 188, 267

BROMOCRIPTINE 59

BROMOCHLORODIMETHYLHYDANTOIN

*See* CHLORINATING COMPOUNDS

BROMO-DRAGONFLY

*See* 1-(8-BROMOBENZO[1,2-B;4,5-B]DIFURAN-4-YL)-2-AMINOPROPANE 212

BROMOFORM 59, 155, 229, 249

BROMOPHOS 155

BROMOPHOS-ETHYL 155

BROMOPROPYLATE 213

BROMOXYNIL 155

BROMPHENIRAMINE 31, 44, 59, 269

BROMUCONAZOLE 127, 155

BROMVALETONE 59

BROTIANIDE 155

BRUCINE 188, 229, 267

BRUGMANSIA 59

BUCLIZINE 44, 59, 269

BUCLOSAMIDE 219

BUDESONIDE 31, 60

BUFEXAMAC 60

BUFOTENINE 200

BUMETANIDE 60

BUNAMIDINE 155

BUNIODYL SODIUM 219

BUPHENINE 60

BUPIRIMATE 214

BUPIVACAINE 60

BUPRENORPHINE 197, 269

BUPROFEZIN 127

BUPROPION 60

BUSERELIN 60

BUSPIRONE 60

BUSULPHAN 60

BUTACAINE 60

BUTACARB 156

BUTAFENACIL 214

BUTHIDAZOLE 127

BUTOBARBITONE 197, 269

BUTOCONAZOLE 44, 60, 264

BUTORPHANOL 197

BUTOXYCARBOXIM 127, 156

BUTOXYPOLYPROPYLENE GYLCOL 214

BUTRACONAZOLE 60

BUTRALIN 127

BUTROXYDIM 127

BUTYL AMINOBENZOATE 60

BUTYL NITRITE 60

BUTYLCHLORAL HYDRATE 60

BUTYPHENONES

*See* HALOPERIDOL

BUTYRIC ACID 156

BZP

*See* BENZYLPIPERAZINE 200

C

C1 ESTERASE INHIBITORS

*See* HUMAN BLOOD PRODUCTS 207

CABAZITAXEL 60

CABERGOLINE 60

CACALIA spp 219

CACODYLIC ACID 156, 188

CADMIUM 265

*See also* CADMIUM COMPOUNDS 156

CADMIUM ACETATE

*See* CADMIUM COMPOUNDS

CADMIUM COMPOUNDS 60, 156, 229

*See* CADMIUM 265

CADMIUM CHLORIDE

*See* CADMIUM COMPOUNDS

CADMIUM NITRATE

*See* CADMIUM COMPOUNDS

CADUSAFOS 156, 188

CAFFEINE

*See* ASPIRIN (+ caffeine) 55

*See* SALICYLAMIDE (+ caffeine) 111

CAJUPUT OIL 21, 156, 229

CALAMUS

*See* ACORUS CALAMUS 219

CALCIFEROL 156, 188, 267

CALCIPOTRIOL 60

CALCITONIN 60

CALCITRIOL 60

CALCIUM CARBIMIDE 60

CALCIUM FOLINATE

*See* FOLINIC ACID

CALCIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS

CALCIUM POLYSTYRENE SULPHONATE 60

CALOMEL

*See* MERCURIC CHLORIDE

CALOTROPIS GIGANTEA 60

CALOTROPIS PROCERA 60

CALUSTERONE 60

CAMBENDAZOLE 156

CAMPHOR 18, 23, 127, 157, 229, 250

*See also* ESSENTIAL OILS 21, 231

CAMPHOR OIL (white)

*See* CINEOLE 159

CAMPHORATED OIL 60

CAMPHOTAMIDE 60

CANAGLIFLOZIN 61

CANAKINUMAB 61

CANDESARTAN CILEXETIL 61

CANDICIDIN 61

CANINE TICK ANTI-SERUM. 61

CANNABICHROMENE

*See* NABIXIMOLS 198

CANNABICYCLOHEXANOL

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL 202

CANNABIDIOL

*See* NABIXIMOLS 198

CANNABIDIOLIC ACID

*See* NABIXIMOLS 198

CANNABIDIVAROL

*See* NABIXIMOLS 198

CANNABIGEROL

*See* NABIXIMOLS 198

CANNABINOIDS

*See* NABIXIMOLS 198

CANNABINOL

*See* NABIXIMOLS 198

CANNABIS 201

CANNABIS SATIVA

*See* HEMP SEED OIL 4

*See* NABIXIMOLS 198

CANTHARIDIN 61, 263

CAPECITABINE 61

CAPREOMYCIN 61

CAPTAFOL 188, 267

CAPTAN 157

CAPTODIAME 61

CAPTOPRIL 61

CAPURIDE 61

CARAMIPHEN 61

CARBACHOL 61

CARBADOX 188, 267

CARBAMATE 13

CARBAMAZEPINE 61

CARBAMIDE PEROXIDE 127, 157, 219, 229, 250

CARBARYL 61, 127, 157

CARBAZOCHROME 61

CARBENDAZIM 188

CARBENICILLIN 61

CARBENOXOLONE 61

CARBETAMIDE 214

CARBETAPENTANE 31

CARBETOCIN 61

CARBIDOPA 61

CARBIMAZOLE 61

CARBOCISTEINE 31

CARBOCROMEN 61

CARBOFURAN 188

CARBON DISULFIDE 157, 229

CARBON DISULPHIDE 250

CARBON TETRACHLORIDE 188, 229, 250, 267

CARBOPHENOTHION 189

CARBOPLATIN 61

CARBOPROST 61

CARBOSULFAN 189

CARBOXIN 214

CARBROMAL 61

CARBUTAMIDE 61

CARBUTEROL 61

CARDIAC GLYCOSIDES

*See* UNDER INDIVIDUAL ENTRIES

CARFENTANYL 197

CARFENTRAZONE-ETHYL 214

CARINDACILLIN 61

CARISOPRODOL 61

CARMUSTINE 61

CARNIDAZOLE 62

CARPROFEN 62

CARVEDILOL 62

CASPOFUNGIN 62

CASSIA OIL 21, 127, 229, 250

CASTOR OIL, MONOMALEATE 157

CATALIN

*See* PIRENOXINE 104

CATECHOL

*See* 1,2-BENZENEDIOL

CATHINE 62

CATHINONE 201

CATUMAXOMAB 62

CEFACETRILE 62

CEFACLOR 62

CEFADROXIL 62

CEFALORIDINE 62

CEFAMANDOLE 62

CEFAPIRIN 62

CEFAZOLIN 62

CEFEPIME 62

CEFETAMET 62

CEFIXIME 62

CEFODIZIME 62

CEFONICID 62

CEFOPERAZONE 62

CEFOTAXIME 62

CEFOTETAN 62

CEFOTIAM 62

CEFOVECIN 62

CEFOXITIN 62

CEFPIROME 62

CEFPODOXIME 62

CEFQUINOME 62

CEFSULODIN 62

CEFTAROLINE FOSAMIL 62

CEFTAZIDIME 62

CEFTIBUTEN 62

CEFTIOFUR 63

CEFTRIAXONE 63

CEFUROXIME 63

CELECOXIB 63

CELIPROLOL 63

CELLULASE DERIVED FROM ASPERGILLUS NIGER 214

CEMENTS, GLUES AND ADHESIVES − MEDICAL AND VETERINARY 208

CEPHACETRILE

*See* CEFACETRILE

CEPHAELIS ACUMINATA (ipecacuanha) 63

CEPHAELIS IPECACUANHA 63

CEPHALEXIN 63

CEPHALONIUM 63

CEPHALORIDINE

*See* CEFALORIDINE

CEPHALOTHIN 63

CEPHAMANDOLE

*See* CEFAMANDOLE

CEPHAPIRIN

*See* CEFAPIRIN

CEPHAZOLIN

*See* CEFAZOLIN

CEPHRADINE 63

CERAMICS 207

CERIVASTATIN 63

CERTOLIZUMAB PEGOL 63

CERULETIDE 63

CETIRIZINE 31, 63, 269

CETRORELIX 63

CETUXIMAB 63

CETYL ALCOHOL 214

CETYL TRANEXAMATE

*See* TRANEXAMIC ACID

CHAMOMILE OIL 214

CHEMISTRY SETS 207

CHENODEOXYCHOLIC ACID 63

CHILD-RESISTANT CLOSURE 2, 20

*See also* NON-ACCESS PACKAGING 3

CHILD-RESISTANT PACKAGING 3

*See also* NON-ACCESS PACKAGING 3

CHINA CLAY 214

CHLOPHEDIANOL 31

CHLORAL FORMAMIDE 63

CHLORAL HYDRATE 63, 269

CHLORALOSE 63

CHLORALOSE (ALPHA-CHLORALOSE) 157

CHLORAMBUCIL 63

CHLORAMPHENICOL 44, 63

CHLORANDROSTENOLONE 63

CHLORANTRANILIPROLE 214

CHLORAZANIL 63

CHLORBUTOL 31, 44

CHLORCYCLIZINE 64

CHLORDANE 157

CHLORDECONE 189, 267

CHLORDIAZEPOXIDE 64, 269

CHLORDIMEFORM 189, 267

CHLORFENAC 128

CHLORFENAPYR 128, 157, 189

CHLORFENETHOL 158

CHLORFENSON 128

CHLORFENVINPHOS 189

CHLORFLUAZURON 214

CHLORFLURENOL 214

CHLORHEXIDINE 128, 158, 189

CHLORIDAZON 214

CHLORINATED TERPENES

*See* TERPENES, CHLORINATED 184

CHLORINATING COMPOUNDS 128, 158, 229, 250

CHLORINE 11, 163, 189, 263, 267

*See also* CHLORINATING COMPOUNDS 128, 158, 230, 250

*See also* DICHLOROISOCYANURATES 251

*See also* DICHLOROISOCYANURIC ACID 131, 163

CHLORINE (GAS) 230

*See also* CHLORINE

CHLORMEQUAT 158

CHLORMERODRIN 64

CHLORMETHIAZOLE 64, 269

CHLORMEZANONE 64

CHLORNIDINE 128

CHLOROCRESOL 128, 230

CHLOROFORM 31, 64, 158, 230, 251

CHLOROMESTERONE

*See* DEHYDROCHLOROMETHYLTESTOSTERONE

CHLOROMETHIURON 189, 267

CHLOROPHACINONE 158

CHLOROPICRIN 158, 189, 267

CHLOROQUINE 64

CHLOROTHALONIL 158

CHLOROTHIAZIDE 64

CHLOROTRIANISENE 64

CHLOROXYDIENONE 64

CHLOROXYLENOLS 214

CHLORPHENIRAMINE 31, 44, 64, 269

CHLORPROMAZINE 64, 269

CHLORPROPAMIDE 64

CHLORPROPHAM 128

CHLORPROTHIXENE 64

CHLORPYRIFOS 128, 158

CHLORPYRIFOS-METHYL 158

CHLORQUINALDOL 64

*See also* CLIOQUINOL

CHLORSULFURON 128

CHLORTETRACYCLINE 64, 128

CHLORTHAL-DIMETHYL 128

CHLORTHALIDONE 64

CHLORTHIAMID 158

CHLORTHIOPHOS 189

CHLORZOXAZONE 64

CHOLECALCIFEROL

*See* COLECALCIFEROL

CHOLERA VACCINE 64

CHOLESTYRAMINE (colestyramine) 64

CHOLINE SALICYLATE

*See* SALICYLIC ACID

CHROMATES vi, 230, 251

CHROMATES (including dichromates 158

*See also* CHROMIUM 265

CHROMIC ACID

*See* CHROMATES 158

*See* CHROMIUM 265

CHROMIUM TRIOXIDE 159, 230, 251

CHRYSANTHEMIC ACID ESTERS

*See* PYRETHRINS 42, 145

CHYMOPAPAIN 64

CICLACILLIN 64

CICLESONIDE 64

CICLOPIROX 31, 44, 64

CIDOFOVIR 64

CILASTATIN 65

CILAZAPRIL 65

CILOSTAZOL 65

CIMETIDINE 44, 65, 251

CINACALCET 65

CINCHOCAINE 32, 65

CINCHOPHEN 219

CINEOLE 21, 159, 230

CINEROLONE

*See* PYRETHRINS 42, 145

CINMETHYLIN 128

CINNAMEDRINE 32

CINNAMON BARK OIL 21, 128, 230, 251

CINNAMON LEAF OIL 21, 159, 230

CINOXACIN 65

CIPROFLOXACIN 65

CISAPRIDE 65

CISATRACURIUM BESYLATE 65

CISPLATIN 65

CITALOPRAM 65

CITRONELLA OIL 214

CLADRIBINE 65

CLANOBUTIN 65

CLARITHROMYCIN 65

CLARY SAGE OIL 214

CLAVULANIC ACID 65

CLEMASTINE 44, 65, 269

CLEMIZOLE 65

CLENBUTEROL 65

CLETHODIM 129

CLEVIDIPINE 65

CLIDINIUM BROMIDE 65

CLIMBAZOLE 129, 160, 230

CLINDAMYCIN 65

CLIOQUINOL 65, 220

CLOBAZAM 65

CLOBETASOL 65

CLOBETASONE 251

CLOBETASONE (clobetasone-17-butyrate) 44, 65

CLOCORTOLONE 65

CLODINAFOP-PROPARGYL 160

CLODRONIC ACID (includes sodium clodronate) 65

CLOFARABINE 65

CLOFAZIMINE 65

CLOFENAMIDE 66

CLOFENTEZINE 129

CLOFIBRATE 66

CLOMAZONE 160

CLOMIPHENE 66, 223

CLOMIPRAMINE 66, 269

CLOMOCYCLINE 66

CLONAZEPAM 66, 269

CLONIDINE 66, 269

CLONITAZENE 201

CLOPAMIDE 66

CLOPIDOGREL 66

CLOPIDOL 214

CLOPROSTENOL 66

CLOPYRALID 129

CLOQUINTOCET-MEXYL 129

CLORAZEPATE 66, 269

CLOREXOLONE 66

CLORPRENALINE 66

CLORSULON 129

CLOSANTEL 160

CLOSTEBOL (4-CHLOROTESTOSTERONE) 66

CLOTHIANIDIN 129, 160

CLOTRIMAZOLE 32, 44, 66, 160, 251, 264

CLOTTING FACTORS

*See* HUMAN BLOOD PRODUCTS 207

CLOVE OIL 21, 129, 160, 230, 251

CLOXACILLIN 66

CLOZAPINE 66, 223, 269

COAL TAR 220

COBALT 66

COBALT NAPHTHENATE 214

COBICISTAT 66

COCA LEAF 201

COCAINE 197

CODEINE 8, 32, 44, 66, 197, 269

CODEINE-N-OXIDE 197

CO-DERGOCRINE 66

CODOXIME 201

COLASPASE 66

COLCHICINE 66

COLCHICUM AUTUMNALE 66

COLECALCIFEROL 189, 267

*See also* VITAMIN D

COLESTIPOL 66

COLESTYRAMINE

*See* CHOLESTYRAMINE 64

COLFOSCERIL PALMITATE 67

COLISTIN 67

COLLAGEN 67

*See also* MEDICAL DEVICES 208

COLOPHONY 214

COLTSFOOT

*See* TUSSILAGO

COMFREY

*See* SYMPHYTUM spp. 147, 221, 261

COMPOUNDED 3

CONCENTRATE OF POPPY STRAW 197

CONIINE

*See* CONIUM MACULATUM 220

CONIUM MACULATUM (coniine) 220

CONTAINERS 9

*See also*  IMMEDIATE CONTAINER 4

*See also* SELECTED CONTAINER 6

CONTRAST MEDIA, RADIOGRAPHIC (RADIOPAQUES)

*See* RADIOGRAPHIC CONTRAST MEDIA 209

CONVALLARIA KEISKI 67

CONVALLARIA MAJALIS 67

COPPER ACETATE 129, 160

COPPER CHLORIDE

*See* COPPER NITRATE 161

COPPER-CHROME-ARSENIC

*See* CHROMATES, AND ARSENIC

COPPER COMPOUNDS 67, 129, 160, 207

COPPER HYDROXIDE 129, 161

COPPER NITRATE 161

COPPER OXIDES 129, 161

COPPER OXYCHLORIDE 129, 161

COPPER SALICYLATE

*See* DIMETHYL SULFOXIDE 164

COPPER

*See* COPPER COMPOUNDS 160

COPPER SULFATE 129, 161, 230

CORIFOLLITROPIN ALFA 67, 223

CORONILLA 67

CORROSIVE SUBLIMATE

*See* MERCUROUS CHLORIDE

CORTICOSTERONE 67

CORTICOTROPHIN 67

CORTISONE 67

CORYMBIA CITRIODORA

*See* EXTRACT OF LEMON EUCALYPTUS 134

COTARNINE 220

CO-TRIMOXAZOLE 67

COUMAPHOS 161, 189

COUMARIN 67

COUMATETRALYL 129, 161, 189, 267

CP 47,497 C8 HOMOLOGUE

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLNONAN-2-YL)PHENOL 202

CP 47,497

*See* 2-[(1R,3S)-3-HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL)PHENOL 202

CREOSOTE 32, 161, 189, 230

CRESOLS 230

*See also* PHENOL 142, 177

CROFELEMER 67

CROSPOVIDONE 214

CROTALARIA spp 220

CROTON OIL

*See* CROTON TIGLIUM 263

CROTON TIGLIUM (croton oil) 220, 263

CROTOXYPHOS 161

CRUFOMATE 162

CRYOPRECIPITATE

*See* HUMAN BLOOD PRODUCTS 207

CRYSTAL VIOLET 67

CRYSTAL WARE

*See* GLASS 207

CUBE

*See* ROTENONE

CULICINOMYCES CLAVOSPORUS 214

CUPRIMYXIN 67

CURARE 67

CURING AGENTS FOR EPOXY RESINS 125

*See* AMINES FOR USE AS CURING AGENTS FOR EPOXY RESINS

*See* Anhydrides, organic acid FOR USE AS CURING AGENTS FOR EPOXY RESINS

*See also* EPOXY RESINS,

CYANAMIDE 162

CYANATRYN 129

CYANAZINE 162

CYANIDES 25, 189, 230, 251

*See also* HYDROCYANIC ACID AND CYANIDES 268

CYANOACRYLATE ESTERS 129

CYANOACRYLIC ACID ESTERS 230

CYANOGEN 189, 267

CYANTRANILIPROLE 130

CYANURIC ACID 130, 230, 251

CYCLAMIC ACID 214

CYCLANDELATE 67

CYCLANILIDE 162

CYCLIZINE 45, 67, 269

CYCLOBARBITONE 197, 269

CYCLOBENZAPRINE 67

CYCLOFENIL 67, 223

CYCLOHEXANE 214

CYCLOHEXANOL ACETATE 214

CYCLOHEXANONE PEROXIDE 130, 230, 251

CYCLOHEXIMIDE 67

CYCLOHEXYLPHENOLS 201

CYCLOPENTHIAZIDE 67

CYCLOPENTOLATE 67

CYCLOPHOSPHAMIDE 68

CYCLOPROPANE 68

CYCLOPROTHRIN 130

CYCLOSERINE 68, 269

CYCLOSPORIN 68

CYCLOTHIAZIDE 68

CYCLOXYDIM 130

CYCRIMINE 68

CYFLUFENAMID 130

CYFLUTHRIN 130, 162

CYHALOFOP-BUTYL 130

CYHALOTHRIN 189

CYHEXATIN 189, 267

CYMARIN 68

CYMIAZOLE 130

CYNOGLOSSUM spp 220

CYOMETRINIL 162

CYPERMETHRIN 130, 162

*See also* ZETA-CYPERMETHRIN, ALPHA-CYPERMETHRIN AND BETA-CYPERMETHRIN

CYPHENOTHRIN 130, 162

CYPROCONAZOLE 130

CYPRODINIL 130

CYPROHEPTADINE 45, 68, 269

CYPROTERONE 68

CYROMAZINE 214

CYSTEAMINE 68, 130, 162, 230, 251, 269

CYTARABINE 68

CYTHIOATE 130, 162

D

D.D.A.V.P.

*See* DESMOPRESSIN 70

DABIGATRAN 68

DACARBAZINE 68

DACLIZUMAB 68

DACTINOMYCIN 68

DALFOPRISTIN 68

DALMATIAN

*See* SAGE OIL 22, 181, 237

DALTEPARIN 68

DAMINOZIDE 130

DANAPAROID 68

DANAZOL 68

DANTHRON 68

DANTROLENE 68, 269

DAPAGLIFLOZIN 68

DAPOXETINE 68

DAPSONE 68

DAPTOMYCIN 68

DARBEPOETIN 68, 224

DARIFENACIN 68

DARUNAVIR 68

DASATINIB 69

DATURA 32, 68

DATURA STRAMONIUM (stramonium) 32, 69

DATURA TATULA (stramonium) 32, 69

DAUNORUBICIN 69

DAZOMET 13, 162

DDT

*See* DICOPHANE 220

DEANOL 69

DEBITTERISED NEEM SEED OIL 3

DEBRISOQUINE 69

DECAMETHONIUM 69

DEET

*See* DIETHYLTOLUAMIDE 132

DEFERASIROX 69

DEFERIPRONE 69

DEFLAZACORT 69

DEGARELIX 69

DEHYDROCHLOROMETHYLTESTOSTERONE 69

DEHYDROCORTICOSTERONE 69

DEHYDROEPIANDROSTERONE

*See* PRASTERONE 106

DEHYDROTESTOSTERONE

*See* BOLDENONE 59

DELAVIRDINE 69

DELAVIRDINE MESYLATE

*See* DELAVIRDINE 69

DELPHINIUM STAPHISAGRIA 33

DELTA-9-tetrahydrocannabinol

*See* DRONABINOL 198, 223, 269

DELTAMETHRIN 131, 162, 189

DEMBREXINE 69, 131

DEMECARIUM 69

DEMECLOCYCLINE 69

DEMETON 190

DEMETON-O-METHYL 190

DEMETON-S-METHYL 190

DENATONIUM BENZOATE

*See* BENDIOCARB 154

*See* DIETHYLENE GLYCOL 132

*See* ETHYLENE GLYCOL 133

*See* METHOMYL 173

*See* METHYLATED SPIRIT(S) 139

DENOSUMAB 69

DEOXYCORTONE 69

DEOXYRIBONUCLEASE 69

DERACOXIB 69

DERMAL USE 3

DERQUANTEL 162

DESFERRIOXAMINE 69

DESFLURANE 69

DESIGNATED SOLVENT 3

DESIPRAMINE 69, 269

DESIRUDIN 70

DESLANOSIDE 70

DESLORATADINE 33, 70

*See also* ANTIHISTAMINES 248

DESLORELIN 70

DESMOPRESSIN (D.D.A.V.P.) 70

DESOGESTREL 70

DESOMORPHINE 201

DESONIDE 70

DESOXYMETHASONE 70

DESVENLAFAXINE 70

DET

*See* N,N-DIETHYLTRYPTAMINE 201

DETOMIDINE 70

DEXAMETHASONE 70

DEXAMPHETAMINE 197

DEXCHLORPHENIRAMINE 33, 45, 70, 269

DEXFENFLURAMINE 70

DEXMEDETOMIDINE 70

DEXTRANS 207

DEXTROMETHORPHAN 33, 70

DEXTROMORAMIDE 197, 269

DEXTROPROPOXYPHENE 70, 197, 224, 269

DEXTRORPHAN 70

DIAFENTHIURON 131

DIALIFOS 190

DIALKYL and DIALKOYL QUATERNARY AMMONIUM COMPOUNDS

*See* QUATERNARY AMMONIUM COMPOUNDS 145, 180, 195

DIALKYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

DIAMPROMIDE 201

DIAMTHAZOLE 70

DIAVERIDINE 70

DIAZEPAM 70, 269

DIAZINON 131, 162

DIAZOXIDE 70

DIBENZEPIN 70

DIBENZODIOXINS, HALOGENATED

*See* HALOGENATED DIBENZODIOXINS 191, 268

*See* DIBENZOFURANS, HALOGENATED *SEE* HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 191, 268

DIBENZOPYRANS 201

DIBOTERMIN 70

DIBROMOPROPAMIDINE 33, 70

DIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

DICAMBA 131, 162

DICHLOBENIL 162

DICHLOFENTHION 162

DICHLOFLUANID 162

DICHLONE 131

DICHLORALPHENAZONE 70

DICHLOROETHYL ETHER 163, 230, 251

DICHLOROETHYLENE 251

DICHLOROISOCYANURATES 230, 251

DICHLOROISOCYANURIC ACID 131, 163

DICHLOROMETHANE (METHYLENE CHLORIDE) 131, 230, 253, 265

DICHLOROPHEN 70, 131, 163

DICHLORPHENAMIDE 70

DICHLORVOS 132, 163, 190

DICHROMATES 230

*See also* CHROMATES 158, 251

DICLAZURIL 214

DICLOBUTRAZOL 132

DICLOFENAC 33, 45, 70, 253, 264

DICLOFOP-METHYL 163

DICLORAN 132

DICLOXACILLIN 71

DICOBALT EDETATE

*See* COBALT 66

*See* EDETIC ACID 74

DICOFOL 132

DICOPHANE (DDT) 220

DICROTOPHOS 190

DICYCLANIL 163

DICYCLOMINE 71

DIDANOSINE 71

DIDECYLDIMETHYLAMMONIUM SALTS 163, 230

DIELDRIN 163

DIENESTROL 71, 253, 273

DIENOGEST 71

DIESEL 231

DIESEL (DISTILLATE)

*See also* HYDROCARBONS, LIQUID 135

DIETHANOLAMINE 132, 163, 231, 253

DIETHAZINE 71

DIETHYL CARBONATE 214

DIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

DIETHYLCARBAMAZINE 71

DIETHYLENE GLYCOL 132, 163, 220

DIETHYLENE GLYCOL MONOBUTYL ETHER 132

DIETHYLHEXYL PHTHALATE 220

DIETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES 177

DIETHYLPHTHALATE 220

DIETHYLPROPION 71

DIETHYLSTILBOESTROL

*See* STILBOESTROL 113

DIETHYLSTILBOESTROL DIPHOSPHATE

*See* FOSFESTROL 80

DIETHYLTHIAMBUTENE 201

DIETHYLTOLUAMIDE 253

DIETHYLTOLUAMIDE (DEET) 132

DIFENACOUM 164, 190, 267

DIFENOCONAZOLE 132

DIFENOXIN 71, 197, 269

DIFENZOQUAT 164

DIFETHIALONE 164, 190

DIFLORASONE 71

DIFLOXACIN 71

DIFLUBENZURON 132

DIFLUCORTOLONE 71

DIFLUFENICAN 214

DIFLUNISAL 71

DIGITALIS LANATA 71

DIGITALIS PURPUREA 71

DIGITOXIN 71

DIGOXIN 71

DIGOXIN-SPECIFIC ANTIBODY FRAGMENT F 71

DIHYDRALAZINE 71

DIHYDROCODEINE 33, 45, 71, 197, 269

DIHYDROERGOTOXINE 71

DIHYDROLONE 71

DIHYDROMORPHINE 197

DIHYDROSTREPTOMYCIN 71

DIHYDROTACHYSTEROL 72

DI-IODOHYDROXYQUINOLINE (iodoquinol) 45, 72

*See also* CLIOQUINOL

DIISOPROPYLAMINE DICHLOROACETATE 72

DIKEGULAC-SODIUM 214

DILTIAZEM 72

DIMEFOX 190

DIMENHYDRINATE 33, 45, 72, 264, 269

DIMENOXADOL 201

DIMEPHEPTANOL 201

DIMERCAPROL 72

DIMETAMFETAMINE

*See* N,N-DIMETHYLAMPHETAMINE 201

DIMETHANDROSTANOLONE 72

DIMETHAZINE 72

DIMETHENAMID-P 164

DIMETHICODIETHYLBENZALMALONATE 132

DIMETHICONE 214

DIMETHINDENE 45, 72, 269

DIMETHIPIN 164

DIMETHIRIMOL 132

DIMETHISOQUIN

*See* QUINISOCAINE 108

DIMETHOATE 164

DIMETHOMORPH 132

DIMETHOTHIAZINE 72

DIMETHOXANATE 72

DIMETHYL ETHER 214

DIMETHYL FUMARATE 72

DIMETHYL SULFATE 190, 253

DIMETHYL SULFONE

*See* DIMETHYL SULFOXIDE 72, 164

DIMETHYL SULFOXIDE 72, 164, 231, 253

DIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

DIMETHYL TIN DICHLORIDE

*See* TIN ORGANIC COMPOUNDS

DIMETHYLFORMAMIDE 132, 164, 231, 253

*See also* DESIGNATED SOLVENT 3

DIMETHYL-PARA-PHENYLENEDIAMINE

*See* PHENYLENEDIAMINES 177

DIMETHYLPHTHALATE 220

DIMETHYLTHIAMBUTENE 201

DIMETILAN 190

DIMETRIDAZOLE 72

DINICONAZOLE 132

DINITROCRESOLS 72, 164, 190, 231, 253, 267

DINITRONAPHTHOLS 72

DINITROPHENOLS 72, 164, 190, 231, 253, 267

DINITROTHYMOLS 72

DINOCAP 190, 253

DINOPROST 72, 223

DINOPROSTONE 72, 223

DINOSEB 190, 267

DI-N-PROPYL ISOCINCHOMERONATE 133

DIOCTYL SODIUM SULFOSUCCINATE

*See* DOCUSATE SODIUM 214

DIOXACARB 164

DIOXANE 164, 231, 253, 263

DIOXAPHETYL BUTYRATE 201

DIOXINS

*See* HALOGENATED DIBENZODIOXINS

DIPENTENE

*See* LIMONENE 215

DIPERODON 72

DIPHACINONE 164

DIPHEMANIL 72

DIPHENAMID 133

DIPHENHYDRAMINE 33, 45, 72, 269

DIPHENIDOL 72

DIPHENOXYLATE 45, 72, 197, 253, 264, 269

DIPHENYLAMINE 214

DIPHENYLPYRALINE 73, 269

DIPHTHERIA TOXOID 73

DIPIPANONE 197

DIPIVEFRIN 73

DIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

DIPROPYLENE GLYCOL MONOMETHYL ETHER 214

DIPYRIDAMOLE 73

DIQUAT 164, 190

DIRITHROMYCIN 73

DIRLOTAPIDE 73

DISODIUM ETIDRONATE

*See* ETIDRONIC ACID 77

DISODIUM PAMIDRONATE

*See* PAMIDRONIC ACID 100

DISODIUM TILUDRONATE

*See* TILUDRONIC ACID 117

DISOPHENOL 73

DISOPYRAMIDE 73

DISPENSING LABELS 4, 272

DISTIGMINE 73

DISTILLATE 231

*See* DIESEL 231

*See* HYDROCARBONS, LIQUID 135

DISTRIBUTOR 4

DISULFIRAM 73, 164

DISULFOTON 165, 190

DISULPHAMIDE 73

DITHIANON 165

DITHIAZANINE 73, 165

DITHIOPYR 133

DITHRANOL 45

DITIOCARB 73

DIUREDOSAN 165

DIURON 214

DIVIDED PREPARATION 4

DMA

*See* 2,5-DIMETHOXYAMPHETAMINE 201

DMAA

*See* 1,3-DIMETHYLAMYLAMINE 220

DMHP

*See* 3-(1,2-DIMETHYLHEPTYL)-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9- TRIMETHYL-6H-DIBENZO (b,d) PYRAN 201

DMT

*See* N,N-DIMETHYLTRYPTAMINE 201

DOB

*See* 2,5-DIMETHOXY-4-BROMOAMPHETAMINE 201

DOBUTAMINE 73

DOCETAXEL 73

DOCUSATE SODIUM (DIOCTYL SODIUM SULFOSUCCINATE) 214

DODINE 165

DOET

*See* 2,5-DIMETHOXY-4-ETHYL-a-AMPHETAMINE 201

DOFETILIDE 73

DOLASETRON 73

DOM

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE 200

DOMPERIDONE 73

DONEPEZIL 73

DOPAMINE 73

DOPEXAMINE 73

DORAMECTIN 133, 165, 190

DORIPENEM 73

DORNASE 73

DORZOLAMIDE 73

DOSAGE UNIT 4

DOTHIEPIN 73, 269

DOXANTRAZOLE 73

DOXAPRAM 73

DOXAZOSIN 73

DOXEPIN 73, 269

DOXORUBICIN 73

DOXYCYCLINE 74

DOXYLAMINE 34, 45, 74, 269

d-PHENOTHRIN 216

d-PULEGONE 22, 236, 177, 180

DROMETRIZOLE TRISILOXANE 214

DRONABINOL (delta-9-TETRAHYDROCANNABINOL) 198, 223, 269

*See also* NABIXIMOLS

DRONEDARONE 74

Droperidol 74, 269

DROSPIRENONE 74

DROSTANOLONE 74

DROTEBANOL 198

DROTRECOGIN 74

DRUG 4

DRY CLEANING FLUID

*See* LIQUID HYDROCARBONS 20, 21

DSMA 165, 190

DUBOISIA LEICHHARDTII 34, 74

DUBOISIA MYOPOROIDES 34, 74

DULCIN 220

DULOXETINE 74, 269

DUTASTERIDE 74

DYDROGESTERONE 74

E

ECGONINE 201

ECONAZOLE 34, 45, 74, 165, 253, 264

ECOTHIOPATE 74

ECOTHIOPATE IODIDE

*See* ECOTHIOPATE

ECTYLUREA 74

ECULIZUMAB 74

EDETIC ACID 74

EDOXUDINE 74

EDROPHONIUM 74

EFALIZUMAB 74

EFAVIRENZ 74

EFLORNITHINE 74

EFORMOTEROL 74

ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 207

ELECTRICAL COMPONENTS 207

ELETRIPTAN 74

ELTENAC 74

ELTROMBOPAG OLAMINE 74

ELVTEGRAVIR 75

EMAMECTIN 133, 165, 190

EMEPRONIUM 75

EMETINE 75

*See also* CEPHAELIS ACUMINATA 63

*See also* CEPHAELIS IPECACUANHA 63

EMODEPSIDE 133, 165

EMTRICITABINE 75

ENALAPRIL 75

ENAMELLING PREPARATIONS

*See* FRITTED GLAZING OR ENAMELLING PREPARATIONS 207

ENDOSULFAN 165, 190

ENDOTHAL 165, 190

ENDOTOXIN

*See* BACILLUS THURINGIENSIS 213

ENDRIN 190

ENESTEBOL 75

ENFLURANE 75

ENFUVIRTIDE 75

ENHANCING AGENTS FOR USE IN ULTRASONIC AND MAGNETIC RESONANCE IMAGING 207

ENILCONAZOLE

*See* IMAZALIL

ENOBOSARM 75

ENOXACIN 75

ENOXAPARIN 75

ENOXIMONE 75

ENPROSTIL 75

ENROFLOXACIN 75

ENTACAPONE 75

ENTECAVIR 75

EPHEDRA 75

EPHEDRINE 75, 224, 253

*See also* EPHEDRA 75

EPICHLOROHYDRIN 190, 253, 267

EPICILLIN 75

EPIDERMAL GROWTH FACTOR 190, 267

EPINASTINE 75

EPIRUBICIN 75

EPITIOSTANOL 75

EPLERENONE 75

EPOETINS 75, 224

EPOPROSTENOL 75

EPOXICONAZOLE 133

EPOXY RESINS 133

EPOXY RESINS, LIQUID 13, 231, 253

EPRINOMECTIN 133, 190

EPROSARTAN 75

EPSIPRANTEL 214

EPTC 165

EPTIFIBATIDE 75

EQUINE ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN

*See* IMMUNOGLOBULINS

ERGOCACIFEROL

*See* VITAMIN D

ERGOMETRINE 75

ERGOT 75

ERGOTAMINE 75

ERGOTOXINE 76

ERIBULIN MESYLATE 76

ERLOTINIB 76

ERTAPENEM 76

ERYSIMUM 76, 263

ERYTHRITYL TETRANITRATE 45

ERYTHROMYCIN 76

ERYTHROPOIETIN 76, 224

ESBIOTHRIN 133, 165

ESCITALOPRAM 76

ESFENVALERATE 133, 165

ESMOLOL 76

ESOMEPRAZOLE 76

ESSENTIAL OILS 4, 21, 231

*See also* CAMPHOR 127, 157

ESTRAMUSTINE 76

ESTROPIPATE (piperazine oestrone sulfate) 76

ETACONAZOLE 190, 267

ETAFEDRINE 34

ETANERCEPT 76

ETHACRYNIC ACID 76

ETHAMBUTOL 76

ETHAMETSULFURON-METHYL 214

ETHAMIVAN 76

ETHANEDINITRILE

*See* CYANOGEN

ETHANOL

*See* METHYLATED SPIRIT(S) 139

*See also* ETHYL ALCOHOL

ETHANOLAMINE 76, 133, 165, 231, 253

ETHCHLORVYNOL 76

ETHEPHON 165

ETHER 34, 76, 133, 165, 231, 253

ETHINAMATE 76

ETHINYLOESTRADIOL 76

ETHIOFENCARB 165

ETHION 191

ETHIONAMIDE 76

ETHISTERONE 76

ETHOATE-METHYL 165

ETHOFUMESATE 133

ETHOGLUCID 76

ETHOHEPTAZINE 76

ETHOPABATE 214

ETHOPROPAZINE 76

ETHOPROPHOS 165, 191

ETHOSUXIMIDE 76

ETHOTOIN 76

ETHOXYETHYLMERCURIC CHLORIDE 254

*See* also MERCURY

ETHOXYQUIN 133

*See* also MERCURY

ETHOXYSULFURON 133

ETHOXZOLAMIDE 76

ETHYL ACETATE 215

ETHYL ALCOHOL 215

*See also* ETHANOL

ETHYL BROMIDE 166, 231, 254

ETHYL BUTYRATE 215

ETHYL CHLORIDE 76

ETHYL FORMATE 166

ETHYL LACTATE 215

ETHYL METHACRYLATE 134, 254

ETHYLAMPHETAMINE 198

ETHYLBUTYLACETYL-AMINOPROPIONATE 215

ETHYLDIENOLONE 77

ETHYLENE CHLOROHYDRIN 166, 254

ETHYLENE DIBROMIDE 191, 267

ETHYLENE DICHLORIDE 166

ETHYLENE GLYCOL 21, 133, 166, 220, 231

ETHYLENE GLYCOL MONOALKYL ETHERS AND THEIR ACETATES 166, 231, 254, 265

ETHYLENE OXIDE 191, 231, 254, 267

ETHYLHEXANEDIOL 77, 220

ETHYLMERCURIC CHLORIDE 254

ETHYLMETHYLTHIAMBUTENE 202

ETHYLMORPHINE 34, 77, 198, 269

ETHYLOESTRENOL 77

ETHYNODIOL 77

ETICYCLIDINE \*(PCE) 202

ETIDOCAINE 77

ETIDRONIC ACID (includes disodium etidronate) 77

ETILEFRIN 77

ETIPROSTON 77

ETODOLAC 77

ETOFENAMATE 34, 77

ETONITAZENE 202

ETONOGESTREL 77

ETOPOSIDE 77

ETORICOXIB 77

ETORPHINE 202

ETOXAZOLE 215

ETOXERIDINE 202

ETRAVINE 77

ETRETINATE 77, 223, 254, 273

ETRIDIAZOLE 134

ETRIMFOS 166

EUCALYPTUS OIL 21, 166, 231

EUGENOL 21, 134, 166, 231, 254

EUPATORIUM CANNABINUM (HEMP AGRIMONY) 220

EVEROLIMUS 77

EXEMESTANE 77

EXENATIDE 77

EXPLOSIVES 207

EXTERNAL 4

EXTRACT OF LEMON EUCALYPTUS 134

EZETIMIBE 77

F

FAMCICLOVIR 45, 77

FAMOTIDINE 34, 77, 254

FAMPHUR 167, 191

FAMPRIDINE

*See* 4-AMINOPYRIDINE

FARFUGIUM JAPONICUM 220

FEBANTEL 167

FELBINAC 34, 77

FELODIPINE 77

FELYPRESSIN 77

FENAMIPHOS 167, 191

FENARIMOL 134

FENAZAFLOR 167

FENBENDAZOLE 134

FENBUCONAZOLE 134

FENBUFEN 78

FENBUTATIN OXIDE 167

*See also* TIN ORGANIC COMPOUNDS

FENCAMFAMIN 78

FENCHLORAZOLE-ETHYL 134

FENCHLORPHOS 167

FENCLOFENAC 78

FENETYLLINE 202

FENFLURAMINE 78, 269

FENFURAM 215

FENHEXAMID 215

FENITROTHION 167

FENOFIBRATE 78

FENOLDOPAM 78

FENOPROFEN 78

FENOPROP 134

FENOTEROL 78, 254

FENOXACRIM 167, 191

FENOXAPROP-ETHYL 134

FENOXAPROP-P-ETHYL 134

FENOXYCARB 215

FENPIPRAMIDE 78

FENPIPRANE 78

FENPROPOREX 78

FENPROSTALENE 78

FENPYROXIMATE 167

FENSON 134

FENSULFOTHION 191

FENTANYL 198

FENTHION 134, 167, 191

FENTHION-ETHYL 191

FENVALERATE 167

FERRICYANIDES

*See* CYANIDES 189

FEXOFENADINE 34, 78

*See also* ANTIHISTAMINES 248

FIBRINOGEN

*See* HUMAN BLOOD PRODUCTS 207

FIBRINOLYSIN 78

FIDAXOMICIN 78

FILGRASTIM 78

FILM OR PAPER, PHOTOGRAPHIC

*See* PHOTOGRAPHIC PAPER or FILM 208

FINASTERIDE 78

FINGOLIMOD 78, 273

FIPRONIL 134, 167

FIROCOXIB 78

FIRST SCHEDULE PAINT 4, 258, 265

FLAMPROP-METHYL 134

FLAMPROP-M-METHYL 134

FLAVOPHOSPHOLIPOL

*See* BAMBERMYCIN 56, 153

FLAVOXATE 46

FLAZASULFURON 134

FLECAINIDE 78

FLEROXACIN 78

FLOCOUMAFEN 167, 191

FLOCTAFENINE 78

FLONICAMID 167

FLORASULAM 134

FLORFENICOL 78

FLUANISONE 78

FLUAZIFOP-BUTYL 168

FLUAZIFOP-P-BUTYL 168

FLUAZINAM 168

FLUAZURON 134

FLUBENDAZOLE 134

FLUBENDIAMIDE 134

FLUCHLORALIN 134

FLUCLOROLONE 78

FLUCLOXACILLIN 78

FLUCOFURON 168, 191

FLUCONAZOLE 46, 79, 254, 264

FLUCYTHRINATE 191

FLUCYTOSINE 79

FLUDARABINE 79

FLUDIOXONIL 134

FLUDROCORTISONE 79

FLUFENAMIC ACID 79

FLUFENOXURON 215

FLUMAZENIL 79

FLUMETHASONE 79

FLUMETHIAZIDE 79

FLUMETHRIN 134, 168

FLUMETSULAM 215

FLUMICLORAC PENTYL 135

FLUMIOXAZIN 168, 191

FLUNISOLIDE 79

FLUNITRAZEPAM 198, 269

FLUNIXIN MEGLUMINE 79

FLUOCINOLONE 79

FLUOCINONIDE 79

FLUOCORTIN 79

FLUOCORTOLONE 79

FLUOMETURON 215

FLUORACETAMIDE 267

FLUORESCEIN 79

*See also* METHYLATED SPIRIT(S) 139

FLUORIDE

*See also* SILICOFLUORIDES 145, 182

FLUORIDES 35, 46, 79, 135, 168, 232, 254

FLUOROACETAMIDE 25, 191

FLUOROACETIC ACID 25, 191, 267

FLUOROMETHOLONE 79

FLUOROSILICATES

*See* SILICOFLUORIDES

FLUOROSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

FLUOROURACIL 79

FLUOXETINE 79

FLUOXYMESTERONE 79

FLUPENTHIXOL 79, 270

FLUPHENAZINE 79, 270

FLUPROPANATE 168

FLUPROSTENOL 79

FLUQUINCONAZOLE 168

FLURANDRENOLONE 79

FLURAZEPAM 79, 270

FLURBIPROFEN 35, 79

FLUROXENE 79

FLUROXYPYR 215

FLUSILAZOL 168

FLUSPIRILENE 79

FLUTAMIDE 79

FLUTICASONE 35, 79

FLUTOLANIL 215

FLUTRIAFOL 168

FLUVALINATE 135, 168

FLUVASTATIN 80

FLUVOXAMINE 80

FLUXAPYROXAD 135

FOLIC ACID 35, 80

FOLINIC ACID 35, 80

FOLLICLE STIMULANT, RECOMBINANT

*See* CORIFOLLITROPIN ALFA 223

FOLLICLE-STIMULATING HORMONE 80, 263

FOLLICLE-STIMULATING HORMONE, HUMAN

*See* UROFOLLITROPIN 223

FOLLICLE-STIMULATING HORMONE, RECOMBINANT HUMAN

*See* FOLLITROPIN ALPHA 223

*See* FOLLITROPIN BETA 223

FOLLISTATIN 80, 224

FOLLITROPIN ALPHA 80, 223

FOLLITROPIN BETA 80, 223

FOLPET 191, 267

FOMIVIRSEN 80

FONDAPARINUX 80

FOOD 207

FORAMSULFURON 135

FORCHLORFENURON 215

FORMALDEHYDE 35, 168, 220, 232, 254

*See also* METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT 173, 256

*See also* PARAFORMALDEHYDE 40, 176, 221

*See* FREE FORMALDEHYDE 4

FORMEBOLONE 80

FORMESTANE 80

FORMETANATE 191

FORMIC ACID 135, 232, 254

FORMOTEROL

*See* EFORMOTEROL

FORMOTHION 168

FOSAMPRENAVIR 80

FOSAPREPITANT 80

FOSCARNET 80

FOSFESTROL (diethylstilboestrol diphosphate) 80

FOSINOPRIL 80

FOSPHENYTOIN 80

FOSPIRATE 135, 168

FOTEMUSTINE 80

FRAMYCETIN 80

FREE FORMALDEHYDE 4

*See also* FORMALDEHYDE 35, 168, 220

*See also* PARAFORMALDEHYDE 40, 176, 221

FRITTED GLAZING OR ENAMELLING PREPARATIONS 207

FRUSEMIDE

*See* FUROSEMIDE 80

FUELS

*See* MOTOR, HEATING or FURNACE FUELS 208

FUELS, HOBBY

*See* MOTOR, HEATING or FURNACE FUELS 208

FUELS, TOY

*See* MOTOR, HEATING or FURNACE FUELS 208

FULLERS EARTH 215

FULVESTRANT 80

FUMAGILLIN 168

FUNGAL PROTEASE DERIVED FROM ASPERGILLUS NIGER 215

FURALAXYL 135

FURALTADONE 80

FURATHIOCARB 135, 191

FURAZABOL 80

FURAZOLIDONE 80

FURETHIDINE 202

FUROSEMIDE (frusemide) 80

FUSIDIC ACID 80

G

GABAPENTIN 80, 270

GALANTAMINE 80

GALANTHUS 80

GALLAMINE 80

GALSULFASE 81

GAMMA HYDROXYBUTYRATE (GHB)

*See* 4-HYDROXYBUTANOIC ACID 202

GAMMA-CYHALOTHRIN 135, 191

GANCICLOVIR 81

GANIRELIX 81

GATIFLOXACIN 81

GEFITINIB 81

GELATIN 207

GELSEMIUM SEMPERVIRENS 36, 263

GEMCITABINE 81, 270

GEMEPROST 81

GEMFIBROZIL 81

GEMIFLOXACIN 81

GEMTUZUMAB OZOGAMICIN 81

GENTAMICIN 81

GENTIAN VIOLET

*See* CRYSTAL VIOLET

GERANIUM OIL 215

GESTODENE 81

GESTONORONE 81

GESTRINONE 81

GHB (GAMMA HYDROXYBUTYRATE)

*See* 4-HYDROXYBUTANOIC ACID 202

GHRH INJECTABLE PLASMID 81

GIBBERELLIC ACID 215

GITALIN 81

GLASS 207

GLATIRAMER ACETATE 81

GLAZED POTTERY 207

GLAZING PREPARATIONS CONTAINING LEAD COMPOUNDS 254

GLIBENCLAMIDE 81

GLIBORNURIDE 81

GLICLAZIDE 81

GLIMEPIRIDE 81

GLIPIZIDE 81

GLISOXEPIDE 81

GLUCAGON 46, 263

GLUCANASE DERIVED FROM ASPERGILLUS NIGER 215

GLUES, CEMENTS AND ADHESIVES − MEDICAL AND VETERINARY 208

GLUFOSINATE-AMMONIUM 135

GLUTARALDEHYDE 36, 135, 168, 232, 254

GLUTATHIONE 81

GLUTETHIMIDE 81, 224, 270

GLYCERYL THIOGLYCOLLATE 169

GLYCERYL TRINITRATE 46, 81, 263

GLYCOLIC ACID 169, 232, 254

GLYCOPYRRONIUM 46, 81

GLYCOSYLATED HYDROQUINONE

*See* HYDROQUINONE

GLYMIDINE 81

GLYPHOSATE 135

GnRH VACCINE 81

GOLIMUMAB 81

GONADORELIN 81

GONADOTROPHIC HORMONES 82

GOSERELIN 82

GRAMICIDIN 82

GRANISETRON 82

GRAPHIC MATERIAL 4

GREPAFLOXACIN 82

GRISEOFULVIN 82

GROWTH HORMONE 263

GUAIPHENESIN 35, 82

*See also* PARACETAMOL (+ guaiphenesin) 40

GUANABENZ 82

GUANACLINE 82

GUANETHIDINE 82

GUANIDINE 82, 169, 232

GUAZATINE 169

H

HACHIMYCIN 82

HAEMATIN 82

HAEMOPHILUS INFLUENZAE VACCINE 82

HALCINONIDE 82

HALOFANTRINE 82

HALOFENATE 82

HALOFUGINONE 82, 191, 267

HALOGENATED DIBENZODIOXINS 268

HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 191

HALOGENATED DIBENZOFURANS 268

*See* HALOGENATED DIBENZODIOXINS AND DIBENZOFURANS 191

HALOPERIDOL 82, 263, 270

HALOSULFURON-METHYL 135

HALOTHANE 82

HALOXON 169

HALOXYFOP 169

HALQUINOL

*See* CLIOQUINOL

HARMALA ALKALOIDS 202

HCB 191, 268

HEIGHT 4

HELICOZEAOCCLUSION BODIES

*See* POLYHEDROSIS VIRUS 217

HELICOVERPA ARMIGERA

*See* NUCLEAR POLYHEDROSIS VIRUS 216

HELIOTROPIUM spp 221

HEMEROCALLIS (HEMEROCALLIS FLAVA) 82

HEMP AGRIMONY

*See* EUPATORIUM CANNABINUM 220

HEMP

*See* CANNABIS 201

*See* HEMP SEED OIL 4

HEMP SEED OIL

*See also* TETRAHYDROCANNABINOLS 204

HEPARINS 82

HEPATITIS A VACCINE 82

HEPATITIS B VACCINE 82

HEPTACHLOR 169

HEROIN 202

HETACILLIN 82

HEXACHLOROPHANE 36, 82, 169, 232, 254

HEXACONAZOLE 135

HEXAFLUOROSILICATES

*See* SILICOFLUORIDES

HEXAFLUOROSILIC ACID

*See* HYDROSILICOFLUORIC ACID

HEXAFLURON 215

HEXAMETHONIUM 83

HEXAMETHYLMELAMINE

*See* ALTRETAMINE 52

HEXAZINONE 135, 169

HEXETIDINE 83

HEXOBENDINE 83

HEXOCYCLIUM 83

HEXOPRENALINE 83

HEXYL ACETATE 215

HEXYTHIAZOX 215

HISTAMINE 83

HMG-CoA REDUCTASE INHIBITORS (including statins) 83

HOBBY FUELS

*See* MOTOR, HEATING or FURNACE FUELS 208

HOMATROPINE 83

HORMONE, FOLLICLE-STIMULATING 80

*See* FOLLICLE-STIMULATING HORMONE 263

HORMONE, GROWTH

*See* GROWTH HORMONE 263

HORMONE, HUMAN FOLLICLE-STIMULATING

*See* UROFOLLITROPIN 223

HORMONE, HUMAN GROWTH

*See* SOMATROPIN 112, 224

HORMONE, LUTEINISING 90, 223

HORMONE, RECOMBINANT HUMAN FOLLICLE-STIMULATING

*See* FOLLITROPIN ALPHA 223

*See* FOLLITROPIN BETA 223

HORMONES, ADRENOCORTICAL 51

HORMONES, GONADOTROPHIC 82

HORMONES, PITUITARY 104

HORMONES, SEX 112

HORMONES, STEROID 113

HUMAN BLOOD PRODUCTS 207

See also BLOOD

HUMAN CHORIONIC GONADATROPHIN 83

HUMAN FOLLICLE-STIMULATING HORMONE

*See* UROFOLLITROPIN 223

HUMAN GROWTH HORMONE

*See* SOMATROPIN 112, 224

HUMAN OSTEOGENIC PROTEIN-1 (OP-1) 215

HUMAN PAPILLOMA VIRUS VACCINE 83

HYALURONIC ACID AND ITS POLYMERS 83

HYDRALAZINE 83

HYDRAMETHYLNON 135, 169

HYDRARGAPHEN 83

HYDRAZINE 169, 232, 254

HYDROCARBONS, LIQUID vi, 13, 21, 135, 232

*See also* DESIGNATED SOLVENT 3

*See also* NAPHTHALENE 175

See *also* LIQUID HYDROCARBONS

HYDROCARBONS, LIQUID AROMATIC 191

*See* HYDROCARBONS, LIQUID 135

HYDROCHLORIC ACID 21, 136, 169, 232, 254

HYDROCHLOROTHIAZIDE 83

HYDROCODONE 198, 270

HYDROCORTISONE 36, 46, 83, 255, 264

HYDROCORTISONE ACETATE 36, 46

HYDROCYANIC ACID 25, 83, 192, 255, 63, 268

HYDROFLUMETHIAZIDE 83

HYDROFLUORIC ACID 136, 169, 192, 232, 255, 268

HYDROFLUOSILICIC ACID

*See* HYDROSILICOFLUORIC ACID

HYDROGEN FLUORIDE

*See* HYDROFLUORIC ACID 136, 169

HYDROGEN PEROXIDE 136, 169, 221, 232, 255

HYDROGEN SULFIDE 192

HYDROMORPHINOL 198

HYDROMORPHONE 198, 270

HYDROPRENE 215

HYDROQUINONE 36, 83, 170, 232, 255

*See also* MONOBENZONE 95

HYDROSILICOFLUORIC ACID 136, 170, 192, 232, 255, 268

HYDROXYCHLOROQUINE 83

HYDROXYEPHEDRINE 83

HYDROXYPETHIDINE 83, 202

HYDROXYPHENAMATE 84

HYDROXYPROGESTERONE 84

HYDROXYPROPYL CELLULOSE 215

HYDROXYSTENOZOL 84

HYDROXYUREA 84

HYDROXYZINE 84, 270

HYGROMYCIN 84

HYOSCINE 36, 84, 263

HYOSCINE BUTYLBROMIDE 36

*See also* HYOSCINE 36

HYOSCYAMINE 36, 84, 263

HYOSCYAMUS NIGER 37, 84, 263

HYPOTHALAMIC RELEASING FACTORS 84, 263

HYPROMELLOSE 84

I

IBAFLOXACIN 84

IBANDRONIC ACID 84

IBOGAINE 84

IBRITUMOMAB 84

IBUFENAC 84

IBUPROFEN 37, 46, 84, 255

*See also* PARACETAMOL (+ ibuprofen) 48, 101

IBUTEROL 84

IBUTILIDE 84

ICATIBANT 84

ICODEXTRIN 215

IDARUBICIN 84

IDOXURIDINE 84

IDURSULFASE 84

IFOSFAMIDE 84

ILOPROST 84

IMATINIB 84

IMAZALIL 136

IMAZAMOX 136

IMAZAPIC 136

IMAZAPYR 136

IMAZETHAPYR 136

IMIDACLOPRID 136, 170

IMIDAPRIL 85

IMIDOCARB 170

IMIGLUCERASE 85

IMIPENIM 85

IMIPRAMINE 85, 270

IMIPROTHRIN 136, 170

IMIQUIMOD 85

IMMEDIATE CONTAINER 4

IMMEDIATE WRAPPER 4

IMMUNOGLOBULINS 85

IMMUNOSERA

*See* ANTISERA 55

IN VITRO DIAGNOSTIC AND ANALYTICAL PREPARATIONS 208

INDACATEROL 85

INDANAZOLINE 37

INDAPAMIDE 85

INDAZIFLAM 170

INDINAVIR 85

INDOLE-3-ACETIC ACID 215

INDOMETHACIN 37, 85, 263

INDOPROFEN 85

INDORAMIN 85

INDOXACARB 136, 170

INFLIXIMAB 85

INFLUENZA AND CORYZA VACCINES 85

INGENOL MEBUTATE 85

INJECTABLE TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS *See* MEDICAL DEVICES 208

INK ADDITIVES

*See* PRINTING INKS OR INK ADDITIVES 208

INOSITOL NICOTINATE 47

INSULIN-LIKE GROWTH FACTOR I 85

INSULIN-LIKE GROWTH FACTORS 85, 224

INSULINS 85

INTERFERONS 85

INTERLEUKINS 85

INTERNAL USE 4

INTRA-ARTICULAR FLUIDS

*See* MEDICAL DEVICES 208

INTRAOCULAR VISCOELASTIC PRODUCTS 208

IODINE 37, 170, 232, 255

*See also* IODOPHORS 170

IODOCARB

*See* 3-IODO-2-PROPYNYL BUTYL CARBAMATE 136, 170

IODOMETHANE 192, 268

IODOPHORS 170, 233

*See also* IODINE 37, 170, 232

IODOQUINOL

*See* DI-IODOHYDROXYQUINOLINE 45, 72

IODOSULFURON-METHYL-SODIUM 136

IODOTHIOURACIL 85

IOXYNIL 170

IPCONAZOLE 136, 170

IPECACUANHA

*See* CEPHAELIS IPECACUANHA 63

*See* CEPHAELIS ACUMINATA 63

IPILIMUMAB 85

IPRATROPIUM 38, 85

IPRATROPIUM BROMIDE 255

IPRIFLAVONE 85

IPRINDOLE 85

IPRODIONE 215

IPRONIAZID 85

IRBESARTAN 85

IRINOTECAN 85

IRON COMPOUNDS 38, 86, 136, 170

IRON OXIDES

*See* IRON COMPOUNDS 38, 137, 170

IRON

*See* IRON COMPOUNDS 170

ISOAMINILE 86

ISOAMYL NITRITE 86

ISOBUTYL NITRITE 86

ISOCARBOPHOS 192

ISOCARBOXAZID 86

ISOCONAZOLE 38, 47, 86, 170

ISOCYANATES (FREE ORGANIC) 170, 233, 256

ISOETARINE 86

ISOEUGENOL 137, 171

ISOFENPHOS 192

ISOFLURANE 86

ISOMETHADONE 202

ISOMETHEPTENE 86

ISONIAZID 86

ISOPHORONE 137, 233

ISOPRENALINE 86, 256

ISOPRENE ALCOHOL 215

ISOPRINOSINE 86

ISOPROPAMIDE 38, 86

ISOPROTURON 192

ISOSORBIDE DINITRATE 47, 86

ISOSORBIDE MONONITRATE 86

ISOSTEARYL ALCOHOL ETHOXYLATE 215

ISOTRETINOIN 86, 223, 256, 273

ISOXABEN 137

ISOXAFLUTOLE 137

ISOXICAM 86

ISOXSUPRINE 86

ISRADIPINE 86

ITRACONAZOLE 86

IVABRADINE 86

IVACAFTOR 86

IVERMECTIN 86, 137, 192

IXABEPILONE 86

J

JAPANESE ENCEPHALITIS VACCINE 86

JASMOLONE

*See* PYRETHRINS 42, 145

JEQUIRITY

*See* ABRUS PRECATORIUS 219

JUNIPERUS SABINE [savin(e)] 221

JWH-018

*See* 1-PENTYL-3-(1-NAPHTHOYL)INDOLE 204

JWH-073

*See* NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE 203

JWH-122

*See* 1-PENTYL-3-(4-METHYL-1-NAPTHOYL)INDOLE. 204

JWH-200

*See* 1-(2-MORPHOLIN-4-YLETHYL)INDOL-3-YL)-NAPTHALEN-1-YLMETHANONE 203

JWH-250

*See* 2-(2-METHOXYPHENYL)-1-(1-PENTYLINDOL-3-YL)ETHANONE 203

K

KANAMYCIN 86

KAOLIN 215

KAVA

*See* PIPER METHYSTICUM 104

KAVALACTONES

*See* PIPER METHYSTICUM 104

KEROSENE vi, 233

*See also* LIQUID HYDROCARBONS 20

*See also* HYDROCARBONS, LIQUID 21, 135

*See also* MOTOR, HEATING or FURNACE FUELS 208

KETAMINE 198

KETANSERIN 86

KETAZOLAM 86

KETOBEMIDONE 202

KETOCONAZOLE 38, 86

KETONE 13

KETOPROFEN 47, 87

KETOROLAC (includes ketoralac trometamol) 87

KETOTIFEN 38, 87

K-HDO

*See* N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM

KHELLIN 87

KITASAMYCIN 87, 137

KRESOXIM-METHYL 215

KUNZEA OIL 215

L

LABELS 4, 9, 273

*See also* DISPENSING LABEL 4

*See also* MAIN LABEL 5

LABELS, DISPENSING 272

LABETALOL 87

LACIDIPINE 87

LACOSAMIDE 87

LAMBDA-CYHALOTHRIN 137, 171, 192

LAMIVUDINE 87

LAMOTRIGINE 87, 270

LAMP OIL

*See* HYDROCARBONS, LIQUID 21

*See* LIQUID HYDROCARBONS 20

LAMPS

*See* ELECTRICAL ACCUMULATORS, BATTERIES, COMPONENTS OR LAMPS 207

LANATOSIDES 87

LANREOTIDE 87

LANSOPRAZOLE 47, 87

LANTHANUM 87

LAPATINIB 87

LARONIDASE 87

LAROPIPRANT 87

LASALOCID 171

LATAMOXEF 87

LATANOPROST 87

LAUDEXIUM 87

LAURETH CARBOXYLIC ACIDS 171, 233

LAURETH-9

*See* LAUROMACROGOL

LAURIC ACID 215

LAUROMACROGOLS 87

LAURYL ALCOHOL (1-DODECANOL) 215

LAURYL ISOQUINOLINIUM BROMIDE 171, 233

LAVENDER OIL 215

LAVANDIN OIL 215

*See also* CAMPHOR 127, 157

*See also* LAVENDER OIL 215

LEAD 15, 88, 265

*See also* LEAD COMPOUNDS 171

*See also* PRINTING INKS or INK ADDITIVES 208

*See also* SELENIUM 181

LEAD COMPOUNDS 137, 171, 221, 233, 256, 265

*See also* GLAZING PREPARATIONS 254

LEAD METALLIC 215

LEFETAMINE 88

LEFLUNOMIDE 88, 256, 273

LEMON EUCALYPTUS OIL

*See* EXTRACT OF LEMON EUCALYPTUS 134

LEMON OIL 137, 233, 256

LEMONGRASS OIL 215

LENALIDOMIDE 88, 223, 256, 273

LENOGRASTIM 88

LEPIDOPTEROUS SEX PHEROMONES 215

LEPIRUDIN 88

LEPTAZOL 88

LEPTOPHOS 192

LEPTOSPERMUM SCOPARIUM OIL (MANUKA OIL) 21, 172, 233

LERCANIDIPINE 88

LETROZOLE 88

LEUPRORELIN 88

LEVALLORPHAN 88

LEVAMISOLE 88, 138, 172

LEVAMPHETAMINE 198

LEVETIRACETAM 88, 270

LEVOBUNOLOL 88

LEVOBUPIVACAINE 88

LEVOCABASTINE 38, 88, 256, 270, 273

LEVOCETIRIZINE

*See* CETIRIZINE

LEVODOPA 88

LEVOMEPROMAZINE 88

LEVOMETHAMPHETAMINE 198

LEVOMETHORPHAN 202

LEVOMORAMIDE 198

LEVONORGESTREL 47, 88

LEVOPHENACYLMORPHAN 202

LEVORPHANOL 198

LEVOSIMENDAN 88

LIDOFLAZINE 88

LIDOCAINE

*See* LIGNOCAINE

LIGHT MINERAL OILS

*See* HYDROCARBONS, LIQUID 135

LIGNOCAINE 38, 88

LIGULARIA DENTATA 221

LIME OIL 138, 233, 256

LIMONENE (dipentene) 215

LINAGLIPTIN 88

LINCOMYCIN 88

LINDANE 38, 88, 138, 172

*See also* BHC 154

LINEZOLID 89

LINOLEIC ACID 215

LINSEED FATTY ACIDS 216

LINSEED OIL

*See* ETHOPROPHOS 166

LINURON 216

LIOTHYRONINE 89

LIPASE

*See* PANCREATIC ENZYMES 100

LIQUID 191

LIQUID AROMATIC HYDROCARBONS

*See* HYDROCARBONS, LIQUID 135

LIQUID EPOXY RESINS 13

LIQUID HYDROCARBONS 13, 21

*See also* HYDROCARBONS, LIQUID 135

*See also* NAPHTHALENE 175

LIQUORICE, DEGLYCYRRHISINISED 216

LIRAGLUTIDE 89

LISINOPRIL 89

LISURIDE 89

LITHIUM 38, 89

LITHIUM PERFLUOROOCTANE SULFONATE 192

LIXISENATIDE 89

LOBELIA INFLATA 38

LOBELINE 38

LODOXAMIDE 38, 89

LOFEXIDINE 89

LOGIPARIN 89

LOMEFLOXACIN 89

LOMUSTINE 89

LOPERAMIDE 38, 89, 256

LOPINAVIR 89

LOPRAZOLAM 89

LORACARBEF 89

LORATADINE 39, 89

*See also* ANTIHISTAMINES 248

LORAZEPAM 89, 270

LORMETAZEPAM 89

LOSARTAN 90

LOXAPINE 90

LUBRICANTS 208

LUFENURON 138

LUMEFANTRINE 90

LUMIRACOXIB 90

LUTEIN

*See* XANTHOPHYLL 218

LUTEINISING HORMONE 90, 223

LYE WATER

*See* ALKALINE SALTS, SODIUM HYDROXIDE OR POTASSIUM HYDROXIDE

LYMECYCLINE 90

LYSERGIC ACID 202

LYSERGIDE 202

M

MACROGOLS 47

MADURAMICIN 138, 192, 268

MAFENIDE 90, 172

MAGNESIUM CHLORATE 138, 233, 256

MAGNESIUM FLUOSILICATE

*See* FLUORIDES

MAGNESIUM PHOSPHIDE

*See* PHOSPHIDES, METALLIC

MAGNESIUM SULFATE 47

MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS 207

MAIN LABEL 5

MALACHITE GREEN 138, 192

MALATHION 47, 138, 172, 233

*See also* ORGANOPHOSPHORUS COMPOUNDS 99

MALDISON

*See* MALATHION

MALEIC HYDRAZIDE 216

MANCOZEB 13, 138

*See also* DITHIOCARBAMATES

MANDIPROPAMID 138

MANDRAGORA OFFICINARUM 90

MANGANESE DIOXIDE 216

MANNITYL HEXANITRATE 47

MANNOMUSTINE 90

MANUFACTURER 5

MANUKA OIL

*See* LEPTOSPERMUM SCOPARIUM OIL 21, 172, 233

MAPROTILINE 90

MARAVIROC 90

MARBOFLOXACIN 90

MARJORAM OIL 21, 138, 233

MAROPITANT 90

MATCHES 208

MAVACOXIB 90

MAZIDOX 192

MAZINDOL 90, 270

MBDB

*See* N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE 203

MCPA 139, 172

MCPB 139

MDA

*See* 3,4-METHYLENEDIOXYAMPHETAMINE 203

MDMA

*See* N,α-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE 201

MDPV

*See* 3,4-METHYLENEDIOXYPYROVALERONE 203

MEASLES VACCINE 90

MEASURE PACK 5

MEBANAZINE 90

MEBENDAZOLE 39, 139, 172

MEBEVERINE 90

MEBHYDROLIN 90, 270

MEBOLAZINE 90

MEBUTAMATE 90

MECAMYLAMINE 90

MECARBAM 192

MECASERMIN 90

MECILLINAM 90

MECLOCYCLINE 90

MECLOFENAMATE 90

MECLOFENAMIC ACID 139

MECLOFENOXATE 90

MECLOQUALONE 202

MECLOZINE 39, 90, 270

MECOPROP 139, 172

MECOPROP-P 172

MEDAZEPAM 90, 270

MEDETOMIDINE 91

MEDICAL AND VETERINARY ADHESIVES, GLUES AND CEMENTS 208

MEDICAL DEVICES 208

MEDICINE 5

MEDIGOXIN (methyldigoxin) 91

MEDROXYPROGESTERONE 91

MEDRYSONE 91

MEFENAMIC ACID 39, 91, 256

MEFENOREX 91

MEFENPYR-DIETHYL 139

MEFLOQUINE 91

MEFLUIDIDE 172

MEFRUSIDE 91

MEGESTROL 91

MELAGATRAN 91

MELALEUCA OIL (tea tree oil) 22, 172, 233

MELANOCYTE STIMULATING HORMONE

*See* AFAMELANOTIDE

MELATONIN 91

MELENGESTROL 91

MELENGESTROL ACETATE 173

MELIA AZEDARACH 221

MELOXICAM 91

MELPHALAN 91

MEMANTINE 91

MENAZON 173

MENINGOCOCCAL VACCINE 91

MENOTROPHIN 91

MEPACRINE 91

MEPENZOLATE 91

MEPHEDRONE

*See* 4-METHYLMETHCATHINONE 203

MEPHENESIN 91

MEPHENTERMINE 91

MEPINDOLOL 91

MEPIQUAT 139

MEPITIOSTANE 91

MEPIVACAINE 91

MEPROBAMATE 91, 270

MEPTAZINOL 91

MEPYRAMINE 39, 47, 91, 270

MEQUITAZINE 91

MERCAPTOMERIN 91

MERCAPTOPURINE 91

MERCURIC CHLORIDE 192, 233

MERCURIC IODIDE 233

MERCURIC NITRATE 233

MERCURIC OXIDE 173, 233

MERCURIC POTASSIUM IODIDE 233

MERCURIC THIOCYANATE 233, 256

MERCUROCHROME 39, 173, 233

MERCUROUS CHLORIDE 234

MERCURY 8, 39, 92, 192, 263, 268

*See also* PHENYLMERCURIC ACETATE 194

MERCURY METALLIC 234

MERCURY, ORGANIC COMPOUNDS 234

MEROPENEM 92

MERSALYL 92

MESABOLONE 92

MESALAZINE 92

MESCALINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE 205

MESNA 92

MESOLSULFURON-METHYL 216

MESOTRIONE 139

MESTANOLONE (androstalone) 92

MESTEROLONE 92

MESTRANOL 92

METACRESOLSULPHONIC ACID AND FORMALDEHYDE CONDENSATION PRODUCT 173, 256

METAFLUMIZONE 139

METALAXYL 139, 173

METALDEHYDE 139, 173, 234

METANDIENONE 92

METARAMINOL 92

METARHIZIUM ANISOPLIAE 216

METAZOCINE 202

METENOLONE 92

METERGOLINE 92

METFORMIN 92

METHABENZTHIAZURON 139

METHACHOLINE 92

METHACRIFOS 173, 192, 268

METHACYCLINE 92

METHADONE 198, 270

METHADONE INTERMEDIATE

*See* 4-CYANO-2-DIMETHYLAMINO-4,4-DIPHENYLBUTANE

METHALLENOESTRIL 92

METHAM 173

METHAM SODIUM

*See* METHAM

METHAMIDOPHOS 192

METHAMPHETAMINE

*See* METHYLAMPHETAMINE

METHANDRIOL 92

METHANOL 3, 139, 173, 234, 256

*See also* MOTOR, HEATING or FURNACE FUELS 208

METHANTHELINIUM 92

METHAPYRILENE 193

METHAQUALONE 202

METHAZOLAMIDE 92

METHAZOLE 193

METHCATHINONE 202

METHDILAZINE 47, 92, 270

METHENOLONE 92

METHICILLIN 92

METHIDATHION 193

METHIMAZOLE 92

METHIOCARB 139, 173, 193

METHISAZONE 92

METHIXENE 92

METHOCARBAMOL 92, 270

METHOHEXITONE 92

METHOIN 93

METHOMYL 173, 193

METHOPRENE 216

METHOTREXATE 93

METHOTRIMEPRAZINE

*See* LEVOMEPROMAZINE

METHOXAMINE 39, 93, 256

METHOXSALEN 93

METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA

*See* EPOETINS

METHOXYCHLOR 139

METHOXYETHYLMERCURIC ACETATE 193, 268

METHOXYETHYLMERCURIC CHLORIDE 193, 268

METHOXYFENOZIDE 216

METHOXYFLURANE 93

METHOXYPHENAMINE 39

*See also* 3,4,5-TRIMETHOXYPHENETHYLAMINE (MESCALINE) 205

METHOXYPHENETHYLAMINE 200

METHOXY-PHENYLETHYLAMINE

*See* 3,4,5-TRIMETHOXYPHENETHYLAMINE 205

METHSUXIMIDE 93

METHYCLOTHIAZIDE 93

METHYL (2*S*, 4a*R*, 6a*R*, 7*R*, 9*S*, 10a*S*, 10b*R*)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2*H*-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE \*(SALVINORIN A) 203

METHYL ACETATE 216

METHYL AMINOLEVULINATE 93

METHYL BENZOQUATE 216

METHYL BROMIDE 193, 268

METHYL CHAVICOL

*See* BASIL OIL 126

METHYL CHLORIDE 256

METHYL ETHYL KETONE 139, 234, 256

*See also* DESIGNATED SOLVENT 3

METHYL ETHYL KETONE PEROXIDE 139, 234, 256

METHYL ISOAMYL KETONE 139, 234, 256

*See also* DESIGNATED SOLVENT 3

METHYL ISOBUTYL KETONE 139, 234, 256

*See also* DESIGNATED SOLVENT 3

*See also* METHYLATED SPIRIT(S) 139

METHYL ISO-THIOCYANATE 174, 257

METHYL MERCURY 93

METHYL METHACRYLATE 174, 221, 257

METHYL NEODECANAMIDE 174

METHYL p-HYDROXYBENZOATE 216

METHYL SALICYLATE 22, 93, 140, 174

METHYL SALICYLATE LIQUID 234

*See also* DIMETHYL SULFOXIDE 164

METHYLAMPHETAMINE 198

METHYLANDROSTANOLONE 93

METHYLATED SPIRIT(S) 22, 139, 234

METHYLCLOSTEBOL 93

METHYLCYCLOPENTADIENYL MANGANESE TRICARBONYL 174, 193

METHYLDESORPHINE 203

METHYLDIBROMO GLUTARONITRILE 174, 221, 257

METHYLDIGOXIN

*See* MEDIGOXIN 91

METHYLDIHYDROMORPHINE 198

METHYLDOPA 93

METHYLENE BISTHIOCYANATE 174, 257

METHYLENE BLUE 93, 139, 193

METHYLENE CHLORIDE

*See* DICHLOROMETHANE 131, 230, 253, 265

METHYLENE DIANILINE

*See* 4,4-DIAMINODIPHENYLMETHANE 190, 251, 267

METHYLENE GLYCOL

*See* FREE FORMALDEHYDE 4

*See* FORMALEDHYDE

METHYLEPHEDRINE 39

METHYLERGOMETRINE 93

METHYLEUGENOL 174, 234, 257

METHYLMERCURY 263

METHYLNALTREXONE 93

METHYLNORBORNYLPYRIDINE 174, 257

METHYLPENTYNOL 93

METHYLPHENIDATE 198

METHYLPHENOBARBITONE 93, 270

METHYLPREDNISOLONE 93

METHYLSULFONYLMETHANE

*See* DIMETHYL SULFOXIDE

METHYLPREDNISOLONE 93

METHYLTESTOSTERONE 93

METHYLTHIOURACIL 93

METHYLTRIENOLONE 93

METHYPRYLONE 93

METHYSERGIDE 93

METIRAM 13, 140

METOCLOPRAMIDE 47, 93

METOFLUTHRIN 174

METOLACHLOR 140

METOLAZONE 93

METOPON 203

METOPROLOL 93

METOSULAM 174

METRAFENONE 140, 174

METRIBOLONE 93

METRIBUZIN 174

METRIFONATE (trichlorfon) 93

*See also* TRICHLORFON 185

METRONIDAZOLE 94

METSULFURONMETHYL 216

METYRAPONE 94

MEVINPHOS 193

MEXILETINE 94

MEZLOCILLIN 94

MIANSERIN 94, 270

MIBEFRADIL 94

MIBOLERONE 94

MICAFUNGIN 94

MICONAZOLE 39, 47, 94, 174, 257, 264

MIDAZOLAM 94

MIDODRINE 94

MIFEPRISTONE 94

MIGLITOL 94

MIGLUSTAT 94

MILBEMECTIN 140, 174

MILBEMYCIN OXIME 94, 140

MILRINONE 94

MINERAL OILS

*See* HYDROCARBONS, LIQUID

MINERAL OILS, LIGHT

*See* HYDROCARBONS, LIQUID 135

MINERAL TURPENTINE

*See* HYDROCARBONS, LIQUID 21, 135

*See* LIQUID HYDROCARBONS 20

MINOCYCLINE 94

MINOXIDIL 39, 94

MIPAFOX 193

MIREX 193, 268

MIRTAZAPINE 94, 270

MISOPROSTOL 94, 257, 273

MITOBRONITOL 94

MITOMYCIN 94

MITOTANE 94

MITOXANTRONE 94

MITRAGYNA SPECIOSA 203

MITRAGYNINE 203

MITRATAPIDE 94

MIVACURIUM CHLORIDE. 94

MMDA

*See* 5-METHOXY-3,4-METHYLENEDIOXYAMPHETAMINE 203

MOCA

*See* 4-DIMETHYLAMINOAZOBENZENE 193

MOCLOBEMIDE 94

MODAFINIL 94

MOLGRAMOSTIM 95

MOLINATE 193, 268

MOLINDONE 95

MOMETASONE 39, 95

MONENSIN 95, 140, 174

MONEPANTEL 140

MONOBENZONE 95

*See also* HYDROQUINONE 36

MONOCLONAL ANTIBODIES 95

MONOCROTOPHOS 193

MONOMALEATE, CASTOR OIL 157

MONTELUKAST 95

MOPERONE 95

MORAMIDE

*See* DEXTROMORAMIDE

MORAMIDE INTERMEDIATE

*See* 2-METHYL-3-MORPHOLINO-1, 1-DIPHENYLPROPANE CARBOXYLIC ACID 203

MORANTEL 140, 174

MORAZONE 95

MORICIZINE 95

MORPHERIDINE 203

MORPHINE 198, 270

MORPHINE METHOBROMIDE 198

MORPHINE-N-OXIDE 198

MOTOR, HEATING or FURNACE FUELS 208

MOTRAZEPAM 95

MOTRETINIDE 95

MOXIDECTIN 95, 140, 175, 193

MOXIFLOXACIN 95

MOXONIDINE 95

MPPP

*See* 1-METHYL-4-PHENYL-4-PIPERIDINOL PROPIONATE 203

MSMA 175, 193

MUMPS VACCINE. 95

MUPIROCIN 95

MURAGLITAZAR 95

MUROMONAB 95

MUSCIMOL 203

MUSTINE (nitrogen mustard) 95

MYCLOBUTANIL 140

MYCOPHENOLATE MOFETIL

*See* MYCOPHENOLIC ACID 95

MYCOPHENOLIC ACID (includes mycophenolate mofetil) 95

MYRISTIC ACID 216

MYROPHINE 203

N

N-(N-DODECYL)-2-PYRROLIDONE 133, 165, 231

*See also* DESIGNATED SOLVENT 3

*See also* N-(N-OCTYL)-2-PYRROLIDONE 141, 176, 235

*See also* N-METHYL-2-PYRROLIDONE 140

N-(N-octyl)-2- PYRROLIDONE 151, 187, 247

*See also* DESIGNATED SOLVENT 3

*See also* N-(N-DODECYL)-2-PYRROLIDONE 133, 165, 231

*See also* N-METHYL-2-PYRROLIDONE 140

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE 155, 235, 258

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE 155

N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,6-DIMETHANAMINE 155, 235, 258

*See also* N,N-BIS(PHENYLMETHYLENE)-BICYCLO-(2.2.1)HEPTANE-2,5-DIMETHANAMINE 155

N,N-DIALLYLDICHLOROACETAMIDE 131

N,N-DIETHYLTRYPTAMINE \*(DET) 201

N,N-DIMETHYL-4-[PHENYLAZO]-BENZENAMINE

*See* 4-DIMETHYLAMINOAZOBENZENE 190

N,N-DIMETHYLAMPHETAMINE (DIMETAMFETAMINE) 201

N,N-DIMETHYLTRYPTAMINE \*(DMT) 201

N,α-DIMETHYL-3,4-(METHYLENEDIOXY)PHENYLETHYLAMINE \*(MDMA) 201

NAA 140

NABILONE 198

NABIXIMOLS 270

NABIXIMOLS (botanical extract of Cannabis sativa) 198

NABUMETONE 95

NADOLOL 95

NADROPARIN 95

NAFARELIN 95

NAFTIDROFURYL 95

NALBUPHINE 96, 270

NALED 140, 175

NALIDIXIC ACID. 96

NALORPHINE 96

NALOXONE 96

NALTREXONE 96

NAME AND ADDRESS 5

NANDROLONE 96

NAPHAZOLINE 39, 257

NAPHTHALENE 8, 23, 175, 263, 234, 257

NAPTHALENE ACETIC ACID

*See* NAA

NAPHTHALOPHOS 175, 193

NAPHTHOYLINDOLES 203

NAPHTHOYLPYRROLES 203

NAPHTHYLMETHYLINDENES 203

NAPHTHYLMETHYLINDOLES 203

NAPROPAMIDE 216

NAPROXEN 39, 96, 257

NAPTALAM 140

NAPTHALEN-1-YL-(1-BUTYLINDOL-3-YL)METHANONE \*(JWH-073) 203

NAPTHYL ACETAMIDE 216

NARASIN 96, 175

NARATRIPTAN 96

NATALIZUMAB 96

NATAMYCIN 96

NATEGLINIDE 96

n-BUTYL BUTYRATE 214

n-BUTYL LACTATE 214

N-COCO-1,3-DIAMINOPROPANE 160

N-CYCLOHEXYLDIAZENIUMDIOXY-POTASSIUM 162

NEBACUMAB 96

NEBIVOLOL 96

NEDOCROMIL 96

NEEM

*See* DEBITTERISED NEEM SEED OIL 3

*See* AZADIRACHTA INDICA 153, 219, 228, 249

*See* AZADIRACHTA INDICA EXTRACTS 125

NEFAZODONE 96

NEFOPAM 96

NELFINAVIR (includes nelfinavir mesylate) 96

NEOMYCIN 96

NEOSTIGMINE 96

NEPAFENAC 96

NERIUM OLEANDER 96, 263

NEROLI OIL 216

NESIRITIDE 96

N-ETHYL MDA

*See* N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE 202

N-ETHYL-α-METHYL-3,4-(METHYLENEDIOXY)PHENETHYLAMINE \*(N-ETHYL MDA) 202

NETILMICIN 96

NETOBIMIN 140, 175

NEVIRAPINE 96

N-HYDROXY MDA

*See* N-α-[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE 203

NIALAMIDE 96

NICARBAZIN 216

NICARDIPINE 96

NICERGOLINE 96

NICKEL SULFATE 175

NICLOSAMIDE 39

NICOCODINE 203

NICODICODINE 203

NICOFURANOSE 96

NICOMORPHINE 204

NICORANDIL 97

NICOTINAMIDE

*See* NICOTINIC ACID 47, 97

NICOTINE 97, 175, 193, 257, 268

NICOTINIC ACID 47, 97

NICOTINYL ALCOHOL 47

NICOUMALONE 97

NIFEDIPINE 97

NIFENAZONE 97

NIKETHAMIDE 97

NILOTINIB 97

NILUTAMIDE 97

NIMESULIDE 97

NIMIDANE 175, 193

NIMODIPINE 97

NIMORAZOLE 97

NIRIDAZOLE 97

NISIN 216

*See also* ANTIBIOTIC SUBSTANCES 54

NISOLDIPINE 97

NITENPYRAM 175

NITISINONE 97

NITRAZEPAM 97, 270

NITRENDIPINE 97

NITRIC ACID 140, 175, 234, 257

NITRIC OXIDE 97

NITROBENZENE 175, 234, 257

NITROFEN 193, 268

NITROFURANTOIN 97

NITROFURAZONE 97

NITROGEN MUSTARD

*See* MUSTINE 95

NITROPHENOLS 175, 234, 257

NITROPRUSSIDES 175, 193, 234, 257

NITROSCANATE 140

NITROUS OXIDE 97

NITROXOLINE 97

NITROXYNIL 175

NIZATIDINE 39, 97, 257

N-METHYL-1-(3,4-METHYLENEDIOXYPHENYL)-2-BUTANAMINE \*(MBDB) 203

N-METHYL-2-PYRROLIDONE 139, 174, 234

*See also* DESIGNATED SOLVENT 3

*See also* N-(N-DODECYL)-2-PYRROLIDONE 133

*See also* N-(N-OCTYL)-2-PYRROLIDONE 141

N-METHYLMETHANAMINE

*See* 1,2-ETHANEDIAMINE POLYMER WITH (CHLOROMETHYL)OXIRANE and  
 N-METHYLMETHANAMINE 133

N-OCTYL BICYCLOHEPTENE DICARBOXIMIDE 141

N-OLEYL-1,3-DIAMINOPROPANE 176

NOMEGESTROL 97

NOMIFENSINE 97

NON-ACCESS PACKAGING 5,

*See also* CHILD-RESISTANT CLOSURE

*See also* CHILD-RESISTANT PACKAGING,

NONOXINOL 9 141, 175, 234

NON-VOLATILE CONTENT 5

NORACYMETHADOL 204

NORADRENALINE 97, 257

NORANDROSTENOLONE 98

NORBOLETHONE 98

NORBORMIDE 141

NORCLOSTEBOL 98

NORCODEINE 198

NORELGESTROMIN 98

NORETHANDROLONE 98

NORETHISTERONE 98

NORFLOXACIN 98

NORFLURAZON 216

NORGESTREL 98

NORIBOGAINE 98

NORLEVORPHANOL 204

NORMETHADONE 198, 270

NORMETHANDRONE 98

NORMORPHINE 204

NORPIPANONE 204

NORTRIPTYLINE 98, 270

NOSCAPINE 39

*See also* OPIUM 198, 270

NOVALURON 216

NOVOBIOCIN 98

NOXIPTYLINE 98

N-PHENETHYL-4-PIPERIDONE 204

N-TALLOW ALKYL-1,3-PROPANEDIAMINE DIACETATE 183

NUCLEAR POLYHEDROSIS VIRUS 216

NUTMEG OIL 22, 141, 234

NUTRITION REPLACEMENT PREPARATIONS FOR PARENTERAL ADMINISTRATION 208

NUX VOMICA

*See* STRYCHNINE

NYSTATIN 39, 47, 98, 257, 264

N-α-[METHYL-3,4-(METHYLENEDIOXY)PHENETHYL]HYDROXYLAMINE \*(N-HYDROXY MDA) 203

O

OCITHILINONE

*See* 2-OCTYL-4-ISOTHIAZOLIN-3-ONE 235

OCTAMYLAMINE 98

OCTATROPINE 98

OCTHILINONE 176

OCTREOTIDE 98

OCTYL ALCOHOLS 216

OCTYL NITRITE 98

OESTRADIOL 98, 141, 263

OESTRIOL 98

OESTROGENS 98

OESTRONE 98, 263

OFATUMUMAB 98

OFLOXACIN 98

OIL OF LEMON EUCALYPTUS (Corymbia citriodora)

*See* EXTRACT OF LEMON EUCALYPTUS 134

OIL OF TANSY 98

*See* TANACETUM VULGARE 115

OIL OF TURPENTINE 22

OLANZAPINE 270

OLAQUINDOX 176

OLEANDOMYCIN 98, 141

OLEANDRIN 98

OLEIC ACID 216

OLMESARTAN 99

OLODATEROL 99

OLOPATADINE 99

OLSALAZINE 99

OMALIZUMAB 99

OMEGA-3-ACID ETHYL ESTERS 99

OMEPRAZOLE 47, 99

OMETHOATE 141, 176, 193

ONDANSETRON 99

OPIPRAMOL 99

OPIUM 198, 270

ORANGE OIL (BITTER) 141, 235, 257

ORANGE OIL, SWEET 216

ORBIFLOXACIN 99

ORCIPRENALINE 99, 258

ORGANO TIN-COMPOUNDS

*See* TIN ORGANIC COMPOUNDS

ORGANOPHOSPHORUS COMPOUNDS 13, 99

ORLISTAT 47, 99

ORNIDAZOLE 99

ORNIPRESSIN 99

OROMUCOSAL USE 5

ORPHENADRINE 99

ORTHO-DICHLOROBENZENE 163, 230, 251

ORTHO-PHENYLPHENOL 142, 235, 258

ORTHO-PHTHALALDEHYDE 143, 178, 236, 258

ORTHOPTERIN 99

ORTHO-TOLIDINE 195, 238, 268

OSELTAMIVIR 99

OUABAIN 99

OVANDROTONE 99

OXABETRINIL 216

OXABOLONE 99

OXACILLIN 99

OXADIARGYL 141

OXADIAZON 176

OXADIXYL 142

OXALATES, METALLIC 258

OXALIC ACID VI, 176, 235, 258

OXALIPLATIN 99

OXALONITRILE

*See* CYANOGEN

OXAMYL 193

OXANDROLONE 99

OXANTEL EMBONATE 142

OXAPROZIN 99

OXAZEPAM 99, 270

OXCARBAZEPINE 99

OXEDRINE 99

OXETACAINE (OXETHAZAINE) 39, 100

OXETHAZAINE

*See* OXETACAINE 39, 100

OXFENDAZOLE 142

OXIBENDAZOLE 142

OXICONAZOLE 39, 47, 100

OXITROPIUM 100

OXOLAMINE 100

OXOLINIC ACID 100

OXPENTIFYLLINE (pentoxifylline) 100

OXPRENOLOL 100

OXYBUPROCAINE 100

OXYBUTYNIN 100

OXYCARBOXIN 142

OXYCLOZANIDE 176

OXYCODONE 198, 270

OXYDEMETON METHYL 194

OXYFLUORFEN 216

OXYMESTERONE 100

OXYMETAZOLINE 39, 258

OXYMETHOLONE 100

OXYMORPHONE 199

OXYPHENBUTAZONE 100

OXYPHENCYCLIMINE 100

OXYPHENISATIN 221

OXYPHENONIUM 100

OXYTETRACYCLINE 100, 142

OXYTHIOQUINOX 142

OXYTOCIN 100, 263

P

PACK / PACKAGING

S*ee* LABELS & CONTAINERS

*See also* MEASURE PACK 5

*See also* PRIMARY PACK 6

PACLITAXEL 100

PACLOBUTRAZOL 142

PAECILOMYCES LILACINUS Strain 251 176

PAINT 5, 265

PAINT, FIRST SCHEDULE 4, 265, 258

PAINT, SECOND SCHEDULE 6, 265, 258

PAINT, THIRD SCHEDULE 6, 265

PALIFERMIN 100

PALIPERIDONE 100, 270

PALIVIZUMAB 100

PALMAROSA OIL 216

PALMITIC ACID 216

PALONOSETRON 100

PAMAQUIN 100

PAMIDRONIC ACID (includes disodium pamidronate) 100

PANCREATIC ENZYMES 100

PANCURONIUM 100

PANITUMUMAB 100

PANTOPRAZOLE 48, 101

PAPAVERETUM 270

PAPAVERINE 39, 101

*See also* OPIUM 198, 270

PAPER 208

*See also* PHOTOGRAPHIC PAPER or FILM 208

PARACETAMOL 48, 101, 258

*See also* ASPIRIN (+ paracetamol) 55

*See also* METOCLOPRAMIDE (+ paracetamol) 47

*See also* SALICYLAMIDE (+ paracetamol) 111

PARA-DICHLOROBENZENE 131, 251

PARA-DICHLOROBENZENE (PDB) 230

PARAFFIN OILS

*See* HYDROCARBONS, LIQUID 135

PARA-FLUOROFENTANYL 204

PARAFORMALDEHYDE 40, 176, 221, 235

PARAHEXYL

*See* 3-HEXYL-1-HYDROXY-7,8,9,10-TETRAHYDRO-6,6,9-TRIMETHYL-6H-DIBENZO (b,d) PYRAN 202

PARALDEHYDE 101

PARAMETHADIONE 101

PARAMETHASONE 101

PARAQUAT 194

PARATHION 194

PARATHION-METHYL 176, 194

PARBENDAZOLE 176

PARECOXIB 101

PARICALCITOL 101

PAROMOMYCIN 101

PAROXETINE 101

PASIREOTIDE 101

PASIREOTIDE DIASPARTATE 101

PATCHOULI OIL 216

PAZOPANIB 101

PCBS

*See* POLYCHLORINATED BIPHENYLS

PCE

*See* ETICYCLIDINE 202

PCP

*See* PHENCYCLIDINE 204

PCPY

*See* ROLICYCLIDINE 204

PDB

*See* PARA-Dichlorobenzene 230

PEBULATE 176

PECAZINE 101

PECTINASE 216

PEFLOXACIN 101

PEGAPTANIB 101

PEGFILGRASTIM 101

PEGINTERFERON 101

PEGVISOMANT 101

PEMETREXED 101

PEMOLINE 101

PEMPIDINE 101

PENBUTOLOL 101

PENCICLOVIR 40, 101

PENCONAZOLE 142

PENCYCURON 216

PENDIMETHALIN 142

PENETHAMATE 102

PENFLUFEN 142

PENICILLAMINE 102

PENNYROYAL OIL 22, 176, 235

PENTACHLORONITROBENZENE

*See* QUINTOZENE

PENTACHLOROPHENOL 177, 194, 258

PENTADECANOIC ACID 216

PENTAERYTHRITYL TETRANITRATE 102

PENTAGASTRIN 102

PENTAMETHONIUM 102

PENTAMIDINE (includes pentamidine isethionate) 102

PENTAZOCINE 199, 270

PENTHIENATE 102

PENTHIOPYRAD 142

PENTOBARBITONE 102, 199, 270

PENTOLINIUM 102

PENTOSAN POLYSULFATE SODIUM 102

PENTOXIFYLLINE

*See* OXPENTIFYLLINE 100

PEPAP

*See* 1-PHENYLETHYL-4-PHENYL-4-PIPERIDINOL ACETATE 204

PEPPERMINT OIL 216

PERACETIC ACID 142, 177, 235, 258

PERFLUIDONE 177

PERGOLIDE 102

PERHEXILINE 102

PERICYAZINE 102, 270

PERINDOPRIL 102

PERMANGANATES 177, 258

PERMETHRIN 102, 142, 177

PERPHENAZINE 102, 270

PERTUSSIS ANTIGEN 102

PESTICIDE 5

PETASITES 221

PETHIDINE 199, 270

PETHIDINE INTERMEDIATE A

*See* 4-CYANO-1-METHYL-4-PHENYLPIPERIDINE 197

PETHIDINE INTERMEDIATE B

*See* 4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID ETHYL ESTER 199

PETHIDINE INTERMEDIATE C

*See* 1-METHYL-4-PHENYLPIPERIDINE-4-CARBOXYLIC ACID 198

PETROL 20, 142, 235

*See also* BENZENE 188

*See also* MOTOR, HEATING or FURNACE FUELS 208

PETROLEUM OILS

*See* HYDROCARBONS, LIQUID

PHEDRAZINE 40

PHENACEMIDE 102

PHENACETIN 102

PHENADOXONE 204

PHENAGLYCODOL 102

PHENAMPROMIDE 204

PHENAZOCINE 204

PHENAZONE 40, 102, 142

PHENAZOPYRIDINE 102

PHENCYCLIDINE \*(PCP) 204

PHENDIMETRAZINE 199

PHENELZINE 102, 270

PHENETICILLIN 102

PHENFORMIN 102

PHENGLUTARIMIDE 102

PHENINDIONE 102

PHENIRAMINE 40, 48, 102, 270

PHENISATIN 102

PHENISOPHAM 142

PHENMEDIPHAM 216

PHENMETRAZINE 199

PHENOBARBITONE 103, 270

PHENOL(s) 41, 103, 142, 177, 235, 258

*See also* CREOSOTE 161

PHENOLPHTHALEIN 103

PHENOMORPHAN 204

PHENOPERIDINE 199, 270

PHENOTHIAZINE 177

PHENOXYBENZAMINE 103

PHENOXYMETHYLPENICILLIN 103

PHENSUXIMIDE 103

PHENTERMINE 103, 224

PHENTHIMENTONIUM 103

PHENTOLAMINE 103

PHENYL MERCURIC CHLORIDE

*See* MERCURY

PHENYL METHYL KETONE 142, 235

*See also* DESIGNATED SOLVENT 3

PHENYLACETYLINDOLES 204

PHENYLBUTAZONE 103

PHENYLENEDIAMINES 177, 221, 235

PHENYLENEDIAMINES AND ALKYLATED PHENYLENEDIAMINES 258

PHENYLEPHRINE 41, 103, 258

*See also* CODEINE (+ phenylephrine) 3

*See also* IBUPROFEN (+ phenylephrine) 37

*See also* PARACETAMOL (+ phenylephrine) 40

PHENYLMERCURIC ACETATE 194, 268

PHENYLPROPANOLAMINE 103, 258

PHENYLTOLOXAMINE 103, 270

PHENYTOIN 103, 258

PHOLCODINE 41, 103, 199, 270

PHORATE 194

PHOSALONE 178

PHOSFOLAN 194

PHOSMET 178

PHOSPHIDES, METALLIC 194, 268

PHOSPHINE 194, 268

PHOSPHODIESTERASE TYPE 5 INHIBITORS 103

PHOSPHONIC ACID 142, 235, 258

PHOSPHORIC ACID 142, 178, 236, 258

PHOSPHORUS 263

PHOSPHORUS, YELLOW 194, 236, 258

PHOSPHOURUS ACID

*See* PHOSPHONIC ACID

PHOTOGRAPHIC PAPER or FILM 208

PHOXIM 178

PHP

*See* ROLICYCLIDINE 204

PHTHALYLSULFATHIAZOLE 103

PHYSOSTIGMINE 103

PHYTASE 216

PHYTOMENADIONE

*See* VITAMIN K

PICARIDIN 143

PICLORAM 216

PICOLINAFEN 216

PICRIC ACID 236, 259

PICROTOXIN 103

PIGEON POX VACCINE 121

PIGMENTS 208

PILOCARPINE 103

PIMARCIN

*See* NATAMYCIN

PIMECROLIMUS 103

PIMELIC ACID 216

PIMINODINE 204

PIMOBENDAN 103

PIMOZIDE 103, 270

PINACIDIL 104

PINDOLOL 104

PINDONE 178

PINE OILS 143, 178

PINOXADEN 143, 178

PIOGLITAZONE 104

PIPECURONIUM 104

PIPEMIDIC ACID 104

PIPENZOLATE 104

PIPER METHYSTICUM (kava) 104

PIPERACILLIN 104

PIPERAZINE 41, 143

PIPERAZINE OESTRONE SULFATE

*See* ESTROPIPATE 76

PIPERIDINE 104

PIPERIDOLATE 104

PIPERONYL BUTOXIDE 216

PIPEROPHOS 178

PIPOBROMAN 104

PIPOTHIAZINE 104

PIPRADROL 104

PIRACETAM 104

PIRBUTEROL 104

PIRENOXINE (catalin) 104

PIRENZEPINE 104

PIRETANIDE 104

PIRIMICARB 143, 178

PIRIMIPHOS-ETHYL 178

PIRIMIPHOS-METHYL 178

PIRITRAMIDE 199

PIROXICAM 104

PIRPROFEN 104

PITAVASTATIN 104

PITUITARY HORMONES 104

PIVAMPICILLIN 105

PIZOTIFEN 105, 270

PLASMA

*See* BLOOD COMPONENTS 2

*See* HUMAN BLOOD PRODUCTS 207

PLASMA SUBSTITUTES

*See* DEXTRANS, GELATIN − SUCCINYLATED & ETHERIFIED STARCHES 207

PLASMA-DERIVED THERAPEUTIC PROTEINS

*See* HUMAN BLOOD PRODUCTS 207

PLATELETS

*See* BLOOD COMPONENTS 2

*See* HUMAN BLOOD PRODUCTS 207

PLERIXAFOR 105

PLICAMYCIN 105

PMA

*See* 4-METHOXY-α-METHYLPHENYLETHYLAMINE 203

PNEUMOCOCCAL VACCINE 105

PODOPHYLLIN 259

*See also* PODOPHYLLUM EMODI 41, 48, 105

*See also* PODOPHYLLUM PELTATUM 41, 48, 105

*See also* PODOPHYLLUM RESIN 263

PODOPHYLLOTOXIN 41, 48, 105, 259

PODOPHYLLUM EMODI (podophyllin) 41, 48, 105

PODOPHYLLUM PELTATUM (podophyllin) 41, 48, 105

PODOPHYLLUM RESIN (podophyllin) 263

POISON 6

POLIDEXIDE 105

POLIHEXANIDE 143, 259

POLIOMYELITIS VACCINE 105

POLIXETONIUM SALTS 143, 178

POLOXALENE 216

POLY (GNRF) OVALBUMIN 217

POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE 217

POLY(OXY-1,2-ETHANEDIYL) 143, 236, 259

POLYACRYLAMIDE 105

POLYDADMAC

*See* POLY DIALLYL DIMETHYL AMMONIUM CHLORIDE 217

POLYESTRADIOL 105

POLYETHANOXY (15) TALLOW AMINE 143, 236, 259

POLYHEDROSIS VIRUS OF *HELICO ZEA* OCCLUSION BODIES 217

POLYLACTIC ACID 105

POLYMYXIN 105

POLYSILICONE-15

*See* DIMETHICODIETHYLBENZALMALONATE

POLYSORBATE 20 217

POLYSULFATED GLYCOSAMINOGLYCANS 105

POLYTHIAZIDE 105

POPPY STRAW CONCENTRATE 197

PORACTANT 105

PORCELAIN 208

PORCINE SOMATOTROPHIN 217

POSACONAZOLE 106

POTASSIUM AZELOYL DIGLYCINATE 178

POTASSIUM BICARBONATE 217

POTASSIUM BROMATE 178, 236

POTASSIUM BROMIDE 106

POTASSIUM CARBONATE

*See* ALKALINE SALTS

POTASSIUM CHLORATE 41, 143, 236

POTASSIUM CHLORIDE 106

POTASSIUM CHROMATE 106

*See* CHROMATES 158

*See* CHROMIUM 265

POTASSIUM CYANATE 178, 236

POTASSIUM HYDROXIDE 22, 143, 178, 221, 236, 259

POTASSIUM METABISULPHITE 143, 236, 259

POTASSIUM NITRITE 143, 179, 194, 236, 259

POTASSIUM PERCHLORATE 106

POTASSIUM PERMANGANATE

*See* PERMANGANATES 177

POTASSIUM PEROXOMONOSULFATE TRIPLE SALT 143, 179, 236

POTASSIUM PERSULFATE 236, 259, 179

POTASSIUM PHOSPHATE

*See* ALKALINE SALTS

POTASSIUM SALTS

*See* ALKALINE SALTS 124, 151, 219

*See* BIFLUORIDES 126, 154, 188, 229, 249, 267

POTASSIUM SILICATE

*See* ALKALINE SALTS

POTASSIUM SORBATE 217

POTASSIUM SULFIDE 143, 236, 259

POULTRY VACCINES 121

PRACTOLOL 106

PRALIDOXIME 106

PRALLETHRIN 144, 179

PRAMIPEXOLE 106

PRAMOCAINE 106

PRAMPINE 106

PRASTERONE (DEHYDROEPIANDROSTERONE, DEHYDROISOANDROSTERONE) 106

PRASUGREL 106

PRAVASTATIN 106

PRAZEPAM 106, 270

PRAZIQUANTEL 106

PRAZOSIN 106

PREDNISOLONE 106

PREDNISONE 106

PREGABALIN 106, 270

PREGNENOLONE 106

PRENALTEROL 106

PRENYLAMINE 106

PREPARATIONS, DIVIDED 4

PRILOCAINE 41, 106

PRIMAQUINE 106

PRIMARY PACK 6

PRIMIDONE 106

PRINTING INKS OR INK ADDITIVES 208

PROBENECID 106

PROBUCOL 107

PROCAINAMIDE 107

PROCAINE 107

PROCAINE PENICILLIN 107

PROCARBAZINE 107

PROCHLORAZ 179

PROCHLORPERAZINE 48, 107, 270

PROCYCLIDINE 41, 107

PROCYMIDONE 194

PROFENOFOS 179

PROFOXYDIM 144

PROGESTERONE 107, 144, 263

PROGESTOGENS 107

PROGLUMIDE 107

PROGUANIL 107

PROHEPTAZINE 204

PROHEXADIONE CALCIUM 144

PROLINTANE 107

PROMACYL 179

PROMAZINE 107, 270

PROMETHAZINE 41, 48, 107, 270

PROMETRYN 144

PROMOXOLANE 107

PROPACHLOR 179

PROPAFENONE 107

PROPAMIDINE 41, 107

PROPAMOCARB 144

PROPANIDID 107

PROPANIL 144

PROPANTHELINE 107

PROPAQUIZAFOP 144

PROPARGITE 179

PROPENTOFYLLINE 107

PROPERIDINE 204

PROPETAMPHOS 179

PROPETANDROL 107

PROPICONAZOLE 144, 179

PROPINEB 13, 179

*See also* DITHIOCARBAMATES

PROPIONIBACTERIUM ACNES 107

PROPIONIC ACID 144, 179, 236, 260

PROPIRAM 199

PROPOFOL 107

PROPOXUR 144, 180

PROPRANOLOL 107, 263

PROPYL ACETATES 217

PROPYLENE GLYCOL 217

PROPYLENE OXIDE 194, 268

PROPYLHEXEDRINE 107

PROPYLTHIOURACIL 107

PROPYPHENAZONE 107

PROPYZAMIDE 144

PROQUAZONE 107

PROQUINAZID 180

PROSCILLARIDIN 107

PROSTAGLANDINS 107

PROSTIANOL 108

PROSULFOCARB 180

PROSULFURON 180

PROTAMINE 108

PROTEIN C

*See* HUMAN BLOOD PRODUCTS 208

PROTHIOCONAZOLE 217

PROTHIOCONAZOLE-DESCHLORO 144

PROTHIOCONAZOLE-TRIAZOLIDINETHIONE 144

PROTHIOFOS 180

PROTHIONAMIDE 108

PROTHIPENDYL 108

PROTHROMBIN COMPLEX CONCENTRATE (PCC)

*See* HUMAN BLOOD PRODUCTS 208

PROTIRELIN 108

PROTOVERATRINES 108

PROTRIPTYLINE 108, 270

PROXYMETACAINE 108

PRUCALOPRIDE 108

PSEUDOEPHEDRINE 48, 108

PSEUDOMONAS FLUORESCENS 217

PSILOCINE

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE 201

PSILOCYBINE 204

PSILOTSIN

*See* 3-(2-DIMETHYLAMINOETHYL)-4-HYDROXYINDOLE 201

PTERIDIUM spp 221

PULMONARIA spp 221

PYMETROZINE 144

PYRACLOFOS 180

PYRACLOSTROBIN 144

PYRAFLUFEN-ETHYL 144

PYRANTEL 41

PYRASULFOTOLE 144

PYRAZINAMIDE 108

PYRAZOPHOS 180

PYRETHRIC ACIDS

*See* PYRETHRINS 42, 145

PYRETHRINS 42, 145

PYRETHROLONE

*See* PYRETHRINS 42, 145

PYRIDABEN 145, 180

PYRIDALYL 180

PYRIDATE 180

PYRIDINOLCARBAMATE 108

PYRIDOSTIGMINE 108

PYRIDOXAL 108

PYRIDOXAMINE 108

PYRIDOXINE 108

PYRIFENOX 145

PYRIMETHAMINE 108

PYRIMETHANIL 217

PYRINURON 194, 268

PYRIPROLE 180

PYRIPROXYFEN 217

PYRITHIOBAC SODIUM 145

PYRITHIONE COPPER 180

PYRITHIONE ZINC 42, 145, 180, 236

PYROVALERONE 108

PYROXASULFONE 180

PYROXSULAM 180

PYRVINIUM 108

Q

QUASSIA 217

QUATERNARY AMMONIUM COMPOUNDS 13, 145, 180, 236

QUAZEPAM 108

QUETIAPINE 108, 270

QUINAGOLIDE 108

QUINALBARBITONE 199, 270

QUINAPRIL 108

QUINBOLONE 108

QUINCLORAC 145

QUINETHAZONE 108

QUINIDINE 108

QUININE 108, 145, 194

QUINISOCAINE (dimethisoquin) 108

QUINOXYFEN 217

QUINTOZENE 145

QUINUPRISTIN 108

QUIZALOFOP ETHYL. 180

QUIZALOFOP ETHYL (D + ISOMER)

*See* QUIZALOFOP ETHYL

QUIZALOFOP-P-ETHYL 145, 181

QUIZALOFOP-P-TEFURYL 181

R

RABEPRAZOLE 48, 109

RABIES VACCINE 109

RACEMETHORPHAN 204

RACEMORAMIDE 199

RACEMORPHAN 204

RACTOPAMINE 109, 145

RADIOGRAPHIC CONTRAST MEDIA (RADIOPAQUES) 209

RADIOISOTOPES 209

RADIOPAQUES

*See* RADIOGRAPHIC CONTRAST MEDIA 209

RALOXIFENE 109

RALTEGRAVIR 109

RALTITREXED 109

RAMIPRIL 109

RANIBIZUMAB 109

RANITIDINE 42, 109, 260

RAPACURONIUM 109

RASAGILINE 109

RASBURICASE 109

RASML

*See* REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS 6

RAUWOLFIA SERPENTINA. 109

RAUWOLFIA VOMITORIA 109

RAZOXANE 109

REBOXETINE 109

RECOMBINANT FOLLICLE STIMULANT

*See* CORIFOLLITROPIN ALFA 223

RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE

*See* FOLLITROPIN ALPHA 223

*See* FOLLITROPIN BETA 223

RED CELLS

*See* BLOOD COMPONENTS 2

*See* HUMAN BLOOD PRODUCTS 207

RED YEAST RICE 109

REDUCERS

*See* HYDROCARBONS, LIQUID 21

*See* LIQUID HYDROCARBONS 20

REMIFENTANIL 199

REMOXIPRIDE 109

REPAGLINIDE 109

REQUIRED ADVISORY STATEMENTS FOR MEDICINE LABELS 6

RESERPINE 109

RESMETHRIN 145, 181

RESTRICTED FLOW INSERT 6

RETAPAMULIN 109

RETEPLASE 109

RETIGABINE 109, 270

RIBAVIRIN 109

RIDAFOROLIMUS 109

RIFABUTIN 109

RIFAMPICIN 109

RIFAMYCIN 110

RIFAPENTINE 110

RIFAXIMIN 110

RILPIVIRINE 110

RILUZOLE 110

RIMEXOLONE 110

RIMITEROL 110

RIMONABANT 110

RIMSULFURON 145

RISEDRONIC ACID 110

Risperidone 110, 270

RITODRINE 110

RITONAVIR 110

RITUXIMAB 110

RIVAROXABAN 110

RIVASTIGMINE 110

RIZATRIPTAN 110

ROBENACOXIB 110

ROBENIDINE 145

ROCURONIUM 110

ROFECOXIB 110

ROFLUMILAST 110

ROLICYCLIDINE \*(PHP or PCPY) 204

ROLITETRACYCLINE 110

ROMIFIDINE 110

ROMIPLOSTIM 110

RONIDAZOLE 110

ROPINIROLE 110

ROPIVACAINE 110

ROSEMARY OIL 217

*See also* CAMPHOR 127, 157

*See also* CINEOLE 159

ROSIGLITAZONE 110

ROSOXACIN 110

ROSUVASTATIN 110

ROTENONE 181

ROTIGOTINE 110, 271

ROXIBOLONE 111

ROXITHROMYCIN 111

RUBELLA VACCINE 111

RUBOXISTAURIN 111

RUPATADINE 111, 271

S

S,S,S-TRIBUTYLPHOSPHOROTRITHIOATE

*See* TRIBUFOS 196

SABADILLA

*See* SCHOENOCAULON OFFICINALE 111

SAFLUFENACIL 145, 194

SAFROLE 181, 221, 237, 260

*See also* SASSAFRAS OIL 181

SAGE OIL (Dalmatian) 22, 181, 237

SAGE OIL (Spanish) 217

*See also* CAMPHOR 127, 157

SALBUTAMOL 48, 111, 260

SALCATONIN 111

SALE OR SUPPLY 24

SALICYLAMIDE 42, 111, 260

*See also* ASPIRIN (+ salicylamide) 55

*See also* PARACETAMOL(*+* salicylamide) 101

SALICYLANILIDE 145

SALICYLIC ACID 48

SALINOMYCIN 111, 181

SALMETEROL 111

SALVIA DIVINORUM 204

SALVINORIN A

*See* METHYL (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-ACETOXY-6a,10b-DIMETHYL-4,10-DIOXO-DODECAHYDRO-2-(3-FURYL)-2H-NAPHTHO[2,1-c]PYRAN-7-CARBOXYLATE 203

SANDALWOOD OIL 217

SANTONIN 48

SAPROPTERIN 111

SAQUINAVIR 111

SARM

*See* SELECTIVE ANDROGEN RECEPTOR MODULATORS 111, 224

SASSAFRAS OIL 181, 237, 260

SAVIN(E)

*See* JUNIPERUS SABINE 221

SAXAGLIPTIN 111

SCABBY MOUTH VACCINE 121

SCHOENOCAULON OFFICINALE (sabadilla) 111

SCHRADAN 194

SCOPOLIA CARNIOLICA 111

SEAWEED & UNFRACTIONED SEAWEED EXTRACTS 217

SECBUTOBARBITONE 199, 271

SECOBARBITAL

*See* QUINALBARBITONE

SECOND SCHEDULE PAINT 6, 258, 265

SEDAXANE 145

SEEDS 209

SELAMECTIN 145

Selected container 6

SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARM) 111, 224

SELEGILINE 111

SELENIUM v, 42, 111, 181, 194, 263, 265

SELENIUM ARSENIDE

*See* ARSENIC 187

*See* SELENIUM 194

SELENIUM COMPOUNDS 237, 260, 265

SELENIUM SULFIDE

*See* SELENIUM 42

SEMDURAMICIN 182, 195

SENECIO spp 221

SERMORELIN 111

SERTINDOLE 112

SERTRALINE 112

SETHOXYDIM 145

SEVELAMER 112

SEVOFLURANE 112

SEX HORMONES 112

SHUI OIL

*See* CAMPHOR

SIBUTRAMINE 112

SIDURON 145

SILANDRONE 112

SILDENAFIL 112

SILICOFLUORIC ACID

*See* HYDROSILICOFLUORIC ACID

SILICOFLUORIDES 145, 182, 237

*See also* FLUORIDES 254

SILICONES 112, 221

SILVER 42, 260

*See also* SILVER NITRATE 182

SILVER NITRATE 182

SILVER SALTS 237

*See also* SILVER NITRATE 182

SILVER SULFADIAZINE 112

SIMAZINE 217

SIMVASTATIN 112

SINBIOALLETHRIN 146, 182

SINGLE-USE TUBES FOR THE ESTIMATION OF ALCOHOL CONTENT OF BREATH 209

SIROLIMUS 112

SISOMICIN (sisomycin) 112

SISOMYCIN

*See* SISOMICIN 112

SITAGLIPTIN 112

SITAXENTAN 112, 224, 260, 273

SLIMICIDES 207

SODIUM ALUMINATE 182, 237, 260

SODIUM BICARBONATE 217

Sodium bromate 182, 237

SODIUM BROMIDE 112

SODIUM CARBONATE

*See* ALKALINE SALTS

SODIUM CELLULOSE PHOSPHATE 112

SODIUM CHLORATE 146, 237, 260

SODIUM CHROMATE

*See* CHROMATES 158

*See* CHROMIUM 265

SODIUM CLODRONATE

*See* CLODRONIC ACID 65

SODIUM CROMOGLYCATE 42, 112

SODIUM DIACETATE 146, 237

SODIUM DICHLOROISOCYANURATE 237

*See also* DICHLOROISOCYANURATES 252

SODIUM 2,2-DICHLOROPROPIONATE

*See* 2,2-DPA

SODIUM DODECYLBENZENE SULFONATE 146, 237, 260

SODIUM FLUORIDE 260

SODIUM HYDROGEN SULFATE 146, 237, 260

SODIUM HYDROSULFITE 146, 237, 260

SODIUM HYDROXIDE 22, 146, 182, 221, 237, 260

SODIUM HYPOCHLORITE

*See* CHLORINATING COMPOUNDS 128, 158

SODIUM LAURETH-6 CARBOXYLATE 146, 237, 260

SODIUM LAURYL SULFATE 182, 237

SODIUM METABISULPHITE 146, 237, 261

SODIUM MORRHUATE 112

SODIUM NITRITE 42, 146, 183, 195, 237, 261

SODIUM NITROPRUSSIDE 112

SODIUM OXYBATE

*See* 4-HYDROXYBUTANOIC ACID

SODIUM PERCARBONATE 146, 237

SODIUM PERCARBONATE (CAS No. 15630-89-4) 146, 183

SODIUM PERSULFATE 183, 238, 261

SODIUM PHOSPHATE 48, 112

SODIUM PICOSULFATE 48

SODIUM POLYSTYRENE SULPHONATE 112, 146

SODIUM PROPIONATE 217

SODIUM SALICYLATE 112

SODIUM SALTS

*See* ALKALINE SALTS 124, 151, 219

*See* BIFLUORIDES 126, 154, 188, 229, 249, 267

SODIUM SILICATE(S)

*See* ALKALINE SALTS

SODIUM STANNATE 146, 238

SODIUM SULFIDE 146, 183, 238, 261

SODIUM TETRADECYLSULFATE 112

SODIUM TRICHLOROACETATE 238

SOLASODINE 112

SOLID 6

SOLIFENACIN 112

SOMATOSTATIN 112

SOMATOTROPIN EQUINE 112

SOMATROPIN (human growth hormone) 112, 224

SONTOQUINE 112

SORAFENIB 113

SOTALOL 113

SPARFLOXACIN 113

SPARTEINE 113

SPECTINOMYCIN 113

SPINETORAM 146

SPINOSAD 146

SPIRAMYCIN 113

SPIRAPRIL 113

SPIRONOLACTONE 113

SPIROTETRAMAT 183

SPIROXAMINE 183

SQUILL 42

STABAXOL

*See* 2,2',6'6'-TETRAISOPROPYL-DIPHENYL-CARBODIIMIDE

STANOLONE 113

STANOZOLOL 113

STAPHISAGRIA

*See* DELPHINIUM STAPHISAGRIA 33

STAR ANISE OIL 146

STATINS

*See* HMG-CoA REDUCTASE INHIBITORS 83

STAVUDINE 113

STEM CELLS

*See* BLOOD COMPONENTS 2

*See also* HUMAN BLOOD PRODUCTS

STENBOLONE 113

STERIC ACID 217

STEROID HORMONES 113

STEROIDAL AGENTS

*See* ANABOLIC STEROIDAL AGENTS 224

*See* ANDROGENIC STEROIDAL AGENTS 224

STILBOESTROL (diethylstilboestrol) 113

STORAGE 25

STP

*See* 2-AMINO-1-(2,5-DIMETHOXY-4-METHYL)PHENYLPROPANE 200

STRAMONIUM

*See* DATURA STRAMONIUM 32, 69

*See* DATURA TATULA 32, 69

STREPTODORNASE 113

STREPTOKINASE 113

STREPTOMYCIN 113

STRONTIUM CHROMATE

*See* CHROMATES 158

*See* CHROMIUM 265

STRONTIUM RANELATE 113

STROPHANTHINS 113

STROPHANTHUS spp 113, 263

STRYCHNINE 25, 113, 195, 238, 263, 268

STRYCHNOS spp 113

STYRAMATE 113

STYRENE 147, 238, 261

*See also* DESIGNATED SOLVENT 3

SUBSTANCE 7

SUCCIMER 113

SUCCINYLATED & ETHERIFIED STARCHES 207

SUCRALFATE 217

SUFENTANIL 199

SUGAMMADEX 113

SULBACTAM 113

SULCOFURON 183, 195, 238, 268

SULCONAZOLE 42, 113

SULESOMAB 217

SULFACETAMIDE 49, 113, 147

*See also* SULFONAMIDES

SULFADIAZINE 113, 147

SULFADIMETHOXINE 113

SULFADIMIDINE 113, 147

SULFADOXINE 114

SULFAFURAZOLE 114

SULFAGUANIDINE 114

SULFAMERAZINE 114, 147

SULFAMETHIZOLE 114

SULFAMETHOXAZOLE 114

SULFAMETHOXYDIAZINE 114

SULFAMETHOXYPYRIDAZINE 114

SULFAMETROLE 114

SULFAMIC ACID 147, 183, 238, 261

SULFAMONOMETHOXINE 114

SULFAMOXOLE 114

SULFAPHENAZOLE 114

SULFAPYRIDINE 114

SULFAQUINOXALINE 114

SULFASALAZINE 114

SULFATHIAZOLE 114, 147

SULFATROXAZOLE 114

SULFENTRAZONE 195

SULFINPYRAZONE 114

SULFLURAMID 183

SULFOMETURON-METHYL 147

SULFOMYXIN 114

SULFONAL

*See* SULFONMETHANE 114

SULFONAMIDES 114

SULFONMETHANE (sulfonal and alkyl sulfonals) 114

SULFOSULFURON 217

SULFOTEP 195

SULFURIC ACID 183, 238, 261

SULFURYL FLUORIDE 183

SULINDAC 114

SULPHANILAMIDE

*See* SULFONAMIDES

SULPHATED POLYSACCHARIDES 217

SULPROFOS 183

SULTAMICILLIN 114

SULTHIAME 114

SUMATRIPTAN 114

SUNITINIB 114

SUPPLY OR SALE 24

SUPROFEN 114

SUTILAINS 115

SUXAMETHONIUM 115

SUXETHONIUM 115

SYMPHYTUM spp (Comfrey) 147, 221, 261

SYNEPHRINE

*See* OXEDRINE

SYNTHETIC CANNABINOMIMETICS 204

T

TACRINE 115

TACROLIMUS 115

TADALAFIL 115

TAFLUPROST. 115

TALIGLUCERASE ALFA 115

TALLOW ALKYLAMINE ACETATES 183

TAMOXIFEN 115

TAMSULOSIN 115

TANACETUM VULGARE 115

TANNIC ACID 217

TANNIC ACID/BENZYL ALCOHOL 217

TANSY OIL

*See* TANACETUM VULGARE 115

TAPENTADOL 199, 271

TAR

*See* PHENOL

TAR ACIDS 183

TASONERMIN 115

TAZAROTENE 115, 261

TAZOBACTAM 115

TBTO

*See* TRI-ALKYL TIN COMPOUNDS/SALTS

-CELL RECEPTOR ANTIBODY 115

TCMTB (2-[THIOCYANOMETHYLTHIO]BENZOTHIAZOLE) 183

TCP

*See* TENOCYCLIDINE 204

TDE (1,1-DICHLORO-2,2-BIS[4-CHLOROPHENYL]ETHANE) 184

TEA TREE OIL

*See* MELALEUCA OIL 22, 172

TEBUCONAZOLE 147

TEBUFENOZIDE 147

TEBUFENPYRAD 184

TEBUTHIURON 184

TEFLUTHRIN 147, 195

TEGAFUR 115

TEGASEROD 115

TEICOPLANIN 115

TELAPREVIR 115

TELBIVUDINE 115

TELITHROMYCIN 115

TELMISARTAN 115

TEMAZEPAM 115, 271

TEMEPHOS 147, 184

TEMOZOLOMIDE 115

TEMPERATURE - BOILING OR DISTILLATION 8

TEMSIROLIMUS 115

TENECTEPLASE 115

TENIPOSIDE 115

TENOCYCLIDINE \*(TCP) 204

TENOFOVIR 115

TENOXICAM 115

TEPOXALIN 115

TEPP 195

TEPRALOXYDIM 147

TERAZOSIN 115

TERBACIL 217

TERBINAFINE 42, 116

TERBUCONAZOLE

*See* TEBUCONAZOLE

TERBUFOS 195

TERBUTALINE 49, 116, 261

TERBUTHYLAZINE 184

TERBUTRYN 147

TERFENADINE 116, 261

*See also* ANTIHISTAMINES 248

TERIFLUNOMIDE 116, 261, 273

TERIPARATIDE 116, 223

TERLIPRESSIN 116

TERMITE BARRIERS 209

TERODILINE 116

TEROPTERIN 116

TERPENES, CHLORINATED 184, 238, 261

TESTOLACTONE 116

TESTOSTERONE 116, 184, 263

TETANUS ANTITOXIN 116

TETANUS TOXOID 116

TETRABENAZINE 116

TETRACAINE

*See* AMETHOCAINE

TETRACHLOROETHANE 195, 238, 261, 268

TETRACHLOROETHYLENE 42, 147, 184, 238, 261

*See also* DESIGNATED SOLVENT 4

TETRACHLORVINPHOS 147

TETRACONAZOLE 148, 184

TETRACOSACTRIN 116

TETRACYCLINE 116, 148

TETRADIFON 184

TETRAETHYLAMMONIUM 116

TETRAHYDROCANNABINOLIC ACID

*See* NABIXIMOLS 198

TETRAHYDROCANNABINOLS 204

*See also* NABIXIMOLS 210

TETRAHYDROCANNABIVAROL

*See* NABIXIMOLS 198

TETRAHYDROZOLINE 42, 261

TETRAMETHRIN 148

TETRAMISOLE 184

TETRAPION

*See* FLUPROPANATE

TETROXOPRIM 116

TFMPP

*See* 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE 205

THALIDOMIDE 116, 223, 261, 274

THALLIUM 195, 25, 268

THALLIUM SULFATE

*See* THALLIUM

THAUMATIN 217

THEBACON 199

THEBAINE 199

THENYLDIAMINE 116, 271

THEOPHYLLINE 49, 116

THERAPEUTIC GOOD 6

THERAPEUTIC USE 6

THEVETIA PERUVIANA 116

THEVETIN 116

THIABENDAZOLE 42, 148

THIACETARSAMIDE 116

*See also* ARSENIC 152

THIACLOPRID 184

THIAMAZOLE

*See* METHIMAZOLE

THIAMBUTOSINE 116

THIAMETHOXAM 148, 184

THIAZAFLURON 184

THIAZOPYR 148

THIAZOSULFONE 116

THIDIAZURON 217

THIETHYLPERAZINE 116, 271

THIFENSULFURON 148

THINNERS

*See* HYDROCARBONS, LIQUID 21

*See* LIQUID HYDROCARBONS 20

THIOACETAZONE 116

THIOBENCARB 148

THIOCARLIDE 116

THIODICARB 148, 184

THIOFANOX 195

THIOFENTANYL 205

THIOGUANINE 117

THIOMESTERONE (tiomesterone) 117

THIOMETON 184

THIOPENTONE 117

THIOPHANATE-METHYL 148, 184

THIOPROPAZATE 117, 271

THIOPROPERAZINE 117

THIORIDAZINE 117, 271

THIOSTREPTON 117

THIOTEPA 117

THIOTHIXENE 117, 271

THIOURACIL 117

THIOUREA 117, 238, 261

THIOUREA AND ALKYL THIOUREAS 184

THIRAM 13, 184

*See also* DITHIOCARBAMATES

THIRD SCHEDULE PAINT 6, 265

THROMBIN

*See* HUMAN BLOOD PRODUCTS 208

THUJONE 22, 184, 238

*See also* SAGE OIL 181

THYME OIL 22, 148, 238

THYMOL 184

THYMOXAMINE (includes thymoxamine hydrochloride 117

THYROID 117

THYROTROPHIN 117

THYROXINE 263

THYROXINE (includes thyroxine sodium) 117

TIAGABINE 117

TIAMULIN 117

TIAPROFENIC ACID 117

TIARAMIDE 117

TIBOLONE 117

TICAGRELOR 117

TICARCILLIN 117

TICLOPIDINE 117

TIEMONIUM 117

TIENILIC ACID 117

TIGECYCLINE 117

TIGLOIDINE 117

TILDIPIROSIN 117

TILETAMINE 117

TILIDINE 199

TILMICOSIN 117

TILUDRONIC ACID (includes disodium tiludronate) 117

TIMBER or WALLBOARD 209

TIMOLOL 118

TIN ORGANIC COMPOUNDS 195

TINIDAZOLE 118

TINTER 6

TINZAPARIN (includes tinzaparin sodium) 118

TIOCARBAZIL 148

TIOCONAZOLE 42, 49, 118

TIOMESTERONE

*See* THIOMESTERONE 117

TIOTROPIUM 118

TIPEPIDINE 118

TIPRANAVIR 118

TIRILAZAD 118

TIROFIBAN 118

TISSUE RECONSTRUCTIVE, AUGMENTATION AND RESTORATION MATERIALS − INJECTABLE

*See* MEDICAL DEVICES 208

TMA

*See* 3,4,5-TRIMETHOXY-α-METHYLPHENYLETHYLAMINE 205

TOBRAMYCIN 118

TOCAINIDE 118

TOCERANIB 118

TOCILIZUMAB 118

TOLAZAMIDE 118

TOLAZOLINE 118

TOLBUTAMIDE 118

TOLCAPONE 118

TOLCLOFOS-METHYL 148

TOLFENAMIC ACID 118

TOLMETIN 118

TOLONIUM 118

TOLPROPAMINE 118

TOLRESTAT 118

TOLTERODINE 118

TOLTRAZURIL 148

TOLUENE 20, 185, 238, 261, 265

*See also* HYDROCARBONS, LIQUID 13

*See also* XYLENE 186

TOLUENEDIAMINE 238, 185, 222, 261

TOLVAPTAN 118

TOLYLFLUANID 185

TOPICAL USE 6

TOPIRAMATE 118

TOPOTECAN 118

TORASEMIDE 118

TOREMIFENE 118

TOXOIDS 119

TOY 6

TOY FUELS

*See* MOTOR, HEATING or FURNACE FUELS 208

TRALKOXYDIM 148

TRAMADOL 119, 271

TRAMAZOLINE 42, 261

TRANDOLAPRIL 119

TRANEXAMIC ACID 119

TRANSDERMAL USE 7

TRANSFLUTHRIN 185

TRANYLCYPROMINE 119. 271

TRASTUZUMAB 119

TRAVOPROST 119

TRAZODONE 119

TRENBOLONE 148

TRENBOLONE (trienbolone, trienolone) 119

TREOSULPHAN 119

TREPROSTINIL 119

TRESTOLONE 119

TRETAMINE 119

TRETINOIN 119, 223, 261, 274

TRIACETYLOLEANDOMYCIN 119

TRIADIMEFON 148, 185

TRIADIMENOL 148

TRIALKYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRI-ALLATE 13, 148

TRIAMCINOLONE 42, 49, 119, 261

TRIAMIPHOS 195

TRIAMTERENE 119

TRIASULFURON 217

TRIAZBUTIL 195

TRIAZIQUONE 119

TRIAZOLAM 119

TRIBENURON-METHYL 149

TRIBUFOS (s,s,s-TRIBUTYLPHOSPHOROTRITHIOATE) 196

TRIBUTYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRICHLORFON 185

*See also* METRIFONATE 93

TRICHLORMETHIAZIDE 119

TRICHLOROACETIC ACID 119, 149, 185, 238, 262

TRICHLOROACETIC ACID ALKALI SALTS 238

TRICHLOROETHENE

*See* TRICHLOROETHYLENE

TRICHLOROETHYLENE 119, 185, 238, 262

TRICHLOROISOCYANURIC ACID 238, 268

*See also* CHLORINATING COMPOUNDS 250

TRICHLOROPHENOL 185, 262

TRICHODERMA HARZIANUM 217

TRICHODESMA AFRICANA 222

TRICLABENDAZOLE 185

TRICLOFOS 119

TRICLOPYR 185

TRICLOSAN 185

TRICOSENE

*See* (Z)-9-TRICOSENE 217

TRICYCLAMOL 119

TRIDEMORPH 185

TRIDIHEXETHYL 119

TRIDIPHANE 149

TRIENBOLONE

*See* TRENBOLONE 119

TRIENOLONE

*See* TRENBOLONE 119

TRIETAZINE 149

TRIETHANOLAMINE 149, 238, 262

TRIETHYL PHOSPHATE 186, 239, 262

TRIETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRIETHYLENE GLYCOL 217

TRIETHYLENE THIOPHOSPHORAMIDE

*See* THIOTEPA

TRIFLOXYSTROBIN 149

TRIFLOXYSULFURON 217

TRIFLUMIZOLE 149

TRIFLUMURON 149

TRIFLUOPERAZINE 119, 271

TRIFLUOROMETHANESULFONIC ACID 186, 239, 262

TRIFLUPERIDOL 119

TRIFLUPROMAZINE 119

TRIFLURALIN 217

TRIFORINE 217

TRIIODOTHYRONINE

*See* LIOTHYRONINE SODIUM

TTRIISOPROPANOLAMINE LAURYL ETHER SULFATE 149, 239, 262

TRILOSTANE 119

TRIMEPERIDINE 205

TRIMEPRAZINE 42, 49, 119, 271

TRIMETAPHAN 120

TRIMETHOPRIM 120

TRIMETHYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRIMIPRAMINE 120, 271

TRIMUSTINE 120

TRINEXAPAC-ETHYL 149

TRINITROPHENOL 120, 186

TRIOXYSALEN 120

TRIPARANOL 222

TRIPELENNAMINE 120

TRIPHENYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRIPLE ANTIGEN VACCINE 120

TRIPROLIDINE 43, 49, 120, 271

TRIPROPYL TIN COMPOUNDS

*See* TIN ORGANIC COMPOUNDS 195

TRIPTORELIN 120

TRISODIUM NITRILOTRIACETATE 186

TRITICONAZOLE 149

TROGLITAZONE 120

TROMETAMOL 120

TROPICAMIDE 120

TROPISETRON 120

TROVAFLOXACIN 120

TROXIDONE 120

TRYPTOPHAN 120

TSH

*See* THYROTROPHIN

TUAMINOHEPTANE 43

TUBERCULIN 120

TUBOCURARINE 120

TULATHROMYCIN 120

TULOBUTEROL 120

TURPENTINE (mineral) 239

TURPENTINE OIL 149

TURPENTINE OIL (VEGETABLE) 239

TURPENTINE OIL

*See also* OIL OF TURPENTINE 22

TUSSILAGO FARFARA 222

TYLOSIN 120, 150

TYMAZOLINE 43, 262

TYPHOID VACCINE 120

U

ULOCLADIUM OUDEMANSII 217

ULTRASONIC AND MAGNETIC RESONANCE IMAGING ENHANCING AGENTS

*See* ENHANCING AGENTS 207

UNICONAZOLE-P

*See* (E)-(S)-1-(4-CHLOROPHENYL)-4,4-DIMETHYL-2-(1H-1,2,4-TRIAZOL-1-YL)PENT-1-EN-3-OL 158

UNOPROSTONE 120

URACIL 121

URAPIDIL 121

UREA 217

URETHANE 121

URINARY CATHETERS

*See* MEDICAL DEVICES 208

UROFOLLITROPIN 121, 223

UROKINASE 121

URSODEOXYCHOLIC ACID 121

USTEKINUMAB 121

V

VACCINE, CHOLERA 64

VACCINE, GnRH 81

VACCINE, HAEMOPHILUS INFLUENZAE 82

VACCINE, HEPATITIS A 82

VACCINE, HEPATITIS B 82

VACCINE, HUMAN PAPILLOMAVIRUS 83

VACCINE, JAPANESE ENCEPHALITIS 86

VACCINE, MEASLES 90

VACCINE, MENINGOCOCCAL 91

VACCINE, MUMPS 95

VACCINE, PIGEON POX 121

VACCINE, PNEUMOCOCCAL 105

VACCINE, POLIOMYELITIS 105

VACCINE, RABIES 109

VACCINE, RUBELLA 111

VACCINE, SCABBY MOUTH 121

VACCINE, TRIPLE ANTIGEN 120

VACCINE, TYPHOID 120

VACCINE, VACCINIA VIRUS 121

VACCINE, VARICELLA 121

VACCINES FOR HUMAN THERAPEUTIC USE 121

VACCINES, INFLUENZA AND CORYZA 85

VACCINES, POULTRY 121

VACCINES, VETERINARY LIVE VIRUS 121

VACCINIA VIRUS VACCINE 121

VALACICLOVIR 121

VALDECOXIB 121

VALGANCICLOVIR 121

VALNOCTAMIDE 121

VALPROIC ACID 121

VALSARTAN 121

VAMIDOTHION 186

VANCOMYCIN 121

VARDENAFIL 121

VARENICLINE 121

VARICELLA VACCINE 121

VASOPRESSIN 121

VECURONIUM 121

VEDAPROFEN 121

VELAGLUCERASE ALFA 121

VEMURAFENIB 121

VENLAFAXINE 121

VERAPAMIL 122

VERATRUM spp. 122

VERNAKALANT 122

VERNOLATE 150

VERTEPORFIN 122

VETERINARY AND MEDICAL ADHESIVES, GLUES AND CEMENTS 208

VETERINARY CHEMICAL 7

VETERINARY CHEMICAL PRODUCT 7

VETERINARY LIVE VIRUS VACCINES 121

VETIVER OIL 218

VIDARABINE 122

VIGABATRIN 122

VILANTEROL 122

VILANTEROL TRIFENATATE 122

VILDAGLIPTIN 122

VILOXAZINE 122

VINBLASTINE 122

VINCA ALKALOIDS

*See* UNDER INDIVIDUAL ENTRIES

VINCAMINE 122

VINCLOZOLIN 196, 262

VINCRISTINE 122

VINDESINE 122

VINFLUNINE 122

VINORELBINE 122

VINYL CHLORIDE 196, 268

VINYL ETHER 122, 218

VIPRYNIUMA

*See* PYRVINIUM

VIRGINIAMYCIN 122, 150

VISNADINE 122

VITAMIN A 122

VITAMIN D 49, 122

VITAMIN K 218

VITREOUS ENAMELS 209

VORICONAZOLE 122

VORINOSTAT 122

W

WALLBOARD

*See* TIMBER 209

WARFARIN 122, 150, 186

WHITE CELLS

*See* BLOOD COMPONENTS 2

*See* HUMAN BLOOD PRODUCTS 207

WHITE LEAD

*See* BASIC LEAD CARBONATE

WHITE MINERAL OILS

*See* HYDROCARBONS, LIQUID 135

WHITE PETROLEUM SPIRIT

*See* HYDROCARBONS, LIQUID 135

*See* LIQUID HYDROCARBONS 20, 21

WHITE SPIRIT 239

*See also* HYDROCARBONS, LIQUID

WHOLE BLOOD

*See* HUMAN BLOOD PRODUCTS 207

WOOD

*See* CREOSOTE 32, 161

WRAPPER, IMMEDIATE 4

WRITING 7

WRITING CORRECTION PENS 209

X

XAMOTEROL 123

XANTHINOL NICOTINATE 123

XANTHOPHYLL (lutein) 218

XIMELAGATRAN 123

XIPAMIDE 123

XYLANASE 218

XYLAZINE 123

XYLENE 20, 186, 239, 262, 265

*See also* HYDROCARBONS, LIQUID 135

*See also* TOLUENE 185

XYLENOLS 239

*See also* PHENOL 142, 177

XYLOMETAZOLINE 43, 262

Y

YELLOW PHOSPHORUS

*See* PHOSPHORUS, YELLOW 236, 258

YLANG YLANG OIL 218

YOHIMBINE 123

Z

ZAFIRLUKAST 123

ZALCITABINE 123

ZALEPLON 123

ZANAMIVIR 123

ZERANOL 123, 186

ZETA-CYPERMETHRIN 186, 196

ZIDOVUDINE 123

ZILPATEROL 123

ZIMELDINE 123

ZINC BORATE 186

ZINC CHLORIDE 43, 186, 239, 262

ZINC CHROMATE

*See* CHROMATES 158

*See* CHROMIUM 265

ZINC COMPOUNDS 123

ZINC NAPHTHENATE 218

ZINC PARA-PHENOLSULFONATE 186

ZINC PHOSPHIDE

*See* PHOSPHIDES METALLIC

ZINC SULFATE 186, 239, 262

ZINEB 13, 150

ZIPRASIDONE 123, 271

ZIRAM 13, 186, 196

ZOLAZEPAM 123

ZOLEDRONIC ACID 123

ZOLMITRIPTAN 123

ZOLPIDEM 123, 271

ZONISAMIDE 123, 271

ZOPICLONE 123, 271

ZOXAZOLAMINE 123

ZUCLOPENTHIXOL 123

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Endnotes about misdescribed amendments and other matters are included in a compilation only as necessary.

**Abbreviation key—Endnote 2**

The abbreviation key sets out abbreviations that may be used in the endnotes.

**Legislation history and amendment history—Endnotes 3 and 4**

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

**Misdescribed amendments**

A misdescribed amendment is an amendment that does not accurately describe the amendment to be made. If, despite the misdescription, the amendment can be given effect as intended, the amendment is incorporated into the compiled law and the abbreviation “(md)” added to the details of the amendment included in the amendment history.

If a misdescribed amendment cannot be given effect as intended, the abbreviation “(md not incorp)” is added to the details of the amendment included in the amendment history.

Endnote 2—Abbreviation key

|  |  |
| --- | --- |
| A = Act | o = order(s) |
| ad = added or inserted | Ord = Ordinance |
| am = amended | orig = original |
| amdt = amendment | par = paragraph(s)/subparagraph(s) |
| c = clause(s) | /sub‑subparagraph(s) |
| C[x] = Compilation No. x | pres = present |
| Ch = Chapter(s) | prev = previous |
| def = definition(s) | (prev…) = previously |
| Dict = Dictionary | Pt = Part(s) |
| disallowed = disallowed by Parliament | r = regulation(s)/rule(s) |
| Div = Division(s) | Reg = Regulation/Regulations |
| exp = expires/expired or ceases/ceased to have | reloc = relocated |
| effect | renum = renumbered |
| F = Federal Register of Legislative Instruments | rep = repealed |
| gaz = gazette | rs = repealed and substituted |
| LI = Legislative Instrument | s = section(s)/subsection(s) |
| LIA = *Legislative Instruments Act 2003* | Sch = Schedule(s) |
| (md) = misdescribed amendment can be given | Sdiv = Subdivision(s) |
| effect | SLI = Select Legislative Instrument |
| (md not incorp) = misdescribed amendment | SR = Statutory Rules |
| cannot be given effect | Sub‑Ch = Sub‑Chapter(s) |
| mod = modified/modification | SubPt = Subpart(s) |
| No. = Number(s) | underlining = whole or part not |
|  | commenced or to be commenced |

Endnote 3—Legislation history

| Name | FRLI registration | Commencement | Application, saving and transitional provisions |
| --- | --- | --- | --- |
| Poisons Standard 2013 | 22 Aug 2013 (F2013L01607) | 23 Aug 2013 (s 3) |  |
| Poisons Standard Amendment No. 2 of 2013 | 27 Aug 2013 (F2013L01625) | 1 Sept 2013 | — |
| Poisons Standard Amendment No. 1 of 2014 | 8 Jan 2014 (F2014L00044) | 1 Feb 2014 except Tylosin (Sch 4 and 5); 1 June 2014 Cocoyl Glycinate (Sch 6): 1 Feb 2015 | — |

Endnote 4—Amendment history

| Provision affected | How affected |
| --- | --- |
| **Schedule 2** |  |
| Schedule 2 | am F2013L01625; F2014L00044 |
| **Schedule 4** |  |
| Schedule 4 | am F2013L01625; F2014L00044 (Tylosin) |
| **Schedule 5** |  |
| Schedule 5 | am F2013L01625; F2014L00044 (Tylosin) |
| **Schedule 6** |  |
| Schedule 6 | am F2013L01625; F2014L00044 (Cocoyl Glycinate) |
| **Schedule 7** |  |
| Schedule 7 | am F2013L01625; F2014L00044 |
| **Schedule 8** |  |
| Schedule 8 | am F2013L01625; F2014L00044 |
| **APPENDIX B** |  |
| Part 3 | am F2013L01625; F2014L00044 |
| **APPENDIX D** |  |
| Appendix D | am F2013L01625; F2014L00044 |
| **APPENDIX E** |  |
| Part 2 | am F2014L00044 |
| **APPENDIX F** |  |
| Part 3 | am F2014L00044 |
| **APPENDIX I** |  |
| Second Schedule | am F2014L00044 |
| **APPENDIX J** |  |
| Part 2 | am F2013L01625 |
| **APPENDIX K** |  |
| Appendix K | am F2014L00044 |
| **INDEX** |  |
| Index | am F2014L00044 |